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ABSTRACT 
Dietary macronutrient composition plays a critical role in health and disease. The 
contribution of dietary carbohydrate source in the development of obesity and related 
diseases is often given minimal attention. The present studies demonstrate that both 
quantitative and qualitative changes in dietary carbohydrate influence body composition 
and adiposity in a rodent model of diet-induced obesity. In heterozygous (fa/+) Zucker 
rats, consumption of a high-fat, carbohydrate-free diet ad libit11m, attenuated weight gain 
and adiposity by increasing energy efficiency and blunting expression of fatty acid 
synthase, a key enzyme in de novo lipogenesis. These effects were independent of 
significant changes in plasma insulin levels. Moreover, the addition of a modest level of 
sucrose to the high-fat diet completely reversed the effects of carbohydrate restriction, 
resulting in significant increases in body weight and adiposity, mediated in part by 
enhanced expression of fatty acid synthase. 
In a separate series of experiments, we evaluated the effects of ad libitum or energy 
restricted (70% of ad libitllf11) high-fat diets, varying in carbohydrate source on adiposity 
in aP2-Ago11ti transgenic mice. In the context of an energy restricted diet, animals 
consuming diets shown to result in lower postprandial blood glucose levels (ROLL and 
MUNG) reduced adipose tissue accumulation in the perirenal and retroperitoneal and 
resulted in smaller adipocytes compared with diets evoking greater postprandial blood 
glucose excursions. 
In ad libitum fed animals, the expression of lipogenic enzymes in the liver and selected 
adipose tissue depots was significantly enhanced by consumption of a high-fat, sucrose­
rich diet. Expression of genes of fatty acid oxidation was enhanced in the muscle of 
lV 
animals consuming the low-glucose response diets. These data suggest that dietary 
carbohydrate source modulates adipose tissue accumulation and body weight by 
partitioning substrate utilization between lipid oxidation in skeletal muscle, and reducing 
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The World Health Organization (WHO) criteria for the classification of overweight 
and obesity are based primarily on the association between body mass index (BMI, 
kg/m2) and mortality. Overweight is classified as having a BMI of 25 - 29.9. A BMI 
greater than 30 is indicative of obesity (1). Data from the Third National Health and 
Nutrition Examination Survey (NHANES III, 1988-1991) demonstrate that age-adjusted 
prevalence of overweight in the United States was 55.9%, while the prevalence of obesity 
was 22.9% (2,3). However, more recent data indicates the prevalence of overweight 
increased to 64.5% in 1999-2000, while the prevalence of obesity increased to 30.5% 
during the same period ( 4). Specifically, 67% of men and 62% of women were 
overweight, while 30.5% of men and 33.4% of women are obese ( 4) . Furthermore, the 
prevalence of overweight among children and adolescents is continuing to increase. In 
1999-2000, more than 15% of 6- through 19-year olds were overweight, while more than 
10% of 2-through 5-year olds were overweight (5). In addition, childhood obesity is on 
the rise as documented by prevalence statistics, which identify 25% of children as 
overweight (6). 
Obesity is second only to cigarette smoking as a cause of death in the United States 
and is cited as a contributing factor in more than 300,000 deaths annually (7-12). 
Allison, et al. (7) analyzed data from six US studies in conjunction with 1991 national 
statistics on BMI distribution, population, and overall death rates and consistently 
estimated approximately 280,000 annual deaths attributable to overweight and obesity, 
either directly or indirectly through re1ated metabolic abnormalities known to occur 
concomitantly with excess body weight. The largest proportion of these deaths occurred 
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in persons with a BMI of at least 30 kg/m2 (J), which is approximately 30% of adults age 
25 and over according to the most recent data from the NHANES continuous survey 
(4). Data from the Framingham Heart Study indicates that the risk of death increases by 
1 % for each pound gained during ages 30 and 42 years, and by 2% between ages 50 and 
62 years (1 1). Furthennore, data from the Health Professionals Follow-Up Study 
demonstrate a positive, linear relationship between BMI and overall and cardiovascular 
disease mortality among men less than 65 years (12) .  Among men over 65 years, waist 
circumference was a stronger predictor of risk of death from cardiovascular disease (12). 
Obesity and related co-morbidities have a significant economic impact, accounting 
for 2-7% of total health care costs in the United States (13,14). Health care costs for 
overweight individuals are more than four thousand dollars greater than those of lean 
subjects subjects. Obese individuals spend roughly $10,000 to 40,000 more for lifetime 
health care than their lean counterparts (13). 
Despite numerous studies demonstrating a positive association between dietary fat 
intake and body fat (15-18), the role of dietary fat in the pathogenesis of obesity remains 
controversial (19-24). Dietary intervention studies indicate that only 2-25% of the 
variation in body weight and composition can be explained by dietary fat intake (19-21); 
a finding variably cited in arguments both for and against limiting dietary fat intake in the 
prevention and treatment of obesity. While data from the Third National Health and 
Nutrition Examination Survey (NHANES III, 1988-1991) (25) demonstrated a 
significant decrease in the mean percentage of total food energy intake (TFEI) and 
saturated fat since the 1960s, the prevalence of obesity, non-insulin-dependent diabetes 
mellitus and related disorders increased during the same period (3-6). These findings 
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suggest that excessive intake of dietary fat is not the only dietary factor influencing body 
weight regulation. 
Despite the controversy regarding dietary fat consumption, major professional 
organizations almost universally recommend consumption of a diet rich in fruits and 
vegetables, low-fat or non-fat dairy products, cereals and whole grains, legumes, nuts, 
fish, poultry and lean meat, while restricting total energy derived from dietary fat to less 
than 30 energy percent (en%), and saturated fat restricted to less than 10% of total daily 
energy (26-32). With regards to dietary carbohydrate, the American Heart Association 
(AHA) recommendations (28,31) encourage the consumption of grain products and 
foods high in soluble fiber, while stating starchy-foods (eg, bread, pasta, cereal, potatoes) 
are preferable to sugars (monosaccharides and disaccharides) (32). The American 
Diabetes Association (ADA) recommends carbohydrate &om foods such as whole 
grains, fruits and vegetables (30). However, with regards to glycemic index, ADA 
recommendations state that the total amount of carbohydrate in meals and snacks is 
more important than the source or type of carbohydrate (30). 
Diets based on the recommendations of the AHA and ADA generally provide 
between 20 and 30% of total energy &om fat and 55 to 60 % of energy &om 
carbohydrates (26-32). While such diets are typically energy restrictive and may reduce 
the risk of obesity and related disorders, the appropriateness of this type diet for all 
individuals is not universally accepted (33-35). Low-fat, rugh-carbohyd.rate diets have 
been shown to elevate plasma triglyceride levels (35), even when the diet is low in simple 
sugars (36,37). This type diet is also associated with an increase in the number of small, 
dense LDL particles (38,39) and reductions in HDL levels (40), an atherogenic lipid 
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profile which is also seen in subjects with visceral obesity, in whom fasting and 
postprandial hyperinsulinemia and peripheral insulin resistance are also commonly 
observed (41 -43). 
Although the metabolic abnormalities associated with low-fat, high carbohydrate 
diets, as well as those seen in obesity, are hypothesized to be the result of higher insulin 
levels, evidence in support of this hypothesis is scant. Fatty acid synthesis induced by 
consumption of a low-fat diet containing a high proportion of simple sugars is increased 
to a similar extent in lean and obese subjects, despite plasma insulin levels that are 2-fold 
higher in the latter (44). Furthermore, no significant relationship is found between 
insulin and fatty acid synthesis when lean and obese subjects are considered separately 
(44). These findings suggest that stimulation of fatty acid synthesis by dietary 
carbohydrate is not directly related to body mass index or plasma insulin levels. 
Consequently, other physiological regulators common to both lean and obese subjects 
may be more relevant to dietary regulation of fatty acid synthesis in vifJO. 
The macronutrient composition of the diet influences energy metabol ism at several 
levels. High-fat diets are generally more palatable than fat-restricted diets, a factor that 
may promote passive overconsumption of high-fat foods (45). Long-term studies of fat­
reduced diets suggest there is a compensatory increase in energy intake as the duration of 
fat restriction continues (46). In the Women's Health Trial (47), compliance to a diet 
which reduced fat intake from approximately 38% to 20% of total energy intake was 
high for the first six months of dietary intervention and was accompanied by a 
significant loss of body weight. Compliance waned as the duration of intervention was 
extended to 24 months and consequently, weight loss was similar to subjects consuming 
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their habitual diet (47). Similarly, in overweight subjects, reducing energy intake derived 
from dietary fat to 17 .6% of total energy for one year did not significantly increase f.at 
loss compared with weight-matched control subjects (47,48). These findings suggest 
that weight loss induced by low-fat diets is transient and difficult to maintain. 
The failure of conventional fat-reduced diets to promote and maintain weight loss 
may partly explain the increasing popularity oflow-carbohydrate diets. In a 
comprehensive review of carbohydrate-restricted diets, lower-carbohydrate diets were 
found to produce greater weight loss than diets containing greater quantities of 
carbohydrate (49). This affect is hypothesized to result from a reduction in energy intake 
rather carbohydrate restriction. However, there are few long-term studies of 
carbohydrate-restricted diets and consequently, there is a notable lack of information 
regarding the efficacy of low-carbohydrate diets in maintaining reduced body weight or 
the possibility of adverse consequences. 
The first long-term (one year), multicenter, randomized, controlled trial of a low­
carbohydrate, high-protein, high-fat, Atkins' -type (50) diet was conducted by Foster, et 
al. (51). The central feature of this diet involves limiting carbohydrate intake without 
restricting consumption of fat and protein. For the first two weeks of the diet, 
carbohydrate intake is limited to 20 grams per day and is then gradually increased until a 
stable and desirable weight is achieved and maintained (50) . The Atkins-type diet was 
compared to a high-carbohydrate, low-fat, reduced-calorie (1200-1 500 and 1500-1 800 
kcal/ d for women and men, respectively) diet for the same duration. Subjects 
consuming the low-carbohydrate diet had lost significantly more weight than the low-fat 
group at 3 months (p<0.01) and 6 months (p=0.02); however, the difference in weight 
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loss was not statistically different between the two groups at 12 months. Both diets were 
associated with improvements in insulin sensitivity, as determined by an oral glucose 
tolerance test. However, the data failed to demonstrate an effect of macronutrient 
composition, independent of weight loss, in obese subjects without diabetes. Compared 
with the low-fat diet, the low-carbohydrate diet was associated with greater decreases in 
serum triglycerides and greater increases in IIDL-cholesterol (51), the levels of which are 
recognized as important risk factors for cardiovascular disease (52,53). 
In a similar, albeit shorter (6 months) study, Samaha, et al. (54) reported that severely 
obese subjects (mean BMI: 43) lost more than twice as much weight (p<0.01) when 
consuming a hypocaloric (by 500 kcal/ d) low-carbohydrate ( < 30 g carbohydrate per 
day) diet compared with weight-matched subjects consuming an isocaloric, low-fat (-30 
en% fat) diet. In nondiabetic subjects, the low-carbohydrate diet induced a greater 
increase in insulin sensitivity (p = 0.01) than did the low-fat diet. Furthermore, 
assignment to the low-carbohydrate diet and the amount of weight lost were each 
independent predictors of improved insulin sensitivity. Compared to the low-fat diet, 
the low-carbohydrate diet induced a greater reduction in serum triglyceride levels, which 
could not be solely attributed to greater weight loss in the low-carbohydrate group (54). 
A study of the same duration was conducting in mildly obese subjects consuming a 
carbohydrate-restricted ( <25 g/ d) diet, with no limit in total energy intake (55). After six 
months, body weight was approximately 10% lower than baseline (p<0.001), leading to a 
significant reduction in BMI (p<0.01). The authors of this study noted that the 
reduction in body weight achieved by adherence to a very-low-carbohydrate diet for six 
7 
months was similar to that achieved in mildly obese subjects treated with Sibutramine� 
(56). 
A 12-week study comparing the effects of a low-fat versus a low-carbohydrate diet 
was conducted in overweight adolescents (57). This study is one of few in which energy 
intake was unrestricted, whereas other studies of low-carbohydrate diets are generally 
hypocaloric (58,59). Subjects assigned to the low-carbohydrate diet were pennitted ad 
libitum intake of dietary protein and fat throughout the 12 week study. During the first 
two weeks, carbohydrate intake was restricted to less than 20 grams per day. 
Carbohydrate intake during weeks 3-12 was increased to 40 grams per day, to be derived 
from nuts, fruits, and whole grain foods. Subjects assigned to the low-fat diet were 
pennitted ad /ibi/11111 intake of fat-free dairy products, fruits and vegetables, while daily 
intake of carbohydrate and fat was restricted to 75 and 40 grams, respectively. Despite 
consuming significantly more energy, particularly from dietary fat (p<0.001), subjects in 
the low-carbohydrate group lost 141% (p<0.04) more weight, than did subjects in the 
low-fat group. Consequently, there was a significantly greater improvement in BMI in 
the low-carbohydrate versus the low-fat group (p<0.05). Simply stated, subjects assigned 
to the low-carbohydrate diet were able to lose a significant amount of weight while 
consuming between 1500-2500 kilocalories per day (kcal/d) (57). 
Conventional wisdom suggests that the main factor in body weight regulation is total 
daily energy intake. However, the partitioning of calories between carbohydrate and fat 
may also influence energy balance. Postprandial fuel utilization is influenced by a variety 
of nutritional factors including circulating levels of glucose, free fatty acids, insulin, leptin 
and gut hormones. The carbohydrate content of a meal is a critical determinant of 
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insulin secretion, which influences postprandial hormonal and metabolite levels, and 
consequently, may alter the pattern of substrate utilization. 
Because of the controversy surrounding the optimal diet for weight loss or 
prevention of obesity, we sought to design studies to address the influence of dietary 
carbohydrate on body weight and composition and to relate these changes to circulating 
metabolites and the expression pattern of several genes implicated in the regulation of 
carbohydrate and lipid metabolism. In our first studies, we evaluated the effects of a 
high-fat diet devoid of carbohydrate on body weight, plasma metabolites, adiposity, and 
expression of fatty acid synthase, a key enzyme of de novo lipogenesis, in both the liver 
and adipose tissue. Furthermore, we examined the effects of adding a minimal amount 
of sucrose to the high-fat diet as means to evaluate the metabolic response to small 
quantities of refined sugars in the context of a high-fat diet. 
Secondly, we designed studies to evaluate the effects of a qualitative change in diet, 
accomplished by varying the source of dietary carbohydrate, on adiposity, plasma 
metabolites and substrate utilization. 1bis approach is quite different from other studies 
which manipulate dietary lipid content or induce elevations in plasma free fatty acids 
through lipid infusion. Our aim was to determine if dietary carbohydrate source per se 
could alter substrate partitioning between adipose tissue, skeletal muscle, and liver and 
ultimately, influence body composition. To this end, we evaluated the expression of 
UCP-2, PPAR-a, PPAR-y, and FAS in white adipose tissue; UCP-3 and PPAR-a in 
gastrocnemius and soleus muscle; and FAS, and PPAR-a in the liver. We sought to 
identify relationships plasma leptin, insulin, and glucose levels and alterations in gene 
expression in response to dietary carbohydrate source. 
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I. Components of the Insulin Resistance Syndrome 
Obesity represents a compensated state of insulin resistance in that hyperinsulinemia 
is observed in obese subjects with nonnal glucose tolerance and this is believed to 
represent beta-cell compensation for peripheral insulin resistance (1-4). Chronic 
hyperinsulinemia may be the earliest detectable metabolic abnormality attributable to 
obesity. The transition to impaired glucose tolerance occurs with the progressive loss of 
compensatory metabolic changes (hyperinsulinemia and post-prandial hyperglycemia) 
and corresponds with the development of defects in both oxidative and non-oxidative 
glucose metabolism (5). Insulin resistance manifests as reduced insulin-stimulated 
glucose uptake and metabolism in adipocytes and skeletal muscle and impaired insulin­
mediated suppression of hepatic glucose uptake (3,6). Thus, there are significant 
impairments in the three main targets of insulin action: liver, skeletal muscle and adipose 
tissue. 
The Insulin Secreto,:y Response 
In normal persons, glucose-induced insulin secretion follows a bi-phasic pattern and is 
initiated when circulating glucose levels exceed 5.5 m.mol/L (2,7,8) . The first phase of 
insulin secretion lasts for 5-10 minutes and is followed by a second, more sustained 
phase which persists for the duration of hyperglycemia (3,8). Chronic hyperglycemia 
(>6.4 mM) dramatically reduces or abolishes the first phase response (9). Insulin 
secretion is very sensitive to changes in plasma glucose levels. The glucose ED50 for 
insulin secretion is 10-15 mmol/L glucose, which is in the lower range of the insulin­
glucose dose response curve (10-13). 
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The rapidity of the early phase response is believed to result from release of pre­
formed insulin from secretory granules docked on or near the plasma membrane of the 
beta cell (14,15). As the early phase response fades, there is a second, more prolonged 
period of insulin release, which persists for as long as plasma glucose levels remain 
elevated (3,4). Fasting and 2-hour oral glucose tolerance test (OGTI) insulin 
concentrations are inversely related to insulin action and consequently, can be 
interpreted as indices of insulin resistance (8,12). 
Normal insulin secretory dynamics, and the acute response in particular, are critical to 
the maintenance of normal glucose tolerance. This has been demonstrated 
experimentally in healthy subjects during hyperglycemic clamps by co-infusion of 
somatostatin to selectively abolish the acute phase of insulin secretion (16, 17). In 
subjects with normal first and second phase insulin secretory responses, infusion of 
glucose alone results in the near complete suppression of hepatic glucose output within 
20 minutes. Abolishing the first phase response by co-infusion of somatostatin, severely 
blunts insulin-mediated suppression of hepatic glucose output, such that only 50% 
suppression is achieved within 20 minutes. The infusion of insulin 10 minutes following 
the simultaneous infusion of somatostatin and glucose, mimics the selective loss of the 
first phase of insulin secretion while the late phase of insulin release is preserved. 
Furthennore, hepatic glucose production remains incompletely suppressed at 150 
minutes, when the normal late phase of insulin secretion is preserved by initiation of 
insulin infusion 10 minutes following the simultaneous infusion of glucose and 
somatostatin, demonstrating the essential role of early insulin secretion in the 
maintenance of glucose homeostasis (17). 
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Marked .impairments in the first phase insulin response are observed early in the 
transition from normal to impaired glucose tolerance (2,4,7). �-cell compensation for 
the insulin resistance associated with obesity is necessary to maintain normal glucose 
tolerance (1 8). In order to overcome the loss of insulin responsiveness in insulin 
resistance states such as obesity, the higher insulin concentration needed must overcome 
the degree of insulin resistance at any given plasma insulin concentration as well as 
nonnaljzing any kinetic defects in insulin action. 
Insulin Hypersecretion 
Insulin hyperseaetion in the basal state and in response to an oral or intravenous 
glucose load is a consequence of obesity (1 ,3). In obese subjects with normal �-cell 
function, insulin resistance is accompanied by an enhancement in the early phase of 
insulin secretion (2). Bonadonna, et al. (19) have shown fasting plasma insulin levels to 
be roughly two-fold higher in obese subjects compared to age-matched, lean controls 
(p<0.001). Hyperinsulinemia in obese subjects was the result of enhanced insulin 
secretion in both the early (0 - 10 min) and late (10 - 120 min) phases of glucose­
induced insulin release, culminating in a total insulin response which was 75% greater in 
obese compared to lean subjects (p<0.01). This is consistent with the findings of 
Hollenbeck, et al. (20), who have demonstrated greater prehepatic insulin production in 
obese subjects compared to lean subjects at all times during an oral glucose tolerance test 
(OGTI). 
In lean and obese subjects insulin sensitivity decreases linearly with BMI, however, 
insulin resistance is 2-3 times more prevalent in obese subjects (21). According to one 
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report, as many as 41 % of obese subjects exhibit fasting hyperinsulinemia. The 
frequency of subjects characterized by enhanced insulin secretion rises in parallel with 
BMI, with nearly half of all subjects with a BMI between 30.1 and 34.9 kg/m2 classified 
as hypersecretors, a figure which rises to 80% in subjects whose BMI exceeded 35 kg/m2 
(21 ,22) . 
First-Pass Hepatic Insulin Extraction 
Following synthesis in the � cell, proinsulin is cleaved to yield insulin and c-peptide, 
which are secreted in equimolar quantities (23,24) . Once secreted, insulin must first 
traverse the liver. In normal subjects, roughly 50% of total secreted insulin is extracted 
and removed in a receptor mediated process during the initial portal passage (25) . 
Normal hepatic extraction is necessary to prevent hyperinsulinemia, and is acutely 
regulated by both glucose and free fatty acids, suggesting this function is linked to 
peripheral indicators of insulin sensitivity (25). As insulin resistance worsens, reduced 
hepatic extraction is necessary to compensate for reduced peripheral sensitivity to insulin 
(28). Thus, the liver plays an important role in regulating the amount of insulin reaching 
systemic circulation. 
Genuth, et al. (25) have demonstrated similar rates of insulin clearance in nounal and 
diabetic subjects, while obese subjects were found to more rapidly catabolized insulin. 
Despite having fasting plasma insulin levels which were 1 .5-fold higher (p<0.001) than 
those observed in normal weight subjects, obese subjects were found to have 
significantly elevated insulin clearance rates (p<0.05). This supports the role of 
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compensatory hyperinsulinem.ia as an adaptive mechanism for peripheral insulin 
resistance associated with obesity (25). 
In.iuence of Excess Adiposity 
Ovemutrition facilitates the development of abnormalities in insulin kinetics and 
insulin action. Mott, et al (29) placed normal weight subjects on a weight maintaining 
diet for 14 days, after which time the energy content of the diet was increased 
progressively over 3 days to induce weight gain. Following 13 days of ovemutrition, 
plasma insulin and glucose responses during an OGTI were not significantly different 
from baseline. However, a significant increase in the insulin response to a meal tolerance 
test (47 en% fat, 29 en% carbohydrate, 24 en% protein) was observed and as a 
consequence, plasma insulin levels were significantly higher over three hours compared 
to subjects consuming a weight maintaining diet (29). 
111 vivo insulin action is characterized by a physiological delay between observed 
increases in plasma insulin levels and onset of insulin action with respect to glucose 
metabolism (30-32). This "rate of activation" for insulin may be altered in insulin 
resistant states. In subjects undergoing euglycemic clamps, the rate of glucose 
metabolism can be computed to detect temporal differences in insulin action. This 
method was employed by Biolo, et al (30) to determine the effects of overall adiposity 
and body fat distribution on insulin-stimulated glucose metabolism. Despite similar BMI 
values in subjects with lower body (40±2 kg/m2) and upper body obesity (41 ±3 kg/m2), 
body fat distribution was found to influence several aspects of insulin action in vivo. 
The rate of glucose metabolism over 120 minutes was greatest in normal weight subjects 
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and was reduced in lower body obesity (p<0.05). Upper body obesity further worsened 
insulin action, as indicated by rates of glucose metabolism significantly lower (p<0.05) 
than normal weight subjects and subjects with lower body obesity but similar BMI. 
Rates of glucose infusion required to maintain euglycemia were similar for obese subjects 
regardless of body fat distribution, and significantly lower (p<0.05) than that required in 
normal weight subjects. 
The rate of onset of insulin action (T11,}, expressed as the time necessary to achieve 
half maximal rates of glucose infusion, was also influenced by body fat distribution. 
Normal weight control subjects and those with lower body obesity had similar T112 
values, whereas subjects with upper body obesity demonstrated significant delays in the 
onset of insulin action (p<0.05). The results of this study demonstrate a selective 
association between body fat distribution and the kinetics of insulin action; upper body 
obesity is associated with a slower rate of onset in insulin action as indicated by 
Gl�t20 min and T,12 values compared to lower body obesity, despite similar BMls (30). 
Abnonnalides Associated with Abdominal Adiposity 
The dynamics of insulin secretion, clearance and physiological actions are subject to 
metabolic influences (4,6,12,29,32-36). Abdominal obesity is strongly associated with 
peripheral insulin resistance and appears to cause several defects in the dynamics of 
insulin secretion and normal hepatic clearance (6,31 ,34). Steady state insulin secretion 
and clearance dynamics have been studied during a period of overnight rest in normal 
weight and abdominally obese subjects (33). During this period, abdominally obese 
subjects had significantly higher plasma glucose levels compared to normal weight 
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controls (p<0.001). Insulin secretion rates were 2.3-fold higher in obese compared to 
nonnal weight control (p<0.001) subjects, whereas hepatic insulin extraction was similar 
in both groups. Consequently, average plasma insulin levels were also significantly 
elevated (3.4-fold) in abdominally obese subjects (p<0.001). Subjects were then 
observed over a 24-hour period during which three mixed meals were consumed. 
Despite similar plasma glucose levels, insulin secretion rates were 2.3-fold higher in 
abdominally obese compared to non-obese subjects (p<0.001), resulting in significantly 
greater insulin output over 24 hours in the abdominally obese subjects (p<0.001), 
accompanied by a reduction in hepatic insulin extraction. As a result, average plasma 
insulin levels were more than 4-fold higher in abdominally obese subjects (p<0.001) (6). 
Polonsky, et al. (3) observed a significant, negative relationship between basal hepatic 
insulin extraction and fasting insulin levels in lean and obese subjects (r=-0.63. p<0.02). 
Although average basal and 24-hour glucose concentrations were similar in obese and 
lean men, obesity was accompanied by significantly higher (2-fold, p<0.05) basal insulin 
levels and higher rates of insulin secretion in the basal state, over a 24-hour period and 
during a euglycemic hyperinsulinemic clamp. Furthermore BMI was positively 
correlated with basal and 24-hour insulin secretion rates (r=0.801 and r=0.895, 
respectively, p<0.001 for both), indicating that the amount of insulin secreted increases 
with increasing body mass. In both obese and lean subjects, fasting insulin levels were 
positively associated with basal rates of insulin secretion (r=0.79-0.82, p<0.003). In 
obese subjects, there was a significant negative correlation between hepatic extraction 
and basal and 24-hour insulin secretion (p<0.002 for both), indicating that impaired 
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hepatic extraction contributes to elevated plasma insulin levels observed in obese 
subjects (3,4). 
The influence of total adiposity and body fat distribution on prehepatic insulin 
production has been estimated by measuring peripheral c-peptide turnover in 
premenopausal women by Peiris, et al (34). Following an overnight fast, basal c­
peptide levels were more than 3-fold higher (p<0.05) in obese women compared to age­
matched non-obese control subjects; an effect largely attributable to a nearly 4-fold 
greater (p<0.05) rate of prehepatic insulin production in obese subjects. These 
abnormalities in insulin secretion were also present when stimulatory concentrations of 
glucose were administere� when obesity was associated with elevated c-peptide levels 
(p<0.05) and greater insulin secretion (p<0.05). Consequently, the cumulative insulin 
response was 2-fold higher (p<0.01) in obese subjects compared to their lean 
counterparts. In fasting, nonobese women, approximately 70% of secreted insulin was 
extracted during the first portal passage. Hyperglycemia reduced hepatic extraction to 
approximately 50% of secreted insulin in lean subjects. There was a wide range of 
fractional extraction in obese women, ranging from 53-94% in the fasting state and 5-
87% during hyperglycemia. In all subjects, plasma insulin levels were correlated with 
post-hepatic insulin delivery in the basal state (r=0.85, p<0.01), as well as during 
intravenous glucose administration (r=0.93, p<0.01). A positive relationship was 
observed between percent body fat and prehepatic insulin production in the basal state 
(r=0.52, p<0.05) and following intravenous glucose administration (r=0.5, p<0.05) (34). 
Using the same subjects, Peiris, et al (34) determined the influence of body fat 
distribution on plasma insulin levels and pre-hepatic insulin clearance. Upper body 
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obesity (WHR > 0.85) was associated with increased post-hepatic insulin delivery 
(p<0.05) and plasma insulin levels (p<0.05) compared with lower body obesity (WHR < 
0. 78). Furthennore, it was noted that as WHR increased, there was a progressive 
decrease in hepatic insulin extraction. Upper body obese women also had greater 
impairments in insulin-mediated glucose disposal, which was a function of both the 
decrease in hepatic extraction (r=-0.72, p<0.01) and the rise in systemic insulin delivery 
following glucose stimulation (r=0.59, p<0.01). Thus, the degree of adiposity and site 
of fat deposition influence insulin metabolism by two distinct mechanisms (34). 
Polonsky, et al (3,4) have demonstrated a significant elevation in total insulin released 
over 24-hours of mixed meal feeding in obese compared to lean subjects (p<0.001). 
Glucose tolerance exerts an effect independent of obesity and persons with impaired 
glucose tolerance (IG1) secrete almost twice as much insulin (p<0.0001) as persons with 
normal glucose tolerance (NG1). 
Proposed Mechanisms of Insulin Resistance in Human Obesity 
Early studies assessing the relationship between obesity and impaired insulin action 
yielded conflicting results. In nonobese males, a statistically significant, negative 
relationship (r=-0.70, p<0.01) has been demonstrated between percent body fat, 
estimated by skinfold thickness and in vivo insulin action measured by the euglycemic 
clamp technique (37). A similar negative relationship (r=-0.70, p<0.01) has been 
reported between obesity defined by BMI and insulin action (assessed by steady state 
plasma glucose levels) in lean and obese subjects (21). Insulin mediated glucose disposal 
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progressively declines as percent body fat approaches 28-30%; no further decrements in 
insulin action are observed above this level of adiposity (21). 
In lean subjects, insulin stimulates a dose-dependent increase in the rate of glucose 
disposal, with an EC50 of -130 µ.U/ml (32). A decrease in the biological effects of 
insulin at any given level of circulating insulin may be due to reduced peripheral 
sensitivity to insulin and/ or decreased maximal responsiveness to the honnone 
(13,38,39). The dose response curve for insulin-stimulated glucose disposal is shifted to 
the right in obesity (32). In obese subjects, reductions in insulin sensitivity may result 
solely from a decrease in the number of insulin receptors (5). Consequently, there is a 
reduction in the level of cellular insulin binding with a parallel reduction in insulin­
stimulated glucose disposal at physiological levels of insulin. While higher plasma insulin 
levels are needed to achieve half-maximal effects on glucose metabolism (EC50: 210 
µU /ml), the response to maximally-stimulating levels of insulin is preserved, suggesting 
the signaling cascade distal to insulin binding its receptor remains intact. A postteceptor 
defect manifests as a rightward shift in the insulin dose response curve (EC50:370 
µU/ml), and loss of responsiveness (32,40). Consequently, there is a blunting of all 
responses to insulin action at maximally stimulating levels of insulin. Compared with 
subjects with a reduced number of insulin receptors, subjects with post-receptor defects 
are more hyperinsulinemic and appear to be more insulin resistant, as indicated by 
greater decrements in glucose disposal at maximally-stimulating concentrations of insulin 
(13,32,40). 
Rizza, et al (32) used the euglycemic, hyperinsulinemic clamp technique to 
characterize the dose-dependent effects of insulin on glucose production and utilization 
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in lean subjects. To detennine the effect of insulin on whole body glucose metabolism, 
the steady-state glucose infusion rate (SSGIR) at each sequential step of the insulin 
infusion was plotted against the corresponding plasma insulin concentration. 1bis 
generated a sigmoidal curve, in which the SSGIR rose steeply up to a plasma insulin level 
of -100 µ.U/ml The ED50 for insulin stimulated glucose utilization was determined to 
be -60 µ.U/ml, with maximum rates of glucose disposal achieved when plasma insulin 
levels reached -675 µ.U/ml 
Whole body glucose homeostasis also relies on the ability of insulin to suppress 
hepatic glucose production ( 41 ). Hepatic glucose production is more sensitive to 
changes in circulating insulin levels than is peripheral tissues glucose utilization; while a 
10-20 µ.U /ml increase in circulating insulin is sufficient for half-maximal suppression of 
endogenous glucose productio� half-maximal stimulation of glucose utilization requires 
an increment in plasma insulin of 40-50 µ.U/ml (41,42). Complete suppression of 
endogenous glucose production occurred when plasma insulin levels reached 
-60µ.U/ml, which is much lower than the concentration required to achieve maximum 
stimulation of glucose utilization (32,42). 
Experimentally induced hyperinsulinemia (25-35 µ.U/ml) induces insulin resistance in 
lean subjects within 40 hours ( 43). This level of hyperinsulinemia significantly reduced 
insulin sensitivity, such that a lower rate of glucose infusion was required to maintain 
euglycemia at submaximally effective plasma insulin levels (p<0.01 vs. saline infusion). 
The requirement for lower rates of glucose infusion was maintained at maximally 
stimulating levels of insulin, indicating an impairment in insulin responsiveness. Despite 
plasma insulin concentrations that were significantly greater following insulin versus 
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saline infusion (p<0.05), adipocyte insulin bmding following 40 hours of 
hyperinsulinemia was similar to that observed following saline infusion. This study 
clearly demonstrates that hyperinsulinemia results in small but significant reductions in 
insulin-stimulated glucose utilization, at both submaximal and maximally effective 
plasma insulin levels (43). Adipocytes and monocytes :isolated from subjects in whom 
hyperinsulinemia had been experimental induced and compared to cells isolated from the 
same subjects prior to hyperinsulinemia. Despite significantly higher insulin levels 
during experimental hyperinsulinemia, insulin binding to adipocytes and monocytes was 
llllchanged, which suggests that hyperinsulinemia impairs insulin action at a step distal to 
insulin binding its receptor (32,43). 
The hyperinsulinemia and insulin resistance of obesity are subject to improvement 
with weight loss. Jones, et al (44) have demonstrated that a 10% reduction in body 
weight significantly improves hyperinsulinemia and insulin resistance in obese subjects. 
Nonetheless, insulin-stimulated glucose utilization remains lower (p<0.05) and the total 
integrated insulin response to a test meal higher (p<0.05), than in lean subjects, 
suggesting greater reductions in body weight are necessary for normalization of these 
aspects of the metabolic syndrome. 
In summary, the pathophysiology leading to the exaggerated hyperinsulinemia 
observed in obesity is the result of the additive effects of peripheral insulin resistance 
(38), reduced hepatic extraction (25,26), and f3-cell hypersecretion (4) . Chronic 
hyperinsulinemia is the price the obese must pay to preserve glucose homeostasis. 
Ultimately, compensatory hyperinsulinemia will worsen peripheral insulin resistance and 
cause further deterioration of whole-body glucose metabolism. The transition from 
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nonnal to impaired glucose tolerance corresponds to the appearance of compensatory 
mechanisms which maintain nonnal glucose homeostasis including hyperinsulinemia and 
postprandial hyperglycemia which prevent defective peripheral glucose utilization and 
storage. Hyperinsulinemia is believed to signal l}-cell compensation for peripheral 
insulin resistance and may be the first clinically detectable abnormality in the transition 
to impaired glucose tolerance in obese subjects ( 45). 
Resistance to glucose storage is also a basic feature of obese subjects still maintaining 
nonnal glucose tolerance (46,47). A key difference between the obese subject with 
impaired glucose tolerance and the obese subject with overt NID D M is the inability of 
the latter to maintain plasma glucose levels within the normal range in both the basal 
state and post-glucose challenge (46-48). However, as insulin resistance worsens, such 
compensatory mechanisms will fail leading to overt glucose intolerance and non-insulin 
dependent diabetes mellitus. 
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II. Physiology of Glucose Homeostasis 
Glucose Homeostasis 
The postabsorptive phase occurs following a 14-16 hour overnight fast. During this 
time, plasma glucose levels average 5mM and plasma insulin levels are low (60 -75 pM) 
(41). The liver is responsible for approximately 80% of glucose released into circulation 
during this period (49,50). Postabsorptively, there is no net storage of glucose and 
glycogenolysis results in the rapid depletion of hepatic glycogen stores in an effort to 
maintain normal circulating glucose levels (49). In this state, the rate at which glucose is 
released into circulation by both the liver and kidney must closely approximate the rate at 
which glucose is removed from circulation, both of which are roughly 10 µmol/kg body 
weight/min (49-51). Initially, 50% of glucose released by the liver is derived from 
glycogenolysis with the remainder arising from gluconeogeoesis (49). The fraction of 
glucose produced from gluconeogenic substrates (lactate, alanine, glutamine) will 
increase as fasting continues (52,53). Studies by Landau, et al. (49) demonstrate that 
gluconeogenesis accounts for roughly 65% of glucose produced during the first 22 hours 
of fasting. This figure rises to -82% with an additional 24 hours of fasting and 96% 
when fasting is extended for 46-64 hours. 
In the basal state, glucose taken up by tissues is either completely oxidized to carbon 
dioxide or is released back into circulation, primarily as alanine and lactate, from which 
glucose can be re-derived via the glucose-alanine and Cori cycles, respectively (53,54). 
Postabsorptive energy needs are largely met by oxidation of free fatty acids, which 
compete with glucose as the fuel substrate of choice for tissues such as the heart and 
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skeletal muscle (55-57). 1bis concept will become even more important in the 
postprandial state. 
Following ingestion of a 75 gram oral glucose load, roughly one-third of ingested 
glucose will be extracted by splanchnic tissues, presumably for direct conversion to 
glycogen (41 ,58,59). The appearance of ingested glucose in systemic circulation is 
apparent within 15 minutes, but peaks between 60 and 120 minutes following glucose 
ingestion. Overall systemic glucose disappearance follows a similar pattern, although the 
rate of glucose clearance peaks around 90 minutes and remains slightly above the 
postabsorptive rate three hours after glucose ingestion (41,58,59). 
The muscle is the major tissue responsible for disposal of an oral glucose load (41). 
Muscle glucose uptake is greatest in the first two hours following glucose ingestion, 
during which time the rate at which glucose is disposed in this tissue is five-fold greater 
than in the postabsorptive period (41). As much as 20% of an oral glucose load is 
extracted from circulation by both the liver and kidney ( 41 ). The liver may extract 
glucose as glucose per se or as lactate, alanine, and/ or glutamine, whose carbon 
backbones originated from previously ingested glucose (41,50). The rate at which the 
brain disposes of glucose is estimated to be -80 mg/min (58). Because the brain has an 
absolute requirement for glucose, this rate should remain unchanged following a glucose 
challenge. Based on the data presented above, four tissues are responsible for disposal 
of at least 90% of an oral glucose load: skeletal muscle (40%), liver (25-35%), kidney 
(15-20%), and brain (15-20%). 
The complete digestion and absorption of the components of a mixed meal and 
restoration of the postabsorptive state takes roughly 6 hours (41). Therefore, persons 
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adhering to the typical 3-meal per day pattern spend most of the day in the postprandial 
state. The rate at which ingested glucose appears in circulation is influenced by many 
factors including the rate of gastric emptying (60), rate of nutrient absorption from the 
gut (61), splanchnic glucose uptake (59), glucose transport dynamics (62), and first- pass 
hepatic glucose extraction (25). The pattern of substrate exchange has been examined in 
normal men by Capaldo, et al (63). Subjects were studied basally and for 5 hours 
following ingestion of a commonly consumed meal (pizza) which contained 75 grams of 
starch, 3 7 grams of protein, and 17 grams of fat. Consistent with previous studies, blood 
glucose levels peaked (p<0.001 vs. basal) 90 minutes after meal consumption. Plasma 
insulin levels, which were low in the basal state, followed similar, albeit delayed pattern 
of increase as observed with plasma glucose levels, and peaked (p<0.01) roughly 1 20 
minutes following meal ingestion. Net splanchnic glucose balance was negative in the 
basal state, indicating net export of glucose. During the 30-60 minutes following meal 
intake, net splanchnic glucose balance rose by 270% (p<0.001) before gradually declining 
towards basal levels. Ingested glucose appeared in portal circulation within 1 5  minutes 
and peaked between 30 and 60 minutes. However, meal-derived glucose continued to 
appear in the portal system at the end of the 5-hour period, although at a slower rate 
than that observed in the immediate postprandial period. In total, the gut absorbed 
approximately 60% of ingested starch. Thus, in contrast to an oral glucose load, 
digestion and absorption of the components of a mixed meal is incomplete over 5 hours. 
Interestingly, meal ingestion was not associated with rapid suppression of hepatic 
glucose production (HGP). The basal rate of HGP was maintained throughout the first 
90 minutes of the postprandial period. At the end of the 5-hour period, maximum 
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suppression of HGP was only 30% lower than the basal rate. This is at odds with the 
findings of Taylor, et aL (64), who have reported a dramatic decrease in hepatic glucose 
production within 10 minutes of ingestion of a mixed liquid meal (milkshake), which 
reached nadir of 67% suppression (p<0.01) within 30 minutes. This apparent 
discrepancy is likely due to the form of the test meal Taylor, et aL (64) supplied all 
carbohydrate as glucose in a readily digestible form. Thus, a liquid meal containing 
glucose as the sole carbohydrate is much more readily digested and absorbed than is a 
solid meal containing more structurally complex carbohydrates and requtting extensive 
mechanical and enzymatic processing prior to absorption. 
Returning to the findings of Capaldo, et aL (63), splanchnic glucose uptake rose from 
the basal level to peak around 120 minutes. Splanchnic glucose clearance followed a 
similar pattern, rising 20-40% above the postabsorptive rate, with peak rates observed 
between 120 and 1 80 minutes. Leg glucose uptake rose from the basal rate to peak 
within 30 minutes. If one assumes that leg muscle represents 25% of whole body 
skeletal muscle mass, the total amount of glucose taken up by skeletal muscle would be 
roughly 30% of meal-derived glucose. Splanchnic lactate balance switched from net 
uptake to net output at 60 minutes, after which lactate balance was near zero. The rate 
of leg lactate production fell to near zero within 90 minutes following meal conswnption 
and remained suppressed by 50% at the end of the five hour period. Plasma free fatty 
acids fell rapidly following meal ingestion and remained low throughout the five hour 
period of the study (63). 
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Altered Hepatic Glucose Metabolism in Obesity 
Obesity is characterized by numerous abnormalities in carbohydrate metabolism 
(65,66). The liver is particularly sensitive to insulin-mediated suppression of endogenous 
glucose production (ED50: -25-50 µU/ml) (32). Endogenously produced glucose arises 
from gluconeogenesis and glycogenolysis, and the regulation of these processes may be 
altered in obesity (49,67-69). When presented with variations in substrate availability, the 
liver is responsible for adjusting the rates of glycolysis, glycogenolysis, and 
gluconeogenesis in order to maintain constant hepatic glucose output (70). 
In nonnal humans, hepatic glycogen content varies considerably during the day. 
Following an overrught fast, the liver contains roughly 75 grams of glycogen. Peale 
glycogen levels of 1 15-120 grams are observed in the hours immediately following the 
last meal consumed on any given day (69,70). Glycogen synthesis is the critical 
determinant of non-oxidative glucose metabolism and consequently, it has been 
suggested that expansion of hepatic glycogen stores in obesity may contribute to 
enhanced hepatic glucose production and consequently, glucose intolerance (71 ,82) . 
In order to understand the role of hepatic glycogen stores on glucose homeostasis, 
Clore, et al C,3) overfed normal subjects in excess of 1000 calories per day for 5 days in 
order to greatly expand hepatic glycogen. Overfeeding was associated with significant 
increases in plasma metabolites, including glucose (p<0.01), insulin (p<0.01), and alanine 
(p<0.01). In response to overfeeding, hepatic glucose output increased significantly 
(p<0.01) and was accompanied by a 42% decrease (p<0.01) in alanine gluconeogenesis, 
as well as a reduction in overall gluconeogenesis. 
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In a study of obese non-diabetic subjects, Muller, et al. (74) found similar rates of 
endogenous glucose production in lean and obese subjects. However, fractional 
gluconeogenesis was 2-fold higher (p<0.05) in obese subjects compared to their lean 
counterparts. In obese subjects, elevated gluconeogenesis was compensated for by 
blunted (by -50%) glycogenolysis (p<0.05) and thus, normal regulation of endogenous 
glucose production was preserved. Hepatic glycogen stores were increased in obese 
compared to lean (p<0.05) subjects, presumably the result of impaired glycogenolysis. 
In contrast to Muller, et al. (74), Felig, et al. (66) demonstrated dysregulation of 
hepatic metabolism in obese subjects. In the basal state, splanchnic glucose release was 
similar in obese and normal weight subjects. Nonetheless, splanchnic uptake of glucose 
precursors (lactate, alanine and glycerol) was 50-130% higher in obese compared with 
lean subjects (66). This suggests that gluconeogenesis makes a greater contribution to 
total hepatic glucose output in obesity. Support for this hypothesis came from balance 
data for glucose and glucose precursors across the splanchnic bed, which demonstrated 
that gluconeogenesis acconnts for 19% of endogenous glucose output in normal weight 
controls compared to 30% in obese subjects. A factor contributing to enhanced 
gluconeogenesis in obesity is the greater fractional extraction of gluconeogenic 
precursors. In lean subjects, 38% of alanine and 26% of lactate is extracted by the liver, 
whereas, 55% of alanine and 39% of lactate, is extracted in obese subjects (p<0.05). 
When plasma insulin levels are increased 60% by glucose infusion, splanchnic glucose 
output is suppressed by 75% in normal subjects. Under the same conditions, HGP in 
obese subjects is suppressed by only 38% (p<0.05 vs. lean), and significant suppression 
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of glucose output in obese subjects is achieved only by increasing plasma insulin levels 
200% above basal (66). 
Severe obesity is accompanied by several noteworthy morphological and 
physiological changes in hepatocytes (75). Hepatocytes from morbidly obese subjects, 
although morphologically intact, are significantly larger in terms of both volume (µ.1/1()6 
cells) and surface area (µ.m�. Fatty infiltration contributes to a 2-fold increase in 
hepatocyte volume and a doubling of surface area compared to non-obese control 
subjects (p<0.01 for both). Insulin responsiveness is maintained only with maximally 
stimulating concentrations of insulin in hepatocytes isolated from obese subjects. 
Although receptor affinity and number of binding sites in hepatocytes from obese 
subjects are comparable to controls, these effects will be diluted by the excess surface 
area and volume (75). 
Cellular Mechanisms Responsible for Abnormal Hepatic Metabolism in Obesity 
Obesity is associated with impairments in insulin-mediated suppression of hepatic 
glucose output as evidenced by a rightward shift in the dose response curve. The 
maximum response to insulin is maintained in obesity, however the ED50 is increased 
(32). Furthermore, alterations in the kinetics of insulin action on hepatic glucose 
production are also observed in obese persons (31). These changes manifest as slower 
onset of suppression, and premature loss of insulin-mediated suppression (76). 
Because glucose transport across the hepatocyte membrane occurs via the non­
insulin dependent glucose transporter, GLUT2 (62), the first regulated step of hepatic 
glucose metabolism is phosphorylation of glucose to glucose-6-phosphate (G6P) by 
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glucokinase (GK) (11). In the basal state, GK is sequestered within the nucleus in 
association with its regulatory protein (18). Glucose concentrations greater than SmM, 
as encountered in the postprandial state, trigger the dissociation of GK from its nuclear 
regulatory protein and translocation of GK from its intracellular site to the cytoplasm of 
the hepatocyte (18). The movement of GK within the hepatocyte is associated with an 
increase in enzyme activity and concomitant rise in intracellular glucose-6-phosphate 
([G6P]J levels (18). 
In normal subjects, an acute rise in intracellular concentrations of G6P after a 
carbohydrate-containing meal or oral glucose load acts in concert with insulin to 
stimulate glycogen synthase activity, thus promoting glycogen synthesis (19,80). The 
stimulatory effect of G6P on glycogen synthase activity occurs simultaneously with 
inhibition of glycogen phospho.rylase (81,82). These events correspond to the duration 
of the rise in plasma glucose and insulin levels above basal levels. The return of blood 
glucose levels to basal levels, removes the constraint placed on glycogen phosphorylase 
activity by the meal-associated increase in intracellular G6P levels, and therefore, 
promotes glycogen breakdown (42). The ability of the liver to alternate between 
glycogen synthesis and degradation represents an important physiological mechanism by 
which glucose can be stored or oxidized depending on the energy needs of the organism. 
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III. Insulin Stimulated Glucose Transport 
Insulin Receptor Structure and Activation by Ligand Binding 
The insulin receptor, a member of the tyrosine kinase receptor family, is composed of 
two extracellular a-subunits and two Ji-subunits linked by disulfide bonds (83,84). The 
extracellular ligand binding domain of the a-subunit is coupled to the tyrosine kinase 
activity of the Ji-subunit by a single transmembrane domain (85-87). Within the a­
subunits, the insulin binding sites are contained in a cysteine-rich region (88,89). The �­
subunits are membrane spanning proteins with an external domain composed of 194 
amino acids, a single 23 amino acid transmembrane domain, and a large intracellular 
domain containing the receptor tyrosine kinase (85-87). 
In the basal state, the a-subunits are unoccupied and the insulin receptor is 
phosphorylated on serine and threonine residues in the �-subunit, which exerts an 
autoinhibitory effect on the receptor kinase activity (90). Binding of insulin to the a­
subunit monomers alters the nature of the interaction between the a-f3 heterodimers, 
relieving the inhibitory constraint and permitting the activation loop of the tyrosine 
kinase domain to contact the other �-subunit (91-93) . This initiates trans-
autophosphorylation by which the tyrosine kinase activity of one Ji-subunit 
phosphorylates specific tyrosine residues on the other f3-subunit (93,94). 
Following stimulation and activation of the insulin receptor, the insulin:insulin 
receptor complex undergoes rapid internalization into endosomal structures (95,96). 
Receptor internalization is a multi-step process initiated by insulin-induced 
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autophosphorylation of specific residues (Tyr1146, Tyr1 150, and Tyr
1 151
) of the �-subunit 
(95). Subsequently, the insulin-receptor complexes are redistributed from cell membrane 
microvilli, where the receptor preferentially localizes in the basal state, along the cell 
surface (97) and internalized into clatherin-coated pits for uptake into intracellular 
endosomal structures (98). 
Signaling Events Following Insulin Receptor Activadon 
Several clusters of autophosphorylation sites have been identified in the 13-subunit of 
the insulin receptor and are critical to normal insulin signaling (99-101). In particular, 
Cys
8BJ in the extracellular domain of the insulin receptor �-subunit appears to be critical 
for the biological actions of insulin (100). Mutation of this residue to serine (C860S) 
does not alter normal autophosphorylation of the receptor itself (101). However, 
insulin-mediated phosphorylation of its major downstream substrate, IRS-1 ,  is severely 
impaired in cells expressing the C860S mutation and internalization of the activated 
receptor is prevented. Consequently, there is a major reduction in the metabolic actions 
of insulin in these cells, which supports the importance of this domain in propagation of 
the insulin signaling cascade (100,101). 
The juxtamembrane domain is critical for the interaction of the insulin receptor with 
IRS-1 (102). Within the juxtamembrane domain, phosphorylation ofTyr
960
, which lies 
just inside the cell membrane, creates a recognition motif for the phosphotyrosine 
binding (PTB) domain of the IRS proteins (103). While mutation of this residue 
interferes with the phosphorylation of endogenous substrates, including IRS-1,  and thus, 
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impedes propagation of the insulin signal, autophosphorylation of the receptor itself is 
unaffected (103,104). 
The C-terminal region of the �-subunit contains several amino acid clusters, which 
either propagate or restrain the insulin signal (105,106). Phosphorylation of three 
cifi "d (f 1 146 T 11SO T 1151) "thin th kin gula d . . spe c res1 ues yr , yr , yr wt e ase re tory omam mcreases 
the activity of the receptor kinase towards intracellular substrates (107,108). Also in this 
region are specific residues (fyr131 6, Tyr1�, which serve to restrain the level of kinase 
activation achieved upon phosphorylation ofTyr1146, Tyr1 150, and Tyr1 151 within the kinase 
activation loop (106,109,1 10) .  Point mutations or truncations of the �-subunit which 
delete these residues increase both the autophosphorylation capacity and the activity of 
the �-subunit tyrosine kinase towards intracellular substrates and consequently, leads to 
excessive activation of the insulin signal (1 1 1 ,112). In addition, specific serine and 
threonine (Ser129\ Ser1294 and Thr1331 in the c-terminal region are phosphorylated in the 
basal state and appear to prevent unnecessary commencement of the signaling cascade in 
the absence of insulin (1 13). 
The major substrate for the activated insulin receptor is IRS-1 (1 14-116). Tyr960 is 
one of the first residues phosphorylated in the insulin receptor following ligand binding 
and is essential for coupling the insulin receptor to IRS-1 (103,114). Two domains 
within IRS-1 interact with the phosphorylated insulin receptor, primarily through the 
region encompassing Tyr%0 (1 17-1 19) .  The amino terminal region of IRS-1 contains a 
pleckstrin homology (PH) domain and an adjacent phosphotyrosine binding (PTB) 
domain, both of which are necessary for interaction with the insulin receptor under 
physiological conditions (1 18-120). The PH domain provides the most sensitive 
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interaction for coupling the insulin receptor with IRS-1, while the PTB domain 
contributes an additional site of interaction, thereby increasing the sensitivity of the 
association between the receptor and IRS-1 (121). The cooperative nature of these 
domains may provide a means by which the cell adjusts the rigidity of the interaction 
with the insulin receptor and thus, regulates amplification of the insulin signal. 
At the molecular level there is evidence for induction of insulin resistance by 
enhanced serine (ser)/threonine (thr) phosphorylation of IRS-1 ,  which impedes its 
interaction with the juxtamembrane region of the insulin receptor and consequently, 
makes IRS-1 a poor substrate for insulin-mediated tyrosine phosphorylation (122,123). 
Consequently, IRS-1 is unable to recruit downstream effector molecules of the insulin 
signaling cascade leading to loss of the biological actions of insulin. 





987) of IRS-1 are phosphorylated in 
response to activation of insulin receptor kinase activity (124). These residues are found 
in the C-terminal region of IRS-1 and, upon phosphorylation, serve as docking sites for 
src homology 2 (SH2) domain of phosphotidylinositol-3-kinase (PI3-K) (125). PI3-K is 
a heterodimeric, dual function lipid kinase composed of a regulatory subunit (p85) and a 
catalytic subunit (pl 10) (126). The p85 subunit serves as an adaptor protein by virtue of 
its tandem SH2 domains, which must interact simultaneously with specific residues in 
IRS-1 and the p1 10 subunit to achieve direct coupling and full activation of the catalytic 
activity (124-127). 
Activation of PI3-K activity occurs by one of two mechanisms (128,129). First, the 
interaction of the SH2 domains of the p85 subunit with specific phosphotyrosine 
residues on IRS-1 may increase the existing catalytic activity PI3-K (130,131). 
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Alternatively, PI3-K may be recruited to its natural substrates in close proximity to the 
plasma membrane (132). The major in vivo catalytic action of PI3-K is phosphorylation 
of the D-3 position of the inositol ring of phosphatidyl-inositol(4,S)bis phosphate to 
yield phosphatidyl-inositol-(3,4,5)-phosphate (PIP3) (133). The lipid by-products 
generated via PI3-K are essential for the major metabolic actions of insulin, including 
glucose uptake (134). 
Glucose Transport Proteins and Cellular Glut4 Traliicking 
The hydrophobic nature of the cell membrane lipid bilayer is impermeable to glucose 
and thus, a transport system is necessary for glucose uptake by cells. To date, five 
homologous transmembrane proteins (GLlIT-1, -2, -3, -4, and -5) have been identified, 
which transport glucose by facilitated diffusion down concentration gradients (135). 
GLUT-1 is a constitutively active glucose transporter with a broad expression pattern. 
Expression of GLUT-1 is highest in the brain, erythrocytes, and endothelial cells and 
glucose transport via GLUT-1 is independent of insulin stimulation (62). The low 
affinity (high K,J glucose transporter, GLUT -2, is responsible for glucose sensing and 
uptake in the kidney, small intestine epithelial cells, liver, and pancreatic J3-cells. GLUT-
3 expression is limited to neurons and the placenta, where it facilitates glucose transport 
across the blood brain barrier. Fructose transport is accomplished by GLUT-5, which 
has very low affinity for glucose. GLlIT-5 is expressed in the small intestine, kidney, 
brain, adipose tissue, and skeletal muscle (136). 
GLUT-4 is the primary insulin-responsive glucose transporter and is 
predominantly expressed in skeletal muscle and adipose tissue (137- 139). Unlike the 
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other facilitative glucose transporters, 90% of GLUf-4 protein is sequestered in 
intracellular compartments in the basal state (140,141). As postprandial blood glucose 
levels rise, the resulting increase in circulating insulin levels activates signaling cascades 
which ultimately result in the ttanslocation of GLUT-4 storage vesicles to the plasma 
membrane (142,143). lrnportantly, this process is readily reversed as insulin levels fall 
In the absence of insulin, GLUf-4 is slowly recycled from intracellular storage 
vesicles to the plasma membrane and T-tubules .in skeletal muscle (139,141,142). To 
date, three such compartments have been identified. The majority of GLUf-4 protein 
(-60%) is found in the tubulo-vesicular elements beneath the plasma membrane 
(144,145). The remaining protein is localized to the trans-Golgi network, clathrin-coated 
vesicles, and endosomal structures (141,142). 
Insulin-stimulated trafficking of GLUT-4-contain.ing vesicles depends on complex 
intracellular mach.inery. Evidence suggests there is a distinct subpopulation of GLUT-4 
containing vesicles which is responsible for the majority of insulin-stimulated glucose 
translocation (142,146,147). These vesicles are enriched in soluble N-ethylmaleimide­
sensitive factor attachment protein receptor (v-SNARE) designated vesicle-associated 
membrane protein (V AMP2) (148,149). At the plasma membrane, docking sites for 
V AMP2 are created by the SNARE proteins syntaxin-4 (Syn4) and syntaxin-associated 
protein-23 (SNAP23) (149,150). 
A protein identified as Synip has been found to associate with Syn4 in the basal state 
in adipose tissue and skeletal muscle (151). The interaction of Synip and Syn4 is mutually 
exclusive of V AMP2 and thus precludes the interaction of the V AMP2-enriched vesicles 
with the t-SNARE complex, effectively preventing fusion of Glut4-containing vesicles 
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with the plasma membrane (151,1 52). Insulin stimulation prompts the dissociation of 
Synip, facilitating the V AMP2-Syn4 interaction necessary for GLUT4 vesicle fusion and 
presentation of GLUT4 proteins on the membrane surface (152,153). 
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IV. Adipose Tissue Metabolism and Alterations in the Metabolic Syndrome 
Major Functions of Adipose Tissue 
The primary function of adipose tissue in humans is regulation of energy balance by 
coordinating the storage of triglycerides during times of energy excess and release of free 
fatty acids (FF A) and glycerol for use as fuel substrates by other tissues during times of 
energy deprivation. Adipocytes store lipid, primarily as triacylglycerol (TAG), within 
large lipid droplets. Lipolysis of these lipid stores yields non-esterified fatty acids 
(NEFAs) and glycerol Once believed to be metabolically inactive, adipose tissue is now 
recognized as a tissue with endocrine, neurocrine and paracrine actions by virtue of its 
many secretory products and expression of various receptors. 
Adipose tissue accumulation is governed by the balance between triacylglycerol 
synthesis (lipogenesis) and breakdown (lipolysis). As its name suggests, hormone­
sensitive lipase (HSL), the chief regulator of lipolysis, responds to various hormonal 
stimuli, including those signals arising from nutritional and dietary factors. Opposing the 
action of HSL are several lipogenic enzymes including lipoprotein lipase (LPL), the 
primary enzyme goveming lipid deposition, and fatty acid synthase (FAS), a key enzyme 
of de novo lipogenesis. 
Honnone-Sensitive Lipase 
Insulin and catecholamines are the only hormones which have significant acute 
effects on human adipose tissue lipolysis (154,1 55) . Lipid mobilization and release of 
free fatty acids are mediated by adipocyte adrenoceptors, which regulate lipolysis via 
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control ofhonnone sensitive lipase (AT-HSL) (156). Unlike adipocytes from other 
mammalian species, catecholamines have acute stimulatory and inhibitory effects on 
lipolysis in humans, which are mediated by f3- and <Xi-adrenergic receptors (156,157). 
Catecholamines, such as norepinepherine, .initiate the lipolytic cascade by binding to 
plasma membrane '31- and (}2-adrenergic receptors (ARs), which are positively coupled to 
adenylate cyclase via the stimulatory G, protein (158). The activation of adenylate cyclase 
results in elevations in intracellular cAMP ([cAMPL) levels. Once formed, cAMP 
interacts with the regulatory subunits of protein kinase A (PKA) resulting in the release 
of the catalytic subunits, and the subsequent phosphorylation and thus, activation of AT­
HSL (156). Following its activation, AT-HSL translocates from the cytosol to the 
surface of the lipid droplet (159). In vivo, AT-HSL catalyzes the rate-limiting step in 
hydrolysis of stored triacylglycerols to diacy]glycerol The net result of increased AT­
HSL activity is an increase in the release of NEFAs and glycerol from adipocytes (160). 
Binding of catecholamines to the adipocyte a2-AR, which is negatively coupled to 
adenylate cyclase via the inhibitory G; protein, counters the stimulatory effects of P-AR 
activation (1 56,157). 
Hyperglycemia and hyperinsulinemia are common findings in obesity and NIDDM. 
These conditions are also associated with elevated rates of lipolysis (161,162) . In vitro, 
neither glucose nor insulin significantly increase isoproterenol-stimulated lipolysis. 
However, the combination of glucose and insulin significantly increases both basal and 
stimulated lipolysis, possibly linking obesity-associated hyperinsulinemia to elevated rates 
of lipolysis (163). 
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Reynisdottir, et al (163) suggest that catecholamine resistance in subjects with the 
metabolic syndrome is entirely attributable to defects in the '32-AR system. In studies of 
abdominal adipocytes isolated from subjects with clinical features of the metabolic 
syndrome (BMI>26 kg/m2, WHR >0.93, insulin resistance, impaired glucose tolerance), 
significant correlations were observed between glucose intolerance and basal lipolytic 
rate, maximum stimulated lipolysis, and J32-AR density. Furthermore, insulin sensitivity, 
as determined by euglycemic-hyperinsulinemic clamp, was found to be strongly 
associated with '32-AR number, fat cell volume, WHR, fasting insulin levels, and glucose 
tolerance. A marked reduction in the maximum lipolytic rate in response to the '32-AR 
selective agonist, terbutaline, was observed in insulin-resistant subjects compared to 
healthy subjects (p<0.001), and was associated with an approximate 50% reduction in �2-
AR density in subjects with metabolic syndrome. Regardless of the stimulatory agent 
used, lipolytic rates were significantly increased over basal level in all subjects, yet these 
responses were blunted by 44-75% in adipocytes from subjects with the metabolic 
syndrome (p<0.01). 
Lipoprotein Lipase 
Lipoprotein lipase is expressed predominantly in skeletal muscle and adipose tissue 
and is regulated in a tissue-specific manner (164-166). Lipoprotein lipase is the rate­
limiting step for triglyceride catabolism by peripheral tissues. The activity of AT-LPL is 
critical for hydrolysis and exchange of lipoprotein-associated triglycerides among 
exttahepatic tissues and circulating lipoproteins, which provide the substrates for an 
expanding adipose tissue mass (165). Greater than 95% of the body's triglycerides are 
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stored in adipose tissue, having been derived from both dietary and endogenous 
triglycerides (160). 
While triglycerides are a very dense source of fuei they, unlike glucose, are insoluble 
in plasma and must be transported associated with lipoproteins. In addition, triglyceride­
rich lipoproteins are too large to cross the capillary endothelium of most tissues; 
consequently, they must be modified in a way that permits their uptake by peripheral 
tissues. 1bis is accomplished through the actions of AT-LPL, which following synthesis 
within parenchymal cells of adipose tissue migrates to the interstitial space and ultimately 
resides on the luminal side of the capillary endothelium of most tissues (165). 
Triglyceride-rich lipoproteins passing through the capillary endothelium are subject to 
hydrolysis by AT-LPL, resulting in the release of glycerol and free fatty acids which can 
be taken up by parenchymal cells of adipose tissue (160). 
The fate of absorbed fatty acids is largely determined by the activity of AT-LPL 
relative to the expression and activity of LPL in peripheral tissues, particularly skeletal 
and cardiac muscle, and is ultimately determined by nutritional and hormonal influences 
(161,164,166). Animal studies have demonstrated that the activity of AT-LPL is 
sensitive to energy and hormonal balance, particularly the availability of glucose and 
insulin (166,167). Insulin upregulates AT-LPL in concert with acylation-stimulating 
protein (ASIP), which is produced locally by adipocytes in response to circulating 
chylomicrons (168). The coordinated actions of insulin and ASIP ensure that the rate of 
triglyceride synthesis in adipocytes is sufficiently rapid so that circulating fatty acid 
concentrations do not exceed a threshold level at which rapid clearance of circulating 
triglycerides would be initiated (167,168).  
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Adipose tissue LPL is increased in genetic and diet-induced obesity, while its activity 
is decreased in insulin-resistant states, including NIDDM (161,166,169). Furthermore, 
the degree to which AT-LPL expression is stimulated in response to weight gain suggests 
that the enzyme acts to preserve the expanded fat mass (170). This is consistent with 
heightened activity of the enzyme in the postprandial state, during which time fatty acids 
are directed to adipose tissue for storage and re-esterification (167,168). The post­
prandial increase in AT-LPL activity is the result of post-transcriptional regulation 
(171,1 72). Opposing the actions of AT-LPL is the skeletal muscle isoform (SM-LPL), 
the activity of which is one-eighth that of the adipose tissue isoform (1 64). 
Availability of fuel substrates, specifically fatty acids and carbohydrates, influence the 
activity and expression of lipogenic enzymes (173,174). An inverse relationship exists 
between fatty acids and carbohydrates, such that an increase in the provision of fatty 
acids ensures inhibition of glucose utilization (56,167,175). A significant negative 
correlation exists between AT-LPL m.RNA and steady state glucose levels (p<0.001). 
The activity of plasma LPL is weakly correlated with plasma insulin levels (p<0.06), 
suggesting that further reductions in LPL activity can be anticipated as insulin resistance 
worsens (167). 
Steady state AT-LPL m.RNA levels have been found to be significantly lower in 
insulin-resistant compared to insulin-sensitive (p<0.001) subjects. The degree to which 
peripheral tissues are re&actory to insulin is also negatively correlated with both plasma 
LPL activity (p<0.03) and AT-LPL m.RNA (p<0.001). However, insulin resistance does 
not adversely influence the activity of AT-LPL. When steady state plasma glucose levels 
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are used as an indicator of insulin resistance, there is a significant inverse relationship 
between plasma glucose levels and AT-LPL mRNA (p<0.001) (167). 
Fatty Add Synthase 
Fatty acids in adipocytes can be derived from circulating lipoproteins via the action of 
lipoprotein lipase or they can be synthesized de novo from carbohydrate-derived 
precursors. Excess glucose promotes lipogenesis by increasing glycolytic flux and 
consequently, increasing the availability of acetyl CoA. Acetyl CoA is the chief substrate 
for the synthesis of long-chain saturated fatty acids which can be subsequently esterified 
and stored as triacy)glycerols in adipose tissue . Fatty acid synthase (FAS) catalyzes all 
reactions involved in the synthesis of long-chain saturated fatty acids (palmitate) from 
acetyl CoA, malonyl CoA and NADPH (176). 
Human FAS is expressed in several tissues (177). Semenkovich, et al. (178) report 
that FAS expression is induced by glucose in a time- and concentration-dependent 
manner, independently of insulin, in HepG2 cells. The level of FAS mRNA increases 
with glucose in the range of 100-4500 mg/L, with much of the increase occurring within 
the physiological range (500-2000 mg/L) for humans with fasting and refeeding and 
maximal effects observed between 1 1-15 hours of exposure to glucose. The effects of 
glucose on FAS activity are pretranslational as evidenced by parallel increases in FAS 
mRNA and activity (178). 
Insulin stimulates FAS expression and activity similarly in lean and obese subjects 
(179). Furthermore, the insulin-induced increase in FAS expression is readily reversed 
upon removal of insulin. Addition of insulin to previously deprived cells increases FAS 
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mRNA content, whereas withdrawal of insulin from insulin-treated cells decreases the 
level of FAS mRNA to levels observed in cells which were never exposed to insulin. 
Thus, adipocytes &om both lean and obese subjects increase FAS expression when 
continuously exposed to insulin (179). 
Normal mice fasted for 48 hours have low circulating insulin levels and low hepatic 
FAS activity, while refeeding a high-carbohydrate, fat-free diet significantly increases 
FAS activity in the liver and adipose tissue, concomitant with increases in circulating 
insulin levels (180). The increase in FAS expression in response to refeeding is less 
vigorous in diabetic animals, suggesting insulin is required for induction of FAS 
expression in vivo (181). 
Antilipolytic Actions of Insulin 
In nonobese, normoglycemic individuals, adipose tissue is exquisitely sensitive to the 
anti-lipolytic effects of insulin. In fact, insulin-mediated suppression of lipid 
mobilization occurs at concentrations of insulin (ED50 = 12-20 pmol/L) much less than 
those required to half-maximally stimulate glucose uptake by skeletal muscle (155,175). 
Insulin-mediated suppression of free fatty acid release is markedly blunted in obese 
subjects as evidenced by a rightward shift in the dose response curve compared to 
normal subjects (1 82). Consequently, plasma free fatty acid levels are often elevated in 
obesity (1 83) . In addition, rates of lipid oxidation are often elevated in obese subjects, 
despite significantly higher plasma insulin levels relative to normal subjects (184). 
While adipose tissue insulin sensitivity is critical to euglycemia, the exquisite 
sensitivity of the intramuscular compartment to insulin-mediated suppression of lipolysis 
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also has important implications in postprandial metabolism (185). In the postabsorptive 
state, free fatty acids (derived from adipose tissue and intramuscular triglycerides) are the 
preferred fuel substrate for resting muscle. During the transition to the postprandial 
state when there is greater glucose availability, the heightened sensitivity of skeletal 
muscle lipolysis to insulin, effectively prevents the continued hydrolysis of intramuscular 
triglycerides and subsequent release of free fatty acids, which would be expected to 
compete with glucose for oxidation. Thus, the acute sensitivity of skeletal muscle to 
insulin-mediated suppression of lipolysis ensures that the switch from the preferential 
use of free fatty acids to oxidation of glucose by skeletal muscle occurs in the 
postprandial state (185). 
The rapid uptake of glucose by adipose tissue following insulin stimulation is 
dependent on GLUT4. While insulin resistance per se does not negatively impact the 
expression of GLUT4 in skeletal muscle of humans or rodents, adipocyte GLUT4 
expression is reduced up to 50% in obese compared with lean subjects (186, 187). The 
reduction in adipose tissue GLUT4 expression in obesity may represent a physiological 
attempt to limit further expansion of adipose tissue stores. 
Regional Adipose Tissue Deposition 
The significance of regional fat distribution was first alluded to more than 50 years 
ago by Vague (188,1 89), who noted a clustering of metabolic abnormalities including 
NIDDM, atherosclerosis, hypertension, biliary calculus and gout in individuals with 
excessive adiposity in the tnmcal region. It is now clear that the anatomical site of 
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excessive adipose tissue accumulation significantly impacts the risk of developing 
chronic disease (190-194). 
The two general types of fat distribution are android (apple shape), in which fat 
accumulates in the truncal region, and gynoid (pear shape), in which fat is distributed 
around the hips and buttocks (1 91,195). Android obesity is the typical male-pattern 
obesity and is associated with increased risk of cardiovascular disease, cerebrovascular 
disease, non-insulin-dependent diabetes mellitus (NIDDM) and hypertension in obese 
men (196,197). Gynoid obesity appears most often in women, however, accumulation 
of fat in the truncal region in women results in metabolic abnormalities similar to those 
seen in abdominally obese men (196,197). 
Waist circumference (WC) and waist:hip circumference ratio (WHR) are the most 
widely used anthropometric measures for assessing regional adiposity (198). WC is an 
aggregate measure of total and abdominal fat mass and is most sensitive when used with 
overweight adults (BMI=25.1 -29.9) (199). Men and women with WC values less than 94 
cm and 80 cm, respectively, are less likely to develop obesity-related chronic diseases 
than are individuals whose WC values exceed 102 cm (men) and 88 cm (women) (199). 
Several studies have demonstrated increases in fasting insulin and glucose levels with 
increasing waist girth. Analysis of data from the Nurse's Health Study (197) has revealed 
WC to be more strongly correlated with weight (r=0.82) and BMI (r=0.81) than WHR 
(r=0.31 and 0.34, respectively). In addition, information gleaned from the Nurse's 
Health Study and others, indicate WC may be a more sensitive predictor of chronic 
disease than WHR (197-201). The relative risk for developing cardiovascular disease in 
women with a waist girth of 96.5 cm or greater is 3.24 compared to women whose WC is 
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71.1 cm or less. Furthermore, the Nurse's Health Study determined that for every 2.54 
cm (1 inch) increase above 71 . 1  cm. relative risk for coronary heart disease is increased 
1.07 fold (197). 
WHR or waist circumference alone has been consistently correlated with intra­
abdominal fat as assessed by computerized tomography (CI) or magnetic resonance 
imaging (MRI) (198,200). The clinical usefulness of the waist-to-hip ratio in predicting 
cardiovascular events in men and women has been established. Megnien, et al. (202) 
found WHR to be significantly positively associated with systolic blood pressure (p < 
0.05), total-to-HDL-cholesterol ratio (p < 0.01 for men and p<0.001 for women), 
fibrinogen (p < 0.001 for men and p<0.02 for women), and diabetes (p<O.(XH for men 
and 0<0.01 for women). Furthermore, WHR was strongly associated with estimated 10-
year mortality and morbidity from cardiovascular events. The estimated percentage of 
coronary heart disease (p < 0.001) and death (p<0.01), myocardial infarction (p<0.01), 
stroke (p<0.01) and total cardiovascular disease (p<0.001) and death (p<0.01) increased 
in parallel with WHR in both men and women (202). 
Site DifTerences in Adipose Tissue Metabolism and Insulin Sensitivity 
The preferential deposition of adipose tissue in one anatomical region over another is 
related to the balance between triglyceride uptake and fatty acid release. There have 
been numerous reports of depot-related differences in adipose tissue metabolism (191-
200). Compared to subcutaneous adipocytes isolated from the gluteal-femoral region, 
visceral abdominal adipocytes exhibit higher rates of basal lipolysis, extensive 
sympathetic innervation, acute sensitivity to the stimulatory actions of catecholamines, 
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yet remains relatively resistant to the antilipolytic actions of insulin (1 82,203). Visceral 
adipose tissue deposits are also responsible for the bulk of free fatty acids released into 
circulation and the proximity of this depot to the liver may be an important factor in the 
pathology associated with central obesity. In fact, visceral adipose tissue drains directly 
to the liver via the portal venous system (1 91). Thus, the liver will be fully exposed to 
the range of fatty acids and cytokines released from the abdominal adipose tissue depot 
(75). Increased substrate flux from the liver, particularly free fatty acids, may induce 
adipocyte hypertrophy, which perpetuates insulin resistance (204-206). Enlarged, insulin 
resistant abdominal adipocytes are slow to respond to the effects of insulin and may 
demonstrate reduced rates of esterification of dietary-derived fatty acids, contributing to 
post-prandial hypertriglyceridemia (207-210). Consequently, circulating free fatty acid 
levels would remain elevated at the most metabolically inopportune time: when glucose 
and insulin levels are elevated and fatty acid oxidation by peripheral tissues is suppressed. 
The metabolic profile of subcutaneous adipocytes is much different (21 1 ,212). 
Subcutaneous adipocytes derived from the gluteal depot exhibit low rates of basal 
lipolysis, are acutely sensitive to the anti-lipolytic actions of insulin and demonstrate 
reduced responsiveness to catecholamine stimulation (213-21 5). In addition there is 
significant expression of the inhibitory �-AR in adipocytes from this depot (21 5). Thus, 
adrenergic receptor profile of subcutaneous adipocytes makes them both antilipolytic 
and relatively resistant to pro-lipolytic catecholamines. 
Hormonal responsiveness is significantly impaired in enlarged adipocytes (208). 
Although basal and catecholamine-induced lipolysis are positively correlated with cell 
size, the antilipolytic effects of insulin are more pronounced in smaller adipocytes. In 
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addition, the capacity to increase glucose conversion to carbon dioxide and triglycerides 
in response to insulin stimulation is significantly blunted in enlarged adipocytes 
(205,206,208). Weight loss as a consequence of dietary intervention or surgical treatment 
is associated with a decrease in adipocyte size as well as reversal of impaired insulin 
responsiveness (204). Improved insulin sensitivity has also been demonstrated in 
animals by surgical removal of visceral fat. Removal of visceral fat reduced plasma 
insulin levels, enhance hepatic insulin sensitivity, and improved insulin-stimulated 
glucose utilization relative to animals in whom visceral fat remained intact. Animals 
retaining visceral fat were less sensitive to the suppressive actions of insulin on hepatic 
glucose output, which supports a causative role for visceral fat in manifestation of at 
least some aspects of the insulin resistance syndrome (216) .  
Contribution of De Novo Lipogenesis in Adipose Tissue 
The contribution of de novo lipogenesis in human adipose tissue is the subject of 
much debate. Recent evidence suggests de novo lipogenesis in adipose tissue significantly 
contributes to increased adiposity in humans (217,218). Body weight gain of nonnal 
subjects overfed with carbohydrate is not explained by the increase in liver lipogenesis 
alone (217). Lean, obese and obese, weight-reduced subjects have been studied to assess 
changes in lipogenic capacity of liver and adipose tissue which may contribute to obesity. 
Compared with control subjects, obese subjects had higher plasma glucose (p<0.01), 
cholesterol (p<0.05), triglycerides (p<0.05), insulin (p<0.01) and leptin (p<0.05) levels. 
In the obese subjects studied after weight loss induced by a hypocaloric diet, plasma 
triglycerides, cholesterol, insulin and leptin all decreased (p<0.05 for all) compared with 
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the values observed prior to weight reduction (21 7). The contribution of hepatic 
lipogenesis to total de novo lipid synthesis was enhanced in obese compared to lean 
(p<0.01) subjects. The reduction in energy intake induced by the hypocaloric diet, 
reduced hepatic lipogenesis (p<0.05) to values comparable to lean subjects (218). 
The Ob Gene Product, Leptin 
The ob gene product, leptin, is 167 amino acid protein produced and secreted 
predominately by adipose tissue which plays an important role in regulation of energy 
intake, body weight, and adiposity (219-221). Serum leptin levels strongly correlate with 
adiposity (r=0.85, p<0.001), BMI (r=0.69, p<0.05), and fasting insulin levels (r=0.57, 
p<0.0001) in both men and women, although women generally have higher circulating 
leptin levels than men (222) In the fed state, leptin is secreted in proportion to adipose 
tissue triglyceride stores and circulates as free leptin or associated with a soluble form of 
the leptin receptor (222-224). 
Ltptin Deficient ob/ ob Mice 
A mutation in the ob gene results in the leptin-deficient ob/ ob mouse, whose 
phenotype is characterized by early onset obesity, hyperphagia, reduced energy 
expenditure, and severe insulin resistance (221,225). ob/ ob mice with complete leptin 
deficiency fail to undergo sexual maturation and demonstrate structural neuronal 
abnoanalities and impaired myelination in the brain (226-228). Leptin treatment can 
accelerate puberty in nonnal prepubescent mice and leptin levels are known to increase 
before puberty in humans (229,230). Despite stable plasma insulin levels in newborn 
56 
mice, plasma leptin levels increase 5-10-fold (p<0.05) within 10 days in C57BL/6J mice 
prior to decreasing to adult levels (231,232). The rise in circulating leptin levels coincide 
with a 6-10-fold increase in ob mRNA in white adipose tissue (232). 1bis surge in leptin 
secretion and expression occurs by a mechanism independent of body fat stores, which 
are stable during the neonatal period during which the increase in leptin levels is 
observed (232). 
In neonatal mice, 12-hours of food deprivation has no effect on plasma leptin levels 
(231,232). In contrast, leptin decreases by 40% in adult mice deprived of food for 12-
hours (233). In normal adult mice housed under 12-hour light and dark cycles and fed 
ad libitum, maximum food intake occurs during the dark cycle, and plasma leptin levels 
exhibit pulsatile, circadian rhythm (233,234) . Plasma leptin levels follow the same 
diurnal pattem in humans, falling to their lowest levels humans just prior to rising (235) . 
The circadian rhythm is absent in obese Zucker (Jal fa) rats (236). 
Administration of recombinant leptin to ob/ ob mice results in significant weight loss 
by suppression of food intake and increased energy expenditure as well as normalizing 
blood glucose and insulin levels (237-240). The rise in energy expenditure is a result of 
both increased physical activity and thermogenesis, primarily involving brown adipose 
tissue (237,238,241). The improvements in glycemia and insulin sensitivity in leptin­
treated ob/ ob mice were initially believed attributable to reduced adiposity. However, in 
pair-feeding studies, leptin infusion resulted in more pronounced reductions in adiposity 
and plasma insulin levels than was produced by equivalent caloric restriction in pair-fed 
animals, suggesting leptin influences both central and peripheral tissues (242). 
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Leptin Resistant db/ db Mice 
Leptin relays peripherally-derived information regarding fat reserves to the central 
nervous system by binding a specific receptor (OB-R) encoded by the db gene in the 
choroids plexus of the brain (243). Alternative splicing of the db gene results in 
truncation of the carboxy terminal cytoplasmic domains (244). Ob-Ra, a shorter isoform 
of OB-R, is expressed in the microvasculature constituting the blood brain barrier and is 
the vehicle by which peripherally secreted leptin gains access to target neurons in the 
hypothalamus (245). The long isoform, OB-Rb, mediates the actions ofleptin in the 
hypothalamus (246) . Mutation of the db gene results in the db/ db mouse, which lacks a 
functional leptin receptor (244,245). The phenotype of the db/ db mouse is characterized 
by early-onset obesity, fasting hyperglycemia, and hyperinsulinemia (225). In addition, 
despite overexpression of the ob gene in adipose tissue, db/ db mice are unable to respond 
to circulating leptin (247). 
Leptin Lt11els in Normal We�ht and Obese H11man.s 
Considine, et al. (222) found that serum leptin levels in obese subjects were more than 
4-fold higher than those of their age-matched lean (p<0.001) counterparts. Leptin levels 
increase in a linear fashion with increasing adiposity, such that an obese subject with a 
serum leptin level of 30 ng/ml will have approximately three-fold more fat mass than a 
lean subject with a serum leptin level of 10 ng/ml (222). Serum leptin levels strongly 
correlate with adiposity (r=0.85, p<0.001), BMI (r=0.69, p<0.05) and fasting insulin 
levels (r=0.57, p<0.0001) (248,249). However, the demonstration that serum leptin 
levels are elevated in obesity appear to conflict with studies documenting a reduction in 
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food intake in ob/ ob mice given exogenous leptin (240). Thus, it seems likely that 
obesity, in addition to being an insulin resistant state, is also characterized by leptin 
resistance. 
The relationships between circulating leptin levels and adiposity have been examined 
in normal weight and overweight/ obese subjects by Havel, et al. (249). Although plasma 
insulin levels were increased two-fold in overweight/obese compared to lean (p<0.01) 
subjects, and similar increases (p<0.01) in plasma leptin levels are observed .in obese 
subjects. In nonnal weight and obese subjects, there is a significant correlation between 
fasting plasma insulin and leptin levels (r=0.61, p<0.0001). Consistent with the notion 
that circulating leptin levels are reflective of total body fat reserves, plasma leptin was 
highly correlated with BMI (r=0.81, p<0.0001) in all subjects, and this relationship was 
persisted when normal weight (r=0.58, p<0.001) and overweight/obese (r=0.59, 
p<0.001) were considered separately. Percent body fat was similarly correlated with 
plasma leptin levels overall (r=0.80, p<0.0001), in nonnal weight (r=0.64, p<0.005) and 
overweight/obese (r=0.69, p<0.002) subjects (249) . 
A strong positive association has also been observed between cerebrospinal fluid 
(CSF) leptin levels and BMI (r=0.40, p<0.05). Despite serum leptin levels that were 
more than 3-fold higher in obesity, CSF leptin is only marginally higher (by 30%, 
p>0.05) in obese than in lean subjects. Consequently, the CSF/serum leptin ratio was 
4.3-fold higher in lean compared to obese (p<0.05) subjects and was inversely associated 
with BMI in all subjects (r=-0.58, p<0.05). The finding of significantly higher 
CSF / serum leptin ratio in lean versus obese individuals suggests that leptin enters the 
brain by a saturable transport mechanism and that this may be the rate-limiting step in 
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leptin action. Obese subjects are often hyperleptinemic, yet fail to reduce their energy 
intake accordingly. The four-fold higher CSF/serum leptin ratio may partially account 
for this effect (250). In this study, an increase in leptin levels above 25 ng/ml as 
observed in obese subjects fails to compensate for leptin resistance. Furthermore, 
Schwartz, et al (248) have demonstrated that the efficiency of leptin uptake, as measured 
by the CSF / serum leptin ratio, is significantly lower in obese compared to lean subjects. 
Leptin binding sites have been identified in many regions of the brain including the 
choroid plexus, which is responsible for secretion of cerebrospinal fluid (251). Banks, et 
al. (252) have shown that the transport rate of leptin across the blood brain barrier is 
impaired in obese mice, which may be due to an inability to upregulate the leptin 
transporter in the face of increasing serum lept:in levels. Subsequently, Banks, et al. (253) 
demonstrated that the leptin transport system is partially saturated at physiological leptin 
levels (-10 ng/ ml). 
Leptin circulates in serum as free hormone and bound to several proteins, including 
the soluble leptin receptor isofonn. The soluble leptin receptor is the shortest isofonn 
and lacks the hydrophobic ttansmembrane domain. Levels of free leptin selectively 
reflect body fat mass while bound leptin serves as a marker of resting energy expenditure 
(254). In both lean and obese women, free leptin levels are closely correlated with 
percent body fat (r=0.73, p<0.0001) (254). 
Regulation of uptin Synthesis and Semtion and 111j/Nena oflns11/in 
The pattern of obese gene expression has been examined in human adipose tissue. A 
single ob mRNA species 4.5 kb in size is abundantly expressed in adipose tissue from the 
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subcutaneous, omental, rettoperitoneal, perilymphatic, and mesenteric fat pads. There 
are significant variations in lepti.n expression between depots in the same individual. The 
highest level of ob expression was detected in the subcutaneous adipose tissue depot. No 
significant amount of ob mRNA has been observed in brain, heart, lung, liver, stomach, 
pancreas, small intestine or skeletal muscle. Furthennore, the lack of an appreciable 
amount of ob mRNA in preaclipocytes suggests that ob gene expression is induced during 
the process of adipocytes differentiation and maturation (255). 
Williams, et al. (256) examined the level of ob mRNA and the response to weight loss. 
Serum lepti.n levels were shown to be four-fold higher in obese compared with lean 
subjects. However, the ob mRNA content of abdominal subcutaneous adipocytes is only 
two-fold higher in obese compared to lean (p=0.005) subjects, suggesting that adipocyte 
hypertrophy contributes to higher lepti.n levels in obesity. To determine if lepti.n 
expression is responsive to changes in body weight, obese subjects were placed on a 
hypocaloric diet for a period of 8 - 12 weeks, which led to a 10% reduction in body 
weight and lowered plasma insulin and leptin levels by 25 and 53%, respectively. Serum 
lepti.n levels were reduced as a result of a 38% reduction in ob mRNA content of 
abdominal subcutaneous adipocytes. Following a four-week period of weight 
maintenance, serwn leptin levels and ob mRNA levels rose slightly but remained 
significantly lower than those observed prior to weight reduction. Thus, an increase in 
adipose tissue mass results in an increase in serum leptin levels at the level of ob gene 
transcription. 
Lepti.n expression and secretion vary by adipose tissue depot. The levels of mRNA 
and leptin secreted into culture media are about two-fold higher in subcutaneous 
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compared to omental adipocytes. Consequently, leptin content is roughly 1 .5-fold higher 
in subcutaneous compared to omental adipose tissue (p<0.005). To determine whether 
leptin secretion or content of adipose tissue is dependent on the synthesis of new 
protein, tissue samples were incubated for 3 hours in the presence of 10 µg/ml 
cycloheximide. Compared to control samples, cycloheximide treatment significantly 
decreased leptin content by 46% and 36% in the omental and subcut.aneous adipose 
tissue samples, respectively (p<0.01 for both) without affecting the rate of leptin 
secretion. In the presence of cyclohexamide, leptin secretion is maintained at 80% of 
untreated levels for the first three hours, but subsequently falls to levels -28% of control 
by the fifth hour. This suggests that adipose tissue secretes preformed leptin for 
approximately three hours, after which time new protein synthesis is required to 
continually secrete leptin (257). 
To investigate the mechanisms underlying increased circulating leptin levels in 
obesity, Lonnqvist, et al (258) measured secretion rates in vitro and mRNA levels of 
leptin in subcutaneous adipose tissue biopsies from lean and obese women. Plasma 
leptin levels were elevated five-fold in obese compared to lean women (p<0.05). Rates 
of leptin secretion were two- to seven-fold more rapid in obese compared to non-obese 
women, when expressed per lipid weight (p<0.05) or per cell number (p<0.05). Obese 
subjects had .larger adipocytes which contained significantly more lipid compared to 
adipocytes from control cells, implying that leptin secretion is enhanced in cells with 
greater lipid volume. Leptin mRNA was elevated two-fold in the obese group (p<0.05). 
Strong positive relationships were found between leptin mRNA and leptin secretion, 
when expressed per lipid weight (r=0.66, p<0.001) or per cell nwnber (r=0.60, p<0.001). 
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Furthermore, approximately 60% of the variation in plasma leptin levels was attributable 
to variations in the secretion rate, suggesting this is a critical factor contributing to 
elevated plasma leptin levels in obesity. In support of this, positive correlations were 
noted between leptin secretion rate and BMI (r=0.71-0.76, p<0.001) and fat cell volume 
(r=0.85-0.89, p<0.001). Fat cell volume, which was also positively correlated with leptin 
mRNA, plasma leptin, and leptin secretion (r=0.7-0.9, p<0.001), explained 50-80% of 
the variation in plasma leptin levels. 1bis study demonstrates that leptin secretion is 
subject to regulation by several factors. Chief among these is the steady state leptin 
mRNA level, which presumably controls the production rate of leptin in adipocytes and 
was elevated "'"two-fold in obese women. Leptin mRNA accounted for -40% of the 
variations in circulating and secreted leptin. Chronic hyperinsulinemia may be an 
additional factor, since plasma insulin levels were strongly correlated with the rate of 
leptin secretion, when expressed per gram of lipid weight (r=0.60, p<0.01) or per cell 
number (r=0.67, p<0.001) (258). 
Utriainen, et al. (259) have shown that following a 6-hour period supraphysiological 
hyperinsulinemia, plasma leptin levels were increased by 88% compared increases 
observed following saline infusion for the same duration. During euglycemic, 
hyperinsulinemic clamp studies, plasma leptin levels increased -62% compared with 
saline infusion. Insulin-induced increases in plasma leptin levels are more pronounced in 
women than in men. Plasma leptin levels were significantly correlated with percentage 
of body fat in men (r=0.52, p<0.05) and wotnen (r=0.92, p<0.001) (259). 
Barr, et al. (260) evaluated leptin secretion following incubation of adipose tissue in 
the presence or absence of insulin. Insulin increased the amount of leptin secreted by 
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80% compared with adipocytes incubated in the absence of insulin. Furthermore, 
insulin changed the subcellular localization of leptin within the cell and decreased 
immunochemical staining of cellular leptin deposits, which is consistent with secretion of 
leptin in response to insulin (260). 
The role of leptin in long-tenn regulation of adiposity and energy expenditure has 
been examined in female Fischer 344 rats raised on either a low-fat complex­
carbohydrate (LFCQ or a high-fat sucrose (HFS) diet for 20 months. Leptin levels were 
significantly elevated in the HFS compared with the LFCC group after 2 weeks of dietary 
treatment and continued to rise throughout the remainder of the study. Consequently, 
leptin levels were significantly elevated in HFS animals compared to LFCC animals at all 
points during the study. Adipocyte size gradually increased in HFS-fed animals during 
the feeding period (p<0.01), being greater at all points in time than adipocytes from 
LFCC-fed animals. The difference in adipocyte size between the two groups was not 
significantly different at 2 weeks. However, by 2 months adipocytes from HFS-fed 
animals twice as large (p<0.01) than those from LFCC-fed animals. Adipocyte size 
continued to increase in HFS-fed animals and reached maximum size at 20 months. In 
contrast, adipocyte size remained relatively unchanged in LFCC-fed animals at 6 and 20-
months. In all animals, there was a strong positive correlation between fat cell size and 
plasma leptin levels (r=0.96, p<0.001) (261). 
Boefy Fat DistrilmtilJ11, !11st11in Action and Smm, Ltpti11 LJVtls i11 Humans 
Leptin appears to play a role in the regulation of body fat distribution and insulin 
action in vivo. Sprague-Dawley rats given ad-libitum access to standard rodent diet for 8 
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days were compared to rats with free access to the same diet while receiving continuous 
exogenous insulin infusion. A pair-fed group that did not receive exogenous leptin were 
also included. Administration of exogenous leptin elevated plasma leptin levels and 
reduced food intake by 50% compared with untreated animals fed ad libit11111. During the 
8-day study, body weight increased by 5. 7% in ad libit11m fed animals while it decreased by 
8.1% in the leptin-treated animals and by 9% in pair-fed animals. The decreases in body 
weight observed in leptin-treated and pair-fed animals were attributable to decreased fat 
mass. Pair-fed animals and lcptin-treated animals experienced similar reductions in total 
body fat (by 24%) and visceral fat (by 21 %). However, when visceral adiposity was 
expressed as the sum of omental, epididymal, and pcrinephric fat depots), a marked and 
specific reduction was observed in leptin-treated animals (by 62%, p<0.001 vs. pair-fed). 
Thus, in addition to the well recognized effects of leptin on food intake and total body 
adiposity, leptin appears to specifically target visceral and intraabdominal adiposity, 
suggesting the hormone may contribute to the regulation of body fat distribution. 
Postabsorptive plasma insulin levels were significantly lower in leptin-treated and pair 
fed animals compared to untreated animals fed ad libit11m (p<0.001). During 
physiological hyperinsulinemia, the rate of glucose uptake in leptin treated rats was 52 
and 33% higher than in control (p<0.001) and pair-fed animals (p<0.001), respectively. 
Thus, leptin administration improved peripheral insulin sensitivity to a greater extent 
than can be attributed to weight reduction by moderate caloric restriction alone. The 
observed improvements in the peripheral actions of insulin were partially accounted for 
by a nearly 2-fold increase in the rate of glycogen synthesis in leptin-treated animals 
compared to pair-fed animals (p<0.001). Leptin also enhanced insulin actions in the 
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liver, by enhancing insulin-mediated suppression of hepatic glucose output, resulting in a 
4-fold reduction in total glucose output in leptin-treated animals (p<0.001) compared to 
control and pair-fed animals. Glucose cycling, which represents the flux through 
glucose-6-phosphatase back into circulation, was also reduced in leptin treated animals 
(p<0.001). Complete suppression of hepatic glycogenolysis was observed in leptin­
treated rats, whereas this process was still active in control and pair-fed animals (262). 
Thus, leptin plays important roles in regulation of adiposity and glucose homeostasis by 
several mechanisms which are independent of its effects on food intake. Specifically, 
this study demonstrates that administration of exogenous leptin selectively decreases 
visceral adiposity, augments insulin-stimulated glucose disposal, and enhances insulin­
mediated suppression of hepatic glucose output. 
To examine the relationships between body fat distribution, insulin sensitivity, and 
leptin levels, these variables have been quantified in healthy individuals classified into 
three groups: lean insulin-sensitive (LIS), lean insulin-resistant (LIR), and obese insulin­
resistant (OIR) . Subjects were classified as insulin resistant based on the insulin 
sensitivity index (SJ calculated during a frequently sampled intravenous glucose tolerance 
test (FSIVGTI). Insulin-resistant subjects were relatively hyperinsulinemic as indicated 
by two-fold higher fasting insulin levels in OIR subjects compared with the insulin­
sensitive group (p<0.001), with an intermediate level in the LIR group (p<0.001 vs. both 
OIR and LIS). Insulin resistance appeared related to central fat deposition as suggested 
by higher WHR in both insulin resistant groups compared with lean, insulin sensitive 
subjects. CT scanning revealed greater fat deposition in the abdominal region of insulin­
resistant subjects (p<0.001). Despite having similar BMis, LIR subjects had 45% more 
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abdominal subcutaneous fat and 70% more visceral abdominal fat compared to the LIS 
group (p<0.01). The increases in abdominal fat were even more pronounced in obese 
subjects, who had 2.5 and 3-foW greater amounts of subcutaneous and visceral 
abdominal fat (p<0.01 for both) compared to lean subjects, regardless of insulin 
sensitivity. The increased abdominal fat area in obese subjects was associated with a 
threefold elevation in fasting leptin levels relative to both sets of lean subjects (p<0.001 
for both). Leptin levels were also twice as high in LIR subjects compared with the LIS 
group (p<0.001 ). Insulin sensitivity was inversely correlated with BMI (r=-0.634, 
p<0.001), WHR (r=-0.498, p<0.001), SCAT (r=-0.57, p<0.001) and IAAT (r=-0.688, 
p<0.001). Using multiple regression analysis, the associations between measures of body 
fat distribution and insulin sensitivity were simultaneously analyzed. In all subjects, 
visceral abdominal adipose tissue deposition was the strongest predictor of insulin 
sensitivity. Leptin levels were most strongly correlated with subcutaneous abdominal fat, 
which explained 54-66% of the variance in leptin levels in men and women (263). 
Short-Term Leptin &g11/ation a,rd Association with Insulin Action 
In rodents subjected to a short term fast, plasma leptin levels decrease much more 
than the amount of adipose tissue lost (240,242). Similarly, lean and obese adults fasted 
for 52 to 96 hours lost less than 4% of body weight while leptin levels decreased 54 to 
72%. In non-obese subjects, seven days of energy restriction mimics fasting, as 
evidenced by minimal weight loss (4% of initial body weight) in the face of a 36% 
reduction in serum leptin levels. These findings suggests that serum leptin levels may be 
more dependent on on-going triglyceride synthesis or glucose uptake by adipocytes 
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rather than by adipose tissue mass which was negligibly affected by short fast. Refeeding 
normal subjects after a 3 day fast returns plasma leptin levels to baseline within 12 hours 
indicating leptin is acutely sensitive to changes in energy availability (264). 
Dietary Inj/llenres 011 Serum Leptin Levels 
To investigate the effect of diet on plasma leptin fasting and postprandial leptin 
levels were measured before and after 14 days' ad libitwn intake of a fat rich (FA1), 
starch-rich (STARCH) or sucrose-rich (SUCROSE) diet in normal weight, post-obese 
women and matched controls. Both the STARCH and SUCROSE diets contained 28 
en% fat, 13 en% protein and 59 en% carbohydrate, the difference being in the sucrose 
content which was 2 en% in the STARCH and 23 en% in the SUCROSE diet. The FAT 
diet contained 46 en% fat, 13  en% protein and 41 en% carbohydrate (2 en% sucrose). 
Energy intake over the 14 day ad libitwn feeding period was lowest in the STARCH 
group (p<0.05). In both post-obese and control groups, fasting leptin levels on day 15  
and the change in fasting leptin (day 15 - day 1) were higher after SUCROSE compared 
to other groups (p<0.01). Total AUC were higher after SUCROSE than STARCH, 
although these values were not statistically significant. These findings can not be 
explained by fasting blood glucose levels which did not differ by diet. The increase in 
fasting leptin may therefore be caused by greater initial postprandial glucose excursions 
as would be anticipated in response to the SUCROSE compared to STARCH diet (265) . 
These findings are consistent with studies which suggest that dietary catbohydrate per se 
influences leptin secretion. In a study of non-obese men fed isoenergetic high-fat or 
high-carbohydrate meals, significant differences were observed in leptin levels at eight 
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hours following meal conswnption (266). Coppack, et al (267) suggest a specific effect 
of dietary carbohydrate on leptin levels in vivo. Five hours after consumption of a high 
carbohydrate (70 en%) meal, a significant increase in tissue leptin was observed 
demonstrating a slow yet specific effect of dietary carbohydrate on leptin secretion. 
To determine the effects of dietary fat content independent of changes in body mass 
on plasma leptin levels, nonnal weight and overweight/ obese subjects underwent a four 
month experimental period during which time they consumed a prescribed weight­
maintaining diet of 31 en% fat for four weeks, 23 en% fat for six weeks and 14 en% fat 
for the final six weeks. To examine the effects of sustained weight loss on plasma leptin 
levels, the four month experimental period was followed by a self-selected ad libitum 
very low fat (< 15 en%) diet for 8 months. Plasma leptin levels were more than 2-fold 
higher in overweight/ obese subjects compared to their normal weight counterparts but 
were unaffected by varying the fat content of the diet. At stable body weight, plasma 
leptin levels correlated with fasting plasma insulin levels (r=0.61, p<0.0001). The 
average weight loss after 8 months of the self-selected diet was approximately 7%. 
Plasma leptin levels were decreased in both normal weight women and 
overweight/ obese women who sustained weight loss of greater than 7% by consumption 
of a self-selected, low-fat diet ad libitum for 6 months. In all subjects, this level of 
weight loss was associated with reductions of -35% in both plasma leptin and insulin 
levels. The decrement in plasma leptin after weight loss was greatest in 
overweight/ obese women compared to their normal weight counterparts (p<0.005), 
although overweight/obese women continued to maintain higher plasma leptin levels 
(p<0.01). Maintenance of reduced body weight at 8 months was not associated with 
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additional reductions in leptin levels. The change in plasma leptin on the low fat diet in 
all subjects was significantly correlated with both the change in BMI (r=0.42, p<0.02) 
and the change in percent body fat (r=0.49, p<0.005). In contrast, changes in plasma 
insulin were not significantly correlated with the change in BMI or percent body fat. 
However, the change in plasma leptin on the self-selected low-fat diet was significantly 
correlated with the change in fasting insulin (r=0.52, p<0.002). Partial regression 
analysis demonstrated that the change in plasma leptin was significantly correlated with 
the change in plasma insulin, independent of changes in BMI (r=0.45, p<0.01) or 
percent body fat (r=0.44, p<0.02). Further analysis was possible by calculating the 
leptin/percent body fat ratio, which corrects for adiposity. This ratio revealed that 
overweight/ obese women have higher plasma leptin levels per unit of adiposity than 
nonnal weight women. However, after 8 months of the self-selected low-fat diet, only 
overweight/obese women had a significant decrease (-30%) in their leptin/adiposity 
ratio in whom both the absolute changes of leptin per unit of adiposity and the 
proportional changes of leptin per proportional change of adiposity were 2.5-3.5 times 
greater than in normal weight women. Thus, a 10% reduction in total adiposity in an 
overweight/ obese women resulted in a 34% decrease in plasma leptin levels, whereas a 
similar change in adiposity decreases plasma leptin by only 13% in normal weight 
women (267). 
In energy-restricted obese humans, improvements in insulin sensitivity and glucose 
tolerance are apparent before any major loss of body fat is detected. The mechanism 
responsible for the early benefits of caloric restriction are not well understood, but 
circulating leptin levels may be one factor. The response of serum leptin to energy 
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restriction has been examined in obese subjects with normal and impaired glucose 
tolerance. Subjects consumed prescribed diets containing 50% of their usual ad libitum 
energy intake for a period of 28 days. At the conclusion of this period, weight loss was 
attributable to comparable loss of fat and lean tissue. Serum leptin levels were 
significantly correlated with measures of total body adiposity prior to ( day 0) and 
following ( day 28) energy restriction. Leptin levels on day 28 were expressed as a 
percentage of day O values in order to test for the influence of specific dietary measures. 
Serum leptin fell 33% by day 4 (p<0.001) with a further 21% reduction seen at day 28 
(p<0.01). Serum leptin at day 4 (expressed as a percentage of day O value) was 
significantly related to the percentage change in grams of dietary carbohydrate intake per 
day (r=0.74, p=0.0005), but no association was noted with changes in dietary fat intake 
or protein. Similarly, there was no correlation between day 4 serum leptin levels (as a 
percentage of day 0) and the percentage change in total energy intake. In multiple 
correlation analysis, which included the three macronutrients, the change in carbohydrate 
intake was a significantly better independent predictor (r=0.68, p=0.027) of the change 
in serum leptin than were dietary protein and fat. Fasting insulin fell significantly by day 
4 (p<0.0001), with no further change noted on day 28. The early change in serum 
insulin was significantly correlated with the change in serum leptin (r=0.57, p=0.01 3) 
during the same period, but was not independent of the change in carbohydrate intake. 
These data suggest that serum leptin levels during the early stages of energy restriction 
are not reflective of dietary fat intake or reduced adipose tissue mass, but may be more 
indicative of changes in dietary carbohydrate intake (265). 
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Dietary carbohydrates may differentially influence 24-hour leptin profiles. For seven 
days, lean subjects consumed one of four diets which varied in glycemic index of the 
dietary carbohydrate and level of dietary fat high GI carbohydrate, 30% fat (highGI); 
low GI carbohydrate, 30% fat (lowGI); high GI carbohydrate, reduced (20%) fat 
(highGI, lowfat); and low GI carbohydrate reduced fat (lowGI, lowfat). No significant 
differences in serum glucose and insulin profiles were observed between diets and there 
were no statistically significant differences in peaks, troughs, or AUCs for glucose or 
insulin. Basal leptin levels were not significantly different between diets. The normal 
24-hour leptin profile was observed with the two lowGI diets: serum leptin levels 
remained low throughout the day, rose above the baseline (0800 hr) values after 2300 hr, 
peaked at 0200 hr, and returned to baseline by 0800 hr. In contrast, the 24-hour leptin 
profile was altered by the high GI diets following which serum leptin levels rose above 
baseline (0800 hr) as early as 1300 hr. The leptin AUC from 1230 hr to 2400 hr and the 
24-hour AUCs with the high GI diets were significantly higher than for the low GI diets 
(p<0.0001) (268). 
Agouti 
The ago11ti gene encodes a 131 -amino acid protein which is subject to temporal and 
spatial regu]ation in rodents(269,270). The ago11ti gene is normally expressed exclusively 
within the hair follicle, regulating the synthesis of eumelan.in (black) and phaeomelan.in 
(yellow) pigment to produce the wild-type agouti pattern of coat coloration: black hairs 
with a subapical yellow band (269,271). Upon binding of cx-melanocyte stimulating 
hormone (cx-MSH) hormone to the melanocortin-receptor-1 (MC1-R), activation of 
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adenylate cyclase causes an increase in intracellular cAMP levels and the production of 
eumelanin. Agouti is expressed only transiently during the middle of the hair growth 
cycle during which time it exerts a paracrine effect on melanocytes, shifting pigment 
production from eumelanin to phaeomelanin mediated by antagonism of melanocortin­
receptor-1 (MC1-R) (272). Dominant mutations at the agouti locus result in the 
constitutive and ubiquitous expression of agouti-signaling protein (ASP) and leads to a 
pleiottopic obesity syndrome. The best characterized dominant mutations are the lethal 
yellow (A') and viable yellow (A "Y) mutants. In contrast to ob/ ob and db/ db mice which 
are characterized by early-onset obesity, A1 and A vr mice develop an obesity syndrome 
that peaks between 8 and 17 months of age (273). Furthermore, ob/ ob and db/ db mice 
demonstrate significant adipocyte hyperplasia while the increased adiposity of obese 
yellow mice is primarily due to adipocyte hypertrophy, much like the human obesity 
syndrome (274). Significant pancreatic �-cell hypetplasia is evident in A vy males by 21 
days of age and thus, precedes the development of hyperinsulinemia and obesity (275). 
Hyperinsulinemia develops in A vy mice at approximately 6 weeks of age, while db/ db and 
ob/ ob mice are hyperinsulinemic at 10 and 15  days, respectively (27 6) . The development 
of hyperinsulinemia in A vr mice is accompanied by the appearance of other metabolic 
abnormalities including hyperphagia, hyperglycemia in males, increased rates of hepatic 
lipogenesis and decreased rates of adipocyte lipolysis (277-279). Obese yellow mice are 
characterized by a slight increase in linear growth, making them unique from other 
rodent obesity models, which are somewhat shorter than their wild-type litterm.ates 
(280). 
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Domio.ant mutations at the agouti locus that result in obesity are characterized by the 
constitutive synthesis of normal (wild-type) agp11ti protein within the hair follicle, 
accounting for the yellow coat color, and the ectopic expression of agouti in most all 
tissues of the animal, which is believed responsible for the development of the 
pleiotropic obesity syndrome as these animals age. Transgenic mice ectopically 
expressing ago11ti from ubiquitous promoters (e.g. �-actin) recapitulate the obese 
hyperinsulinemic phenotype, indicating the pleiotropic obesity syndrome of the yellow 
mouse is a direct result of ectopic ago11ti expression. Disruption of MC1-R function 
results in obese mice with black fur but lacking the subapical yellow band, indicating the 
obesity phenotype is not dependent on the synthesis of yellow pigment. The working 
hypothesis for the induction of obesity by ectopic overexpression of notmal ago11ti 
protein .involves antagonism of melanocortin receptors, specifically MC4-R, in regions of 
the brain known to be critical for regulation of feeding behaviors and body weight. The 
significance of MC4-R signaling in body weight regulation is supported by MC4-R 
deficient mice which develop an obesity syndrome which mimics the ago11ti syndrome 
(281). 
M11ri11e Obesi!J &mltingfrom Ectopic Ago11ti F.xpresswn 
Wild-type ago11ti cDNA was placed under the transcriptional control of the human �­
actin promoter to generate transgenic mice that ectopically express normal (wild-type) 
ago11ti in all tissues. To accentuate the effect of ectopic ago11ti expression on weight gain, 
animals were fed a high-fat diet throughout their lifespan. The average weight of agi11ti 
transgenes became greater significantly (p<0.01) greater than their wild-type littennates 
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at 4 and 6 weeks of age in females and males, respectively. Ultimately, agp11ti transgenes 
were 1 .3- to 1.7-fold heavier than their age- and sex-matched wild-type littennates. By 
20 weeks of age, agp11ti transgenes have significantly higher insulin levels compared to 
controls, with the most pronounced hyperinsulinemia occurring in males compared to 
females. Consistent with a more severe state of hyperinsulinemia, male transgenes had 
plasma glucose levels that were approximately 70% higher than in control animals at 20 
weeks of age (280). 
R.elalionships Between Agp11ti and uptin 
Both diet-induced obesity and genetic obesity due to the yellow agp11ti mutation are 
associated with significantly elevated ob mRNA levels. In normal C57BL/6J mice fed a 
high-fa4 high-carbohydrate diet for 14 weeks, there was a significant elevation in ob 
rnRNA per µg of total RNA compared to the level observed in control mice on standard 
rodent chow. To produce an equivalent state of acute nutritional stimulation in mice on 
each diet, food was removed 7 hours prior to the beginning of the dark cycle and mice 
sacrificed 30 minutes after an intraperitoneal injection of glucose just before lights out. 
In lean mice, ob mRNA was significantly elevated in 7-hour fasted, glucose injected mice 
compared to mice fasted for 48 hours (p<0.05). This acute effect of nutritional status 
was not observed in mice fed the high-fat diet for 14 weeks. Body weight and serum 
insulin were also significantly elevated in diet-induced obese mice (p<0.05). When lean 
and obese mice were analyzed together, linear regression indicated that ob mRNA was 
significantly correlated with body weight (r=O. 79, p<0.05) and serum insulin levels 
(r=0.54, p<0.05) (282). 
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Compared to lean wild-type C57BL/ 6J mice, ob mRNA was significantly elevated 
in genetically obese yellow (C57BL/6J-A� mice (p<0.05). Administration of glucose to 
lean mice was associated with a significant induction in ob mRNA (p<0.05), an effect 
that was absent in obese agouti mice. Because obese yellow mice also have an expanded 
adipose tissue mass, the amount of total leptin secreted by these mice is even greater 
(282). 
The human homologue of agouti is expressed in both adipose tissue and pancreas. 
The relationship between ago11ti expression and adipocyte fatty acid synthase expression 
and activity has been investigated in human subcutaneous adipocytes. Agouti appears to 
be up-regulated during the process of human pre-adipocyte differentiation as suggested 
by the greater abundance (4-fold) of agouti protein in human mature adipocytes 
compared to preadipocytes (p<0.005). Using human adipose tissue biopsies obtained 
during elective surgery, adipose tissue agouti content was significantly correlated with 
both FAS mRNA level (r=0.846, p<0.002) and FAS activity (r=0.782, p<0.005) (283). 
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V. Skeletal Muscle Metabolism and Alterations in the Metabolic Syndrome 
Skeletal Musde Characteristics 
Hwnan and rodent skeletal muscle is a tnixture of two main muscle fiber types (284-
286). In humans, muscle fiber types may be distinguished based on their different 
metabolic and histochemical characteristics (287,288). Type I fibers are appropriately 
called "slow-twitch" fibers, based on their slower contraction velocity compared to Type 
II ("fast-twitch") fibers (289). Type II fibers are subdivided into two classes, Type Ila 
(fast twitch oxidative fibers) and Type Ilb fibers (fast twitch glycolytic fibers) (289) . 
Because there is substantial overlap in the oxidative capacities of Type I and Type II 
fibers, fiber type does not provide a direct measure of the oxidative capacity of skeletal 
muscle. Oxidative capacity is known to be related to mitochondrial density, which can 
be assessed by NADPH staining (290). Studies comparing muscle fibers from lean 
subjects have shown that type I fibers have the greatest oxidative capacity, as indicated 
by higher activity of enzymes which serve as markers for oxidative metabolism including 
succinate dehydrogenase, 3-oxoacid CoA transferase, citrate synthase, 3-hydroxyacyl 
CoA dehydrogenase, and malate dehydrogenase (291). There is a strong correlation 
between the proportion of type I fibers and oxidative capacity as determined by 
mitochondrial NADPH staining (r=0.95, p=0.0001) and citrate synthase (CS) activity 
(r=0.35, p=0.03) (285). Type Ilb fibers are adapted for glucose oxidation and 
demonstrate increased activity of glycolytic enzymes such as phosphofructokinase, 
hexokinase, lactate dehydrogenase and pyruvate dehydrogenase (287). 
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Fiber Type InOuences Insulin Binding 
In vitro studies using rodent cell lines have revealed differences in insulin binding and 
glucose uptake based on muscle fiber type. Whole muscle sections were incubated with 
1251-insulin and 2-deoxy-D-glucose for 4 hours to permit steady state conditions after 
which time insulin binding and glucose uptake were measured. Greater insulin binding 
and greater basal and insulin-stimulated 2-deoxy-D-glucose occurred in soleus (primarily 
Type I fibers) compared to gasttocnemius (predominately Type II fibers) muscles 
(292,293). A possible explanation for the observed associations between insulin 
resistance and muscle fiber type can be found in the pattern of glucose transporters 
expressed by fiber types. Type I fibers have increased levels of GLUT-4, which would 
be transported to the membrane more readily when the supply of capillaries to the fiber 
is more dense (293). 
Muscle Fiber Type in Obese Subjects 
Tanner, et al. (294) have demonstrated a clear relationship between muscle fiber type 
and obesity. Obese women were shown to have a lower percentage of type I and a 
rugher percentage of type Ilb muscle fibers compared to lean subjects (p<0.001 for 
both). Furthermore, BMI was positively related to the relative percentage of type llb 
fibers (r=0.49, p<0.001). This study also found that muscle from obese African­
American women contained a lower percentage of type I fibers than comparably obese 
Caucasian women (p<0.05) . Consequently, African-American subjects had more type 
Ilb fibers than their Caucasian counterparts (p<0.01). 1bis is consistent with 
epidemiological studies which have documented a higher prevalence of obesity and two 
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fold greater incidence ofNIDDM in obese African-American women compared to 
obese Caucasian women (295-297). Obese African-American women are also more 
insulin resistant and have an impaired capacity for fat oxidation compared with 
Caucasian women (298). These findings are also consistent with a reduction in the 
percentage of type I fibers in muscle biopsies from obese African-American women 
compared to weight-matched Caucasian women (296,299). 
Obese subjects often fail to lose a significant amount of weight with intervention and 
are prone to weight regain (300). A reduction in the percentage of type I fibers would be 
expected to impair the ability of skeletal muscle to oxidize lipids and predispose one to 
weight regain (294). To determine if a relationship exists between muscle fiber 
composition and the capacity for weight reduction, biopsies from the rectus abdominus 
muscle were obtained from women (BMI -52 kg/m2) undergoing gastric bypass surgery 
to induce weight loss (301). Prior to surgery, the percentage of type I and type Ila fibers 
were roughly equal, and three-fold greater than the percentage of type lib fibers in 
abdominal muscle preparations. BMI was significantly reduced following the surgery. 
The relative percentage of type I fibers at the time of surgery was positively associated 
with the change in BMI (r=0.55, p<0.05) and the percentage of body weight lost 
(r=0.56, p<0.05). Although this study does not permit the identification of the precise 
mechanism(s) by which alterations in fiber type contribute to obesity, the data suggests 
that the histochemical characteristics of muscle fibers may be partially predictive of 
obesity (301). 
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Glucose Transport and Uptake by Skeletal Musde 
The importance of skeletal muscle in glucose homeostasis is apparent during an oral 
glucose tolerance test, when glucose uptake by skeletal muscle increases 5-10 fold (302). 
Skeletal muscle may contribute to insulin resistance and glucose tolerance that is 
associated with obesity as suggested by studies demonstrating decreased glucose uptake 
by skeletal muscle in obese subjects (302,303). 
Insulin influences both the uptake and intracellular fate of glucose in skeletal muscle 
at steps distal to its vasodilatory actions. During moderate insulin stimulation, Kelley, et 
al. (304) suggests that the phosphorylation of glucose, rather than transmembrane 
transport, becomes the key step controlling further glucose metabolism by cells. Thus, it 
seems necessary to define the respective contributions of glucose transport and 
phosphorylation in normal physiology as well as alterations that occur in insulin resistant 
states. 
Basal glucose uptake by muscle occurs in a process mediated by a specific glucose 
transport protein, GLUT-1, which appears to be bound to the plasma membrane, 
without regard to plasma insulin levels (62). Basal glucose transport may also be 
facilitated by GLUT-3. Insulin-stimulated glucose uptake is facilitated by the insulin­
sensitive glucose transport protein, GLUT-4. In the postabsorptive state, the bulk of 
GLUT-4 proteins are sequestered in intracellular vesicles associated with low-density 
microsomes. In vastus lateralis muscle biopsies taken from normal fasting human 
subjects, the ratio of the three principal glucose transporters was determined to be 2: 1 :3 
for GLUT-1 ,  GLUT-3 and GLUT-4. In the basal state, the plasma membrane glucose 
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transporter pool in the basal state is approximately 25% GLUT-1, 45% GLUT-3, and 
30% GLUT-4 (305). 
Transport of glucose across the plasma membrane is the first rate-limiting step in 
glucose metabolism under physiological conditions (306). Once glucose enters the 
skeletal muscle cell, it is immediately phosphorylated to glucose-6-phosphate (G6P) via 
the enzyme hexokinase (HK) (307). The conversion of glucose to G6P traps glucose 
within cells, preventing its efflux from cells, and thus, maintains a concentration gradient 
for the movement of free glucose across the sarcolemma (307). In the basal state, 
intracellular free glucose levels are negligible (308). However, when hyperinsulinemia or 
hyperglycemia are present, free unphosphorylated glucose accumulates within the 
myocytes and steps distal to transmembrane transport become rate limiting (308,309). 
Skeletal muscle expresses two isoforms of hexokinase: hexokinase I (HK I) and 
hexokinase II (HK 11) (307). Although there is significant sequence conservation 
between the two isofonns, they are regulated in distinct manners in skeletal muscle. HK 
II appears to be the insulin-responsive isoform, as insulin induces HK.II transcription in 
vitro (31 0). 
In subjects undergoing euglycemic, hyperinsulinemic clamps, insulin rapidly 
stimulates glucose uptake, while there is a delay of 2-4 hours before changes in HKII 
expression are detected (31 1). The acute increase in glucose transport and 
phosphorylation is mediated by an insulin-mediated shift in the intracellular distribution 
of HK.II from the cytoso� where it is localized in the basal state, to the mitochondria, 
where the enzyme will be in close proximity to elevated levels of ATP, which will further 
increase the activity of the enzyme (312). 
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In the basal state, human skeletal muscle concentrations of G6P are nonnally -100 
µM (313). Skeletal muscle HK II activity is positively correlated with GLUT-4 activity, 
which safeguards against excessive accumulation of intracellular G-6P ([G6PJi· 
Consequently, insulin stimulation of skeletal muscle in vivo increases the 
expression/translocation of GLUT-4 and causes a simultaneous, parallel increase in HK 
II expression. G-6P is a critical metabolic intermediate whose levels largely determine 
the metabolic fate of glucose within the muscle cell (313). 
Multiple defects in glucose metabolism occur in insulin resistant conditions, including 
obesity and NIDDM (314-316). Non-invasive methods for the in vivo investigation of 
skeletal glucose utilization have facilitated a greater Wlderstanding of the proximal steps 
of glucose metabolism and their contribution to glucose homeostasis. One of these 
methods, nuclear magnetic resonance (NMR) spectroscopy, has yielded evidence to 
suggest that the transmembrane transport of glucose is the primary site of regulation of 
glucose metabolism during euglycemic states. Quantitation of intracellular levels of free 
glucose and G6P demonstrated that about 90% of glucose flux is controlled by 
regulating the ttansmembrane transport of glucose during euglycemia as well as during 
conditions of mild hyperinsulinemia with hyperglycemia (317). However, this remains 
controversial since it is unclear if this relationship is maintained over a range of insulin 
levels. 
In lean subjects with normal glucose tolerance, moderate insulin infusion stimulates leg 
glucose uptake to levels 3-4-fold higher than in obese subjects and subjects with 
NIDDM. Insulin stimulates an 8-10-fokl increase (above basal) in fractional glucose 
clearance in lean subjects, which is a significantly greater effect than is observed in either 
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obese or NIDDM subjects, which experienced similar decrements versus lean subjects. 
Moderate insulin infusion increases glucose phosphorylation 5-fold above basal in lean 
subjects, while simultaneously reducing the level of free glucose in the interstitial space. 
These responses are absent in obese and NIDDM subjects, indicating major 
impairments in both glucose transport and phosphorylation (318). 
At supraphysiological levels of insulin, rates of glucose clearance significantly increase 
above basal levels in lean, obese and NIDDM subjects. 'Ibis suggests that obese 
subjects and those with NIDDM are experiencing decrements in insulin sensitivity but 
maintain the capacity to increase glucose uptake in response to maximally-stimulating 
levels of insulin. However, hyperinsulinemia reduced free glucose levels to below basal 
levels and resulted in a more pronounced increase in glucose transport and 
phosphorylation compared with subjects with NIDDM. Thus, in obese subjects with 
nonnal glucose tolerance, hyperinsulinemia can alleviate the impairment in both glucose 
transport and phosphorylation that were observed with moderate insulin levels. In 
contrast, hyperinsulinemia failed to significantly reduce free glucose levels, suggesting a 
more profound defect in glucose transport and phosphorylation in these subjects (318) .  
Skeletal Muscle Lipid Metabolism and Lipop.rotein Lipase 
Skeletal muscle demonstrates significant metabolic flexibility, readily altering its 
pattern of substrate utilization based on availability. Skeletal muscle is a major 
contributor to whole-body lipid oxidation. Fatty acids oxidized by skeletal muscle may 
originate from several sources. Nonesterified fatty acids (NEF As), derived from 
tri.acy]glycerols released from adipose tissue by the action of hormone sensitive lipase 
83 
(HSL), account for the majority (80-90%) of the muscle lipid fuel needs during mild 
exercise or fasting conditions (319). Alternatively, free fatty acids may be liberated from 
circulating triglyceride-rich lipoproteins by the muscle isoform of lipoprotein lipase 
(mLPL). Following feeding, as much as 30% of circulating triglycerides may be utilized 
by skeletal muscle as an energy substrate (319,320). Finally, skeletal muscle may oxidize 
free fatty acids derived from endogenously stored intramuscular triglycerides following 
the action of the isoform of HSL found in skeletal muscle (321 ).  
The muscle isoform of lipoprotein lipase (mLPL) hydrolyzes the bonds between fatty 
acyl residues and glycerol in triglycerides (321 ,322). However, the adipose tissue and 
muscle isoforms are subject to reciprocal regulation such that when LPL activity is 
increased in one tissue, it will be decreased in the other. In contrast to adipose tissue 
LPL, insulin decreases the activity of mLPL (323,324). In addition to tissue specificity, 
the activity of mLPL is five-fold greater in oxidative, slow twitch red muscle compared 
to glycolytic fast twitch muscles. In addition, mLPL has a phospholipase A2 activity 
which facilitates the hydrolysis of the lipid layer surrounding the core triglycerides within 
lipoproteins (325). This makes the triglyceride rich core of the lipoprotein particle 
accessible to the lipase activity of mLPL. Roughly half of the fatty acids generated by 
the action of mLPL on circulating lipoproteins will be extracted and stored within 
muscles for use as an oxidative fuel source when needed (326). 
In resting, fed humans, lipolysis of circulating triglyceride-rich lipoproteins 
(chylomicrons and very-low-density lipoproteins, VIDL) provide 50-80% of fatty acids 
taken up by skeletal muscle (326). This is accomplished by the muscle isoform of 
lipoprotein lipase (mLPL). Isoforms of LPL are found at the capillary endothelium of 
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various tissues, including adipose tissue, skeletal muscle and cardiac muscle. The highest 
levels of LPL are found in adipose tissue and skeletal muscle (327). FF As liberated by 
the action of LPL are either metabolized immediately to meet prevailing energy needs or 
are re-esterified and stored in endogenous pools from which they can be mobilized and 
oxidized on demand as energy needs dictate. In general, muscles with a predominance 
of slow-twitch oxidative fibers contain the highest level of mLPL, consistent with a 
greater reliance on lipid oxidation for meeting energy needs (325). In contrast, muscles 
composed mainly of fast-twitch white fibers which have higher glycolytic capacity, have 
much less mLPL activity (327). 
While insulin stimulates the activity of AT-LPL in a dose-dependent manner, 
devations in plasma insulin down-regulate the muscle isoform of LPL (164, 1 66). 
Physiological elevations in circulating insulin during a euglycemic clamp has been shown 
to decrease thigh muscle LPL activity (p<0.05), whereas thigh glucose upuke is 
significantly increased (p<0.05). The increase in glucose uptake was positively associated 
with the decrement in mLPL activity (r=0.93, p<0.05) (328). 
The role of mLPL is to provide fatty acids to meet energy needs. The overexpression 
of LPL has been shown to reduce circulating triglyceride levels, however, this is 
associated with higher blood glucose levels. Thus, it seems that overexpression of mLPL 
may induce insulin resistance by forcing skeletal muscle to oxidize lipids at the expense 
of available glucose. Transgenic mice overexpressing human LPL (MCKhLPL) in 
skeletal muscle have been shown to have higher blood glucose levels than wild type 
control mice. 1bis suggests a role for mLPL in skeletal muscle insulin resistance. 
Following consumption of a high carbohydrate diet, fasting MCKhLPL transgenic mice 
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demonstrate a decrease in RQ, suggesting a shift in substrate utilization in favor of lipids 
that is not observed in wild type mice. Consistent with this, fasting levels of citrate, a 
potent inhibitor of phosphofructokinase, were observed in the quadriceps muscle of 
MCKhLPL mice compared to wild type mice (p=0.013). Higher muscle glucose-6-
phosphate levels in MCKhLPL compared to wild type mice (p=0.013) may have also 
contributed to the development of insulin resistance, as suggested by the need for lower 
rates of glucose infusion to maintain euglycemia during euglycemic hyperinsulinemic 
clamps in MCKhLPL compared with nontransgenic mice (p=0.015) (329). 
Obese subjects often have increased triglyceride-rich VLDL levels in circulation 
(330). This may be the result of overproduction by the liver or decreased removal from 
circulation, presumably due to defective action of LPL (330,331). Negative correlations 
have been found between body weight, insulin and mLPL have been found in normal 
weight and obese subjects (332,333). In a group of obese women, a strong, negative 
correlation between basal mLPL activity and total body fat as assessed by BMI (r=-0.67, 
p<0.01). Moreover, mLPL was inversely related to the insulin response during an oral 
glucose tolerance test (r=-0.50, p<0.05) (334) . These findings suggest that 
hyperinsulinemia may be the pathological factor for altered mLPL activity since obese 
subjects are often hyperinsulinemic and insulin has an acute inhibitory effect on the 
activity of mLPL (328). A significant negative association was found between fasting 
triglycerides and mLPL activity (r=-0.48, p<0.05), suggesting that the lower LPL activity 
in muscle of obese subjects is at least partly responsible for higher triglyceride levels 
(334) . 
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Regulation of Fatty Acid Oxidation in Skeletal Musde 
Several p1asma membrane proteins that bind free fatty acids have been identified in 
various tissues including skeletal muscle. These proteins include plasma membrane 
binding protein (FABP pm), fatty acid translocase (FAT/CD36), and fatty acid transport 
protein (FATP) (334-337). Red oxidative skeletal muscle contains more FABP pm than 
white glycolytic muscle (335). Fatty acid t:ranslocase and fatty acid transport protein are 
also more abundant in red compared to white muscle (337). Maximal transport of fatty 
acids into red vesicles is 1.8 fold-greater than in white vesicles (337). Once inside the 
myocytes, fatty acids are transported by a cytosolic fatty acid binding protein (F ABP c) 
(337). 
Following uptake by the myocytes, fatty acids must first be activated to long chain acyl 
CoAs (LCA.CoAs) before transport across the mitochondrial membrane by camitine 
palmitoyl transferase-1 (CPT-1) (338). Malonyl CoA inhibits the transport ofLCACoAs 
into the mitochondria by directly inhibiting CPT-1 (339-341). Excessive malonyl CoA 
levels thus leads to accumulation of LCACoAs in the cytosol (342). While intramuscular 
lipids are unlikely to serve as a source of free fatty acids for use by distant tissues, the 
accumulation of lipids within myocytes may lead to excessive concentrations of 
intracellular fatty acyl CoAs or other fatty acid metabolites which can modulate local 
glucose utilization (343,344). Within muscle, free fatty acids (FF A), primarily palmitate, 
oleate, and linoleate, are activated to long-chain acyl CoAs before transport across the 
mitochondrial membranes by CPT-1, for subsequent �-oxidation. LCACoAs are also 
substrates for the esterification of FF As for synthesis of triglycerides and phospholipids 
(345,346). 
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Triglycerides per se are unlikely to be the primary cause of skeletal muscle insulin 
resistance since they are an inert storage form of lipid. The balance between oxidation 
and re-esteri.fication of plasma derived free fatty acids within muscle is the key 
determinant of fatty acid storage within the tissue (348). Nonesterified fatty acids are 
transported through the cytosol by fatty acid binding proteins (F ABPs) (335). Prior to 
their oxidation, long chain fatty acids must be activated to long chain acyl CoAs and then 
translocated into the mitochondrial by CPT-1. Activity of CPT-1 is a key regulatory of 
muscle fatty acid oxidation (338). CPT-1 is highly sensitive to allosteric inhibition by 
ma.lonyl CoA, the immediate precursor of de novo synthesized fatty acids (339) . Insulin 
and glucose suppress muscle lipid oxidation indirectly by increasing the content of 
ma.lonyl CoA (344). 1bis would suppress the activity of CPT-1 preventing the transport 
of LCACoAs into the mitochondria for oxidation. Consequently, LCCoAs would 
accwnulate within the cytosol A possible link between elevated cytosolic LCCoA levels 
and insulin resistance may involve the activation of some isoforms of PKC. Chronic 
glucose infusion to rats causes lipid accumulation and elevations in cytosolic LCCoA 
levels and chronic activation of PKC-a. Activation of this PKC isofonn is finding 
common in several rodent models of obesity and insulin resistance (344). 
Intramyocellular Lipids 
The majority of lipoprotein-derived fatty acids will be sequestered within specific 
intramuscular lipid pools where they will be available for immediate oxidation as energy 
needs dictate. Adipocytes located between muscle fibers are termed extramyocellular 
lipids (EMCL) while intramuscular lipids (IMCL) are triglycerides localized to the cytosol 
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in close proximity to the mitochondria in myocytes (349,350). Although the 
intramuscuJar lipid pool is small compared to whole-body stores, muscle lipids constitute 
an important source of oxidizable energy. While this pool does not contribute to 
circulating fatty acids, intramuscular triglycerides can be rapidly hydrolyzed to supply 
energy to muscles at rest and during exercise (351). 
Computed tomography (C1) can be used for the analysis of regional body 
composition. This method permits the direct visualization and measurement of adipose 
tissue volume and density, rather than derivation of these values from other measures. 
CT can also be used to assess the composition of lean tissue based on x-ray attenuation 
values within each pixel of a CT scan. The attenuation of CT radiation represents the 
average attenuation or density of the tissue examined. Skeletal muscle and adipose tissue 
have very different attenuation values on CT; skeletal muscle CT values are positive 
while those for adipose tissue are negative (352). Furthermore, skeletal muscle with 
relatively lower attenuation values have been found to contain more lipid deposits. 
Kelley et al have used CT to assess the effects of obesity on lean tissue density. Mean 
CT attenuation values were first defined in muscles of lean subjects. Nonna! density 
muscle (NDM) was defined as an area having attenuation values between 35 and 100 
Hounsfield units (HU). Lean tissue with attenuation values of 0-34 HU was labeled as 
low density muscle tissue (LDL1). The attenuation values for LDLT were below those 
for NDM but above the attenuation values of adipose tissue (-200 to -1 HU). In normal 
weight healthy subjects, NDM accounted for 90±2% of lean tissue volwne and 60±6% 
of overall volume of the midthigh, whereas LDLT accounted for 9±1% of lean tissue 
volwne and 6± 1 % of midthigh volume. BMI was inversely related to lean-tissue density 
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(r=-0.73, p<0.001). The relationship between obesity (BMI) and lean tissue density was 
particularly strong in the posterior flexor muscle (r=-0.84, p<0.001). There was no 
association between NDM volume and BMI. However, the volume ofLDLT was 
positively correlated with BMI (r=0.63, p=0.003). Furthermore, there was a strong 
positive association between LDLT and adipose tissue volume (r=0.80, p<0.0001). 
Thus, the effect of obesity on thigh composition is to selectively increase the volume of 
LDLT without affecting NDM (353). In obese subjects, muscle attenuation was found 
to be the strongest positive correlate with insulin sensitivity (r=0.48, p<0.01). Thus, 
Jtlarbling of muscle with fat deposits may contribute to the progressive deterioration of 
insulin sensitivity in skeletal muscle of obese subjects. 
Importantly, the improvement in insulin sensitivity that accompanies weight loss may 
be partly due to the depletion of intramyocellular lipid deposits. lntramyocellular lipids 
are substantially reduced subjects maintaining reduced body weight following gastric by­
pass surgery (p<0.05). Although fat accumulates within myocytes of morbidly obese 
subjects, the majority of lipid is deposited between muscle fibers. However, weight loss 
selectively depletes intramyocellular lipids, without affecting extramyocellular lipid 
deposits. Furthermore, the depletion of intramyocellular lipids in weight reduced 
subjects was positively associated with improvements in whole body glucose disposal 
(r=0.49, p<0.004), independently of changes in overall adiposity or changes in 
extramyocellular lipids (354). These findings are consistent with rodent studies in which 
intramyocellular lipid accumulation induced by high-fat feeding or by inhibition of fat 
oxidation was found to closely correlate with in vivo insulin-mediated glucose disposal 
(355). 
90 
To gain a clearer understanding of the factors determining IMCL formation and the 
time course of their deposition, Bachman, et al (356) subjected lean healthy subjects to a 
series of lipid infusions during euglycemic, hyperinsulinemic clamp studies. In lean 
subjects, hyperinsulinemia is insufficient to induce IMCL formation. Similarly, lipid 
infusion to significantly raise plasma NEF A levels, fails to significantly increase IMCL 
levels. However, the combination of hyperinsulinemia and elevated plasma NEF A levels 
significantly increases IMCL in tibialis anterior muscle within 2 hours, while 4 hours is 
required to elevate IMCL levels above basal in soleus muscle. Maximal IMCL formation 
occurred within 6 hours in tibialis anterior muscle, and was significantly greater than the 
maximum IMCL level in soleus muscle. A strong association was noted between IMCL 
content and GIR during the clamp studies in both the TA (r=-0.98, p<0.003) and SOL 
(r=-0.97, p<0.005) muscles. 
In normal subjects, brief periods of dietary intervention have been shown to 
influence IMCL levels in tibialis anterior muscle. Consumption of a high-fat, low­
carbohydrate diet for three days led to a 50% increase in the IMCL level of tibialis 
anterior muscle, and was associated with reduced insulin sensitivity, as indicated by a 
reduction in the rate of glucose infusion necessary to maintain euglycemia during 
hyperinsulinemic clamp studies. In contrast, subjects fed a high-carbohydrate, low-fat 
diet for 3 days demonstrated a non-significant decrease in IMCL in ttbialis anterior and 
soleus muscle, while insulin sensitivity was unchanged (356). 
Nuclear magnetic resonance (NMR) spectroscopy provides a non-invasive method 
that differentiates between intramyocellular (IMCL) and extramyocellular (EMCL) lipid 
content (357-359). This technology has been employed by a number of researches to 
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assess the role of skeletal muscle lipid content in the insulin-resistance associated with 
obesity. Sinha, et al (357) were the first to use this method in pediatric subjects to 
demonstrate that muscle lipid content and insulin sensitivity are closely related and 
independent of other factors known to influence insulin sensitivity and insulin action in 
vivo, including total body fat and central adiposity. In obese children, soleus muscle 
IMCL and EMCL levels were both more than 200% higher (p<0.01) than levels in lean 
children. Using 1H-NMR spectroscopy, it was shown that in soleus muscle both IMCL 
and EMCL are considerably greater in obese compared to lean children. IMCL and 
EMCL content were positively associated with overall indices of obesity including BMI 
(r=0.665, p<0.001) and percent total body fat (r=0.69, p<0.0001). Similar positive 
associations were observed between EMCL and indices of overall adiposity. 
Furthennore, subcutaneous and visceral fat were shown to be positively associated with 
IMCL (r=0.539 and 0.729, respectively, p<0.01) and EMCL (r=0.795 and 0.861, 
respectively, p<0.01). Perhaps the most significant finding of this study was that whole 
body insulin sensitivity (assessed by glucose infusion rate during euglycemic, 
hyperinsulinemic clamp) varied as a function of IMCL (r=-0.59, p<0.02) and was more 
strongly predictive than EMCL (r=-0.53, p<0.05). Also noteworthy is that the 
relationship between IMCL and insulin sensitivity is independent of percent body fat and 
subcutaneous abdominal fat, but not of visceral fat. These relationships suggest that 
insulin sensitivity and increased intramyocellular lipid accumulation are pathological 
features of obesity in a young population. 
Virkamaki, et al (360) have found impairments in two specific actions of insulin as a 
consequence of excessive IMCL accumulation. Healthy, non-obese (BMI: 25.7±0.7 
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kg/m� men were divided into two groups, based on high (HilMCL) or low (LoIMCL) 
content as determined by 1H-NMR spectroscopy. The HiIMCL and LoIMCL groups 
had identical mean BMis, similar lean body mass, and comparable volumes of visceral 
and subcutaneous fat. However, men with HiIMCL exhibited significant impairments in 
insulin-stimulated whole body glucose uptake and insulin-mediated suppression of 
circulating FF A levels compared to men of comparable BMI but with LoIMCL content. 
Men with HilMCL content had basal insulin levels that were 46% higher (p<0.05) than 
LoIMCL subjects. Despite achieving similar levels of glycemia during euglycemic 
clamps, plasma insulin levels remained -20% higher in HiIMCL compared to LoIMCL 
(p<0.05) subjects. In the fasting state, serum free fatty acid concentrations were similar 
in both groups. However, during experimental hyperinsulinemia, FF A levels declined 
more slowly (p<0.01) and remained higher (p<0.05) in HiIMCL compared to LoIMCL 
subjects. IMCL content was positively correlated with mean FFA levels during 
hyperinsulinemia (r=0.53, p<0.02) (360). This is consistent with lipid infusion studies 
which document increases in IMCL during hyperinsulinemia but not under fasting 
conditions and is speculated to be the result of increased FF A availability and inhibition 
of inttamyocellular lipolysis by insulin facilitating additional lipid accumulation in muscle 
(356). 
Changes In Skeletal Musde Lipid Metabolism In Response To High Fat Feeding 
High fat feeding induces a number of significant changes in fatty acid metabolism in 
red gastrocnemius muscle of rats. The alterations in lipid metabolism in response to diet 
has been studies using the fatty acid tracer [9,10-3HJ-2-bromopalmitate (3H-R-BrP), 
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which permits the tissue specific measurement of fatty acid uptake (361). When used in 
conjunction with 14C-pa1mitate {'4C-P) the fate of fatty acids entering the cell can also be 
evaluated. Compared to the standard diet, high-fat feeding increased whole body fatty 
acid clearance, and fatty acid clearance by gasttocnemius muscle and white adipose tissue 
under basal and insulin stimulated conditions (p<0.05 for all). Compared the standard 
diet, the high fat diet increased lipid storage in gast:rocnemius muscle in the basal state 
(p<0.05) and during lipid infusion (p<0.05) (361). 
One possible mechanism by which high fat feeding enhances fatty acid clearance into 
red gasttocnemius muscle is by increasing the activity of the enzymes of lipid 
metabolism. Compared to contto� high fat feeding increased (p<0.01) the activity of 
acyl CoA synthase (ACS), the enzyme that catalyzes the first committed step of 
intracellular fatty acid metabolism by activating fatty acids to long-chain acyl-CoA (362). 
Furthermore, ACS activity was correlated with both lipids direct to intramuscular storage 
(r2=0.36, p<0.05) and triglyceride content (r2=0.49, p<0.02) of the red gastrocnemius 
muscle. The results of this study suggest that muscle undergoes a series of metabolic 
adaptations which pennit this tissue to more efficiently utilize the most abundant 
substrate available (363). 
Restoration of Insulin Responsiveness With Wewht Loss and Energy Restriction 
While over nutrition is known to be associated with impaired glucose metabolism and 
insulin action, moderate caloric restriction (-60-70% of ad libitum intake) improves 
insulin action in humans and rodents. Because it is the greatest consumer of available 
glucose, skeletal muscle is potentially the most important target for interventions 
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designed to improve insulin sensitivity. In addition, skeletal muscle is extremely 
responsive to alterations in substrate availability and quickly adapts to changes in the 
availability of glucose, lipids, and protein (363). 
To determine the effect of weight loss on in vivo glucose disposal, Friedman, et al 
(364) performed euglycetnic insulin clamps in subjects before and after elective gastric 
by-pass surgery. Surgery resulted in loss of 36% of initial body weight and subjects were 
allowed to stabilize at this reduced weight prior to study. Although glucose disposal 
increased roughly three-fold following weight loss (p<0.01), rates remained well below 
those observed in lean subjects under identical conditions. Even so, this represents a 
substantial improvement. Whereas the glucose disposal rate in obese subjects prior to 
weight loss was 27% of lean subjects, this improved to 78% of normal after weight loss. 
Furthennore, weight loss induced a 2-fold increase (p<0.01) in maximal glucose 
transport activity, and consequently, restored maximal insulin-stimulated glucose 
transport activity to 88% of normal, non-obese subjects. These improvements could not 
be attributed to changes in GLUT-4 expression which was unchanged by weight loss. 
Given that skeletal muscle is responsible for more than 80% of insulin-stimulated 
glucose uptake, these findings are consistent with the development of a reversible defect 
in skeletal muscle insulin sensitivity during the course of obesity (364). 
Dean, et al. (365) studied the effects caloric restriction on insulin action in rats. 
Moderate energy restriction for five days increased insulin-stimulated glucose transport 
in rat epitrochlearis 38% (p<0.05), a level of improvement is maintained for at least 20 
days. There was no evidence for changes in total GLUT-4 levels, indicating improved 
insulin action by a separate mechanism. In a separate study, Cartee, et al (366), energy 
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restriction extended for 5 months improved insulin-stimulated glucose uptake in rat 
muscle by 59%. Thus, it is likely that the bulk of the improvement in glucose transport 
occurred following the first few days of energy restriction (365,366). 
Subsequently, Dean et al. (367) sought to identify the mechanisms by which energy 
restriction enhances insulin action, independent of changes in total GLUT-4 levels in 
skeletal muscle. Rats were fed standard rodent chow ad libi/11111 or at 60 en% of ad libit11111 
intake. In muscle preparations for energy-restricted rats, the rate of insulin-stimulated 
glucose transport was nearly 2-fold higher (p<0.05) than in ad libit11m fed rats, despite 
similar levels of cell surface GLUT-4. Energy restriction altered neither the magnitude 
nor time course of the insulin-stimulated increase in IRS-1-associated PI3-K activity, 
suggesting energy restriction enhances a more distal step in the insulin signaling cascade, 
perhaps involving alterations in the subcellular localization of PI3-K activity, known to 
be an important aspect of insulin signal transduction (367). 
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VI. Energy Expenditure and Mitochondrial Uncoupling Proteins 
Components of Energy Expenditure 
In humans, basal energy expenditure is attributable to three components. The 
resting metabolic rate (RMR) is that energy expending by a resting, fasted subject in bed 
in the morning under ambient conditions. This component of daily energy expenditure 
includes the cost of fueling the metabolic systems of the body and maintenance of 
nonnal body temperature (368,369). RMR accounts for 60-70% of daily energy 
expenditure in most adults and as such is the single greatest component of basal energy 
requirements. Adaptive thermogenesis is defined as the energy required in excess of 
RMR in response a variety of factors including food intake, cold or heat acclimation, 
stress, and drug metabolism (368). Physical activity is the last component of daily 
energy needs and is by far the most variable component in adults. While this component 
can account for a significant amount of energy needs, physical activity represents only 
20-30% of total daily energy expenditure in most adults (369). 
Functions of UCPs in Mitochondrial Respiradon and ATP Generation 
Uncoupling proteins (UCPs) are mitochondrial transport proteins which dissociate 
mitochondrial respiration from oxidative phosphorylation such that heat, rather than 
ATP, is generated (370-372). Structurally, UCPs are composed of six membrane 
spanning a-helices, with both the C- and N-termini oriented in the cytoplasm. 
Mitochondria are the major sites of cellular ATP production. The metabolism of energy 
substrates generates electron carriers, such as NADH, that shuttle to the mitochondrial 
inner membrane, where they donate electrons to the electron transport chain (373). As 
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electrons move down this chain, protons are pumped out of the mitochondrial matrix by 
cotnplexes I, III and IV, creating a proton gradient. The UCPs function as metabolic 
uncouplers by dissipating this electrochemical gradient. Subsequently, protons may re­
enter the mitochondrial matrix by using the energy inherent to the proton gradient in a 
reaction coupled to ATP synthesis via ATP synthase and which requires oxygen 
consumption (370-373). Alternatively, protons may "leak" across the mitochondrial 
inner membrane in a process which by-passes ATP synthesis (374,375). Proton leakiness 
is recognized as a component of resting metabolic rate, with skeletal muscle proton leaks 
contributing an estimated 20-50% of total energy expenditure (376). 
UCP-1 and Brown Adipose Tissue Thennogenesis 
UCP-1 is a dimeric protein located in the inner mitochondrial membrane and is 
expressed exclusively in brown adipocytes (372). UCP-1 catalyzes the purine nucleotide­
sensitive transport of monovalent unipolar anions, including fatty acid anions. Purine 
nucleotide inhibition occurs by binding of the nucleotide to a regulatory region on the 
cytosolic side of the inner mitochondrial membrane (371 ,372). 
Brown adipose tissue (BA 1) differs from white adipose tissue primarily in 
mitochondrial density and lipid content (377). Adipocytes from brown fat are rich in 
mitochondria and contain stnall lipid droplets, while white adipocytes contain large lipid 
droplets and comparatively fewer mitochondria (377,378). In contrast to its role in 
humans (379), brown adipose tissue in rodents and most other mammals, is critical for 
maintaining body temperature via non-shivering thennogenesis (380). The thennogenic 
capacity of BAT is due to the expression of UCP-1 which disrupts the link between 
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mitochondrial respiration and oxidative phosphorylation from ATP generation, releasing 
energy as heat (373). UCP-1 expression in BAT is increased by cold (381), a1- and J3-
adrenoccptor activation (382), norepinepherine (382), NEF As (383) and PP AR agonists 
(384), while fasting and energy restriction suppress sympathetic stimulation of brown 
adipose tissue and consequently downregu1ates expression ofUCP-1 (385). 
Human Homologs of UCP-1 
In humans, BAT is active only transiently during infancy (379). Thus, regulation of 
body weight by increased energy expenditure due to mitochondrial uncoupling in BAT is 
unlikely. However, two homologues of UCP-1 have been identified in several human 
tissues (386,387). UCP-2 is expressed in a variety of human tissues including white 
adipose tissue, skeletal muscle, heart, liver, and pancreas (388,389). In rodent brown 
adipose tissue, UCP2 mRNA levels are highest before birth (390). Maximum levels of 
UCP2 mRNA are observed 48 hours after birth and correspond to the period of greatest 
mitochondrial biogenesis in BAT (390). 
In humans, UCP-3 expression is abundant only in skeletal muscle, although low levels 
of expression are detectable in brown adipocytes (387). In humans, two species of UCP-
3 mRNA have been identified; the fully functional long form, UCP-3L and a short fonn 
(UCP-3s) (387). A polyadenylation site at the junction of intron 6 and exon 7 of the 
UCP-3 gene results in premature truncation of roughly half of all transcripts. UCP-3s 
lacks the last 37 amino acid residues of the C-terminal region found in UCP-1 and UCP-
2 (387), which is required for purine nucleotide inhibition of UCP-1 uncoupling activity 
(391). 
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Evidence Against A Tbermoregu.Jatory Function for UCP-2 and UCP-3 
Acute cold exposure induces expression of UPC-3 in skeletal muscle, which is 
consistent with involvement of UCP-3 in non-shivering thermogenesis (392). However, 
expression of both UCP-2 and UCP-3 are elevated during starvation and energy­
restriction, physiological conditions during which energy conservation is critical and 
thennogenesis is suppressed accordingly (393). Expression of UCP-3 in skeletal muscle 
is also upregulated by conditions which increase free fatty acids, including fasting (394). 
Lastly, fasting studies conducted at thennoneutral temperatures to prevent the increase 
in energy needs that necessarily follow weight loss secondary to food deprivation, 
demonstrate that expression of UCP2 and UCP3 in muscle remain elevated (395). 
Role of UCP-2 in Hepatic Lipid Handling 
In severe obesity, chronic elevations in serum free fatty acids increase lipid flux to the 
liver, where fatty acids can uncouple mitochondrial oxidative phosphorylation from ATP 
generation leading to ATP depletion and ultimately cell necrosis (396). UCP-2 is not 
nonnally expressed to an appreciable degree in adult rat hepatocytes. However, lipid 
treatment of cultured hepatocytes results in a dose-dependent induction of UCP-2 (397). 
The induction of UCP-2 mediated uncoupling may limit synthesis and accumulation of 
triglycerides in hepatocytes by depleting cellular ATP levels necessary for triglyceride 
synthesis (397). Thus, in vitro studies demonstrating a stimulatory effect of increased 
lipid availability on hepatocyte UCP-2 expression, suggest a potential mechanism for 
disposing of excess substrates by induction of UCP expression in adipose tissue and 
skeletal muscle in vivo (384,398). 
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Induction of UCP-2 in Obesity 
UCP-2 expression is barely detectable in the livers of lean mice, however, UCP-2 
m.RNA and protein levels are elevated five- to six-fold in genetically obese ob/ ob mice 
(396). Hepatic UCP-2 induction in obesity may be an adaptive mechanism whereby the 
cell can dispose of excess energy substrates by activating pathways which uncouple 
substrate oxidation from energy production. There is a general increase in mitochondrial 
protein leak and mitochondrial oxidative capacity in hepatocytes from ob/ ob mice. 
Baseline ATP levels were -50% lower in ob/ ob mice compared to littermates. Portal 
vein occlusion rapidly decreased ATP levels in lean and ob/ ob mice, but the extent of 
ATP depletion is more dramatic in ob/ ob mice. 
The implications of this study are two-fold. By decreasing the efficiency of ATP 
production in the face of excessive substrate supply, the cell is able to balance ATP 
production with cellular energy needs. The downside of this system is that the ability to 
respond to acute stresses, such as an ischemic period, may be compromised. This is 
illustrated by the rapid depletion of cellular ATP stores when blood flow was occluded 
and the sluggish nature of ATP repletion upon reperfusion in ob/ ob compared with 
littenn.ate controls (396,397). 
UCP-2 as a Negadve Modulator of Insulin Secredon 
Normally, the ATP production within the pancreatic �-cell is tightly coupled to 
glucose metabolism, permitting these processes to proceed in parallel Within the �-cell, 
glucose oxidation increases cellular ATP levels and thus, raises the A TP:ADP ratio. The 
�-cell responds to the increased A TP:ADP ratio by closing membrane ATP-sensitive 
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potassium (KATP) channels, resulting in membrane depolarization, calcium (Ca2J influx 
through voltage-dependent calcium channels (VDCCs), and ultimately, insulin secretion. 
Under euglycemic conditions, the �-cell KATP channels are open, permitting potassium 
efflux from the cell and the resting membrane potential is clamped at -70 m V. When the 
glucose concentration to which the �-cell is exposed rises, ATP levels increase and 
displace ADP bound to KATP channels, permitting their closure. With regards to the �­
cell, the uncoupling of glucose metabolism from ATP generation may impair the ability 
of the �-cell to secrete insulin in response to glucose (399). 
The physiological role of endogenous UCP2 in regulating insulin secretion has been 
studied in Ucp2 gene knockout (-/-) mice by Zhang, et al. (400). Homozygous -/- mice 
lack an intact Ucp2 gene and fail to express UCP2 transcripts in all tissues which 
normally express high levels of UCP-2 mRNA including heart, kidney, spleen, white 
adipose tissue, and pancreatic islets. When incubated with glucose, islets from UCP-2 
deficient mice have higher concentrations of ATP and secrete 2-3 times more insulin 
than islets from control mice incubated under identical conditions. 
In the fed state, serum insulin levels are 2.8-fold higher and blood glucose levels 18% 
lower in UCP-2 deficient mice compared with wild type controls. Partial UCP-2 
deficiency (UCP-2+/- mice), are characterized by a phenotype intermediate between 
homozygous deficient and wild-type mice, with serum insulin levels elevated 2-fold and 
blood glucose levels reduced by 1 1  % compared to wild type controls. Fasting reduced 
blood glucose levels to a similar extent in control and homozygous mice, but insulin 
levels remained 3-fold higher in fasted homozygous animals compared to wild-type 
controls as a consequences of higher basal insulin secretion in UCP-2 deficient mice. 
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UCP-2 deficient mice maintain normal sensitivity to exogenously administered insulin, 
making it unlikely that the increase in insulin secretion occurred secondarily to peripheral 
insulin resistance (400). 
To assess the physiological consequence of induction of UCP-2 in islets in obese 
states, Zhang, et al. (400) subsequently crossed UCP-2 knockout mice were with ob/ ob 
mice, a mouse model of human obesity and non-insulin dependent diabetes mellitus. As 
a consequence of obesity, ob/ ob mice develop extreme insulin resistant and consequently, 
expand their �-cell mass 10- to 30-fold, in an unsuccessful effort to maintain 
nottnoglycemia (224). UCP-2 deficiency did not influence the course of obesity in ob/ ob 
mice. Beginning at 5 weeks of age, UCP-2 deficient ob/ ob mice had significantly higher 
insulin levels and lower blood glucose levels compared to ob/ ob mice with an intact 
UCP-2 gene. The improvement in glucose tolerance observed in UCP-2 deficient ob/ ob 
mice was largely due to enhanced �-cell function since UCP-2 deficient ob/ ob did not 
demonstrate enhanced sensitivity to exogenously administered insulin. 
Following administration of an exogenous glucose load, ob/ ob mice exhibit markedly 
elevated plasma glucose levels and significantly lower insulin response to lean littermates. 
In UCP-2 deficient ob/ ob mice, insulin levels rose significantly within 15 minutes and 
consequently, blood glucose levels were significantly reduced relative to ob/ ob mice. 
Thus, UCP-2 deficiency ameliorated the abnormalities of the insulin response normally 
observed in obese ob/ ob mice and further demonstrates that that UCP-2 negatively 
regulates glucose-induced insulin secretion (400). 
The mechanism by which obesity leads to enhanced UCP-2 expression in the �-cell is 
unknown. However, Lameloise, et al. (401) have established a link between UCP-2 
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expression, fatty acid excess and impaired glucose-stimulated insulin secretion. Chronic 
exposure to elevated free fatty acid levels may lead to the accumulation of long-chain 
acyl-CoA esters in the �-cell, which may open KATP-channels and hypetpolarize the 
membrane. This could prevent glucose-induced closure of KATP-channels and 
consequently, membrane depolarization. In vitro, incubation of INS-1 cells with glucose 
for 72 hours is associated with an increase in cellular ATP levels (p<0.02) and an 
increase in the A TP�P ratio (p<0.02), followed by membrane depolarization. When 
oleate is added to the incubation medium, neither ATP levels nor the A TP:ADP ratio are 
increased and the change in membrane potential is less than half that observed in control 
glucose-treated cells. This suggests that fatty acid exposure results in a low level of 
depolarization and impairs the capacity of the membrane to undergo further 
depolarization (401). 
UCP-3 as a Detenninant of Energy Expenditure 
While there is a notable lack of evidence to support a role for UCP-2 and UCP-3 in 
therm.oregulation, an increasing body of evidence suggests UCP-3 expression may be a 
critical determinant of energy expenditure (402). In non-diabetic male Pima Indians, 
BMI was positively associated with the level of UCP-3L mRNA in skeletal muscle (r=-
0.53, p=0.025). No association could be demonstrated between the level ofUCP-2 
expression and BMI in these subjects. Resting metabolic rate is an important 
determinant of 24-hour energy expenditure and the expression of UCP2 and UCP-3 in 
skeletal muscle suggests these uncoupling proteins may contribute to 24 hour energy 
expenditure. After adjusting for fat mass and fat free mass, sleeping metabolic rate 
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(SMR) was positively correlated with UCP-3L expression in skeletal muscle (r=0.69, 
p=0.006). If one assumes that m.RNA levels reflect UCP-3 protein content, these 
findings suggest that reduced expression of UCP-3L in skeletal muscle results in low 
sleeping metabolic rate. Low RMR is recognized as a factor which predisposes one to 
weight gain. Thus, it is interesting to speculate that individuals with low skeletal muscle 
UCP-3 expression may eventually have higher body weight compared to individuals with 
normal expression levels. 
Role for UCP-.1 in Insulin Stimulated Glucose Transport 
UCP-3 is normally expressed at low levels in L6 myotubules, making this an ideal 
system for studying the metabolic regulation of UCP-3. Huppertz, et al. (403) 
overexpressed human UCP-3 in rat L6 myotubules and observed 2-fold increases in 
glucose transport and GLUT-4 recruitment to the plasma membrane, which is similar to 
the effects observed in normal L6 myotubules treated with 100 nM insulin, suggesting 
enhanced UCP-3 expression in skeletal muscle in vivo may improve glucose homeostasis. 
Total cellular GLUT-4 levels are similar in control myotubles and those overexpressing 
UCP-3, and both cell types respond to 100 nM insulin with similar increases cell surface 
GLUT-4 content. The effects of UCP-3 to enhance glucose transport seem to be 
specific for skeletal muscle, since neither basal nor insulin-stimulated glucose uptake is 
increase by overexpression of UCP-3 in 3T3-L1 adipocytes (403) . 
L6 myocytes grown in glucose-free medium rely on oxidative phosphorylation, as 
opposed to glycolysis, to meet energy needs. Overexpression ofUCP-3 blocks oxidative 
phosphorylation and renders these cells unable to survive short term glucose deprivation 
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(404). Control myocytes begin to lose their characteristic morphological traits following 
6 days of exposure to a glucose-free environment. In contrast, L6 myotubules 
overexpressing UCP-3 lose their tubular structure and die within 2-3 days, which is 
consistent with the physiological consequences of uncoupling mitochondrial respiration 
and oxidative phosphorylation (404,405). 
Nutridonal Moduladon of UCP-2 and UCP-3 Expression 
Developmental changes in UCP2 and UCP-3 expression in skeletal muscle and 
alterations in response to nutritional changes have established that UCP-2 is relatively 
insensitive to nutritional intervention (394). In mice, UCP-2 mRNA is detectable in 
skeletal muscle at birth and the level of UCP-2 mRNA increases rapidly on the first day 
following birth with maximum levels of expression observed on the second day of life 
after which time, there is a progressive decline in UCP-2 expression (390). 
In contrast, UCP-3 rnRNA is almost undetectable at birth. There is a sudden, rapid 
increase in UCP-3 mRNA in skeletal muscle during the first day of life which is followed 
by a slower, progressive induction of UCP-3 expression. Maximum UCP-3 expression 
occurs on day 15  and corresponds to peak suckling activity of pups. Standard rodent 
chow is a high carbohydrate formula to which pups are weaned around day 21 of life. 
The shift in dietary macronutrient content from mother's milk (high fat) to rodent chow 
is associated with a decline in UCP-3 mRNA. Fasting of 15 or 21 day old mice was 
associated with an increase in serum NEF A levels and a parallel increase in expression of 
UCP-3 in muscle. UCP-2 expression was unchanged by fasting. Thus, the changes in 
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UCP-3 expression closely parallels changes in NEF A levels, whlle UCP-2 is insensitive to 
nutritional detenninants such as starvation and dietary macronutrient intake (390,394). 
To explore the roles of UCP-2 and UCP-3 in body weight regulation and substrate 
metabolism, Semac, et al. (384,392) examined expression of UCP-2 and UCP-3 in 
intrascapular brown fat and skeletal muscle in response to 50% energy restriction for 2 
weeks. At the end of the 2-week period of energy restriction, were divided into two 
groups: one group was sacrificed to examine the changes in UCP expression during 
energy restriction, while the second group was pair-fed to ad-libit11m controls to 
determine changes in UCP expression in response to refeeding. 
After 2 weeks of energy restriction, serum fatty acids were elevated and body fat of 
energy restricted animals was 50% below that of control animals (p<0.01). Nonetheless, 
no differences in body weight or energy intake were observed between refed and control 
animals following the two week refeeding period, suggesting animals were able to 
recover the weight lost during the period of energy restriction. Refed animals laid down 
body fat at a rate nearly 3-fold faster than control animals and consequently, on days 7 
and 14 of refeeding, body fat mass was significantly greater in refed versus control 
animals, despite similar body weights for the two groups. Thus, it seems that virtually all 
excess energy consumed during the refeeding period was directed toward lipogenesis. 
Energy expenditure was roughly 1 7% lower in refed animals, which contributed to a 2-
fold enhancement in energy efficiency, further promoting the flux of substrates towards 
lipogenesis. 
Expression of all three UCPs in intrascapular brown adipose tissue was reduced by 
energy restriction, and restored to control levels by day 5 of refeeding. Energy 
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restriction also increased the levels of UCP-2 and UCP-3 mRNA in gastrocnemius and 
soleus muscle compared to ad libitum fed control anjmals. That such significant 
upregulation of UCP-3 expression occurs during a period of energy restriction, when 
circulating free fatty acids would represent the predominant fuel utilized by muscle, 
implicates UCP-3 as a critical factor regulating lipid utilization. 
Interestingly, there was a more pronounced enhancement of UCP-3 expression in the 
gastrocnemius muscle (5-fold elevation, p<0.01 vs control) than in the soleus muscle (2.5 
fold increase, p<0.08 vs control). Following three days of refeeding, UCP3 expression 
was reduced relative to control animals. During refeeding, the gastrocnemius muscle 
again demonstrates greater metabolic flexibility compared to the soleus muscle. After 3 
days of refeeding, UCP-3 expression in gastrocnemius muscle was 12-fold greater in 
control compared to refed animals (p<0.01). Expression ofUCP-3 in soleus muscle was 
also increased in control compared to refed anjmals, albeit to a lesser degree (2.6-fold, 
p<0.05). UCP-3 levels in soleus muscle of refed aruma1s were restored to control levels 
by day 5 of refeeding, while levels in gastrocnemius muscle remained markedly 
suppressed below control levels following 10 days of refeeding. The pattern of UCP-3 
expression in skeletal muscle is consistent with the metabolic characteristics of both 
soleus and gastrocnenuus muscles. UCP-3 expression was increased in both muscles by 
energy restriction (384,392). This is consistent with the changes in lipid availability and 
glucose sparing by skeletal muscle during this time. 
The enhancement ofUCP-3 expression during the energy restricted period was 
greatest in the gastrocnemius muscle, which is composed of both oxidative and 
oxidative/ glycolytic fiber types. In contrast, the soleus muscle is composed primarily of 
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slow-twitch oxidative fibers and consequently has very low glycolytic capacity. Thus, 
soleus muscle relies more heavily on lipids for fuel even in the basal state and therefore, 
has very little capacity to further increase lipid utilization during a period of energy 
restriction when free fatty acids are more available (284). Suppression of UCP-3 levels 
during refeeding is associated with increase glucose availability and less reliance on lipids 
(384,392). As previously noted, soleus muscle is more heavily reliant on lipids as an 
energy substrate, which is consistent with the more attenuated effects of refeeding on 
UCP-3 expression in this tissue. 
The regulation of UCP-2 in response to fasting and refeeding followed the same 
pattern in soleus and gasttocnemius as that observed for UCP-3. Energy restriction was 
associated with increased levels of UCP-2 mRNA, with a more pronounced effect 
observed in gastrocnemius muscle. Refeeding restored UCP-2 levels in soleus muscle by 
day 3 of the refeeding period, while UCP-2 levels in gastrocnemius remained 
incompletely restored compared to control animals following 10 days of refeeding. 
Thus, UCP down-regulation during refeeding, effectively "spares" lipids from oxidation 
directing them instead to replenish adipose tissue stores in advance of a future period of 
energy deprivation. 'This study examined extremes in lipid availability. The question 
then arose as to whether more subtle changes in lipid availability would influence UCP 
expression (382,394). 
Samec, et al (395) examined the effects of dietary fat level in energy restricted animals 
upon refeeding. Two groups of energy restricted (50% of ad libit11111 intake) were refed 
with either a low-fat (6 en%) or high-fat (53 en%) diet for two weeks. Compared to 
control animals fed the low-fat diet, previously energy restricted animals subsequently 
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refed (isocalorically) the same diet had markedly lower levels of UCP-2 and UCP-3 
mRNA in gastrocnemius muscle (p<0.001). despite lower energy expenditure (-1 6%, 
p<0.001) and a 3-fold (p<0.001)  greater rate of adipose tissue accumulation. Compared 
with animals refed the low-fat diet, animals refed isocaloric amounts of the high-fat diet 
had higher levels of UCP-2 and UCP-3 in muscle, but lower energy expenditure (-12%) 
and increased (33%) body fat accumulation. Thus, refeeding the high-fat diet overcomes 
the suppression of UCP-2 and UCP-3 expression observed during refeeding the low-fat 
diet. Although no differences were detected between groups after 5 days of refeeding, 
plasma free fatty acid levels were higher in animals refed the high-fat diet (p<0.01) than 
in low-fat refed and control animals (395). 
Further support for the role of UCP-3 in lipid handling comes from human studies 
examining the effects of NEFA on UCP-3 expression (406). In the absence of 
hyperinsulinemia, infusion of a triglyceride emulsion elevates plasma glycerol, NEF A, 
triglyceride and �-hydroxybutyrate levels. In addition, there is a significant decrease in 
the rate of glucose oxidation (p<0.02), which is accompanied by a parallel increase in 
lipid oxidation (p<0.05). Triglyceride infusion specifically enhances the expression of 
UCP-3 in skeletal muscle, without affecting the level of UCP-2 expression. Skeletal 
muscle UCP-3 mRNA levels were positively associated with plasma NEF A levels 
(r=0.53, p=0.005), lipid oxidation rates (r=0.56, p=0.004), and plasma f3-
hydroxybutyrate levels (r=0.48, p=0.013). An inverse relationship between UCP-3 
mRNA levels in skeletal muscle and rates of glucose oxidation (r=-0.61 ,  p=0.001) was 
also observed (406). 
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When hyperinsulinemia was induced by exogenous insulin infusion, the rate of whole 
body lipid oxidation during triglyceride infusion is similar to that observed in the absence 
of insulin. However, hyperi:nsulinemia overrode the effect of triglyceride infusion on 
muscle UCP-3 m.RNA and abolished the relationship between UCP-3 m.RNA and 
plasma NEF As. Thus, plasma NEF A levels and lipid oxidation rates are important 
regu]ators of skeletal muscle UCP-3 expression in vivo. The finding that 
hyperinsulinemia blocks the increase in skeletal muscle UCP-3 expression associated 
with increased lipid availability, may link obesity-associated hyperinsulinemia and 
preferential use of lipids, when glucose is readily available (406). 
Effects of Obesity and Weight Reduction on the Expression of UCPs 
Vidal-Puig, et al. (407) have demonstrated a significant reduction in the levels of 
skeletal muscle UCP-3L (by 38%, p<0.0059) and UCP-3S (by 48%, p<0.0047) mRNA in 
weight-reduced subjects compared to lean and obese individuals. UCP-2 mRNA levels 
in skeletal muscle were similar in lean and obese subjects, while the level of UCP-2 
mRNA was increased by 30% in weight-reduced subjects. During active weight loss 
resulting in a 10% reduction in body weight, adipose tissue UCP-2 mRNA levels 
increased by 58%. With four weeks of maintaining the reduced body weight, UCP-2 
mRNA levels fell to 26% of their peak level observed during active weight loss. Thus, 
UCP-2 and UCP-3 mRNA levels respond discordantly to a sustained reduction in body 
weight. Whereas the levels ofUCP-3L and UCP-3S in skeletal muscle were decreased in 
weight-reduced previously obese individuals, UCP-2 mRNA levels increased. Active 
weight loss was also associated with an increase in the level ofUCP-2 tnRNA in adipose 
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tissue, which moderated as wejght stabilized. Based on these findings, the inability to 
maintain higher levels of UCP-3 in skeletal muscle may contribute to reduced energy 
expenditure in weight-reduced subjects (408). Furthermore, these findings suggests that 
the conditions of active wcight loss and maintenance of reduced-body weight are 
physiologically distinct and may be associated with alterations of substrate availability 
and utilization during these conditions ( 407). 
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VII. Metabolic Regulation by Peroxisom.al Proliferator-Activated Receptors 
Isotypes and General Pa ttern of Tissue Distribudon 
Peroxisome proliferators-activated receptors (PPARs), members of the nuclear 
hormone receptor superfamily, are transcription factors known to be important in the 
regulation of lipid storage and utilization, adipocyte differentiation, and insulin action 
(409,410). The PPARs are ligand-activated transcription factors th.at control gene 
transcription by binding to the promoter region of target genes in response to small 
lipophilic compounds including retinoic acid, thyroid hormone, vitamin D, and fatty 
acids (41 1-413). Three subtypes have been identified and each has a distinct tissue 
distribution pattern. In adult rodents, PP AR-a is expressed most abundantly in tissues 
with high rates of fatty acid utilization including, brown adipose tissue, liver, proximal 
tubules of the kidney, intestinal mucosa, heart, vascular endothelium and skeletal muscle 
(414). 'This isoform has been specifically implicated in the control of lipoprotein 
metabolism, fatty acid oxidation, and fatty acid uptake. PP AR-y expression is highest in 
white and brown adipose tissue, although it is expressed to a lesser degree in the large 
intestine and retina (414). 
Attempts to generate PPAR-y null mice were unsuccessful; homozygous PP AR-y­
deficient mice were embryonic lethal and identified this isoform as playing a critical role 
in placental development (41 5,41 6). In vitro and in vivo studies have demonstrated the 
necessity of this isofonn in adipogenesis ( 417). Alternative splicing yields two distinct 
products, PPAR-yt and PPAR-y2. PPAR-y2 contains an N-terminal span of 30 amino 
acids which is absent in PPAR-yt (418). PPAR-� has a broad expression pattern and is 
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found in higher amounts than PPAR-IX and PP AR-y in all tissues with the exception of 
adipose tissue (414,419) .  Recently, PPAR-� activation has been linked to basal lipid 
metabolism, inflammation, and colon cancer (420-422). 
Structural Organization and Mechanism of Activation 
The three PP AR isotypes share common structural organization. The amino-terminal 
A/B domain is poorly conserved between the three isotypes and contains the ligand­
independent transactivation domain, the phosphorylation state of which contributes to 
the regulation of the IX- and y- isoforms (423,424). The central (C-domain) contains the 
DNA-binding region and is highly conserved between isotypes, with two zinc finger-like 
regions and an IX-helical DNA-binding motif. The ligand binding domain (LBD), 
composed of 13 «-helices and a small four-stranded �-sheet, of PPAR-IX and PPAR-y is 
about twice the size of other receptors, which permits binding of a wide range of ligands 
( 425). An additional IX-helix at the base of the LBD facilitates the entry of ligands by 
increasing the size of the pocket as well as conferring ligand specificity (426,427). 
Ligand binding to the PP ARs induces a conformational change which allows 
recruitment of co-activators and the release of repressors (426,428). Activation of 
PP ARs requires dimerization with the 9-cis retinoid X receptor (RXR) which results in 
the formation of a stable complex that is capable of binding PP AR response elements 
(PPREs) in the promoter region of genes under the transcriptional control of PPARs 
(425,429,430). The consensus PPRE sequence is 5'-AACT AGGNCA A AGGTCA-3' 
(431). These elements bind PPAR-RXR heterodimers in a ligand-independent manner, 
with the PP AR occupying the 5' extended half site while RXR is situated in the 3' half 
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site with one nucleotide spacing between the two half sites. In the absence of ligand, the 
PP AR/RXR heterodimer is associated with a multi.protein corepressor complex that 
contains intrinsic histone deacetylase activity which serves to inhibit active gene 
transcription (425,426,431). Upon binding of ligand, the corepressor complex 
dissociates and a coactivator complex, containing histone acetylase activity, is recruited 
to the PPAR-y/RXR heterodirner to facilitate gene transcription (432,433) . 
Tissue Distribution of PPAR lsotypes and Variations in Altered Metabolic States 
In nearly all adult rodent tissues, PPAR-� is the most abundantly expressed isotype, 
with highest levels of expression (by -4-fold) in the digestive tract, with lower levels of 
expression in the kidney, heart, diaphragm, and esophagus. The expression of PP AR-ex 
in brown adipose tissue is approximately 4-fold higher than its expression in the liver, 
heart, diaphragm, skeletal muscle, esophagus and kidney. Expression of PP AR-a in the 
liver is three-fold higher than the level of expression found in the small intestine and 
skeletal muscle. In white adipose tissue, PP AR-a expression is detected at negligible 
levels. PPAR-y1 mRNA is abundant in both white and brown adipose tissue, where its 
expression is comparable to PP AR-ex. Adipose tissue expression of PP AR-yt is three­
fold higher than is observed in the colon and cecum. Compared to the adipose tissue, 
much lower levels of PPAR-y1 expression are found in the spleen, stomach, lung, heart, 
small intestine, and liver. Both PP AR-y isoforrns have been consistently found in the 
lung, white adipose tissue, brown adipose tissue, and skeletal muscle, although the level 
of PPAR-y2 expression is 1 8-33% of the level of PPAR-y1 (434). 
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In adult rats fasted overnight, the expression of PP AR-� decreases by 75 and 80% in 
the liver and kidney, respectively. PPAR-<X expression is dramatically increased in the 
liver, small intestine, and colon following a 12-hour fast. Fasting increases the 
expression of PPAR-<X in the liver by 75%, underscoring the important role of this 
isoform in hepatic lipid metabolism ( 434). Of the two PP AR-y isofonns, only -y2 
appears to be regulated by fasting, resulting in a 50% reduction of PPAR-y2 in white and 
brown adipose tissue (434) . 
To evaluate the tissue distribution and potential role of the PPARs in insulin action in 
fat and skeletal muscle of humans, muscle biopsies were obtained from lean, obese and 
subjects with NIDDM. In all subjects, appreciable amounts of all three known PP AR 
isoforms were present in skeletal muscle. PPAR-a protein expression was consistently 
greater (5- to 9-fold, p<0.05) in muscle than in abdominal adipose tissue from the same 
subject. The high levels of PPAR-a protein in muscle relative to fat (7.6:1) suggest a role 
for PPAR-a in muscle fatty acid metabolism. PP AR-� protein levels were equally 
abundant in muscle and adipose tissue. The relative expression of PPAR-y protein in fat 
and muscle was similar in non-diabetic and diabetic subjects, however PP AR-y2 protein 
was detectable only in adipose tissue. PP AR-yt seems to be the predominant isoform 
expressed in skeletal muscle, while adipose tissue contains both the -yt and -y2 isoforms. 
In muscle, no differences in expression of PPAR-a, -�. or -y protein expression were 
detected between diabetic and non-diabetic subjects. Similarly, the relative expression of 
PP AR-y mRNA and protein was similar in muscle from diabetic and non-diabetic 
subjects with significant correlations between PPAR-y protein and mRNA in both non-
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diabetic (r=0.61, p<0.05) and diabetic (r=0.80, p<0.05) groups. The finding of both the 
-a and -y isofonns of PP AR in skeletal muscle suggests these receptors influence 
different but related aspects of skeletal muscle metabolism (435) . However, only PPAR­
y protein expression appears to be influenced by the prevailing metabolic state, with the 
highest levels of the protein being found in the most insulin resistant subjects. 
Furthermore, the relationship between PPAR-y protein and skeletal muscle insulin action 
and glucose disposal is either a cause or consequence of diabetes as these alterations are 
not observed in non-diabetic subjects suggesting PP AR-y is the isofonn through which 
insulin influences glucose and lipid metabolism in skeletal muscle (435). 
The liver plays a critical role in glucose homeostasis and lipid metabolism in vivo. 
While PPAR-a is abundantly expressed in the liver, basal expression of PPAR-y in the 
liver is very low (434). PPAR-y mRNA expression is reportedly increased in the liver of 
ob/ ob mice; however, it is unclear if there are any functional consequences of this 
upregulation (436). PPAR-(X mRNA was abundantly expressed in the liver of control 
animals and was increased by 2.3-fold in ob/ ob and by 2.2-fold in db/ db mice relative to 
their respective controls. Basal hepatic expression of PP AR-y was low in control 
animals, but expression is increased by 7.9-fold in ob/ ob and by 9.4-fold in dh/ dh mice 
compared with littennate controls (437). Similar levels of PPAR-6 mRNA were detected 
in livers of control, ob/ ob and db/ dh mice. Adipose tissue PPAR-y mRNA levels were 
similar in control, ob/ ob and db/ dh mice (438). These data suggest that the increased 
expression of PPAR-cx and PPAR-y in the liver is related to the development of obesity. 
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Levels of PP AR-ci and -'Y mRNA in liver were examined in ob/ ob mice at the age of 5 
and 10 weeks to determine the relationship between the onset of obesity and the increase 
in PPAR isofonn expression. At five weeks of age, ob/ ob mice exhibit a modest increase 
(of -40%) in body weight compared to age-matched littermate controls. However, by 
10  weeks of age, the weight of ob/ ob mice is almost 150% of age-matched controls. 
Comparable levels of PPAR-ci mRNA is detected in the liver of control and ob/ob mice 
at 5 weeks of age but levels are increased 2.8-fold in ob/ ob mice at the age of 10 weeks. 
Induction of PPAR-y mRNA in liver appears to be an earlier consequence of obesity 
with levels increased by 7. 7- and 9 .3-fold in 5- and 10-week old ob/ ob mice, respectively 
(437,438). 
Despite the low level of PP AR-y in human skeletal muscle, its expression in this 
tissue has been the focus of much attention because of the central role skeletal muscle 
plays in the development of insulin resistance. Lapsys, et al. (439) determined if PPAR-y 
expression in human skeletal muscle was associated with the expression of genes known 
to be important in lipid metabolism. PPAR-y m.RNA expression was significantly 
correlated with expression of LPL (c = 0.54, p=0.003) and F ABP (c = 0.324, p=0.034).  
Furthermore, PP AR-y expression was significantly correlated with expression of CPT-1 
(c = 0.42, p=0.012), a key enzyme involved in �-oxidation of fatty acids. Together, 
these findings suggest that enhanced PPAR-y activity in skeletal muscle may regulate 
lipid metabolism by up-regulation of lipid metabolizing genes. Such regulation seems 
contrary to the improvements in skeletal muscle insulin action attributed to the PP AR-y 
agonists ( 440), since increased activity of lipid metabolizing enzymes may increase 
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intramyocellular lipid levels. Alternatively, skeletal muscle may adapt to TZD treatment 
over several weeks so that the net result of this type therapy is to simultaneously increase 
lipid flux to adipose tissue and reduce circulating lipid levels by enhancing skeletal 
muscle lipid utilization ( 440). 
Endogenous and Synthedc PPAR Ligands 
PP ARs have a large ligand-binding pocket which allows the receptors to 
accommodate a number of different ligands (41 1). In vitro studies have identified a 
number of fatty acid derivatives capable of binding to and activating PP ARs (413,414). 
PP AR-<X have the highest affinity for fatty acids, preferring long chain unsaturated fatty 
acids such as linoleic, linolenic and arachidonic acid (413,441,442) . Llnolenic and linoleic 
acids bind all three PPAR isotypes but have the highest affinity for PPAR-<X (442). 
Inflammatory mediators including 8(S)-hydroxy-eicosatettaenoic acid (8(S)-HETE) and 
leukotriene B4 are specific for PP AR-<X, whereas the linoleic acid metabolite 1 5-deoxy-
Ll12, 14-prostaglandin J2 (PGJ2) is the most potent natural ligand for PPAR-y identified 
thus far (443). Long chain polyunsaturated fatty acids are effective PPAR-� natural 
ligands ( 444). 
The fibrates are a class of drugs prescribed for the treatment of dyslipidemia, most of 
which preferentially activate PPAR-a (445). The class of drugs known as 
thiazolidinediones (fZDs) was discovered during the screening of a nwnber of 
compounds for hypolipidemic actions (446-448). These compounds differ primarily in 
their side chain structures (449). In rodent models of insulin resistance, these drugs were 
consistently shown to reduce blood glucose levels and improve hyperinsulinemia (449). 
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Three TZDs, which specifically activate PPAR-y, have been studied extensively in 
humans: ttoglitazone (Rezulin*}, rosiglitazone (Avandia*}, and pioglitazone (Actos*} 
(448). Of these rosiglitazone has the highest binding affinity for PPAR-y. Troglitazone 
has the weakest binding affinity for PP AR-y and was the first TZD introduced for the 
treatment of NIDDM in humans (448). However, ttoglitazone was withdrawn from the 
market in March 2000 after its use was linked to severe hepatotoxicity leading to hepatic 
failure and death (450,451). Rosiglitazone and pioglitazone have been available for 
clinical use since 1999 (452,453). The regulation of inflammatory processes by PPAR-ix 
and PPAR-y may be mediated in part by activation of these isotypes with non-steroidal 
anti-inflammatory drugs, such as indomethacin and fenoprofen (454). 
Physiological Functions of PPAR-«. Activation 
The physiological functions of PP AR-ix have been examined using the PP AR-a null 
mouse (PPAR-a·1). The phenotype of the fasted PPAR-a·1· mouse, which is more severe 
than the phenotype of fed PP AR-a null mice, includes hypoglycemia, hypothermia, 
elevated plasma free fatty acids, and fatty liver. That fasting induces a more impaired 
phenotype than that observed in fed animals underscores the pivotal role of PPAR-a in 
the adaptive response to fasting. These mice have a reduced capacity for metabolism of 
long chain fatty acids, which contributes to dyslipidemia, expansion of adipose tissue 
stores, and excessive hepatic lipid accumulation (455-459). When fasted, PPAR-a null 
mice have severe and prolonged hypoglycemia (460,461). PPAR-cx expression could 
affect glucose homeostasis by virtue of its expression in several tissues: the liver, 
pancreatic �-cells, and peripheral insulin-sensitive tissues (419,462). PPAR-cx·1· mice 
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develop fatty liver characterized by pronounced accumulation of large lipid droplets in 
hepatocytes in response to high-fat feeding. PPAR-a·1• mice maintain numerous lipid 
droplets following an overnight fast, which may be partially mediated by circulating free 
fatty acid levels that are 2-fold higher in fasted PP AR-a·1· mice compared with fasted 
wildtype controls (461). 
Plasma �-hydroxybutyrate is an important end product of fatty acid oxidation and is 
produced exclusively by the liver. Fasting greatly .increases plasma �-hydroxybutrate 
levels in wild-type mice, an effect not observed in PPAR-a deficient mice. 
Consequently, plasma �-hydroxybutrate levels in fasted wildtype mice were 7-fold higher 
(p<0.01) than in fasted PPAR-a deficient mice, suggesting a marked impairment in 
induction of &tty acid oxidation in mice lacking functional PPAR-a in liver. Enhanced 
fatty acid oxidation during fasting ensures that an adequate gluconeogenic response is 
mounted to maintain blood glucose levels. In the early stages of a prolonged fast, blood 
glucose levels are largely maintained by glycogenolysis. Within 5 hours following food 
withdrawal from PPAR-ix deficient mice, there is a rapid and precipitous fall in blood 
glucose levels, compared to the more sustained and less pronounced fluctuations 
observed in wild-type mice. The rapidity with which hypoglycemia develops in food 
deprived PPAR-a·1• mice suggests a reduction in glycogen stores in the livers of fed 
PPAR-a·1• mice. As fasting is prolonged, blood glucose levels continued to fall in PPAR­
ix·/- mice, suggesting impairments in gluconeogenesis as well. Despite the inability of 
PPAR-cx·1· to maintain nonnal glucose homeostasis during fasting, glucose response 
curves following .intraperitoneal injection of glucose were similar in PPAR-ix·1· and wild-
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type mice, implying peripheral insulin sensitive does not suffer as a result of PP AR-at 
deletion (460,461). 
Guerre-Millo, et al. (462) examined the effects of PP AR-at deficiency on glucose 
homeostasis and insulin resistance induced by high-fat feeding. Compared with wildtype 
mice fed standard rodent chow, high-fat fed wildtype mice developed hyperglycemia and 
hyperinsulinemia, a compensatory response reflecting peripheral insulin sensitivity also 
seen as a contributing factor in obesity induced by high-fat feeding. Conversely, 
PP AR-<X-/- mice fed the high-fat diet maintained normal blood glucose and insulin levels. 
Despite the absence of hyperinsulinemia in high-fat fed PPAR-<X-/· mice, adipose tissue 
mass (p<0.05) and circulating leptin levels (p<0.05) were significantly higher than 
control mice fed standard rodent chow. Liver weight was elevated compared to animals 
consuming standard chow in both high-fat fed wild-type (p<0.05) and PPAK1· (p<0.05) 
mice, but was more pronounced in the absence of functional PP AR-at. 
To more directly determine if insulin resistance developed in PPAR-a·1· mice, 
intraperitoneal insulin and glucose tolerance tests were preformed. Glucose and insulin 
response curves were similar in wild type and PPAR-<X_,_ mice fed the standard diet. In 
contrast, high-fat fed wild-type mice demonstrated a blunting of the hypoglycemic 
response to insulin, such that both the AUCg1IICOle and the AUC.,.u1in was significantly 
greater (by -50%, p<0.05) than in wildtype mice consuming the standard diet. None of 
these abnormalities were observed in high-fat fed PPAR-«-/- mice. The insulin resistance 
index (IR index), calculated as the product of the areas under the glucose and insulin 
curves obtained during the glucose tolerance test, demonstrated that the high-fat diet 
caused a four-fold increase in the IR index of wild-type mice (p<0.05), whereas no 
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change was observed in PP AR-ex-/- mice. Based on these data, a phenotype of insulin 
resistance emerges in wild-type mice in response to high-fat feeding, whereas lack of a 
functional PPAR-a appears to protect against hlgh-fat diet related impairments in insulin 
action. Furthermore, these data suggest a role for PPAR-cx in control of peripheral 
glucose utilization in response to dietary fat. According to the Randle hypothesis (55), 
increased fatty acid oxidation would impair insulin-stimulated glucose uptake. PPAR-a-1· 
mice have a reduced capacity for fatty acid utilization in insulin-sensitive tissues, which 
would favor the increased use of glucose in tissues such as skeletal muscle and 
intrascapular brown adipose tissue. Thus, the PP AR-ex response may contribute to the 
accumulation of intracellular fatty acid-derived signaling molecules that may 
subsequently impair insulin-stimulated glucose utilization and promote the development 
of insulin resistance. No major impairments of �-cell insulin release were observed in 
PPAR-cx null mice, regardless of diet (462). This is somewhat unexpected since one 
would expect that lack of PP AR-ex would reduce fatty acid oxidation in islets, resulting in 
excessive lipid accumulation which is known to impair the insulin response to glucose 
(463). 
Effects of Synthedc PPAR� Agonists on Metabolic Reguladon 
Mancini, et al ( 464) examined the effects of fenofibrate treatment on the 
development of obesity in response to high-fat feeding. Normal rats experienced a 25% 
increase in body weight following 2 months of high-fat feeding, whereas this increase in 
body weight was prevented in rats treated with fenofibrate while consuming the same 
high-fat diet. Consequently, final body weights were similar for control animals 
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consuming standard rodent chow and fenofibrate-treated animals consuming the high fat 
diet, with body weight of both groups 16% lower (p<0.05) than in untreated high-fat fed 
rats. In a separate group of animals consuming the high-fat diet, fenofibrate treatment 
was not initiated until the beginning of the second month, when body weights were 
already significantly greater (p<0.05) than control animals fed standard rodent chow. 
Fenofibrate was administered to one group solely during the second month of high-fat 
feeding. However, fenofibrate treatment solely during the second month of high-fat 
feeding, attenuated weight gain such that these animals weighed 14% less (p<0.05) than 
untreated, high-fat fed animals. Furthermore, the effect of fenofibrate was greater in 
animals treated only in the second month of high-fat feeding. Visceral fat mass in high 
fat fed animals was 163% of that from animals consuming the standard diet (p<0.05). 
Fenofibrate treatment of high-fat fed animals for one or two months reduced WAT 
mass by 42 and 55%, respectively compared to untreated high-fat fed animals (p<0.05). 
There was a tendency for greater resting metabolic rate in fenofibrate-treated animals but 
this did not reach significance. Hepatic PPAR-cx mRNA levels were increased 1.7-fold in 
fenofibrate-treated animals compared to untreated high-fat fed controls. Gastrocnemius 
UCP-2 mRNA levels were decreased by 3.3- and 2.2-fold after 1 and 2 months of 
fenofibrate treatment, respectively, whereas expression of UCP-3 in this tissue was 
unaffected. The final weight of fenofibrate treated high-fat fed animals was similar to 
control which suggests that under conditions of enhanced fatty acid availability, 
fenofibrate prevents excessive weight gain and likely promotes mobilization of adipose 
tissue lipid stores (464). 
124 
Physiological Functions of PPAR-y Activation 
To examine the physiological role of PPAR-y in vivo, Kubota, et al. (465) generated 
PP AR-y-deficient by targeted disruption of the PP AR-y gene. Homozygous PP AR-y 
deficient mice (PPAR-y -/) were embryonic lethal due to placental dysfunction. 
Heterozygous PPAR-y+/- mice showed nonnal weight gain and insulin sensitivity on 
standard rodent chow. To determine the role of PPAR-'Y in high-fat diet-induced obesity 
and insulin resistance, wild type and PPARy+I- mice were fed either a high-carbohydrate 
(HC) or high-fat (HF) diet. There was no difference in body weight gain between wild 
type and PPAR-y+I- animals consuming the HC diet for 15 weeks. Wildtype mice 
consuming the HF diet gained significantly more body weight than did wildtype mice fed 
the HC diet. In contrast, PPAR-f1· mice consuming the HF diet gained very little 
weight. Wildtype mice fed the HF diet had significantly greater adipose tissue 
accumulation than either wild type or PPAR-y+1- mice consuming the HC diet. Thus, 
PPAR-y+I- mice were somewhat protected from excessive adipose tissue accumulation 
nonnally induced by chronic consumption of a high-fat diet. Wildtype animals fed the 
HF diet had marked hepatic lipid infiltration, which was absent in HF-fed PPAR-y
+l­
animals. Total white adipose tissue mass of epididymal, retroperitoneal, and perirenal fat 
pads was reduced by 70% (p<0.01) in HF-fed PPAR-y+I- mice compared to HF-fed wild 
type mice. Adipocytes from wild type and PP AR-'Y+/- mice fed the HF diet were 
considerably larger than adipocytes from mice fed the HC diet. However, adipocytes 
from PPAR-y+/- mice fed the high-fat diet were significantly smaller than wild type mice 
fed the same diet. 
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After 15 weeks of high fat feeding, the glucose lowering effect of insulin was 
markedly larger in PPAR-·(
1• than in wild type mice. Thus, PPAR-·(1.mice were insulin 
sensitive while HF-fed wild type mice were insulin resistant. Consistent with greater 
insulin sensitivity, plasma insulin levels were significantly lower in PPAR-·(1• mice after 
HF feeding compared to wild-type animals fed the same diet. Glut-4 m.RNA levels in 
epididymal adipose tissue were reduced in both mouse genotypes by high-fat feeding, 
but remained approximately 2-fold higher in PPAR-"(+/- mice compared to wild type, 
which may partially account for the increased sensitivity to insulin in these animals. 
To determine if the physiological benefits of partial PP AR-y ablation observed in 
PPAR-"(+/- mice could be overridden by increasing the activity of PPAR-"(, wild type and 
PPAR-"(+/- mice were given a low dose (0.004% wt/wt) of pioglitazone, a PP AR-y 
agonist, while consuming the high-fat diet. Pioglitazone treatment for 5 weeks increased 
body weight gain and total white adipose tissue mass of epididymal, retroperitoneal and 
perirenal fat pads in both mouse genotypes compared to untreated animals. In HF-fed 
wild type mice, pioglitazone treatment normalized blood glucose and insulin levels, and 
thus, lessened the severity of insulin resistance induced by the high-fat diet. In contrast, 
PPAR-y+I- mice treated with pioglitazone experienced increased serum insulin levels 
without any change in blood glucose levels, indicating a reduction in insulin sensitivity. 
Thus, pioglitazone treatment further reduced insulin sensitivity in PPAR-"(+/- mice, 
effectively driving them toward a state of insulin resistance similar to that induced by the 
high-fat diet in untreated wild type mice. In wildtype mice, pioglitazone treatment 
caused a modest but significant decrease in adipocyte size, associated with an increase in 
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adipocyte number. Smaller adipocytes are known to be more responsive to insulin than 
larger adipocytes. In contrast, PP AR-y
+f. mice, pioglitazone treatment caused a 
significant increase in adipocyte size without altering the total number of adipocytes. 
1bis suggests that increased PPAR-y activity in these mice abolished the protection from 
adipocyte hypertrophy in response to high fat diet in these animals. The net effect of 
increased PPAR-y activity in PPAR-·(1· animals by low dose pioglitazone was sufficient 
to cause adipocyte hypertrophy but unable to stimulate differentiation. 
Despite the reductions in adipose tissue mass and adipocyte size, leptin mRNA levels 
were markedly increased in PPAR-y+f. animals on the high fat diet compared to wild 
type. Furthermore, serum leptin levels were -1 .8-fold higher in PPAR-y+f. animals on 
HF-diet compared to wild type. 1bis is attnbutable to the greater secretory capacity of 
adipocytes in PPAR-y+f. animals compared with wild type. Despite higher serum leptin 
levels in high-fat fed PPAR-y+I-, daily leptin administration resulted in similar reductions 
in food intake and body weight in high-fat fed PP AR-y+f- and wild-type mice, suggesting 
leptin sensitivity was unaltered 
Supraphysiological activation of PP AR-y by TZD markedly increase triglyceride 
content of white adipose tissue, thereby decreasing the triglyceride content of the liver 
and muscle, leading to amelioration of insulin resistance. Unfortunately, this occurs at 
the expense of an expanded adipose tissue mass (466). Heterozygous PPAR-y deficiency 
(PPAR-y+1) decreases the triglyceride content of white adipose tissue, skeletal muscle, 
and liver in association with increased leptin expression, increased fatty acid oxidation, 
and decreased lipogenesis, thereby ameliorating high-fat diet induced obesity and insulin 
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resistance. TZDs increase total white adipose tissue mass while at the same time 
stimulating adipocyte differentiation and apoptosis, which prevents adipocyte 
hypertrophy and the subsequent secretion of adipocyte-derived factors (eg. 1NF-a, free 
fatty acids) which contribute to the development of insulin resistance. Thus, insulin 
resistance is improved by two seemingly contradictory states: PP AR-y deficiency and 
supraphysiological PPAR-y activation. 
PP.AR-y Expression in Insulin-Resistant Humans and Treatment with 7ZDs 
To determine whether the in vivo metabolic milieu influences the expression of 
PPARs in muscle, Loviscach, et al (467) examined the relationships between PPAR 
protein levels and clinical characteristics of subjects. Multiple regression analysis showed 
no influence of age, BMI, fasting NEF As, fasting triglycerides, blood glucose, glycated 
hemoglobin, and fasting serum insulin on PP AR protein levels in the study group as a 
whole or in diabetic and non-diabetic subjects individually. Because PP AR-y has been 
implicated in skeletal muscle insulin sensitivity, the relationship between these variables 
was explored. The insulin-stimulated glucose disposal rate was determined during the 
last 30 minutes of a hyperinsulinemic euglycemic damp and used as an index of insulin 
action in skeletal muscle. In diabetic subjects, there was an inverse relationship between 
muscle PPAR-y protein and maximum GDR (r=-0.47, p<0.05). Conversely, in non­
diabetic subjects there was a nonsignificant trend for increasing PPAR-y protein with 
increasing GDR, the opposite of the association noted in diabetic subjects. This 
suggests an abnonnality in PPAR-y expression in subjects with NIDDM. 
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Diabetic subjects were further classified according to severity of insulin resistance 
estimated by glucose disposal rate during clamp studies. Diabetic subjects with severe 
insulin resistance showed significantly higher muscle PP AR-y protein levels compared 
age and weight matched diabetic subjects with moderate insulin resistance (p<0.01) and 
low insulin responsive non-diabetic subjects (p<0.01 ). Thus, the most insulin resistant 
diabetic subjects had the highest level of PPAR-y protein in muscle. Expression of 
PP AR-y protein in muscle was not significantly altered from baseline levels by 3 hours of 
insulin infusion (467). 
Insulin (0.1 µmol/Q induces a rapid and transient increase in PP AR-y2 mRNA, with 
a maximal effect after 2 hours (77±21%) and return to baseline levels by 3 hours. In 
contrast, PP AR-yt mRNAs increased slowly and steadily during the 6 hour of incubation 
with insulin, achieving values 57±8% higher than basal by the end of the incubation. 
Dose response curves clearly demonstrate that induction of PPAR-yt and PP AR-y2 
mRNA is dependent on insulin level The half maximal effect occurred with insulin 
concentrations of -1-5 nmol/1 for both isoforms (468). 
Based on the results of their in vitro studies, Rieusset, et al. ( 468) characterized the 
expression of PPAR-yt and PPAR-y2 in subcutaneous adipose tissue and skeletal muscle 
in subjects over a wide range of BMI. To investigate the acute effect of insulin on 
PPAR-y expression, control, obese non diabetic and subjects with NIDDM underwent a 
3-hour euglycemic hyperglycemic clamp. GIR required to maintain euglycemia was 
greatest in control subjects (p<0.05 vs. both), and significantly lower in obese subjects 
and non-obese subjects with NIDDM, indicating profound insulin resistance with 
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respect to whole body glucose disposal in obese and diabetic subjects. Plasma free fatty 
acids decreased in all groups during the insulin clamp but remained higher in obese and 
NIDDM subjects than in control (p<0.05). 
This study demonstrates that insulin acutely upregulates PPAR-y mRNA and protein 
levels in human adipocytes. In subcutaneous abdominal adipose tissue, mRNA levels for 
both PP AR-yt and PPAR-y2 were increased two-fold following a 3-hour insulin 
infusion. The stimulatory effect of insulin is observed in lean, obese and subjects with 
NIDDM. In isolated human adipocytes, insulin induced PPAR-y mRNA in a dose­
dependent manner, with half maximal stimulation achieved at concentrations of 1-5 
nmol/1, suggesting this in vivo effect was due to direct action of insulin on adipocytes. 
In vivo, a 3-hour period of hyperinsulinernia led to a two-fold increase in PPAR-yt and 
PP AR-y2 mRNA levels in abdominal subcutaneous adipose tissue. This effect is 
observed in lean and obese subjects, with or without NIDDM, which suggests that these 
pathologies are not associated with altered regulation by insulin of PPAR-y gene 
expression. Furthermore, although obese subjects and those with NIDDM were 
markedly insulin resistant with regards to whole body glucose uptake, the findings of this 
study indicate that the pathway involved in regulation of PPAR-y expression in not 
resistant to insulin action. This study also confirmed previous reports in which the basal 
expression level of PPAR-y in adipose tissue is not altered in obese subjects or those 
with NIDDM ( 468) . 
The in vivo regulation of both PPAR-y splice variants (PPAR-yt and -y2) have been 
examined in obese and weight-reduced subjects by Vidal-Puig, et al. (469). PPAR-yt 
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mRNA expression was highest in adipose tissue with much lower levels of expression 
detected in liver, skeletal muscle and heart. The expression of PPAR-y2 mRNA was 10-
25% of that seen in adipose tissue, with comparable levels found in lean, obese and 
diabetic subjects. To determine if obesity is associated with abnormal aclipose tissue 
expression of PPAR-y, subcutaneous aclipose tissue biopsies were obtained from lean 
and obese subjects and levels of PPAR-y transcripts, normalized with 18S expression, 
determined. Adipose tissue expression of PPAR-y2/18S was increased 43% (p<0.05) in 
obese subjects compared to age- and sex-matched lean controls. In contrast, levels of 
PPAR-y1/18S expression were similar or slightly reduced in obesity. There was a strong 
positive correlation between the ratio of PPAR-y2/-y1 and BMI in all subjects (r=0.70, 
p<0.001). Sexually dimorphic expression was apparent with increased expression of 
both PPAR-y1 (p<0.05) and PPAR-y2 mRNA (p<0.01) in subcutaneous adipose tissue 
of women compared to men with comparable BMI. In response to energy restriction, 
obese subjects demonstrated improved metabolic control characterized by a 10% 
reduction in body weight and fasting insulin levels that were 26% lower (p<0.01) than 
before weight loss. These changes were accompanied by a 25% reduction (p<0.05) in 
adipose tissue PPAR-y2 expression. Reduced PP AR-y2 expression was a transient effect 
as pre-weight loss expression levels were re-established after maintaining reduced body 
weight for four weeks. Expression of PPAR-y1 was not influenced by weight loss (468). 
Cha, et al (470) examined the influence of short-term (2 days) troglitazone 
administration in subjects with NIDDM. Troglitazone treatment increased basal glucose 
uptake by 26% (p<0.05) and enhanced insulin-stimulated glucose uptake by 23% 
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compared with untreated subjects with NIDDM. The improvements in basal and 
insulin-stimulated glucose uptake in subjects treated with troglitazone occurred in the 
absence of any changes in the level of GLUT-4 protein. However, troglitazone 
increased basal and insulin-stimulated glycogen synthase activity by 132 and 77% 
(p<0.05), respectively compared with untreated subjects with NIDDM. Skeletal muscle 
palmitate oxidation was 68% (p<0.005) greater in troglitazone-treated NIDDM 
compared with untreated diabetic controls. This was partially attributable to the 
troglitazone-associated increase (1 13±41% above controi p<0.025) in expression of 
FAT/ CD36, a protein which facilitates fatty acid transport by skeletal muscle cells ( 469). 
The level of PPAR-y1 in skeletal muscle is only 10-15% of the level found in adipose 
tissue. No differences in basal levels of skeletal muscle PPAR-y1 expression are detected 
between lean, obese and diabetic subjects and expression of PPAR-y1 is not correlated 
with BMI or WHR regardless of adiposity or diabetic status. However, a strong positive 
relationship was found between skeletal muscle PP AR-y1 expression and percent body 
fat in both lean and obese subjects (r=O. 76, p<0.05), with an even stronger association 
observed in subjects with NIDDM (r=0.82, p<0.05). In all subjects, basal skeletal 
muscle PP AR-y1 expression was significantly higher in those whose body fat accounted 
for more than 25% of body weight compared to subjects with less than 25% body fat 
(p<0.02). No relationship was observed between skeletal muscle PP AR-y1 m.RNA 
expression and fasting insulin levels. During a five-hour euglycemic insulin clamp, 
skeletal muscle PPAR-y1 mRNA levels were correlated with the rate of glucose disposal 
in obese (r=0.92, p<0.01), but not lean or diabetic subjects. Obese and diabetic subjects 
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were markedly insulin resistant, with GDR during the last 30 minutes of the damp that 
were only 31 and 67%, respectively, of those in lean subjects. Despite obvious 
reductions in insulin sensitivity in obese and diabetic subjects, no differences in skeletal 
muscle PPAR-y1 mRNA levels were found between the three groups (471). 
Interplay Between PPAR Isotypes and Mitochondrial Uncoupling Proteins 
Although PP AR-« is predominantly expressed in the liver and skeletal muscle, it is 
also detectable in BAT (407,410). In vitro data indicates that stimulation with a PPAR-y 
agonist is sufficient to induce differentiation of cultured brown adipocytes, along with 
induction of UCP-1 expression (472). The potential for regulation of UCP-1 gene 
expression by PPAR-y and the involvement of PPAR-y and PPAR-<X in lipid metabolism 
and homeostasis suggests the in vivo effects of PP AR activation may involve UCP-1 .  
To examine these possibilities, Kelly, et al (473) treated animals with PPAR-y 
agooists or a specific PP AR-� agonist, followed by determination of expression levels of 
different UCP isofonns in various tissues. Sprague Dawley rats were given an oral dose 
(5 mg/kg/day) of the thiazolidinedione (fZD) AD5075, a potent and selective PPAR-y 
ligand, for 14  days. Consistent with previous reports, there was a 2- to 4-fold increase in 
the mass of intrascapular BAT depot. TZD treatment increased UCP-1 expression by 
300% compared to untreated control mice. TZD treatment for 14 days also increased 
intrascapular BAT UCP-2 mRNA (by 3-fold) and UCP-3 mRNA (by 2.5-fold). In 
contrast to the effects of TZD treatment on UCP gene expression in BAT, the 
expression of UCP-2 and UCP-3 in skeletal muscle and the epididymal fat pad was 
unaltered (473). 
133 
Berger, et al (474) demonstrated that administration of selective PPAR-"( agonists to 
diabetic db/ db mice for at least 10 days normalizes blood glucose and triglyceride levels 
and improves insulin sensitivity. Concomitantly, the mass of the inttascapular BAT 
depot is increased 100-150%. PPAR-y agonist treatment reduced blood glucose levels 
by 70-80% and normalized serum triglycerides compared with untreated db/ db mice. 
Furthermore, agonist treatment increased the levels of UCP-1 and UCP-3 mRNA in 
BAT by 200% and 300%, respectively, compared to untreated animals. 
The expression patterns of UCP-2 and PP AR-ex overlap. Treatment of either obese 
db/ db or lean db/+ mice with a selective PP AR-ex agonist for 10 days resulted in UCP-2 
mRNA levels that were 400% of values in vehicle-treated control animals. Other 
consequences of in vivo PPAR-a activation included increased levels of acyl CoA oxidase 
mRNA (2.6-fold, p=0.01) and FABP protein (2.8-fold, p=0.015) in liver and 50% 
reduction in serum triglyceride levels in treated db/ db mice relative to control In 
contrast, PP AR-ex agonist treatment did not affect UCP-2 mRNA levels in liver in either 
normal lean or obese Zucker rats. In summary, in vivo administration of a potent and 
selective TZD PPAR-"( agonist to normal rats for 1 4  days results in the up-regulation of 
all three isoforms in BAT without affecting UCP-2 or UCP-3 in WAT or muscle (474). 
PP AR-y2 expression is increased by a low-calorie diet and is down-regulated in 
adipose tissue of obese subjects. 1bis is also the major isoform involved in activation of 
adipocyte differentiation. Increased levels of plasma fatty acids caused a marked 
induction of PPAR-y2 mRNA above baseline (200±8%, p<0.05), suggesting that fatty 
acid supply may be directly involved in modulating the expression of genes relevant for 
fat cell differentiation. It has been shown that transcriptional activation of PPAR-y2 
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triggers fat cell differentiation by transactivation of adipose-specific genes including 
those involved in lipid storage and metabolism. Other genes induced during 
differentiation include leptin, UCP-2, UCP-3 and lNF-rx. ffigh fat feeding increases 
leptin gene expression in rats but it is unclear if an acute increase in NEF A availability 
has any direct effects on leptin expression in humans (469). 
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VIII. Dietary Carbohydrate 
Dietary recommendations evolve to reflect our current understanding of foods and 
food constituents and their role in maintaining health. To illustrate this point, consider 
the Dietary Guidelines for Americans issued by the United States Department of Health 
and Human Services. The 1980 and 1985 guidelines focused on reducing the overall fat 
content of the diet while increasing consumption of dietary fiber. Regarding dietary 
carbohydrate intake, the guidelines encouraged Americans to "eat foods with adequate 
starch and fiber"(475,476). This statement was revised in 1990 to emphasize the 
importance of vegetables, fruits, and grains in a healthy diet (477). Furthermore, the 
revised statement shifted emphasis away from starch, which was increasingly regarded by 
the public as a component of foods that promoted weight gain. The revised guidelines 
preceded the issuance of the Food Guide Pyramid in 1992 ( 478). To emphasize the role 
of grain products in forming the foundation of the Food Guide Pyramid and as the 
single greatest contributor to total dietary energy intake, the guideline statement was 
reissued in 1995 to encourage consumption of "grain products, vegetables, and fruits" 
(479). 
Analysis of the 1994-1996 USDA's Continuing Survey of Food Intakes by 
Individuals Survey (CSFII) determined that U.S. adults consumed an average of 6. 7 
servings of grain products per day, yet only one of these was classified by the Food 
Guide Pyramid as a whole grain food (480). Furthermore, 36% of those surveyed 
averaged less than one whole grain serving per day. Thus, considerable debate has arisen 
regarding the formulation and utility of the dietary guidelines as presented in the Food 
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Guide Pyramid (481-483). Currently, the debate is focused on the nature of dietary 
carbohydrates and the extent to which they should contribute to total energy intake. 
Carbohydrates in the Diet 
Carbohydrates form the foundation of the human diet, comprising 40-75% of total 
energy intake worldwide (484). The major carbohydrate-containing foods in the human 
diet are cereals, sweeteners, root crops, legumes, vegetables, fruits, and milk products. 
On a dry weight basis, cereals contain 65-75% carbohydrate, 6- 12% protein, and 1-5% 
fat (484). Cereal grains are also rich sources of other nutrients known to promote good 
health including fiber, micronutrients, and phytochemicals, making them the most 
nutrient-dense source of dietary carbohydrate. Com, wheat and rice, the most widely 
consumed cereals, account for 75% of the world's cereal crops (484,485). The United 
States produces 41 % of the world's com crop, 20.6% of which is processed to some 
extent prior to human consumption. Total grain and cereal consumption approaches 
100 grams per day in North America (486). 
Sugars, primarily derived from sugar beet and sugar cane, are the second largest 
contributor to dietary carbohydrate. Both sugar beet and sugar cane typically contain 1 5-
16% sucrose and thus contribute only 12% of the carbohydrate produced worldwide 
(484). However, discretionary sugar intake in the United States has been estimated to be 
1 1-12% of total energy intake (487). 
Roots and tubers make up the third largest group of food carbohydrates with 
potatoes being the dominant crop of this group. Other widely consumed roots and 
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tubers include cassava, yams, sweet potatoes and taro. In gener3.4 root crops contain 15-
30% carbohydrate, of which 70-75% is starch ( 484). 
Legumes in the Western diet include peas, beans, lentils, peanuts, and other podded 
plants used as foods (488). The most widely consumed legume in the United States is 
the pinto bean followed by kidney beans, Northern beans, and lima beans. Beans and 
other legumes, which are typically 50-60% carbohydrate by weight, also contain 
significant amounts of dietary fiber, vitamins, and minerals. Unfortunately, less than 1/3 
of adults in the United States consume one serving of beans in any three-day period 
(489). Worldwide, fruit and vegetable production far exceeds legumes. However, with 
the exception of bananas and plantains, legumes contain significantly more carbohydrate 
than do fruits and vegetables (484). 
Digestion and Absorption of DietaLy Carbohydrates 
Mechanical and enzymatic digestion of carbohydrate-containing foods begins in the 
mouth where chewing breaks food into smaller pieces and thus, increases the surface 
area over which salivary a-amylase can act, ultimately influencing the rate of absorption 
(490). Although the time spent in the mouth is very short and carbohydrates undergo 
only a negligible amount of enzymatic hydrolysis in the oral cavity, chewing facilitates 
enzymatic digestion by disrupting the physical structure of foods (490,491). For 
example, as bread is chewed, it loses its cohesive structure resulting in smaller particles 
and release of some starch granules from the gluten protein matrix (491). Similarly, 
shorter strands are produced by chewing spaghetti although the general shape of the 
pasta is maintained. Despite the brevity of oral digestion (20-30 seconds), Hoebler, et al 
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(491) have demonstrated that roughly 50% of starch in bread is hydrolyzed and 
solubilized into smaller molecular weight oligosacchardies, rendering it more available 
for further digestion. Because of its dense structure, only 2.5% of the starch in pasta is 
hydrolyzed during the oral phase of digestion (492) . 
The activity of salivary a-amylase is quickly lost in the acidic environment of the 
stomach. Digestion of amylose and amylopect:in is a two-stage process which resumes in 
the duodenum (490,493). Starch hydrolysis is initiated by pancreatic a-amylase, an 
enzyme specific for internal a-1 ,4-glycosidic bonds; a-1,6 bonds are not susceptible to 
the action of a-amylase, nor are the a-1,4 bonds of glucose units, which form branch 
points and are sterically inaccessible to the enzyme (490,493,494). Under physiological 
conditions, little free glucose is formed by the action of a-amylase in the intestinal lumen 
(490). Starch hydrolysis proceeds as single glucose residues are sequentially removed 
from the non-reducing end of the a-1,4 chain by the action of sucrase. a-dextrinase is 
the sole enzyme responsible for hydrolysis of non-reducing, terminal a-1 ,6 bonds 
(490,493,494). Following complete hydrolysis of starches and disaccharides, the resulting 
monosaccharides can be absorbed across the intestinal mucosa (495). 
Classification of Dietary Carbohydrates 
Monosaccharides and Disaccharides 
Historically, dietary carbohydrates have been classified based on degree of 
polymerization, much as dietary fatty acids are classified based on chain length (496). 
Monosaccharides are structurally the simplest form of carbohydrates and are often called 
139 
"simple sugars" since they cannot be hydrolyzed to yield smaller units (496). The most 
abundant and nutritionally important monosaccharide found in nature is glucose. In 
addition to being the sole constituent of starches, glucose is also a component of each of 
the three major disaccharides. Along with glucose, fructose (fruit sugar) is found in the 
free form in varying amounts in fruits, berries and vegetables. The third 
monosaccharide, galactose, is found in its free form only in very small quantities. 
Sucrose is the most important disaccharide in the diet and upon hydrolysis yields glucose 
and fructose ( 496). Lactose, also a disaccharide, is found in the greatest quantities in 
milk products, with cow's milk containing approximately 50 grams of lactose per liter 
(496,497) . Other foods containing significant amounts of lactose include yogurt, cottage 
cheese, and ice cream ( 498) 
Dietary S larch 
Quantitatively, plant starch is the most important food carbohydrate and, along with 
glycogen, represents the only polysaccharides susceptible to human digestive enzymes 
(490) . Starch granules are found in seeds, roots, and tubers as well as stems, leaves, and 
fruits (484,485). Photosynthetic plants synthesize and deposit starch in densely packed, 
water-insoluble granules ranging from 1 to 100 µm in diameter (485,499) . The 
amyloplast is the organelle responsible for synthesis of both amylose and amylopectin 
and thus, largely determines starch granule composition (500,501). Starch granules 
consist of amylose and amylopectin in varying proportions, depending on the botanical 
species, and small amounts of non-carbohydrate components including lipids, protein 
and phosphorus (501,502). 
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Amylose is a long essentially linear polymer of a-1 ,4-linked D-glucose units 
(499,503). There is evidence that larger amylose molecules may contain a very small 
number of a-1 ,6-linked D-glucose branches; however, the typical amylose molecule 
contains 500 to 600 anhydrous glucose units and is free of branching (500,503). Most 
starches contain 1 5-25% amylose, although there is considerable variation, ranging from 
wrinkled peas, which contain 85% amylose to waxy maize, which is less than 1 % amylose 
(486,504,505). 
In most starches, amylopectin, the larger of the two starch components, is found in 
much higher quantities than is amylose (500,501,503). Amylopectin has a highly 
branched bi-model structure of short, linear a1 ,4-linked D-glucose arrays with a-1 ,6-
branch points, accounting for 5% of the total structure and occurring approximately 
every 25 glucose units (499,500). Such extensive branching induces significant flexibility 
and permits efficient packaging of the short chains of amylopectin to form doubles 
helices, which subsequently associate in clusters forming the crystalline region of the 
granule (499,500). Alternating with the crystalline regions are amorphous zones created 
through the branch points of amylopectin with amylose filling in any gaps created in the 
expanding granule, particularly along the outer surface (501 ,503). Compared to the 
crystalline core of the granule, the amorphous, gel-like phase has a more open 
configuration and thus, is more susceptible to enzymatic attack, chemical modifications 
and swelling upon hydration (505,506). The core of cereal starch granules is 
characterized by very densely packed amylopectin double helices (507). Alternatively, 
tuber starches are less densely packed with amorphous pores, which can accommodate 
water (505,507). It should be noted that there is no clear line of demarcation between 
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the amorphous and crystalline phases of starch within the granule. Consequently, larger 
amylose polymers may participate in double helices with amylopectin and co-localize 
within the core where they are less likely to leach from the granule when subjected to 
enzymatic or thermal stress (503,505) . 
Ditta,y Fiber 
Dietary fiber is a heterogeneous group of non-starch plant polysaccharides (NSP), 
which resist degradation by human digestive enzymes (505,508,509). The most abundant 
NSPs, including cellulose, hemicellulose and pectin, are found as structural components 
of plant cell walls (505). NSPs also include storage polysaccharides such as fructans (e.g. 
inulin), glucomannans (e.g. konjac-mannan), and galactomannans (e.g. guar gum) 
(505,508-510). 
Dietary fiber is c1assified into two types, soluble or insoluble, based on its behavior in 
aqueous solution (51 1). Water soluble dietary fibers include pectins, gums, mucilages, 
algal polysaccharides, some hemicelluloses, and some of storage polysaccharides 
(509,512). Pectin is composed of a linear backbone of 1,4-linked galacturonic acids 
interrupted by side chains of neutral sugar residues (509,510). Apples are rich sources of 
pectin, which contribute to the matrix of the plant cell walls. Pectins are insoluble in 
unripe apples, but become more soluble as the fruit ripens (513). Pectins have high 
water-holding capacity enabling them to form viscous gel networks in the intestinal tract, 
which can bind organic compounds, such as bile acids (509,510). Pectins escape 
enzymatic hydrolysis in the small intestine but are almost completely degraded by colonic 
microflora (508). Gums and mucilages are non-structural plant polysaccharides, which 
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like pectin, form viscous networks in aqueous solutions (505,509). One of the more 
common gums, guar gum, is found in the endosperm of the Indian cluster bean (514). 
It has been argued that dietary fiber should also include the fraction of starch in 
foods th.at can resist digestion in the human small intestine due to a number of highly 
variable factors (505,508,509). Englyst, et al. (515-517) have classified resistant starch 
into three fractions, RSi, RS2, and RS3, based on the means by which starch escapes 
intestinal degradation. Starch which is physically inaccessible to the actions a-amylase by 
virtue of its entrapment within the food matrix are assigned to the RS1 fraction. 
Inaccessible starch granules are found in whole or partially milled grains, legumes or 
other starch-containing foods, the size or physical structure of which protects it from 
digestion. The RS2 fraction includes starch associated with the crystalline portion of the 
starch granule, which would necessitate complete gelatinization prior to digestion. 
Starch rendered resistant to a-amylase as a result of retrogradation constitutes the RS3 
fraction (515-518) .  Recently, a fourth category of resistant starch, RS,0 was added to 
include chemically modified starches that are resistant to enzymatic degradation (509). 
PkJsio-Chtmital Properties efDietao Fib" 
Numerous physiological effects have been attributed to dietary fiber, reflecting the 
complexity and diversity of their physical and chemical components. The nutritionally 
important properties of fiber are its water holding capacity, viscosity, binding and 
absorptive capacity, bulking capacity, and fermentability (508,509,51 1 ). Soluble and 
insoluble fibers have very different physio-chemical properties and consequently, have 
different local effects in the gastrointestinal tract (509,518,51 9). Few foods contain 
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soluble fiber to the exclusion of insoluble fiber and vice versa. As a result, the extent to 
which a fiber is soluble in aqueous solution and the rate at which it is absorbed is largely 
determined by the ratio of soluble fiber to insoluble fiber in a food in much the same 
way the amylose:amylopectin ratio detennines the nature and rate of starch digestion 
(508). 
Hydration capacity is a function of the extent to which the plant cell walls can retain 
water and in part, determines the fate of ingested fibers (509,51 1 ). In general, fibers 
composed primarily of plant cell wall components have greater water retention capacity 
than fibers containing secondary structures. Processing techniques such as grinding, 
drying, heating, and extrusion cooking, can disrupt the physical structure of the plant cell 
matrix, and thus, influence hydration capacity (508,509). Such mechanical processes 
increase the porosity of the starch granule exposing more of the matrix components to 
digestive enzymes (505). 
Viscous dietary fibers are those that fonn thickened gel-like networks in the aqueous 
environment of the stomach and small intestine (509,518,520). Viscosity is a property 
that is exclusive to soluble fibers (508). Viscous fibers are known to delay gastric 
emptying, slow intestinal absorption of sugars, and increase fecal loss of bile acids 
(519,521-523). 
Bulk volume influences a number of local gastrointestinal properties including transit 
time, colonic fermentation, and fecal excretion (508,509,524). Although both soluble 
and insoluble fibers can serve as fuel substrates for colonic microflora, insoluble fibers 
alone retain their structure in the colon and thus, contribute to fecal weight (525). 
Wheat bran has the greatest capacity to increase fecal bulk by virtue of its poor 
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fermentability, low hydration capacity and negligible viscosity in the aqueous 
environment of the intestinal lumen and colon (526). In contrast, pectin is a highly 
fermentable, highly viscous soluble fiber that contributes little to fecal weight (510). 
Plgsiplojjcal FJficts ofViscw Soluble Fibers 
Viscous soluble fibers form a thickened gel-like matrix in the aqueous environment 
of the intestinal lumen and thus, increase the viscosity of the digesta (509,51 8,520). The 
viscosity of the intestinal contents may play an important part in determining the rate of 
gastric emptying and small bowel transit, the extent to which digestive enzymes are able 
to interact with food components, micelle formation, and absorption of nutrients by the 
intestinal mucosa (509,527-530) . The gel network formed by the partial solubilization of 
viscous fibers in the small intestine effectively increases the thickness of the unstirred 
water layer which serves as a barrier to nutrient absorption at the intestinal brush border 
without affecting the total volume of digesta absorbed (520,531). 
Addition of viscous fibers to the diet may delay nutrient absorption by influencing 
the hormonal response to other food components (528,529). Cholecystokinin (CCI() is 
a gastric hormone released in response to the presence of fat within the intestinal lumen 
and is thought to be largely responsible for the satiating effects of dietary fat (532-534). 
Increasing the viscosity of intestinal components retards fat absorption and extends the 
digestive process further along the length of the small intestine (534). Plasma CCK 
levels rise following consumption of a mixed meal (533) and Burton-Freeman, et al. (534) 
observed increases in postprandial CCK levels following the incorporation of viscous 
fibers into a low-fat mixed meal (20 energy% fat) that were similar to those observed 
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following consumption of a high fat meal (30 en% fat). Similarly, Bourdon, et al. (535) 
reported that plasma CCK levels remained significantly elevated for six hours following 
consumption of high-fiber pasta enriched with �-glucan, CCK levels returned to baseline 
within three hours of ingesting low-fiber pasta. Although plasma glucose levels were 
similar, plasma insulin levels were lower (p<0.05) following the high-fiber versus the 
low-fiber pasta. 
The Glycemic Index and Dietary Carbohydrates 
The classification of foods according to their blood glucose response was first 
undertaken by Otto and Nildas (536) in order to allow incorporation of a variety of 
carbohydrate-containing foods into the diabetic diet while keeping the glycemic impact 
relatively constantly. Wolever, et al. (537) developed the concept of glycemic index (GI) 
as a physiologically based method of classifying foods according to their post-prandial 
blood glucose response and as a supplement to information regarding the chemical 
composition of foods found in food tables. 
The glycemic index is defined as the incremental area under the blood glucose curve 
in response to a standardized carbohydrate load, ie., the blood glucose response curve 
above the level of fasting blood glucose (537). The glycemic index for a particular food 
is derived by expressing the individual glycemic index as a percent of a reference food, 
typically white bread or glucose (537,538). The portion of food tested generally contains 
50 grams of available carbohydrate to allow direct comparison to the same portion of 
reference food (537-539). The glycemic indices of selected foods are shown in Table 1 .  
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Simple Sugan 
Legumes & Tubers 
Cereal Grains 
& Grain Based Foods 
Breakfast Cereals 
Fruits & Fruit Juice 
Dairy Products 
Table 1 








Mung Bean Noodles 
Potato, baked 
Barley Bread, whole meal 
Oat Ban Bread 
Rye Bread, whole meal 
White Bread, wheat flour 
Pita 
Spaghetti. durum wheat 
Spaghetti. whole meal 
Sweet com, cooked 




Rolled Oats, porridge 








Glucose White Bread 
(GI = 100) (GI = 100) 
20 ± 5 29 ± 0 
50 ± 9 85 ± 1 
43 ± 0 61 ± 0 
42 ± 9 59 ± 12 
28 ± 4  39 ± 6 
26 ± 4 36 ± 5 
31 ± 0 44 ±  6 
33 ± 7 47 ± 10 
85 ± 9 121 ± 16 
67 ± 1 96 ± 6 
47 ± 3  68 ± 5 
58 ± 6 83 ± 8 
73 ± 2 105 ± 3 
57 ± 2 82 ± 7 
57 ± 6 81 ± 8 
37 ± 5 53 ± 7 
53 ± 4 78 ± 6 
47 ± 3 68 ± 4 
69 ± 8 98 ± 7 
42 ± 5 60 ± 7 
81 ± 3 1 16 ± 5 
58 ± 4 83 ± 5 
66 ± 1 94 ± 1 
38 ± 2 52 ± 3 
40 ± 1 57 ± 1 
51 ± 1 73 ± 2 
42 ± 2 60 ± 3 
42 ± 3 60 ± 5 
52 ± 3 74 ± 4 
Milk, whole 27 ± 4 38 ± 6 
Milk, skim 32 ± 5 46 ± 4 
Yogurt, low fat, aspartame sweetened 14 ± 4 20 ± 2 
Yogurt, low fat, sucrose sweetened 33 ± 7 47 ± 3 
• Adapted from Foster-Powell, K., et al. (2002) International table of glycemic index and glycemic load values: 2002. Am J Clin 
Nutr 76, 5-56. 
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To approximate the glycemic index of a meal, the carbohydrate content of each food 
is determined. The proportion of carbohydrate contributed by each food is then 
multiplied by its glycemic index and the values are totaled to give the glycemic index of 
the meal (537-539). Wolever, et al. (538) detennined that this method of combining the 
glycemic indices of meal components yields a glycemic index within 2% of the measured 
value for the aggregate meal 
Factors Inf111endng the Gfycemic &sponse 
DqJ-to-Dqy Plgsiological Variations 
There is considerable controversy regarding the practical application of glycemic 
index due to the variable nature of responses observed among individuals. After 
studying diabetic subjects at weekly intervals over a four month period, Wolever, et al 
(540) observed significant differences in the absolute glycemic responses between 
different individuals, as well as significant intra-subject variability to the same food tested 
on different days, the severity of which was influenced by the degree of glucose 
intolerance of a given subject. Consequently, Wolever et al suggest that most of the 
variability in GI values is due to day-to-day physiological variations within the same 
subject. Subsequently, Wolever, et al. (541) observed that the glycemic response in a 
given subject is influenced by a number of physiological and hormonal factors which 
fluctuate throughout a 24-hour period, and the results are most reliable when test meals 
are consumed following an overnight fast. 
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Simple S11gars 
Given that glucose and fructose are both monosaccharides, it was initially assumed 
that similar blood glucose response curves would be obtained following ingestion of a 
solution containing 50 gram of either monosaccharide. However, when compared to a 
50 gram oral glucose load (GI = 100), fructose produced a mean score of only 23, while 
the same amount of sucrose, a mixture of glucose and fructose, produced a mean score 
of 60 (542). This suggests that the GI for a given sugar can be influenced by the molar 
ratio of glucose to other monosaccharides (537,542,543). Sucrose and lactose each 
contain 1 glucose molecule and thus, have glycemic indices lower than an equivalent 
amount of glucose. On the other hand, maltose, which is fonned from two glucose 
molecules, has a glycemic index of 105 (542,543). 
An additional factor influencing the blood glucose response to simple sugars is the 
mechanism and rate of absorption in vivo (495). While glucose is actively absorbed in 
the small intestine and appears rapidly in circulation. In contrast, fructose is primarily 
metabolized by the liver and consequently, little fructose appears in circulation nor does 
the glucose derived from fructose contribute to the postprandial glycemic response 
(490). 
Natl{f"al/y Ocaming vers1{SAdded Sugars 
There is debate over the nature of the blood glucose response to naturally occurring 
sugars in plant foods compared to foods containing added sugars. Brand-Miller, et al. 
(544) found that in general, the median GI of the foods containing only naturally­
occurring sugars was similar to that of foods to which sugars had been added during 
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processing. No significant differences in GI values were observed for cakes, muffins 
and most cookies made with or without added sugars. 1bis may be the result of sugars 
being converted to carbon dioxide by yeast during the baking process (545). However, 
s.ignificant differences were observed among dairy products, canned peaches, and 
beverages according to the presence or absence of added sugars (544). Sucrose, which is 
highly water-soluble, ties up water molecules making them unavailable to starch. 
Consequently, the addition of sucrose inhibits the swelling of starch and retards 
gelatinization in a dose-dependent manner (546). 
Starch VtrSIIS Sugar 
The term complex carbohydrate has been part of the conswner lexicon since the 
1970s and has been used to describe a heterogeneous group of foods. When originally 
proposed as a mandatory component of the Nutrition Facts segment of the nutrition 
label, the term complex carbohydrates was defined as the swn of digestible 
polysaccharides with a degree of polymerization greater than nine; little attention was 
paid to the complex physiological effects of dietary carbohydrates. Lack of a clear 
definition for what constitutes complex carbohydrates, methodological considerations, 
and the physiological effects of various dietary carbohydrates led to the omission of the 
term from the mandatory nutrition labels (547). 
Conventional wisdom suggests that the metabolic effects of simple sugars should be 
more detrimental than an equivalent amount of dietary starch. The substitution of 
dietary starch for dietary sugar results in significant metabolic changes. Wolever, et al. 
(548) have demonstrated that starchy meals result in much less variable postprandial 
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blood glucose levels than do oral glucose loads. In subjects tested over three days, the 
intra-subject variability in the postprandial blood glucose response was significantly 
greater following ingestion of 75 grams of glucose compared with 50 g of white bread or 
50 grams of carbohydrate derived from an oat bar. The intrasubject variability 2 hours 
after ingesting the glucose load was 2-3 times higher than for white bread or oat bar, 
suggesting more accurate determinations of glucose tolerance can be obtained using 
starch rather than the typical glucose load . 
.Anglose and Anglopectin Content 
Ultimately, all starch is susceptible to digestion by human a-amylase (485,490) . Both 
amylose and amylopectin are susceptible to enzymatic hydrolysis by a-amylase, present 
in saliva and pancreatic secretions; in addition, the a-1,6 branches of amylopectin are 
susceptible to isomaltase found in the brush border of the small intestine (485,490). As a 
result, amylopectin has many more sites of enzymatic attack than does amylose and is 
more rapidly degraded than is straight-chain amylose (485,490). Amylose is 
characterized by extensive hydrogen bonding, which results in a more compact structure 
and effectively reduces the surface area over which a-amylase can act (506). Thus, the 
rate of starch digestion and the postprandial response are influenced by the ratio of 
amylose to amylopectin within the starch granule. 
Heat Processing and Gelatinization 
Starch granules are insoluble in cold water but may be partially solubilized 
(gelatinized) by heating above 60-70° C in excess water to disrupt the native starch 
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structure (51 8,549). The constituent molecules of starch granules are held together 
primarily by hydrogen bonds, which weaken when heated. Swelling begins in the center 
of the granule where the hydrogen bonds are less rigid and spreads toward the periphery 
of the granule (500). Significant swelling begins at the initial gelatinization temperature 
(-60° C) and increases the porosity of the starch structure allowing further influx of 
water, disruption of the botanical structure and dispersion of the semi-crystalline 
amylose-amylopectin complex pennitting leaching of smaller amylose polymers from the 
granule (500,501 ,503). With continued swelling, fully hydrated granules separate from 
the protein matrix in which they were encased and may escape into the aqueous 
environment. Consequently, gelatinization increases the susceptibility of starch to a­
amylase (505). As a result of partial gelatinization, a-amylase is able to act throughout 
the starch granule instead of being restricted to the surface as it was in the native starch 
granule (500,505) . Because of its linear structure, the amylose content of a particular 
starch largely determines its gelation properties (502,506) . Upon cooling of a gelatinized 
starch, the dispersed amylose and amylopectin molecules may reassociate and partially 
return to a granular state in a process known as retrogradation (518). Amylose 
undergoes retrogradation much more rapidly than does amylopectin (518). Thus, 
amylose becomes more rigid and stable during storage than does amylopectin. Although 
cooling results in partial restoration of the native starch structure, retrograded starch is 




Typical legume starch granules are embedded in a protein matrix making isolation of 
the starch per se difficult (550,551). Legume starch granules are generally oval in shape 
and contain 30-40% amylase, significantly more than is found in widely consumed cereal 
grains (502). In addition to having greater amylase content, legumes contain twice as 
much protein as cereals and roots or tubers (502). 
Legumes, such as lentils, contain significant amounts of fiber and yield flattened 
glycemic responses, similar to those obtained following ingestion of viscous soluble 
fibers, such as guar gum and pectin (521 ,552). The favorable glycemic response to 
legumes was initially attributed to an increase in intestinal viscosity. To test this 
hypothesis, viscosity was determined by measuring the rate at which glucose was released 
from dialyzed leguminous foods compared to dialysate containing only glucose solution 
as a control. If legumes were acting by increasing viscosity as was believed, the rate of 
glucose released from the legumes would be reduced in proportion to the amount of 
lentils in the dialysis bag. However, there were no differences in the rate of glucose 
released between legumes and the glucose solution, suggesting the flatter blood glucose 
response to legumes was not mediated by an increase in viscosity of the cligesta (492) . 
Subsequently, Wong, et aL (553) hypothesized that the tight botanical structure 
characteristic of legumes may limit the extent to which carbohydrate contained in the 
core granule may be accessed by hydrolytic enzymes. Prior to cooking, whole lentils were 
subjected to various fonns of mechanical distress (mashing, blending, grinding), which 
increased the surface area to different degrees. The rate of starch hydrolysis was greatest 
(p<0.001) for ground lentils, which had the greatest surface area, and lowest for mashed 
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lentils, demonstrating the important influence of physical structure and surface area on 
digestion and absorption (492,553). 
O'Dea, et al. (554) have demonstrated greater postprandial glucose responses to 
ground versus whole lentils (p<0.001). There was also a different time course for the 
postprandial response with peak glucose levels observed at 30 minutes following ground 
lentils, while the response to whole lentils was delayed until 60 minutes post ingestion. 
Despite a higher peak glucose level in response to ground lentils (p<0.025), the 
attenuated response to whole lentils led to nearly identical total AUCG for the two foods. 
The postprandial insulin response closely paralleled glucose responses with peak values 
occurring at 30 minutes following mashed lentils and 60 minutes after whole lentils. 
Although the time course of the insulin responses were different, neither peak insulin 
values nor A UC1 differed between the foods. The divergence of the postprandial 
glucose and insulin responses suggests that factors other than the rate of glucose 
absorption influence the magnitude of the insulin response to leguminous foods and that 
the metabolic response can not be predicted solely by the rate of starch digestion in vitro 
(554,555) .  
Wong, et al. (553) demonstrated that commercially prepared canned beans were more 
susceptible to hydrolysis by <X-amylase compared with home-cooked beans of the same 
botanical species. Following treatment with a-amylase, nearly half of total starch 
contained in canned navy beans had been hydrolyzed, whereas the same treatment led to 
hydrolysis of less than 10% of total starch in home-prepared beans. These differences 
are presumably due to the method of preparation. Traditional home cooking of dry 
beans usually involves overnight soaking followed by prolonged boiling, while 
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commercial methods employ much higher temperatures and pressure treatment, which is 
more disruptive to the structure of the starch granule (549). 
Cena/ Grains 
Wheal and Corn 
Cereal grains are characterized by a multi-Jayer botanical structure which includes the 
pericarp, testa, germ, aleurone, and endosperm. The greatest contributor to cereal grain 
structure is the endosperm which contains the starch, as well as vitamins and minerals. 
Surrounding the endosperm is the aleurone Jayer, which is a rich source of B vitamins, 
minerals and protein (556). 
Most cereal grains undergo some form of mechanical or thermal processing prior to 
conswnption or inclusion in other foods. Milling and grinding of cereal grains reduces 
particle size and increases the surface area over which digestive enzymes can act (557-
559). Less severe mechanical treatments, which do not destroy the botanical structure, 
nonetheless introduce physical imperfections into the otherwise smooth kernel surface, 
rendering the starch more accessible to hydrolytic enzymes (557,559). 
The extent to which physical structure of the grain is disrupted during processing is 
an important factor influencing postprandial metabolism (500,505,557). For example, 
intact grains retain the outer bran and germ Jayers, which serve as physical barriers to 
enzymatic digestion, and cooking is only partially effective in removing these Jayers 
(549,560,561). The milling process by which flour is made separates the bran and germ 
layers from the starchy endosperm, which is subsequently ground into flour (559). 
Typical wheat starch is 30% amylose and 70% amylopectin in granules of variable size 
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(2-35 µm) (556,559). Wheat starch granules are affixed to storage proteins by a matrix of 
water-soluble proteins, which swells rapidly upon hydration, facilitating starch hydrolysis 
(546). 
Heaton, et al (562) examined the glucose and insulin responses of normal volunteers 
to wheat-based meals varying only in the extent to which the wheat had been processed. 
There was a trend for plasma glucose levels to rise higher and fall lower in response to 
flour-based meals compared to cracked or whole wheat meals, in which particle size was 
significantly larger. The area under the glucose curves followed a pattern similar to 
blood glucose levels, but there were no significant differences for either plasma glucose 
level or the area under the blood glucose curve. This suggests that with respect to the 
postprandial glucose response, starch particle size is irrelevant. However, particle size 
had a significant impact on plasma insulin levels. Stepwise increases in peak plasma 
insulin concentrations and area under the insulin curve were observed as the particle size 
of the wheat decreased. The largest differences were noted between fine and coarse 
flours, with the area under the insulin curve being 38% higher after fine flour (p = 
0.0063) . Similar results were observed for maize-based meals. There were no 
differences in plasma glucose responses, however, plasma insulin levels rose much more 
after com flour than after cracked or whole com. The area under the insulin curve was 




Among grain-based products, pasta has been consistently reported to yield flattened 
postprandial glucose responses, with the blood glucose response to spaghetti is 40-60% 
lower than that of white bread in healthy and diabetic subjects (543,563-565). The 
blunted glycemic response to pasta may be due to a number of factors. Over the last 
decade the pasta industry has introduced new production processes which expose the 
product to higher temperatures and result in more complete gelarinization of starch 
(566,567). High-temperature drying of spaghetti increases protein denaturation and 
results in a considerable loss of a-amylase activity in vitro (566,567). Dexter, et al (568) 
have also noted that higher processing temperatures yield finner products, which may 
further influence the susceptibility of pasta products to enzymatic degradation in vivo. 
Most pasta is made of semolina from durum hard wheat. Semolina, which is 60-70% 
starch, is derived from the endosperm of the wheat kernel. During the production of 
pasta, the starch contained in semolina undergoes partial hydrolysis due to the presence 
of naturally occurring amylases (566,567). Prior to cooking, microscopic examination of 
durum semolina pasta reveals perfectly intact starch granules within a gluten protein 
matrix. When cooked, a protein matrix encapsulates the starch granules, which become 
swollen and partially gelatinized (566). However, starch granules remain largely intact, 
partially attributable to the viso-elastic nature of the associated gluten, which serves as a 
protective barrier against hydrolysis. 
In an attempt to understand the mechanisms influencing the postprandial response to 
pasta, Granfeldt, et al. (569) compared two pasta products, which differed only in 
physical structure (spaghetti and macaroni) , to bread prepared with pasta ingredients. In 
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diabetic subjects, macaroni resulted in a higher AUCg1ucose than spaghetti (p<0.05) . 
Furthermore, the peak glucose response above the fasting level was significantly lower 
(p<0.05) for spaghetti than for bread prepared from the same ingredients as the 
spaghetti. Thus, it appears the physical structure has a significant effect on the 
postprandial response. The blunted response to spaghetti has been attributed to larger 
particle size and higher product density, both of which influence the susceptibility of 
starch to a-amylase (569). 
Interestingly, cooking time appears to exert little influence on the blood glucose and 
insulin responses to a pasta meal in healthy subjects (570). Relative to an oral glucose 
load, blood glucose and insulin responses were sjgnificantly lower following 
consumption of a pasta meal, regardless of cooking time. Although the exact 
mechanism to which these findings can be attributed are unclear there are several 
possibilities. During the manufacturing of pasta, partial gelatinization of starch is known 
to occur (546). Alternatively, the protein matrix which envelopes the starch granules in 
pasta may be similar regardless of cooking time and responsible for the blunted response 
of the pasta meals compared to glucose (566). 
The carbohydrate content of pasta can be reduced by the addition of milk or whey 
proteins, eggs, animal proteins, processed bran, and gluten (563,566,569). However, the 
industry lacks a standardized method for preparation of commercially available pasta 
makes it difficult to determine the nature and mechanisms influencing the postprandial 
response to pasta products. Granfeldt, et al. (569) examined the importance of 
processing conditions, physical structure and added nutrients on the postprandial 
response to pasta-based meals. Healthy subjects were given test meals with an 
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equivalent amount of available carbohydrate from extruded high-temperature dried 
spaghetti and three varieties of fresh linguine (thick, thin, thin with egg) made from the 
same ingredients. A reference bread was baked from the same ingredients as in the pasta 
products. The four pasta products produced significantly lower peak values for glucose, 
insulin, and c-peptide in the early phase (40, 50, and 60 minutes) compared to the bread 
made from the pasta ingredients (p < 0.05 for all). The early phase (60 and 90 minutes 
post ingestion) glucose and insulin responses to the thin linguine were significantly 
higher than the thin linguine prepared with egg (p < 0.05). Consistent with this, the 
addition of egg to the thin linguine produced resulted in lower AUC values for insulin 
(p<0.05) and c-peptide (p<0.05) at 120 minutes the same product without added egg. 
Guillford, et al. (570) demonstrated an increased insulin response to a spaghetti meal 
upon addition of protein, whereas the glycemic response was unchanged, suggesting the 
amount of protein contributed by the addition of egg was insufficient to potentiate the 
insulin secretory response. 
Oats and Barlev .. 
Commercial preparation of oats involves removal of the outer husk layer followed by 
two steaming steps, which result in softer, more pliable particles and inactivation of any 
naturally-occurring lipases. The soft oats are then rolled and exposed to pulses of warm 
water after which they are dried by exposure to ambient air. This process removes the 
outer husk which is a rich source of lignin and insoluble nonstarch polysaccharides, 
including cellulose and arbinoxylans. In addition, this process disrupts the native 
structure of the aleurone cell, which makes the cereal grain more susceptible to digestive 
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enzymes (557). The major component of the soluble fraction of oats is the linear 
polysaccharide, (1,3)(1 ,4)-�-D-glucan (�-glucan), which is contained in the aleurone layer 
(571,572). Oat bran is derived by dehulling whole oats and contains 7-19% �-glucan, 
while rolled oats contain approximately 4% �-glucan (571 ,572). 
Most commercially available breakfast cereals are heat processed; consequently, the 
starch is more or less completely gelatinized (557). However, steam rolling and 
processing of oats is carried out at lower temperatures resulting in incomplete starch 
gelatinization (557,571). Granfeldt, et al. (573) demonstrated the importance of degree 
of gelatinization and product thickness on post-prandial glucose and insulin responses to 
rolled oat in healthy subjects. Dehulled oats were subjected to varying degrees of 
roasting and steaming or used raw to prepare rolled flakes of different thickness. The 
glycemic (GI = 88-1 18) and insulin (II = 84-102) indices for thin (0.5 mm) rolled oat 
flakes were similar to white bread; thicker (1 .0 mm) oat flakes produced significantly 
lower GI (GI = 70-78) and insulin (11 = 58-77) values relative to white bread (p<0.05). 
Oatmeal is most commonly consumed as a breakfast cereal by cooking rolled oats in 
water to give a thick, highly viscous porridge. There are two common methods for 
preparing porridge from rolled oats. In the rapid cooking method, rolled oats are added 
to boiling water, allowed to return to a boil and simmer for 10 to 15  minutes before 
being consumed. A smoother porridge is obtained using the gradual boil method, 
whereby rolled oats are added to cold water, gradually brought to a boil and then 
simmered for 10-15 minutes prior to eating. These two cooking methods appear to be 
very similar, however, there are significant differences in the cooked mixture based on 
the method of preparation. In either case, exposure of the oats to boiling water results 
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in protein denaturation and starch gelatinization and consequently, increases the amount 
of readily digestible starch. However, the rapid-boil method results in an oatmeal 
porridge which retains a greater quantity of f3-glucan and is markedly more viscous than 
a porridge prepared by the gradual-cook method. Microscopically, rapid cooking results 
in swollen, but otherwise largely intact starch granules. Conversely, gradual cooking 
leads to more extensive gelatinization as evidenced by disruption of cell walls, distorted 
starch structures and the absence of recognizable starch granules when viewed 
microscopically Thus, the gradual cooking method results in greater structural 
disruption of cell wall structures and permits greater release of soluble f3-glucan from the 
cooked product (574). Therefore, while cooking may facilitate digestion of botanical 
structures otherwise resistant to human digestive enzymes, it may also lead to 
solubilization and loss of the Jl-glucan fraction (526,574). 
The degree of gelatinization, method of preparation and physical structure is a 
significant determinant of the postprandial response to oat products. Whole kernel 
porridges were prepared by boiling intact oat kernels in water. Rolled oats were served 
raw or as a porridge by cooking in boiling water. The whole oat kernel porridge 
produced significantly lower glucose (p<0.05) and insulin (p<0.05) responses compared 
to rolled oat porridge and white bread. Interestingly, the rolled oat meals, whether 
served as raw muesli or as oatmeal porridge, resulted in postprandial glucose and insulin 
levels and similar to white bread (526). Researchers hypothesized that although starch in 
rolled oats is only partially gelatinized (62%), this coupled with the disruption of the 
kernel structure during processing, was sufficient to facilitate more efficient digestion 
and absorption in vivo (526,557,571,574). 
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The swelling and viscosity properties of 13-glucan are similar to those of guar gum and 
significantly greater than psyllium (572). However, oat bran is commercially available, 
whereas guar gum is not. Braaten, et al (575) have demonstrated similar physiological 
effects of oat gum and oat bran containing equivalent amounts of 13-glucan. In addition 
to white bread, wheat farina, which has a texture similar to oatmeal porridge, was 
included as a reference meal. Normal subjects and subjects with NIDDM were fed 
porridge meals containing either wheat farina, wheat farina plus an equal amount of f3-
glucan from either oat gum or oat bran. Fat and carbohydrate content of the meals were 
equal, however, the wheat farina meal plus oat bran contained a greater amount of 
protein due to the need to equalize the amounts of f3-glucan in the test meals. In normal 
subjects, plasma glucose levels were higher (p<0.05) at 20, 30, and 40 minutes following 
the wheat farina meal than either of the f3-glucan supplemented meals. In all control 
subjects plasma glucose returned to baseline within 180 minutes. The three hour AUC 
for plasma glucose was approximately 28% greater (p<0.05) after the wheat farina meal 
compared to meals containing 13-glucan as either oat gum or oat bran in control subjects. 
Similar trends were observed in patients with NIDDM, albeit at higher baseline levels. 
The exception occurred in NIDDM subjects for which the wheat farina plus oat bran 
meal resulted in a greater three hour AUC for insulin (p<0.05). This may be attributable 
to the higher protein content of this meal and the potentiation of the insulin secretory 
response by dietary protein. For both normal and NIDDM subjects, plasma glucose 
excursions were more rapid and of greater magnitude following the wheat farina meal 
compared to those meals containing added 13-glucan. 
162 
T11bers 
A wide range of GI values (GI= 56-85) have been reported for potatoes depending on 
species, method of preparation, and storage (543). Because potatoes contribute 15-20% 
of total starch consumed in industrialized countries, there is considerable interest in 
determining the factors to which the variable glycemic indices can be attributed (486). 
Starch grains are most concentrated in the cortex, lying just below the skin of 
potatoes. Within the cortex, numerous round and oval shaped granules are housed in a 
thin layer of parenchymal cells. In raw potatoes, the cell walls of the parenchymal layer 
are quite strong and embedded in a polysaccharide matrix, making them highly resistant 
to a-amylase (576,577). 
Roughly 50% of the starch in raw potatoes is resistant to enzymatic digestion 
compared to only 3% in freshly cooked potatoes (576-578). Heat treatment does not 
completely disrupt granule structure but results in significant swelling that may permit 
leaching of smaller amylose molecules (578). Heating of potatoes also leads to other 
changes including protein denaturation, reduced cell adhesion properties, and loss of cell 
membrane integrity, which may facilitate diffusion of some cellular contents (578,579). 
The net result of cooking is gelatinization of the starch and softer, more easily separated 
cells in the tissue. Upon cooling, retrogradation occurs, altering the nature of the starch 
previously rendered susceptible to a-amylase by cooking such that 12% of the total 
starch in the potato is now resistant to enzymatic digestion (577,580). 
Englyst, et al. (580) conducted studies to determine the changes in digestibility and 
carbohydrate absorption resulting from cooking and storage of potatoes by collection 
and measurement of effluent collected from ileostomy patients. Overall starch recovery 
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in effluent increased significantly following consumption of a cooled, cooked potato 
(p<0.05) compared to a freshly cooked, hot potato and a control (non-plant 
polysaccharide containing) diet. Similarly, total carbohydrate recovered was significantly 
lower following the control and fresh cooked, hot potato compared to the cooled potato 
(p<0.05). Overall, 9% of the carbohydrate in the fresh cooked potato and 18% of that 
in the cooled potato was recovered in the effluent. Thus, the retrogradation that occurs 
upon cooling, renders the starch in potatoes less available for digestion and absorption 
by the gut compared to the effects of gelatinization. Reheating the cooled potato by 
microwave oven or steaming also improved the digestibility of the cooled potato 
resulting in significantly less total starch excretion compared to the cooled potato 
(p<0.05). 
J<mits 
I1!,011ence ofRipeness and Botanical Structure 
Fruits are generally harvested prior to prime ripeness to allow for transport and 
acquisition by consumers. Prior to ripening, fruit has a very rigid structure with well­
defined cellular structures. As fruit ripens, intrinsic hydrolytic enzymes are activated 
which result in softer tissue and diffuse cell walls (51 3). 
As consumed, bananas are a rich source of raw, largely indigestible starch (581). The 
starch content of bananas is known to decrease as the fruit ripens; consequently, a 
relatively unripe banana (yellow skin with small amounts of green at the tip) contains 
roughly 37% starch on a dry weight basis, whereas an overripe banana contains only 3% 
starch. Free sugars, which constitute 56-75% of total carbohydrate content on a dry 
164 
weight basis, increases as bananas ripen. Consequently, the ratio of starch to free sugars 
can be as much as 20-fold higher in an unripe compared to an overripe banana 
(513,582). Consistent with the changes in starch and glucose availability during ripening, 
Wolever, et al. (583) observed that the glucose response to ripe and overripe bananas 
were 25% and 50% greater (p<0.05), respectively, than the response to an under-ripe 
banana. Thus, the changes in carbohydrate composition which occur during ripening, 
clearly impact the metabolic response to fruits. 
To further examine the influence of botanical structure on the glycemic response, 
Haber, et al (584) compared whole apples to fiber-free apple puree and fiber-free apple 
juice. Despite the relatively small amount of total fiber in apples (1.5% by weight), it is 
the fiber that is responsible for the physical structure and appearance of the fruit. Apple 
juice, which contains a significant amount of carbohydrate, can be considered fiber-free 
apples since the fibrous structure has been completely removed. On the other hand, 
apple puree retains the fiber but the physical structure has been significantly disrupted. 
There were no significant differences in the peak blood glucose levels after whole apples 
compared to juice or puree. However, both apple juice and apple puree resulted in 
higher serum insulin levels and less satiety than did whole apples (p<0.05). There are 
several potential explanations for these findings. First, the physical form of a whole 
apple reduces the rate at which it can be consumed compared with juice and puree, 
which can be swallowed relatively quickly. Although the postprandial glucose responses 
were similar after consumption of whole apples, fiber-free juice, and fiber-free puree, 
consumption of juice and puree led to rebound hypoglycemia, which was not observed 
following ingestion of whole apples. This may be partially attributable to the disruption 
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of the fibrous structure of whole apples in preparing apple juice and puree. Fiber 
depleted foods are known to be more rapidly absorbed than high fiber foods (24,37,43). 
That apple puree gave an intermediate response suggests that particle size, in addition to 
intact structure, influences postprandial responses. The peak insulin level occurred more 
rapidly and was almost 2-fold higher (p<0.001) following apple juice compared to the 
whole apple. Consequently, the area under the insulin curve was also greater following 
juice compared to apples (p<0.01). Apple puree resulted in an intermediate peak insulin 
level, which was higher than after whole apples (p<0.01) yet lower than after juice 
(p<0.01). 
"Role of Gastrointestinal Hormones and Co-ingested Macro nutrients 
The interaction between increased availability of glucose, fatty acids and amino 
acids complicates the understanding of those factors that determine the postprandial 
response to a mixed meal. The term "enteroinsulinar axis" is used to include all 
metabolic factors, which contribute to enhanced insulin secretion following a meal. 
Several gut peptides have been demonstrated to be insulin secretagogues in vitro 
including gastrin, secretin, cholecystokinin (CCK), gastric inhibitory peptide (GIP) and 
glucagon like peptide 1 (GLP-1) (585-587). 
The rate at which the stomach empties is regulated by stimuli generated in the 
stomach and small intestine. At least 15  different endocrine cell types, many of which 
secrete more than one type of hormone, have been identified in the gastrointestinal tract 
(586). Furthermore, the hormones secreted by the gastrointestinal tract are not confined 
to the area in which they are secreted but rather have endocrine and neurocrine effects as 
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well. The signals arising from the various gastrointestinal hormones are especially 
important in the duodenum, where the rate at which chyme is emptied by the stomach 
must be carefully regulated such that the absorptive capacity of the small intestine is not 
exceeded (532). 
Progressive increases in dietary protein up to 50 grams enhances the insulin response 
in a dose-dependent manner and extends the time course of the insulin response such 
that plasma levels are elevated above baseline for longer periods compared to a 
carbohydrate load which does not contain protein (588) . As the amount of dietary 
protein in a mixed meal increases, the mean incremental serum glucose level is reduced 
in parallel (588,589). 
Dietary fat modifies gastrointestinal function by multiple mechanisms. Fat is known 
to delay gastric emptying, which may exert beneficial metabolic effects on postprandial 
glycemia by reducing the rate of carbohydrate delivery to the absorptive cells of the small 
intestine (590). However, the same combination of carbohydrate and fat reportedly 
attenuates postprandial glycemia via the stimulatory effect of dietary fat on gastric 
inhibitory peptide (GIP) secretion, which may subsequently augment the insulin 
response (591).  The infusion of GIP resulting in supraphysiological plasma 
concentrations is insulinottopic at basal glucose levels in animals; however, in man GIP 
acts as an insulin secretagogue only under hyperglycemic conditions (587). This has 
been demonstrated by Verdonk. et al. (591) .  Fat ingestion under hypoglycemic and 
euglycemic conditions resulted in significant elevations of GIP above basal levels 
(p<0.01) without influencing insulin levels. Despite similar elevations in GIP levels 
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during hyperglycemic conditions, plasma insulin levels following fat ingestion were 
significantly greater than those observed prior to fat ingestion (p<0.01). 
There are conflicting findings regarding the co-ingestion of fat and carbohydrate. 
Compared with the response to boiled potatoes, Collier, et al (592) observed a reduction 
in the postprandial glucose response (p<0.05) when butter was given with boiled 
potatoes, which is consistent with the effects of dietary fat in delaying gastric emptying. 
However, serum GIP levels were 8-fold higher (p<0.005) in subjects consuming the 
potato with added butter, and was accompanied by an enhanced insulin secretory 
response (p<0.01) compared to subjects consuming the potato alone. 
Siddhu, et al. (590) designed a more elaborate study to evaluate the effect of 
macronutrient content on the postprandial response. The glycemic and insulin response 
to glucose (G) were compared to isocaloric meals of variable macronutrient 
composition. The glycemic response to glucose plus com oil (Geo) was similar to that 
of glucose alone; however, the insulin response to Geo was significantly lower than the 
response to glucose at 120 minutes (p<0.01). Consistent with this, the area under the 
insulin curve (AUCi) was significantly lower following the GCo meal compared to 
glucose alone (p<0.01). Thus, it appears fat alone exerts little effect on postprandial 
glycemia, although it does reduce the insulin response. This conflicts with other reports 
indicating a blunting of the glycemic response when fat is included test meals (591 ,593). 
Partial isocaloric substitution of casein for com oil (GCoCs) led to a significant blunting 
of the overall glycemic response as demonstrated by a lower AUCG compared to glucose 
alone (p<0.01). Although the AUC1 for GCoCs was similar to G, the insulin level at 2 
hours was significantly lower for the GCoCS meal (p<0.01). In this case, the 
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improvement in postprandial glycemia may be the result of increased insulin secretion in 
response to the inclusion of protein. A significant reduction in both the glycemic and 
insulin responses were observed following the addition of pectin (P) to the GCo meal. 
The glycemic response to GCoP (AUCG) was roughly 45% lower than following GCo 
(p<0.05) . There was an even more profound reduction in the insulin response with 
lower insulin levels (p<0.01) being apparent at 1 .5-and 2-hours following the GCoP 
meals in addition to an overall reduction in the insulin response compared to GCo 
(p<0.01). The addition of dietary fiber as cellulose (GcoCsCl) reduced the glycemic 
response at 1-hr and 1 .5-hr and in terms of AUCG (p<0.01). Cellulose was without 
effect on insulin levels. The lowest glycemic and insulin responses were achieved with 
the combination of glucose, com oil, casein and pectin (GCoCsP). Compared to all 
other meals, GCoCsP resulted in significantly lower blood glucose responses at all times 
during the 2-hour glucose tolerance test (p<0.05), lower plasma insulin levels at 2-hours 
(p<0.01), smaller AUCG (p<0.05) and smaller AUC1 (p<0.05). Thus, the 
hypoinsulinemic effects of pectin were able to overcome the stimulatory effects of casein 
on insulin secretion. 
Metabolic Bene.its of a Low Glycemic Index Diet 
Inf111ence of Dietary Carbol?Jdrate S011rre on Postprandial Metabolism 
The metabolic effects of glucose, fructose, sucrose and starch ( com starch, 27% 
amylase, 73% amylopectin) on postprandial glucose and insulin responses, energy 
expenditure and substrate utilization were investigated in lean males following a 75 gram 
carbohydrate load (594). Plasma glucose levels peaked at similar levels 30 minutes 
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following ingestion of glucose and sucrose and at 60 minutes following ingestion of 
starch. Peak plasma glucose levels obtained 30 minutes after fructose ingestion were 
significantly lower (p<0.01) than for all other carbohydrates tested. After achieving peak 
values, plasma glucose levels returned to baseline at 60 minutes with fructose, at 90 
minutes with glucose and sucrose, and 120 minutes with starch. Postprandial reactive 
hypoglycemia was observed from 150-300 minutes following ingestion of glucose and 
sucrose, and from 240 to 300 minutes following the fructose load. In contrast, 
postprandial blood glucose levels remained above baseline levels from 2 to 6 hours 
following ingestion of the starch load. The 6-hour integrated glycemic response above 
baseline was higher with glucose and starch than with fructose (p<0.05), with an 
intermediate response observed with sucrose (p<0.05 vs. fructose) . 
Plasma insulin levels followed a pattern similar to glucose levels following 
carbohydrate ingestion. Peak insulin levels were highest at 30 minutes following glucose 
ingestion (p<0.01 vs. all other carbohydrates) and lowest 30 minutes following fructose 
(p<0.05 vs. all other carbohydrates) . Intermediate peak insulin levels were observed 60 
minutes following ingestion of starch and 30 minutes after sucrose. Insulin levels 
returned to baseline at 150 minutes with fructose and sucrose, at 180 minutes for 
glucose, and at 240 minutes with starch. Plasma insulin levels fell below basal levels 
(p<0.05) from 240 to 360 minutes following fructose, glucose, and sucrose. The 
incremental AUC for insulin was highest for glucose (p<0.001 vs. all carbohydrates), 
lowest for fructose (p<0.01 vs. sucrose and starch), with intermediate values following 
sucrose and starch. 
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For all carbohydrates, there was a significant increase (p<0.0001) in energy 
expenditure following ingestion. The peak increase in energy expenditure was higher 
(p<0.05) with sucrose compared with all other carbohydrates. Energy expenditure 
returned to baseline at 1 50 minutes with sucrose, 1 80 minutes with glucose and starch, 
and at 210 minutes with fructose, and remained at baseline levels for the remainder of 
the study. The total integrated increment in energy expenditure above baseline was 
similar with fructose and sucrose, and higher with sucrose compared with starch 
(p<0.05) and glucose (p<0.01). The fact that sucrose and fructose yielded the lowest 
insulin responses but resulted in the greatest increase in thennogenesis is somewhat at 
odds with previous studies, which suggest that insulin is an important determinant of 
carbohydrate-induced thermogenesis. 
Following ingestion of all carbohydrates, there was an increase (p<0.001) in 
carbohydrate oxidation above basal levels. Carbohydrate oxidation increased to similar 
peak levels at 60 minutes with fructose and sucrose. These values were significantly 
greater (p<0.01) and occurred more rapidly (p<0.05) than with glucose and starch. 
Carbohydrate oxidation returned to baseline levels at 210 minutes following ingestion of 
glucose, starch and sucrose, and at 240 minutes after ingestion of fructose. Total 
carbohydrate oxidation over 6 hours was significantly rugher (p = 0.008) with fructose 
and sucrose compared with glucose and starch. The integrated exogenous carbohydrate 
oxidation over 6 hours, which represents the amount of ingested carbohydrate that was 
directly oxidized, was significantly higher (p<0.001) with fructose and sucrose compared 
with glucose and starch. Exogenous carbohydrate oxidation with fructose was also 
significantly greater (p<0.01) than with sucrose. The contribution of endogenous 
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glycogen stores to total carbohydrate oxidation was estimated by determining the 
difference in cumulative total carbohydrate oxidation and cumulative exogenous 
carbohydrate oxidation. There was a tendency for higher endogenous carbohydrate 
oxidation with fructose and sucrose compared with glucose and starch, but these 
differences did not reach the level of significance. 
The decline in fat oxidation below basal levels was greatest 30 minutes following 
ingestion of fructose and 60 minutes after sucrose. The decrement occurred much later 
and to a lesser degree following starch (at 150 min) and glucose (at 120 min) compared 
with fructose and starch (p<0.01 for both). After achieving nadir, lipid oxidation 
returned to baseline at 21 0 minutes with fructose and sucrose and at 270 minutes 
following glucose and starch. 
These results demonstrate that the postprandial metabolic response is influenced by 
the type of carbohydrate ingested. That these effects are most pronounced when 
integrated over a 6-hour period following carbohydrate ingestion, suggest that the 
carbohydrate composition of the diet may have important implications for substrate 
utilization and energy balance (594). 
Using continuous indirect calorimetry, Ritz, et al. (595) have demonstrated different 
patterns of substrate utilization in the postprandial period following consumption of a 
test meal containing carbohydrate content equivalent to 50 g of glucose as a high 
(glucose) compared with a low (manioc starch, 16% amylose) glycemic index 
carbohydrate. Peak glucose levels were achieved 30 minutes after the glucose meal and 
were significantly greater (p<0.01) than following ingestion of the starch meal. After 
reaching peak values, blood glucose levels in subjects consuming the high-glucose meal 
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fell below postabsorptive levels at 1 80 minutes prior to returning to baseline. In 
contrast, plasma glucose levels beyond peak levels remained above baseline and were 
significantly higher (p<0.01) from 180 to 270 minutes in subjects consuming the starch 
meal than after the glucose meal. Insulin levels peaked at 30 minutes and returned to 
baseline at 360 minutes following ingestion of both meals. However, insulin levels 
remained significantly higher (p<0.01) after the starch-containing meal between 1 50 to 
270 minutes compared with glucose. Plasma free fatty acid levels decreased following 
ingestion of both meals, reaching nadir at 1 50 minutes following the glucose meal and 
1 80 minutes following the starch-containing meal. No significant differences were 
detected until 180 minutes, after which time plasma free fatty acid levels were 
significantly lower (p<0.01) after the starch meal. With both meals, free fatty acid levels 
rose above baseline from 270 to 360 minutes. 
Glucose oxidation rose above basal levels following the glucose and starch meals. 
Rates of glucose oxidation remained relatively constant in both groups until 200 minutes 
when rates began to decrease but remained significantly higher (p<0.01) after the starch 
meal until the end of the test. Consequently, total glucose oxidation over the 6-hour 
period was approximately 21% higher in subjects consuming the starch (p = 0.0002) 
compared with the glucose meal. Carbohydrate oxidation was negatively correlated with 
plasma free fatty acid and glucose levels after both the glucose (r=0.63, p = 0.0001; 
r=0.39, p = 0.0007; respectively) and starch (r=0.33, p=0.01 ; r=0.35, p=0.03; 
respectively) meals. Glucose oxidation was correlated with plasma insulin levels (r=0.47, 
p=0.0001) following the glucose meal only. 
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Fat oxidation fell following both the glucose and starch meals. Fat oxidation 
remained significantly lower (p<0.01) for the starch compared with the glucose meal 
from 220 minutes until the end of the test. At the conclusion of the test, fat oxidation 
had returned to baseline in subjects consuming the starch meal, while remaining above 
baseline from 240 to 360 minutes in subjects consuming the glucose meal. There was a 
tendency for higher total fat oxidation over 6 hours after glucose compared with starch, 
but these values did not reach significance. 
The Metabolic 'Response to Mixed Meals Containing Sucrose versus Starch 
In a study by Storlein, et al. (596) male Wistar rats were randomly assigned to 
consume either a high-starch or high-sucrose diet for one month to evaluate the 
metabolic effects of different dietary carbohydrates on insulin action. Basal heat 
production was similar in starch and sucrose fed rats. Dietary carbohydrate source 
appeared to have no effect on heat production in response to a glucose gavage or 
noradrenaline administration, as similar increases in heat production were observed in 
both groups in response to these stimuli. 
While basal blood glucose levels were similar in both groups, sucrose feeding 
significantly increased basal insulin levels by 35% (p<0.05) compared with arurnals fed 
the high-starch diet. Sucrose feeding impaired the ability of insulin to suppress hepatic 
glucose product, consequently, rats fed the sucrose-rich diet required a significantly 
lower rate of glucose infusion (p<0.05) to maintain euglycemia during hyperinsulinemic 
clamp studies compared with starch-fed rats. Hyperinsulinemia suppressed hepatic 
glucose output by 76% in starch-fed animals but only 34% suppression was achieved in 
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the high-sucrose group (p<0.01), and the difference in endogenous glucose production 
between the high-sucrose and high-starch groups accowited for 64% of the difference in 
glucose infusion rates during clamp studies. Sucrose feeding also significantly reduced 
(p<0.01) peripheral glucose disposal. which accowited for the remaining difference in 
glucose infusion rates between the two groups. 
No differences in tissue-specific glucose metabolism were detected between groups 
at basal insulin levels. However, at clamp insulin levels glucose metabolism was reduced 
in sucrose compared with starch-fed animals in muscle (white gastrocnemius, plantaris), 
white adipose tissue (epididymal, inguinal, subcutaneous) and interscapular brown 
adipose tissue. While none of the decrements in glucose metabolism in individual tissues 
of sucrose-fed animals reached the level of significance, the cumulative effect was to 
reduce glucose metabolism in these tissues by 10% compared with starch-fed animals. 
Thus, four weeks of sucrose feeding is associated with impaired insulin action in several 
tissues, which reduces total body glucose metabolism. Furthermore, these impairments 
precede any detectable changes in body weight or adiposity, underscores the subtle 
nature of metabolic disturbances arising from chronic ingestion of refined carbohydrate 
diet. 
Pawlak, et al. (597) investigated the development of insulin resistance and obesity in 
rats fed diets identical in macronutrient composition (35 en% fat, 20 en% protein, 45 
en% carbohydrate), but containing either a low (amylose) or high (amylopectin) glycemic 
index (GI) starch. For comparison purposes, a third group was fed a high (60 en%) fat 
diet, which is known to induce hepatic and peripheral insulin resistance. To ensure that 
any changes in adiposity and insulin sensitivity were due to diet, rather than body weight, 
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arumals in the low and high GI diet groups were fed for 7 weeks, while arumals 
conswning the high fat diet were fed for only 4 weeks so that final body weights in all 
groups were similar. 
Epididymal fat pad mass was lower (p<0.05) in the low-GI group compared with 
both the high-GI and high-fat groups. When expressed relative to body weight (g/100 g 
body weight), epididymal fat pad mass in arumals consuming the low-GI diet was 22 and 
41% lower (p<0.05) than in high-GI and high-fat fed arumals, respectively. Thus, 
despite any detectable differences in body weight, animals consuming the low-GI diet 
accumulated significantly less adipose tissue than animals consuming the high-GI and 
high-fat diets. 
There were no differences in fasting insulin levels between groups, but basal plasma 
glucose levels were greater in the high-fat (p<0.05) compared with the low- and high-GI 
groups. During an intravenous glucose tolerance test high-fat fed rats had higher plasma 
glucose levels (p<0.05) compared with the low- and high-GI groups at all time points 
measured, suggesting high-fat feeding impaired glucose uptake, making these arumals less 
able to clear the glucose load. In contrast, both the incremental AUC8hx:osc and peak 
glucose levels achieved during the IVGTI were not different in low- and high-GI fed 
rats. During the IVGTI, peak insulin levels in the high-GI group were not different 
from high-fat fed rats, but both were approximately 25% greater than arumals 
consuming the low-GI diet (p<0.05). Furthermore, the integrated insulin response over 
the first 30 minutes was 31% higher in the high-GI (p<0.05) compared with low-GI 
group. There were no significant differences in the AUC;n,ulin calculated for high-fat vs. 
high-GI fed rats. 
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The type of starch in the diet failed to influence glucose sensitivity in the liver or 
peripheral tissues under basal or clamp conditions. Rates of insulin-stimulated glucose 
turnover were similar in all three groups, which suggests diet did not significantly 
influence whole-body glucose utilization. High-fat feeding lowered the glucose infusion 
rate (GIR) required to maintain euglycemia by approximately 30% (p<0.05) compared 
with both the high- and low-GI diets. Insulin-mediated suppression of hepatic glucose 
output was also reduced by 70% (p<0.05) in high-fat compared with high- and low-GI 
groups. 
Thus, it appears that despite higher postprandial glucose and insulin levels, the high­
GI diet was not associated with changes in peripheral and hepatic glucose disposal. 
However, despite containing similar amounts of fat, high-GI fed rats demonstrated an 
exaggerated first-phase insulin response during the IVGTI compared with low-GI fed 
rats. One can speculate that insulin hypersecretion after only 7 weeks of high-GI feeding 
may alter the pattern of substrate utilization even in the absence of changes in insulin 
sensitivity. Furthermore, rats fed the high-GI diet remained glucose tolerant yet 
epididymal fat mass was increased, implicating high-GI carbohydrates in the 
pathogenesis of obesity (597). 
To track the development of hyperinsulinemia and obesity in response to diet, female 
Sprague Dawley rats were fed either a high-fat sucrose (HFS; 39 en% fat, 40 en% 
sucrose) or a low-fat, complex carbohydrate (LFCC; 9 en% fat, 68 en% starch) diet and 
the influence of these diets on adiposity and insulin sensitivity assessed at 2 weeks, 2 
months, and 2 years (598). After only two weeks of ad libitum consumption of the HFS 
diet, plasma insulin levels were significantly elevated (p<0.05) compared with animals 
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consuming the LFCC diet. HFS fed animals would maintain higher insulin levels 
(p<0.05) than LFCC animals after 2 months, 6 months, and 2 years on the diets, which 
demonstrates the influence of diet on insulin levels beyond the effects of aging. 
Consistent with the hyperinsulinemia induced by only 2 weeks of HFS feeding, 
sarcolemmal vesicle insulin-stimulated glucose transport was reduced by approximately 
16% (p<0.05) compared with the LFCC group. 1bis trend continued, such that glucose 
transport remained 21-23% lower in HFS compared with LFCC fed animals at 2 months 
(p<0.05) and at 2 years (p<0.05). These differences cannot be attributed to differences 
in muscle protein, since protein yield in sarcolemma preparations were similar for both 
groups at each point in time. 
Total body fat, expressed as percent body weight, was approximately 30% greater 
(p<0.05) following 6 months of HFS-feeding compared with the LFCC diet. Significant 
adipocyte hypertrophy was apparent at 2 months in HFS (p<0.05) rats and adipocytes 
continued to enlarge (p<0.05) compared with LFCC animals at 6 months. 
This study further demonstrates the insidious nature of diet-induced 
hyperinsulinemia, which was present within 2 weeks in the HFS animals, and confirms 
its establishment prior to other aspects of the metabolic syndrome, including obesity. 
Furthermore, it seems that hyperinsulinemia and insulin resistance are not a consequence 
of obesity, but rather, can be attributed to consumption of a sucrose-rich diet (598). 
To further examine the relationships between sucrose-induced insulin resistance and 
changes in lipid metabolism which may favor the development of obesity, female 
Sprague Dawley rats were fed the same diets (described above) for 6 months and 
observed for changes in adipocyte size and hormone-sensitive lipase (HSL) activity (599). 
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Consistent with previous findings, consumption of the HFS diet for only two weeks 
significantly elevated (p<0.01) plasma insulin levels compared with the LFCC diet. 
Mean adipocyte cell volume was not significantly different in rats consuming the HFS 
compared with LFCC diet after two weeks. However, at 2 months, adipocyte volume of 
the HFS rats was 83% (p<0.01) greater than in the LFCC group. Consequently, mean 
cell number per gram of tissue for LFCC rats was 75.3% (p<0.01) greater than in HFS 
rats. Adipocyte volume in HFS rats further increased beyond 2 months, reaching 
149.8% (p<0.01) of LFCC rats at 6 months. Due to the increase in cell volume, there 
was a further reduction in mean cell number per gram of tissue in HFS animals, such 
that cell number per gram of tissue was only 40.87% (p<0.01) of that seen in LFCC-fed 
animals. Interestingly, adipocytes of LFCC rats did not increase in volume or decrease in 
number during the 6 month feeding period. These findings demonstrate that adipocyte 
hypertrophy is one consequence of a refined-sugar diet that can be prevented by the 
consumption of a low-fat, complex carbohydrate diet. 
Plasma glycerol levels, which are indicative of in vivo lipolysis, were not significantly 
different at 2 weeks, however, by 2 months, glycerol levels in the HFS were 47.3% 
(p<0.05) greater than in the LFCC group. Thus, in vivo lipolysis was increased within 2 
months by consumption of a diet known to induce hyperinsulinemia. Furthermore, 
plasma glycerol levels continued to increase in HFS animals, such that they were 91 .4% 
(p<0.01) higher than in LFCC animals at 6 months. 
Neither basal nor isoproterenol-stimulated HSL activity was significantly different 
between diets at 2 weeks. At 2 months, basal HSL activity was nearly two-fold higher in 
adipocytes from HFS (p<0.01) compared with LFCC animals. To determine if the 
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increase in basal lipolytic rate in HFS- fed aoima1s was due to increased sympathetic 
nervous system activity, animals were injected with the �-adrenergic receptor blocker, 
propranolol, and the effect on basal glycerol release determined. In control cells, basal 
glycerol release was similar to that observed following administration of propranolol, 
demonstrating the effects of the HFS diet to increase basal lipolysis are not mediated by 
enhanced sympathetic activity. Isoproterenol-stimulated lipolysis in adipocytes from 
HFS animals at 2 months was 1 .72-times (p<0.01) the rate of LFCC animals. This trend 
continued, resulting in basal HSL activity in adipocytes from HFS animals at 6 months 
being nearly three-fold greater (p<0.01) than in adipocytes from LFCC animals. 
Isoproterenol-stimulated HSL activity at 6 months in adipocytes from HFS fed animals 
was 1 .71-times (p<0.01) that observed in LFCC animals. Fat cell size was positively 
correlated with both basal (r=0.98, p<0.01) and isoproterenol-stimulated (r2 = 0.88, 
p<0.01) lipolysis. These findings of elevated lipolysis in enlarged adipocytes are 
consistent with studies previously performed in both rodents and humans (205,208) and 
demonstrates that feeding a diet rich in sucrose leads to increases in basal and 
isoproterenol-stimulated HSL activity and adipocyte hypertrophy in as little as 2 months 
(599). 
To assess the response of adipose tissue lipoprotein lipase (LPL) activity to a refined­
sugar diet, normal Sprague-Dawley rats were rendered overweight and insulin resistant 
by 4 weeks of ad libitum consumption of a high-fat, high-sucrose (HFS) diet and 
compared with control (chow-fed) insulin-sensitive animals (600). Despite similar initial 
body weights in both control and HFS animals, final body weight was modestly greater 
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(p<0.05) in HFS than control animals. The inguinal, epididymal, and retroperitoneal fat 
pads were 50-70% larger (p<0.05) in HFS fed animals compared with controls. 
Fasting plasma glucose levels were modestly (by 16%, p<0.04) higher in HFS-fed 
animals, while plasma insulin levels were 2-fold higher (p<0.003) in animals fed the HFS 
diet compared to control During hyperinsulinemic clamp studies, the steady-state GIR 
needed to maintain euglycemia in HFS-fed animals was approximately 50% lower 
(p<0.0001) than in control animals. 
Following a 24-hour fast, plasma glucose and insulin levels were similar in HFS and 
control animals. To determine the effects of diet on postprandial metabolism, both 
groups of animals were refed standard rodent chow. Between 3 and 6 hours after 
refeeding, plasma glucose levels were 3-fold higher (p<0.001) in HFS compared with 
control animals, despite similar plasma insulin levels in both groups. Hyperglycemia in 
the absence of elevations in plasma insulin levels suggest that the HFS diet impaired the 
normal insulin secretory response. Following a 24-hour fast, the activity of LPL in three 
adipose tissue depots (inguinal, retroperitoneal, and epididymal) was similar for control 
and HFS-fed animals. Refeeding increased LPL activity in all three fat depots 
(p<0.0001) in control animals, with peak activity occurring at 3 hours in the inguinal and 
epididymal depots and at 6-hours in the retroperitoneal fat pad. In contrast, only a slight 
increase (30% above fasting) in LPL activity was observed in HSF-fed animals following 
refeeding. Three hours following refeeding, LPL activity in all three depots was 2-fold 
higher (p<0.003) in control compared with HFS-fed animals, which coincided with the 
time when HFS-fed animals demonstrated significantly elevated (p<0.05) plasma 
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triglyceride levels compared with chow-fed controls, suggesting a link between LPL 
activity and the known hypertriglyceridemic effects of refined carbohydrates. 
Activity of soleus muscle LPL was consistently lower in HFS- compared with 
control-fed animals. These differences reached significance (p<0.05) at 1 and 3 hours 
post-refeeding. In the vastus lateralis muscle, refeeding significantly increased (p<0.05) 
LPL activity only in control animals. As in the soleus muscle, LPL activity was 
consistently lower in vastus lateralis of HFS- compared to control-fed animals at all 
points in time, and was nearly 4-fold lower one hour following onset of refeeding. Thus, 
this study demonstrates that HFS feeding causes significant impairments in the 
postprandial LPL response in both adipose tissue and skeletal muscle. The HFS diet 
induced profound insulin resistance with respect to glucose uptake within 2 weeks. 
Refeeding fasted animals standard rodent chow results in elevations in plasma insulin 
levels, which should be sufficient to stimulate LPL activity in adipose tissue and 
simultaneously decrease its activity in skeletal muscle. However, this study clearly 
demonstrates that chronic conswnption of a diet containing a refined carbohydrate 
(sucrose) rendered LPL in adipose tissue refractory to the influence of insulin. 
Nonetheless, insulin resistant HSF-fed animals appeared to maintain the ability to 
decrease muscle LPL activity in response to elevations in plasma insulin levels resulting 
from refeeding. However, the activity of skeletal muscle LPL was blunted in HFS 
compared with control-fed animals, which may have contributed to the higher 
postprandial triglyceride levels in these animals (600). 
To determine if the deleterious effects of HFS feeding could be overcome by dietary 
change, female Sprague Dawley rats were fed the HFS and LFCC diets for 22 months, 
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with a subgroup of animals consuming the HFS diet switched to the LFCC diet 
(HFS/LFCq at 20 months for the remainder of the study (2 months) (601). There were 
no differences in energy intake between the HFS and LFCC groups during the first 20 
months. Nonetheless, energy efficiency was 46% lower (p<0.01) in the LFCC compared 
with the HFS animals. However, the difference in energy intake between the LFCC and 
HFS groups accounted for only 2.5% of the 123 g difference in body weight between the 
groups. After 22 months, body weight of HFS-fed animals was 44% (p<0.01) greater 
than for animals consuming the LFCC diet. At 20 months, a subgroup of HFS-fed 
animals was switched to the LFCC for 2 months, which resulted in a 1 6% (p<0.05) 
reduction in body weight. 
Heparin-releasable LPL activity in abdominal adipose tissue was 50% (p<0.05) 
greater in HFS compared with LFCC animals. Conversely, heparin-releasable LPL 
activity in the plantaris muscle was reduced by 58% (p<0.05) in the HFS compared with 
the LFCC group. A 33% reduction (p<0.05) in LPL activity was observed in the soleus 
muscle of HFS- compared with LFCC-fed animals. 
In the abdominal depot, abundance of LPL protein was similar in both groups, 
indicating the elevation in LPL activity of HFS-fed animals is not merely a by-product of 
adipocyte hypertrophy. However, gastrocnemius muscle LPL protein levels were 
significantly reduced (p<0.01) by the HFS diet and was restored (p<0.02) in animals 
switched to the LFCC diet for 2 months. 
In summary, chronic consumption of the HFS diet induced reciprocal changes in 
adipose tissue and skeletal muscle LPL activity. Enhanced LPL activity in adipose tissue 
occurring concomitantly with attenuated activity in skeletal muscle established a 
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metabolic environment favoring obesity. However, conversion from the HFS to the 
LFCC diet for only two months induced significant improvements in body weight, 
plasma lipids, and LPL activity, suggesting that dietary manipulation should constitute a 
first-line defense in the treatment or prevention of obesity (601). 
In addition to the influence of dietary carbohydrate per se on whole body lipid 
metabolism mediated via hormone-sensitive lipase and lipoprotein lipase, Kabir, et al. 
(602) have demonstrated an influence on fatty acid synthase, a key enzyme of de novo 
lipogenesis. Rats that chronically consumed a diet high in waxy cornstarch (0.5% 
amylase) exhibited significantly elevated rates of basal and insulin-stimulated glucose 
metabolism in adipocytes compared with rats that consumed a diet rich in mung bean 
starch (32% amylase). Consequently, rats that consumed the diet rich in waxy 
cornstarch had adipocytes of larger diameter compared with those that consumed mung 
bean starch. Although insulin responses did not differ significantly between the diets, 
animals consuming mung bean starch had lower postprandial insulin peaks than did rats 
consuming waxy com starch. Persistently low insulin levels may partially explain 
differences in adipocyte size observed in this study. Kabir, et al. (603) further 
determined that varying the glycemic index of dietary carbohydrates appears to stimulate 
adipocyte de novo lipogenesis specifically. Chronic consumption of waxy com starch 
significantly increased adipocyte fatty acid synthase in both normal and streptozotocin­
induced diabetic rats compared to rats fed a low glycemic index starch diet. The high 
glycemic index diet was also associated with increased adipocyte size and reductions in 
insulin sensitivity, whereas the low glycemic index diet resulted in reduced activity of 
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fatty acid synthase and corresponding decreases in adipocyte diameter, as well as 
improved insulin sensitivity. 
Similarly, Byrnes, et al (604) demonstrated lower insulin sensitivity in rats fed high 
amylopectin (waxy cornstarch, 0% amylose) compared to high amylose cornstarch (61 % 
amylose) diets. After 1 week of feeding, animals consuming the high amylopectin diet 
gained 25% (p<0.01) more weight than animals consuming the high amylose diet. This 
disparity was no longer apparent after two weeks of feeding and by the end of the 9 
week feeding period, weight was similar for both groups. However, rats fed the high­
amylose diet demonstrated faster clearance of a glucose load compared to high­
amylopectin fed rats (p<0.001). Furthermore, the rate of glucose disappearance after 10  
minutes was significantly lower in  rats consuming the high amylopectin diet compared to 
those consuming the high-amylose diet (p<0.05). During the first 15  minutes of an 
intravenous glucose infusion, plasma insulin levels were significantly higher in rats fed 
the high-amylopectin diet compared to the amylase-fed animals (p<0.05). Although this 
discrepancy was no longer observed beyond 15 minutes, the peak insulin response in rats 
fed the high-amylopectin diet was almost twice (p<0.05) that of rats fed the high­
amylose diet. These findings suggest that chronic consumption of a high glycemic index 
diet by rats promotes insulin resistance as demonstrated by slower clearance of infused 
glucose and hypersecretion of insulin. 
In a study similar to those of Kabir, et al (602,603), Lerer-Metzger, et al. (605) the 
metabolic effects of chronic ingestion of high (wheat) and low (mung bean) glycemic 
index starches on glycemic control, lipid metabolism and adiposity, were compared in 
normal and diabetic rats fed diets composed of a single carbohydrate source for five 
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weeks. Body weight was comparable for both diets at the end of 5 weeks. Plasma 
glucose levels were 26% lower (p<0.05) in animals fed the mung bean diet compared 
with the wheat diet, regardless of diabetic status. Plasma insulin levels were -32% 
higher (p<0.05) in diabetic animals fed the wheat versus the mung bean starch diet. In 
nondiabetic animals there was a nonsignificant trend for higher insulin levels with the 
wheat compared with the mung bean diet. Plasma triglyceride and free fatty acid levels 
were 17 and 45% higher (p<0.05 for both), respectively, in wheat fed animals compared 
with those consuming the mung bean diet. 
Adipocytes isolated from animals fed the mung bean starch diet were 28% smaller 
(p<0.01) than adipocytes from animals fed the wheat starch diet. Dietary carbohydrate 
source influenced both size and number of adipocytes in normal rats. Consistent with 
adipocyte hypertrophy induced by the wheat starch diet, adipocyte number was reduced 
by 21 % (p<0.05) compared with animals fed the mung bean diet. 
Improved Lipoprotein Metabolism I!} Low-GI Food.r in Hyperlipidemic S11bjects 
Obesity is believed to increase the risk of cardiovascular disease via its influence on 
lipid metabolism. Jenkins, et al. (606) designed a three-month study to determine if the 
plasma lipid profile of hyperlipidemic subjects could be improved by reducing the overall 
glycemic index of the diet by 20% by manipulation of dietary carbohydrate source, 
without altering the overall macronutrient composition of the diet. Subjects reduced the 
mean glycemic index of their diet by approximately 13 units (p<0.01 vs. usual diet) by 
replacing high-glycemic index foods (wheat bread, potatoes, cold breakfast cereals) with 
low-glycemic index foods (rye bread, oat bran, beans, spaghetti) and consequently, 
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approximately 24% of total dietary energy was derived from low glycemic index foods 
and a small but significant reduction (by 8%, p<0.01) in total energy intake. Compared 
to baseline levels, the low glycemic index diet reduced serum and total and IDL­
cholesterol by approximately 10% (p<0.005), while serum triglycerides fell -16% 
(p<0.001). The reduction in dietary glycemic index was significantly related to the 
decrements in both total (r=0.634, p<0.05) and LDL-cholesterol (r=0.794, p<0.001). 
Fiber intake during the low glycemic index period was inversely (r=-0.583, p<0.05) 
associated with HDL-cholesterol. Interestingly, the low glycemic index diet was 
associated with a decrease in the ratio of polyunsaturated to saturated (P /S ratio) fat 
intake compared to the control periods yet significant relationships were noted for P /S 
ratio and total (r=-0.659, p<0.05) and IDL-cholesterol (r=-0.644, p<0.05) during the 
low glycemic index phase. When considering the mean level of dietary macronutrient 
intake throughout the entire three month period, as opposed to small differences 
between the low glycemic index and control phases, the lipid lowering effects were most 
dramatic in subjects whose diet tended to have a higher P /S ratio and higher dietary 
fiber content. In this context, the most significant association was found between the 
fall in serum triglycerides and the mean (3-month) dietary fiber content of the diet 
(r=0.803, p<0.01). In addition, the fall in LDL (r=0.616, p<0.05) and HDL-cholesterol 
(r=0.617, p<0.05) and the overall P/S ratio of the diet were significant. A small but 
significant reduction in body weight of 0.4 kg (p<0.05) occurred between the fourth 
week of the pre-test period and the fourth week of the low glycemic index phase; 
however, this reduction in body weight was not significantly associated with the 
improvements in lipid profile seen during the low glycemic index phase (606). 
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Comparison of a L>w-GI Diet with the AHA Step I Diet 
It has been suggested that conventional dietary recommendations, which promote the 
consumption of a low-fat, high-carbohydrate diet may have had the unintended 
consequence of increasing intake of simple sugars and refined starches, which are known 
to adversely influence risk of developing chronic diseases including obesity, non-insulin 
dependent diabetes mellitus, and cardiovascular disease. The American Heart 
Association (AHA) step 1 diet is a reduced fat (30 en%) diet, which emphasizes fat 
reduction over carbohydrate selection (607). A study of abdominally obese (WC: 
1 17.4±8.4 cm) subjects compared the short-term (6 days) effects of an ad libitum low­
glycemic index (low-fat, high-protein) diet, in which carbohydrates with a glycemic index 
greater than 55 were excluded, with the American Heart Association phase I diet 
consumed ad libitum (608). A pair-fed group was included in which the energy content of 
the diet was matched to the low-glycemic index group but with macronutrient 
composition of the AHA step 1 diet. 
During the ad libitum phase of the study, energy intake of the low-glycemic index diet 
group was spontaneously reduced by 25% (p<0.05) compared with subjects consuming 
the AHA diet. Although the low glycemic index diet was less energy (p<0.05) dense 
than the AHA diet, the differences in energy intake between the two groups remained 
significant after adjustment for energy density. In the short-term, ad libitum consumption 
of the AHA diet had no influence on body weight, however, significant decreases in 
several anthropometric indices were noted following the consumption of the low­
glycemic index diet ad libitum for the same length of time. Weight loss on the low GI 
diet (p<0.001) was accompanied by reductions in both waist girth (p<0.001) and hip 
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circwnference (p<0.001). Similar reductions in body weight (p<0.001 vs. AHA) and 
waist circumference (p<0.02 vs. AHA) were observed during the pair-feeding phase. 
While these changes are significant, it is important to note that initial changes in body 
wcight in response to a change in diet do not necessarily reflect loss of body fat, nor are 
they predictive oflong-tenn changes in body composition. 
Dietary regimen had no effect on plasma cholesterol levels, however, the 
consumption of the AHA phase I diet ad libitum resulted in a 28% increase in fasting 
triacylglycerol levels (p<0.05) and a 10% reduction in HDL-cholesterol levels (p<0.01). 
Consequently, the AHA diet, either ad libitum or with energy restriction, was associated 
with a significant increase in the cholesterol:HDL ratio (p<0.05), an accepted index of 
cardiovascular disease risk. In contrast, ad libitum consumption of the low-glycemic 
index diet was associated with a 35% reduction in plasma triacy)glycerol levels 
(p<0.0005), while plasma HDL-cholesterol levels and the cholesterol:HDL ratio were 
unchanged. 
The AHA step 1 diet, either in its ad libitum or hypoenergetic fonn, failed to influence 
fasting plasma insulin and apolipoprotein B levels, nor was IDL particle diameter 
affected. In contrast, the ad libtium low glycemic index diet resulted in significant 
reductions in fasting plasma insulin levels (p<0.05 versus baseline) and increased LDL 
particle size (p<0.05). Postprandial glucose excursions were also reduced by the ad 
libtium low glycemic index diet compared with either AHA diet. Fasting plasma insulin 
levels were significantly lower (p<0.05) in subjects consuming the low-glycemic index 
diet compared with the AHA diet after 6 days. Furthermore, the insulin response to an 
oral glucose load was reduced by the low glycemic index diet, yet remained unchanged 
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with either AHA diet regimen. In summary, the benefits of a low-glycemic index diet are 
rapid and dramatic, and include a spontaneous reduction in energy intake, reduced 
fasting plasma insulin levels, and a less atherogenic lipid profile, characterized by an 
increase in LDL particle size, in abdominally obese subjects. These findings indicate a 
significant reduction in spontaneous energy intake and improvements in the metabolic 
risk profile of abdominally obese subjects following consumption of a low glycernic 
index diet for only seven days. Based on these results, dietary advice given to subjects at 
risk for chronic disease must be carefully evaluated. 
ACNte Effects of Dietary Carool!Jdrate on Insulin S ensitivifY 
To establish whether individual insulin sensitive responses are acutely affected by 
major alterations in dietary carbohydrate source, a crossover study was conducted in 
which subjects consumed a high-sucrose (50 en% sucrose) or high-starch (50 en% 
starch) diet as four meals over a 2�hour period (609). Rates of glucose disappearance 
determined during an insulin tolenuice test were similar for both meals, suggesting no 
alterations in insulin-stimulated glucose uptake. Similarly, insulin-mediated suppression 
of plasma NEF A levels were comparable for both meals. Nonetheless, the brevity of 
this study does not permit speculation regarding the long term effects of dietary 
manipulation of this sort. 
Despite the apparent failure of dietary manipulation to influence insulin sensitivity in 
fasting subjects in the short-term, several parameters of postpnuidial metabolism were 
responsive to alterations in dietary carbohydrate source. Following the high-sucrose diet, 
blood glucose levels rose more rapidly and to higher peaks (p<0.05) after each meal 
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compared with the high-starch diet. After achieving peak postprandial levels, blood 
glucose levels fell more rapidly (p<0.05) with the high-sucrose diet and reactive 
hypoglycemia was observed after breakfast and lunch in sucrose-fed subjects. In 
contrast, postprandial blood glucose levels remained above fasting levels at all times with 
high-starch feeding. 
Both diets suppressed postprandial NEF A levels, while causing a gradual rise in 
triacy)glycerol levels after breakfast, with a further increase in the hour immediately 
following the noon meal. Subsequently, the similarities in the postprandial triacylglycerol 
response are lost. Following the noon high-starch meal, plasma triacylglycerol levels 
gradually declined towards fasting levels. In contrast, plasma triglycerides continued to 
rise following the noon high-sucrose meal, and peak levels were delayed until following 
the afternoon meal, before beginning a gradual decline. Nonetheless, an additional peak 
in triglyceride levels occurred two hours following the evening sucrose meal, and 
consequently baseline levels were achieved only following an overnight fast. Although 
blood lactate and pyruvate concentrations peaked approximately one hour after each 
meal in both diet groups, postprandial levels were as much as three-fold higher (p<0.05) 
with the high-sucrose diet than with the high-starch diet (609) . 
Alterations in Insulin Action &su/ti11gfrom Chronic Changes in Dietary Carbof?ydrate Source 
The influence of dietary carbohydrate source on insulin action and muscle substrate 
utilization was investigated by feeding healthy men isoenergetic diets containing 46 en% 
carbohydrate, as either low or high glycemic index carbohydrates, for 30 days (610). 
Fasting glucose and insulin levels were unchanged from baseline following thirty days of 
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consuming either the low or high glycemic index diets. Fasting plasma fatty acids rose 
by 52% from baseline (p<0.05) after three days of consuming the low glycemic index 
diet and remained elevated above baseline in these subjects for three weeks. However, at 
the conclusion of the study, there were no differences in plasma fatty acid levels between 
low and high glycemic index diet groups. After the lunch meal, serum insulin levels in 
the low glycemic index diet group on day three were significantly lower (p<0.05) than 
those encountered with the high GI diet. 
Following thirty days of consuming the low glycemic index diet, there was a 
significant decrease (- 13%, p<0.05) in muscle glycogen concentration compared to 
baseline. In contrast, muscle glycogen concentration remained constant with the high 
glycemic index diet, but was significantly greater (p<0.05) than in subjects consuming the 
low glycemic index diet. 
Metabolic Effects of a Low-GI Diet in Normal Weight and Obese Subjects 
While the exact mechanism by which dietary glycemic load influences energy 
metabolism is unknown, it has been suggested that the high insulin levels associated with 
consumption of high-glycemic index foods may favor deposition of fuels for storage as 
opposed to promoting their oxidation. 
Bisschop, et al. (61 1) evaluated the dose response effects of isocaloric variations in 
dietary carbohydrate and fat content on postabsorptive free fatty acid release and fat 
oxidation in healthy subjects. Subjects consumed a sequence of three diets for seven 
days each containing 15 en% protein but differing in carbohydrate and fat content. The 
control diet provided 44 en% carbohydrate and 41 en% fat. The high-carbohydrate diet 
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provided 85 en% as carbohydrate, whereas the high fat diet provided 83 en% as fat and 
2 en% carbohydrate. Fasting insulin levels were 39% lower (p<0.01) after the high-fat 
compared with the high-carbohydrate and control diet periods. Lower insulin levels in 
the high-fat group may have influenced the appearance rate for palmitate which was 66% 
greater (p<0.01) than the high-carbohydrate and control diets. Consequently, plasma 
free fatty acid levels, which were similar between the high-carbohydrate and control 
diets, were 67% greater after the high-fat diet (p<0.01). 
Similar respiratory quotients (RQ) were observed after the high-carbohydrate and 
control diets, but RQ was slightly but significantly lower (10%, p<0.05) after the high-fat 
diet. Whole-body fat oxidation increased 47% (p<0.01) with the high-fat diet compared 
with both the high-carbohydrate and control diets. Because the diets used in this study 
were isoenergetic and isonitrogenous, the observed effects are solely attributable to the 
variations in dietary carbohydrate and fat. These findings in conjunction with results 
from Poppitt, et al. (612) who demonstrated that chronic consumption of a high-fat diet 
is associated with increased plasma fatty acid levels during hyperinsulinemic euglycemic 
clamps, suggest that high-fat feeding reduces plasma insulin levels and the reduces the 
ability of insulin to suppress free fatty acid release (61 1). 
Metabolic Benefits of Diets &ch in Whole Grain Foods 
To examine the potential benefits of a diet rich in whole-grain rather than refined­
grain foods on insulin sensitivity, independent of changes in body weight, overweight 
hyperinsulinemic adults were used in a randomized, crossover controlled feeding trial 
consisting of two 6 week periods (613). The habitual diets of the subjects prior to 
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beginning the study indicated relatively low median intake of fruit (1.0 serving/day), 
vegetables (2.2 servings/cl), carbohydrate (4-0 en%/d), and high intake of total fat (4-0 
en%/d) and saturated fat (4-0% of fat). 
Body weight was not significantly different between the whole-grain and refined-grain 
periods. There was a nonsignificant trend for lower blood glucose levels following the 
whole grain period. Fasting insulin levels were modest (10%) but significantly (p<0.05) 
lower following the whole-grain versus the refined-grain period. 
The homeostasis model for insulin resistance was computed using fasting insulin and 
glucose levels as a means for estimating insulin sensitivity (12). Based on this modei 
insulin sensitivity was significantly improved (p<0.01) by consumption of whole-grains 
compared with refined sugars consumed for the same duration. A greater rate of 
glucose infusion (p<0.01) was required to maintain euglycemia under hyperinsulinemic 
conditions following the whole-grain compared with the refined grain diet, suggesting a 
diet rich in whole grains improves insulin sensitivity. This study suggests that a whole 
grain diet can improve insulin sensitivity independently of changes in body weight in 
obese, hyperinsulinemic adults. 
Schwarz, et al. (614) examined the influence of diet on hepatic de now lipogenesis 
(DNL) was compared in weight-stable subjects consuming a balanced, low-fat, high (68 
en%) carbohydrate (46% complex carbohydrates, 54% simple sugars) compared with a 
standard high-fat (4-0 en%) diet for five days. De now lipogenesis was minimal in lean 
and obese, nonnoinsulinemic subjects consuming the high-fat, low-carbohydrate diet for 
five days, whereas a significantly higher rate of de now lipogenesis (p<0.05) was observed 
in obese hyperinsulinemic subjects following the same diet protocol. DNL was similar 
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in lean and obese nonnoinsulinemic subjects after consuming the low-fat, high­
carbohydrate diet for five days. However, DNL was significantly higher (p<0.05) in 
obese hyperinsulinemic subjects compared with weight-matched normoinsulinemic 
subjects consuming the same diet. Thus, obese hyperinsulinemic subjects demonstrate 
higher rates of de novo lipogenesis following consumption of high-fat and low-fat diets, 
and this appears to be an insulin-mediated effect since elevated DNL is not observed in 
obese subjects with normal plasma insulin levels. 
These findings are also consistent with the proposed benefits of reduced glycemic 
load since hepatic DNL was minimal on the high fat diet and was significantly enhanced 
by a low-fat diet containing simple sugars (614). 
Efficary of a Lo111-GI Diet in the Prevention or Treatment of Obesity 
To evaluate the extent to which dietary glycemic index can modulate body weight, 
Bouche, et al. (615) assigned healthy subjects to consume either a high- or low-glycemic 
index for five weeks. During the low-glycemic index (LGI) period, carbohydrates with a 
GI of less than 45 were recommended, whereas foods with a GI greater than 60 were 
recommended during the high-GI (HGI) period. Total daily energy intake and 
macronutrient composition was similar at the end of the two dietary periods. 
The 24-hour plasma glucose profile was compared for an effect of diet. The 
incremental AUCs for plasma glucose after the LGI breakfast and lunch were 
consistently lower (by -61%, p<0.001) than those observed after the HGI meals. 
Furthermore, reactive hypoglycemia was observed four hours following consumption of 
the HGI breakfast. Postprandial insulin levels were consistently lower following the 
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LGI than after the HGI diet. Peak morning insulin levels and morning insulin 
incremental AUCs were approximately 41 and 48% lower, respectively (p<0.01 for 
both), for the LGI versus the HGI diet. Likewise, afternoon insulin peaks and the 
afternoon insulin incremental AUC were -18 and 31% lower (p<0.001), respectively, 
following the LGI. 
Five weeks of the LGI diet induced a significant reduction in total fat mass (700 -
1000 g) and consequently, the change in adiposity (compared with baseline) was 
significantly greater in the LGI group compared with the HGI group (p<0.05) . The 
greatest reduction in adiposity occurred in the truncal region, accounting for at least 500 
grams of total fat loss in all subjects consuming the LGI diet. Moreover, these was a 
tendency for subjects consuming the low glycemic index diet to increase total lean mass 
(p = 0.0'7), an effect which was notably absent in subjects consuming the HGI diet. 
Thus, the failure of the LGI diet to reduce body weight appears to be the result of 
compensatory changes in fat and lean tissue mass. 
Expression of genes involved in lipid metabolism and adiposity was examined in 
abdominal subcutaneous adipose tissue. Compared with the level of expression prior to 
dietary intervention, consumption of the LG I diet reduced expression of ob and LPL by 
36 and 38% (p<0.05), respectively. In contrast, the HGI diet increased LPL expression 
by 48% (p<0.05 vs. baseline) and was accompanied by trend for increased ob expression 
(12% above baseline, p=0.07). 
This study demonstrates that the simple substitution of low glycemic index 
carbohydrates for those with a high glycemic response for five weeks specifically reduces 
abdominal adiposity, reduces the expression of lipid related genes in the abdominal 
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depot and improves daily postprandial blood glucose and insulin responses. Although 
the decrements in plasma glucose and insulin levels were not associated with any changes 
in whole-body glucose metabolism or insulin sensitivity it is conceivable that maintaining 
a reduction in total fat mass with the associated increase in lean body mass as observed 
with the LGI diet, would contribute to improved glucose homeostasis and insulin action 
over the long-term (615). 
In a similar study, S1abber, et al. (616) compared two conventional, fat-reduced diets 
of identical macronutrient distribution, but which differed in the type of dietary 
carbohydrate. The low insulin response diet contained only carbohydrates known to 
evoke a low insulin response, such as lentils, pasta, rolled oats, com, and long grain rice. 
In contrast, the control diet contained potatoes, white bread, and processed 
carbohydrates; all of which are known to result in higher postprandial glucose and 
insulin responses. In the 12-week parallel study, both diets resulted in similar reductions 
in body weight. Fasting glucose levels were not influenced by diet. Both diets reduced 
fasting insulin levels (p<0.01) compared with pre-study levels, however, the decrement 
induced by the low-insulin response diet was 3-fold greater than that caused by the 
control diet. There were no significant effects of diet on the 30- and 120-minute 
glucose-stimulated insulin concentration. At the end of the 1 2  week intervention, the 
control diet significantly increased fasting c-peptide levels, resulting in a reduction in the 
insulin:c-peptide ratio. The low-insulin response diet failed to influence c-peptide levels, 
but the insulin:c-peptide ratio was reduced nonetheless, suggesting the low-insulin 
response diet improved hepatic insulin extraction without affecting insulin secretion. 
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Following the parallel study, each group was crossed over to the other diet for an 
addition 12 weeks. In subjects crossed over to the low insulin response diet, fasting 
insulin levels were significantly reduced (p<0.05 vs. pre-crossover), whereas a non­
significant increase in plasma insulin level was observed in subjects crossed-over to the 
conventional diet. Changing from the control to the low-insulin response diet also 
decreased (p<0.05) insulin levels 120 minutes after meal consumption, whereas no such 
effect was observed in subjects crossed over to the control diet, despite the similar 
energy content of the diets and the equivalent reduction in body weight induced by the 
diets. These findings suggest that while weight loss in response to energy restriction is 
similar between the two diets, the low insulin response diet resulted in a more substantial 
improvement in the postprandial insulin response in hyperinsulinemic, obese women. 
Furthermore, the deterioration of the insulin:c-peptide ratio in subjects consuming the 
conventional diet, implicates refined sugars and processed carbohydrates specifically in 
the pathogenesis of islet secretory dysfunction in this population (616). 
Lnvering G!Jcemic LJJad lry Manipulation of Dietary Carbol?Jdrate-to-Fat Ratio 
The modest success of dietary recommendations such as the AHA step 1 diet led 
investigators to examine other dietary manipulations. The CARMEN (Carbohydrate 
Ratio Management in European National diets) Study was a multi-center randomized ad 
libit11m feeding trial, which examined the effects of alterations in the ratio of fat to 
carbohydrate, as well as the ratio of simple to complex carbohydrates per se on body 
composition and lipid profile in overweight and moderately obese adults (BMI: 26-35 
kg/m2) (617). 
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Subjects were randomly assigned to control or one of two intervention groups for 6 
months. Subjects in the low-fat, high-complex carbohydrate group were to reduce fat 
intake by 10 en%, while reducing the ratio of simple to complex carbohydrates from 1 .0 
to 0.5. Subjects in the low-fat, high-simple carbohydrate group also reduced fat intake 
by 10eno/o were to make the same changes in dietary fat intake but were to increase the 
ratio of simple to complex carbohydrates from 1 .0 to 1 .5. 
At the conclusion of the study, energy intake was significantly lower (p<0.05) in the 
low-fat, high-complex carbohydrate group compared with both the low-fat, high-simple 
carbohydrate and control diets. While energy density was significantly decreased from 
baseline in both the low-fat, simple- and low-fat, complex-carbohydrate groups 
compared with control (p<0.001), the decrease was significantly greater (p<0.001) in the 
low-fat, complex carbohydrate group compared with the low-fat, simple-carbohydrate 
diet. 
The low-fat diets, without regard to carbohydrate type, produced similar reductions 
(p<0.0001) in body weight and total fat mass. In contrast, modest but significant 
increases (p<0.001) in both body weight and fat mass were observed in the control 
group. This study confirms the benefits of a fat-reduced diet with respect to body 
weight regulation but more importantly, is the finding that dietary carbohydrate source 
per se significantly influences body weight and adiposity. Although the low-fat, simple­
carbohydrate diet reduced body weight and fat mass relative to the moderate fat control 
diet, ad libitum consumption of a low-fat, high-complex carbohydrate diet induced a 
produced more significant reductions in body weight and adiposity than the low-fat, 
simple-carbohydrate diet (617). 
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The mechanism by which a low-fat, high-carbohydrate diet reduces body weight 
remains unclear. In some cases, weight loss occurring with the long-term consumption 
of a reduced fat diet is due to a reduction in energy intake. Alternatively, a lugh­
carbohydrate diet may increase diet-induced thermogenesis compared with a high-fat 
diet, suggesting the resulting weight loss is due in part to an increase in energy 
expenditure. As a follow-up to the CARMEN study and to clarify the mechanism by 
which improvements in body weight and adiposity were induced by a low-fat, lugh­
complex carbohydrate diet, Vasilaras, et al. (61 8) examined 24-hour energy expenditure 
(EE) and substrate oxidation in overweight and obese subjects prior to and following 6 
months ad libitum intake of a low-fat diet rich in either simple or complex 
carbohydrates. For comparison purposes, a control diet with macronutrient 
composition corresponding to the typical European diet was included. 
During the intervention period, average ad libitum energy intake was similar for the 
three diet groups and there were no differences in energy expenditure or basal metabolic 
rate attributable to diet. However, diet intervention was associated with alterations in the 
pattern of substrate oxidation. Carbohydrate oxidation was significantly higher in 
subjects consuming the high-complex carbohydrate diet compared with the control diet. 
Fat oxidation was significantly higher (p = 0.032) in the control group compared with 
the complex carbohydrate group, with an intermediate rate of fat oxidation observed in 
the simple carbohydrate group. Compared with baseline, fat oxidation decreased by 17  
and 25% in  the simple and complex carbohydrate groups, respectively, while the control 
diet increased fat oxidation by 3%. Differences in substrate utilization between diets are 
reflected in body weight. The complex carbohydrate diet reduced body weight by 3%, 
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while a comparable increase in body weight was observed in the control and simple 
carbohydrate groups. 
Efficacy of a Low-GI Diet in the Treatment ojObesi!J in Adolescents and Children 
In a study of obese (> 120% IBW) adolescents, Ludwig, et al. (619) report 
differential effects of mixed meals varying in both amount and type of carbohydrate. 
This was a crossover study consisting of three separate 24-hour admission periods 
separated by a 1- to 2-week wash-out period. A different test meal (low-, medium- or 
high-GI) was given at each admission. Subjects were admitted at 6:00 pm, consumed a 
low-GI dinner and bedtime snack prior to sleeping. The next morning, subjects 
completed a hunger scale rating. An isocaloric low-, medium-, or high-GI test meal was 
given for breakfast and consumed completely within 20 minutes. The high-GI (instant 
oatmeal) and medium-GI (rolled oats) breakfast meals were isoenergetic and 
macronutrient distribution was identical. In the third breakfast (low-GI meal) a 
vegetable omelet was served, thereby, partially replacing carbohydrate with protein and 
fat. 
The mean area under the glycemic response curve for the high-GI meal was twice 
that of the medium-GI meal (p<0.001) and nearly four-fold higher (p<0.001) than the 
low-GI meal. The mean plasma glucose concentration nadir fell below baseline and 
consequently was lower after the high-GI meal than after the medium- and low-GI meals 
(p=0.02 for both). The area under the insulin response curve after the high-GI meal was 
56 and 1 15% higher (p<0.01 for both) than after the medium-GI and low-GI meals, 
respectively. Plasma glucagon levels, which rose after the low-GI meal, were suppressed 
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after both the medium- and high-GI meals, an effect likely mediated by the protein 
content of the meals and the inhibitory effects of hyperglycemia on glucagon secretion. 
The combination of increased insulin levels and suppressed glucagon levels should 
favor glucose uptake in muscle and liver while restraining hepatic glucose production 
and suppressing adipose tissue lipolysis. Indeed, serum free fatty acids from 2.5 to 4.5 
hours after meal ingestion were suppressed to a greater degree following the high-GI 
compared with the low-GI meal (p<0.05). 
Effects of a uw-Gl Diet in Diabetic Subjects 
Obesity, insulin resistance, hypertension, hypertriglyceridemia, and low HDL levels 
are hallmarks of non-insulin dependent diabetes mellitus (NIDDM). The current dietary 
prescription for subjects with NIDDM advises a diet containing less than 30 en% total 
fat (10 en% saturated fat, up to 10 en% polyunsaturated fat, at least 10 en% 
monounsaturated fats), 15-20 en% protein, with the remainder of energy needs (55-60 
en%) provided by carbohydrate (620). However, many studies suggest this 
macronutrient composition actually accentuates the hypertriglyceridemia associated with 
NIDDM. Furthennore, because weight loss is known to improve insulin sensitivity, 
blood pressure and plasma lipid profile in obese subjects, researchers have begun 
investigating the potential benefits of an energy-restricted, low-glycemic index, high­
carbohydrate in subjects with NIDDM. 
Increasing the carbohydrate content of the diet often results in an increase in dietary 
fiber, making it difficult to discriminate between the influence of these two dietary 
components on metabolism. There is substantial evidence supporting the benefits of 
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dietary fiber per se on glycemic control and lipid metabolism, yet fewer studies exist 
which clearly demonstrate improvements in these metabolic variables by dietary 
carbohydrate, independently of dietary fiber (621-623). 
To more clearly elucidate the separate influences of dietary carbohydrate and fiber on 
glycemic control and lipid profile, diabetic subjects (Type 1 and Type 2) consumed three 
weight-maintaining (2200 kcal/d) diets for 10 days each: low-carbohydrate (42 en%), 
low-fiber (20 g/ d); high-carbohydrate (53 en%), low-fiber (16 g/ d); high-carbohydrate 
(53 en%), high-fiber (53 g/ d) (623). There were no significant changes in fasting blood 
glucose levels during any of the dietary periods. The 2-hour post-prandial blood glucose 
level were similar after the high-carbohydrate/low-fiber and the low-carbohydrate/low­
fiber diets, yet both were significantly higher than after the high-carbohydrate/high-fiber 
(p<0.01) diet. Variations in blood glucose levels observed when changing from the low­
carbohydrate/low-fiber diet to either the high-carbohydrate/low-fiber or high­
carbohydrate/high-fiber diet were evaluated to determine whether the two high­
carbohydrate diets, with different amounts of vegetable fiber, differentially influenced 
blood glucose levels. In the end, neither type of diabetes nor diet significantly influenced 
fasting blood glucose levels. 
In subjects with type 1 diabetes, a greater reduction in 2-hour post-prandial blood 
glucose level was observed after the high-carbohydrate/high-fiber than following the 
high-carbohydrate/low-fiber diet. In subjects with NIDDM, there was a modest 
increase in the 2-hour post-prandial blood glucose concentration following the high­
carbohydrate/low-fiber diet, whereas the high-carbohydrate/high-fiber diet was 
associated with a comparable decrease in postprandial glycemia. Dietary treatment 
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exerted a significant (p<0.02) influence on 2-hour glucose levels, independent of type of 
diabetes. Thus, increasing the content of digestible carbohydrate in the diet (up to 53 
en%) without a coincident increase in dietary fiber intake, does not substantially improve 
glycemic control in diabetic subjects. Conversely, increasing both carbohydrate and fiber 
intake favorably influences post-prandial glucose metabolism in subjects with type 2 
diabetes. 
LDL levels were reduced to a greater extent (p<0.001) following consumption of the 
high-carbohydrate/high-fiber diet than after the low-carbohydrate/low-fiber diet or the 
high-carbohydrate/low-fiber diet in both groups of subjects. Total cholesterol levels 
followed a similar pattern with the lowest levels occurring with the high­
carbohydrate/high-fiber diet compared with the low-carbohydrate/low-fiber diet 
(p<0.001) and the high-carbohydrate/low-fiber diet (p<0.01). 
While diet had no effect on total serum triglyceride levels, VLDL levels were 
significantly reduced after the high-carbohydrate/high-fiber diet (p<0.05) compared with 
the high-carbohydrate/low-fiber diet. Thus, in addition to improving glycemic control, a 
concomitant increase in dietary carbohydrate and fiber intake induces a less-atherogenic 
lipid profile in diabetic subjects (624). 
A long-term study of increased intake of fiber-rich, low-glycemic index natural foods 
on glycemic control has been conducted in type 1 diabetic subjects (625). Subjects were 
assigned to consume a weight-maintaining high- (HF) or low-fiber (LF) diet of similar 
macronutrient composition (20 en% protein, 30 en% fat, 50 en% carbohydrate), but 
containing different amounts of soluble fiber from fresh foods (HF: 50 g/ d, LF: 1 5  g/ d) 
for 24 weeks. 
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Compared with the LF diet, chronic consumption of the HF diet reduced the mean 
daily blood glucose concentration by 24% (p<0.001). In addition, subjects consuming 
the HF diet reported a reduction in the number of hypoglycemic episodes per month 
(p<0.01) compared with the LF diet. Thus, in type 1 diabetic subjects, chronically 
increasing consumption of fresh foods rich in dietary fiber and with a low glycemic index 
favorably influences blood glucose control and reduces the frequency of hypoglycemic 
events. Importantly, these effects occurred in the absence of any significant effect of 
diet on body weight or required daily insulin dosage, which were similar in both groups 
at the conclusion of the study (625). 
The beneficial effects of a low-glycemic index diet are not universally accepted. 
Hellibron, et al. (626) sought to determine the influence of glycemic index on glycemic 
control and lipid profile, in overweight, type 2 diabetic subjects managing their condition 
through diet. After consuming an energy-restricted (1500 kcal/ cl), }ugh-saturated fat 
(SF A; 17 en% saturated fat, 50 en% carbohydrate) diet for four weeks, subjects were 
randomly assigned to either a rugh- (75 GI units) or low- (43 GI units) GI, energy­
restricted (1500 kcal/cl) diet (60 en% carbohydrate) for eight weeks. 
All subjects lost a modest amount of weight during the first four weeks of energy 
restriction, despite consuming a diet relatively rugh in saturated fat. All subjects 
experienced significant reductions in mid-upper arm, hip and waist circumference, as 
well as subscapular and suprailiac skin-fold measurements following 12 weeks of energy 
restriction. Despite similar levels of energy intake, subjects with low glucose tolerance 
lost 34% (p<0.01) less weight than subjects with a greater degree of glucose tolerance. 
Consistent with the influence of glucose tolerance on overall body weight, more modest 
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reductions in hip (p<0.01) and waist (p<0.01) circumferences, as well as subscapular 
skin-fold thickness (p = 0.01) were observed in subjects with low glucose tolerance. 
During the first four weeks of energy restriction, subjects experienced significant 
improvements in glycemia, as evidenced by a 6% reduction (p=0.008) in fasting blood 
glucose levels and a 13% reduction (p = 0.001) in AUCg1ucose· Triglyceride levels were 
reduced by 14% (p=0.007) and total cholesterol levels fell by 4% (p=0.004), while LDL 
and HDL concentrations were unchanged. Weight loss was significantly correlated with 
changes in AUCg1ucosc (r=0.381 , p = 0.01), triglycerides (r=0.306, p=0.04), and total 
cholesterol (r=0.547, p<0.001). 
The diets varying in glycemic index were initiated at week four. Between weeks 4 and 
12, weight loss did not differ according to diet. Fasting plasma glucose levels were 
reduced an additional 4-5% (p<0.01), and AUCg;;ucose was further reduced by 8-12% 
(p<0.001), without regards to dietary glycemic index. Similarly, fasting triglyceride levels 
were reduced an additional 6-10% (p=0.03) between weeks 4 and 12, independently of 
diet. When examined separately, subjects with low glucose tolerance consuming the low 
GI diet had a greater (18%, p=0.02) reduction in LDL levels compared with the high GI 
group. However, with the exception of LDL levels, glycemic index of the diet had no 
independent influence on glycemic control or lipid metabolism, suggesting that the 
major factor responsible for the improvements in glycemic control and lipid profile was 
the reduction in body weight, rather than dietary macronutrient composition (625) . 
Because of the controversy surrounding the physiological factors influencing glycemic 
index and the lack of agreement regarding the importance of dietary carbohydrate source 
in the prevention and treatment of obesity in humans, we designed studies to evaluate 
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the effects of high-fat diets of identical macronutrient composition but varying in the 
source of dietary carbohydrate on the development of obesity and overall metabolic 
control in a rodent model of diet-induced obesity. 
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I. Effect of Dietary Carbohydrate on the Development of Obesity in 
Heterozygous Zucker (fa/+) Rats1 
Abstract 
Rats carrying one copy of the fa allele are predisposed to diet-induced metabolic 
disturbances which contribute to hyperinsulinemia, obesity and dyslipidemia. To 
investigate the role of dietary carbohydrate and fat in the development of these 
conditions, we fed 6-week old male heterozygous (fa/+) lean rats carbohydrate-free diets 
containing primarily saturated fat either ad libitum or pair-fed. These diets were 
compared to standard chow and to a high saturated fat mixed diet containing 10% 
energy from sucrose for 4 weeks. The carbohydrate-free diet resulted in significantly 
lower circulating glucose levels compared to all other groups (p < 0.05). Weight gain 
was negligible in the carbohydrate free groups compared to standard diet and 10% 
sucrose diet (p<0.05). This was reflected in energy efficiency which was markedly 
reduced (90%) in the carbohydrate-free groups compared to the other groups (p<0.05). 
Corresponding changes were noted in fat pad mass. The subscapular and epididymal fat 
pads were increased 42% and 44%, respectively, in animals consuming the 10% sucrose 
diet compared to all other groups (p<0.01). Comparable changes in fatty acid synthase 
(FAS) mRNA were observed in response to the carbohydrate-free diet, which resulted in 
a 53% decrease in adipocyte FAS mRNA (p<0.01). Addition of 10% sucrose to the diet 
completely reversed this effect resulting in a 69% increase in adipocyte FAS mRNA 
compared to the carbohydrate-free groups (p<0.05). Similarly, hepatic FAS mRNA was 
elevated by 51% and 66% in the 10% sucrose and standard diet groups respectively, 
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compared to the carbohydrate-free groups. Therefore, diets that contain minitnal 
carbohydrate may minimize net lipid storage and adiposity. 
Introduction 
During the last 40 years, the prevalence of obesity among adults aged 20 to 74 years 
in the United States increased from 13.4% to 30.9% (1-3). Results from the Behavioral 
Risk Factor Surveillance Survey indicate that roughly one-third of U.S. adults are actively 
attempting to lose weight (4). While it is not possible to ascertain the various methods 
employed by those currently attempting to lose weight, the increasing popularity of low­
carbohydrate diets suggests Americans are straying from the conventional low-fat, high­
complex carbohydrate diet prescription. Those advocating the use of low-carbohydrate 
diets claim such a diet results in rapid and significant reductions in body weight (5,6). In 
addition to the USDA Dietary Guidelines (7), professional organizations, including the 
American Heart Association (8,9), the American Diabetes Association (10), and the 
American Dietetic Association (1 1), are concerned that low carbohydrate diets may have 
serious long term health consequences, including increased risk for cardiovascular 
disease, non-insulin dependent diabetes mellitus, dyslipidemia, and hypertension. A 
systematic review of the literature on the efficacy of low-carbohydrate diets in the 
treatment of obesity found that weight loss occurring with carbohydrate-restricted (� 60 
g/d carbohydrate) diets was predicted by energy intake, duration of diet, and baseline 
body weight, but not by carbohydrate intake (12). 
There is evidence that rats adapted to a high-protein, carbohydrate-free diet have 
normal blood glucose levels, and decreased lipogenesis in both the liver and adipose 
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tissue (13-15). Similar metabolic adaptations may contribute to the weight reducing 
effects of low-carbohydrate diets in humans. The conclusions drawn from studies 
examining the metabolic consequences of high-protein diets in rats are largely based on 
comparisons with balanced diets. Consequently, there is little information available 
regarding the physiological consequences arising from the inclusion of small amounts of 
refined carbohydrate in these otherwise high-fat, high-protein diets. 
The role of liver and adipose tissue in total lipid synthesis was compared in rats fed 
either a high protein (70% casein w /w) or nutritionally balanced, control (17% casein) 
diet (1 3). While the contribution of the liver to total carcass triacylglycerol synthesis was 
similar in rats fed the high protein (24%) and control (20%) diets, adipose tissue 
lipogenesis accounted for 57% of total triacylglycerol synthesis in control-fed rats, but 
only 26% in animals fed the rugh-protein, carbohydrate-free diet. There was a marked 
reduction in the in vivo rates of triacylglycerol-fatty acids synthesized in epididymal, 
retroperitoneal, intermuscular, and subcutaneous adipose tissue depots in animals fed the 
high-protein compared with the control diet. Despite the absence of carbohydrate in the 
high-protein diet, plasma insulin levels were similar with both diets (13). Other studies 
have documented plasma insulin levels that are similar or somewhat lower in animals fed 
high-protein, carbohydrate-free diets (1 5,16). Brito, et al. (17) sought to clarify the 
adaptive changes in adipose tissue metabolism induced by the high-protein, 
carbohydrate-free diet. The rate of glucose uptake in vivo of rats fed the high-protein diet 
was reduced to 40% and 34% of control values in the epididymal and retroperitoneal 
adipose tissue depots, respectively. Moreover, glucose uptake was normalized and the 
activity of pyruvate kinase restored when the high-protein diet was replaced with the 
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balanced diet for a brief (12 hours) period of time. While these adaptations were 
accompanied by an increase in plasma insulin levels and a reduction in plasma glucagon 
levels, the possibility of a direct stimulatory effect of increased substrate (glucose) 
availability cannot be excluded. Similarly, in vitro rates of glucose uptake in fat cells 
isolated from rats adapted to the high-protein diet incubated with 1 mmol/L glucose 
were only 49% of the rate in cells isolated from control-fed animals. This was 
accompanied by a significant reduction in the activity of key glycolytic enzymes: 
hexokinase, phosphofructo-1 -kinase, and pyruvate kinase (1 7). 
While it is well accepted that dietary macronutrient composition can influence the 
development of obesity, the contribution of a specific macronutrient (carbohydrate or 
fat) remains controversial. Consequently, the purpose of this study was to examine the 
role of the level of dietary carbohydrate on the development and treatment of obesity in 
lean rats susceptible to diet-induced obesity. Specifically, we assessed the metabolic 
effects of a high-fat diet devoid of dietary carbohydrate to a high-fat diet containing a 
minimal (10%) amount of sucrose on body weight regulation, glucose tolerance, de novo 
lipogenesis and lipid metabolism. We propose that the effects of dietary fat in 
conjunction with a minimal amount of sucrose will exert synergistic effects on adiposity 
and that their concomitant ingestion may significantly increase total body weight. 
Materials and Methods 
Animal Model 
Rats were produced in two crosses segregating.fa. F2 litters were obtained by BN/Crl 
X Crl:ZUC:fo intercross (18). F3 progeny of Brown Norway (BN)/Crl times Cd times 
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Crl: (ZUC)BR:fo. In cross 1, both dam and sire were fa/+, so that three genotypes, 
+/+,fa/+ ,fa/ fa, were included among the progeny; however, obese (fol fa) were 
excluded from this study. Subsequent generations were produced by crossing BNZ F2-
fa/ + males with ZUC + / + females, so that only fa/+ and + / + were generated in cross 
2 (19). 
The current study was designed to evaluate the synergistic effects of dietary fat and 
carbohydrate in a rodent model of obesity. Zucker fatty rats (fa/ fa) have a missense 
point mutation in the gene for the leptin receptor, which results in the substitution of 
proline for glutamine at position 269 in the extracellular ligand binding domain (20). 
This mutation impairs leptin binding and impedes the signaling mechanisms regulating 
food intake and satiety, resulting in hyperphagia-induced obesity (20) . Studies of the 
physiological consequences of impaired leptin s.ignaling were initially conducted .in 
animals homozygous for the fa allele (fol fa). As research continued, it was detennined 
that the fa mutation, like many other mutations, exhibits hap lo.in-sufficiency, such that 
animals heterozygous for the fa allele (fa/ fa) have half the normal level of functional 
leptin receptors and are characterized by a phenotype the severity of which is 
intermediate between.fa/fa and Fa/Fa animals (19,21 ,22). Consequently, we chose to 
investigate the interaction between dietary carbohydrate and fat in heterozygous Zucker 
(fa/ +) rats. 
Animals were phenotyped at 4 weeks of age on the basis of body weight. Forty 
heterozygous male Zucker lean rats (fa/+) of 6 to 8 weeks in age were adapted to 
handling for use in this study. Animals were housed in individual stainless steel hanging 
cages in a climate-controlled environment with a 12-h light-dark cycle. 
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Experimental Diets 
Prior to this study, animals had been maintained on standard rodent chow. All diets 
were semi-purified and were based on AIN-93 guidelines for rodent diets as shown in 
Table 2 (23). Animals were randomly assigned to one of three dietary treatment groups: 
standard diet, carbohydrate free diet, 10% sucrose diet. Animals were allowed ad libit11m 
access to food and water throughout the feeding period. A fourth group was included as 
a pair fed control group. These animals consumed the carbohydrate-free diet adjusted 
for the energy intake of the standard diet group on the previous day. This group also 
had ad libit11m access to water throughout the feeding period. Animals spilled only 
minimal amounts of food; all spilled food was collected and recorded. Food intake was 
measured and replaced daily. Body weight was recorded every two days. This protocol 
was approved by the University of Tennessee Institutional Animal Care and Use 
Committee. At the completion of the study, animals were anesthetized with sodium 
pentobarbital (50 mg/kg body weight) and killed by exsanguination while under 
anesthesia. 
Tiss11e Collection 
The liver, selected fat pads, soleus muscle, and gastrocnemius muscle were dissected 
and immediately weighed. Tissues were then snap frozen in liquid nitrogen and stored at 
-80
° C until time of analysis. 
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Table 2 
Composition of AIN-93 Based Semi-Purified Diets 
Standard Carbohydrate Free 
Com nent I % enc I % enc 
Cornstarch 550 57 0 0 
Soybean oil so 12 77 1 1  
Coconut oil 0 0 482 69 
Casein 200 21 314 20 
Sucrose 100 10 0 0 
AIN mineral mixt 35 35 
AIN vitamin mix2 10 10 
Cellulose3 50 77 
Dlrmethionine 3 3 
Choline bitartrate 2 2 
1 American Institute of Nutrition Mineral Mixture 76 (ICN Pharmaceuticals, Costa Mesa, CA) 
2American Institute of Nutrition Vitamin Mixrure 76 (ICN Phannaceuticals, Costa Mesa, CA) 
lFiber used was Alphacel Non-nutritive Bulk (ICN Phannaceuticals, Costa Mesa, CA) 
10 % Sucrose 
% enc 
0 0 









Diets were isonitrogenous for percent total energy contribution. Energy content: Standard diet, 16.15 kJ/g; carbohydrate-free diet, 
26.32 kJ/g; 10% sucrose diet, 24.48 kJ/g. 
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Blood Collection 
Blood was obtained at sacrifice in non-fasted animals by cardiac puncture of the left 
ventricle using a heparinized 5 cc syringe and a 20 gauge, 1-inch needle. To prevent 
hemolysis of red blood cells, the needle was removed from the syringe prior to transfer 
of blood into an EDTA-containing vacutainer blood collection tube. Blood samples 
were kept on ice prior to centrifugation at 1000 rpm for 15 minutes at 4° C to collect 
plasma. Plasma samples were subsequently stored at -80°C until time of analysis. 
Extraction of Total Cellular RNA from Adipose Tissue 
Total RNA was extracted from adipose tissue by the guanidine-HCl method (24,25) . 
Adipose tissue samples (0.5 to 1 .0 g) were homogenized using a polytron homogenizer 
in 4 M guanidine isothiocynate (GTC) containing �-mercaptoethanol (14 µl per ml of 
GTC). The homogenate was then passed through a 26 gauge, 1-inch needle into a 5 cc 
syringe. Subsequently, the homogenate was carefully layered over 4 ml of 5.7 M cesium 
chloride (CsCl; pH 7.0) and centrifuged at 29,000 rpm for 20 hours at 20° C (26). 
Following centrifugation, the supernatant was removed using a 5 ml transfer pipet and 
the pellet allowed to air dry before being resuspended in 25 µl ofDEPC-treated water 
and transferred to an autoclaved 1 .5 ml eppendorf tube. The sample was allowed to 
precipitate in 1 ml 1 00% ethanol (EtOH) overnight at -20° C. Following precipitation, 
samples were centrifuged at 10,000 rpm for 30 minutes at 4° C. The supernatant was 
removed and the pellet washed in 1 ml of 70% EtOH. After washing, the pellet was 
allowed to air dry prior to being resuspended in 10-20 µl of DEPC-treated water and 
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quantified using dual wavelength (260/280 nm) spectrophotometry (27). The sample 
was then stored at -20° for further analysis. 
&traction of RNA.from the Uver 
Total RNA was extracted from the liver by the phenol-chloroform extraction method 
(25). A sample of the medial lobe of the liver (0.5 to 2 g) was homogenized using a 
polytton homogenizer in 10 ml of 4 M guanidine isothiocynate (GTC) with �­
mercaptoethanol (14 µl per ml of GTC). The homogenate was then transferred to a 
polypropylene centrifuge tube and one starting volume of phenol:choloroform:isoamyl 
alcohol (25:24: 1, pH 7.9) added prior to vortexing. The homogenate was placed on ice 
for 15 minutes prior to centrifugation at 10,000 x g for 15 minutes at 4° C. Following 
centrifugation, the aqueous layer was transferred to a clean polypropylene centrifuge 
tube containing 1 ml of 3 M sodium acetate and samples mixed by inversion. 
Subsequently, 5 ml of acid phenol:chloroform:isoamyl alcohol (125:24: 1, pH 4.5) was 
added to each sample. The samples were vortexed and allowed to sit on ice for 15  
minutes prior to centrifugation at 10,000 x g for 20 minutes at 4° C. Following 
centrifugation, the aqueous layer was transferred to a 15 ml centrifuge tube. Samples 
were allowed to precipitate overnight in 100% isopropanol at -20° C. 
Samples were transferred to clean polypropylene centrifuge tubes prior to 
centrifugation at 10,000 x g for 20 minutes at 4° C. Following centrifugation, the 
supernatant was decanted and the pellet allowed to air dry for 15  minutes at room 
temperature. The pellet was washed in 4 M lithium chloride (LiCI). Subsequently, the 
pellet was resuspended in nuclease-free water containing 0. 1 mM EDTA. The samples 
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were allowed to precipitate for 30 minutes at -20° C prior to centrifugation at 10,000 x g 
for 30 minutes at 4° C. The supernatant was decanted and the pellet resuspended in 
100% ethanol. The samples were allowed to incubate overnight at -20° C. 
Samples were transferred to clean polypropylene centrifuge tubes and centrifuged at 
10,000 x g for 20 minutes at 4° C. The supernatant was decanted and the pellet 
resuspended in formamide prior to quantification using dual wave length (260/280 nm) 
spectrophotometry (27). 
Gel Electrophot?sis and Northern Blotting 
Gel electrophoresis and Northern blotting was performed as described by Herrin, et 
al. (28). All supplies were cleaned with RNase ZAP (Ambion, Austin, TX) prior to use. 
For Northern blot analysis, RNA was size fractionated on 1 % agarose gels prepared by 
boiling 1 g agarose (Llfe Technologies, Carlsbad, CA) in 82 ml of 1 X 4-
morpholinepropanesulfonic acid (1 X MOPS) in a conventional microwave oven set on 
medium (80%) heat for 1 minute. The solution was then cooled at room temperature to 
50° C. After cooling, 18 ml of 37% (12.3 M) formaldehyde was added under the fume 
hood to yield a final concentration of 2.2 M formaldehyde. The solution was poured 
into a Horizon 1 1-14 medium gel electrophoresis apparatus (Life Technologies, 
Carlsbad, CA.) containing a 10-well comb and allowed to cool at room temperature until 
the gel was cloudy in appearance. When the gel had cooled, the buffer tanks were filled 
with 1X MOPS to approximately 3-5 mm above the gel. The gel comb was then 
carefully removed. 
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Denaturing buffer (67.5% formamide, 1X MOPS, 22.5% formaldehyde) was added to 
each sample of RNA to yield a final volume of 1 8  µI. The samples were denatured by 
boiling for 5 minutes and then immediately placed on ice to cool. When the samples had 
cooled, 2 µI of loading dye (50% glycerol, 1 mM EDTA, 0.4% bromophenol blue) was 
added to each sample. Samples were mixed by vortexing prior to being pipetted into 
wells of the gel. 
The gel was run at 100 volts for 3 to 4 hours or until the blue dye front had migrated 
approximately % of the length of the gel. The gel was stained in ethidium bromide (1 
µg/ml) with gentle shaking for 20 minutes. Following this period, the ethidium bromide 
was decanted and the gel inspected for quality using an ultraviolet light box. To remove 
the ethidium bromide, the gel was transferred to a tray containing DEPC-treated water 
for 10 minutes with gentle shaking. 
RNA was transferred to Hybond nitrocellulose membrane (Amersham, Piscataway, 
NJ) by Northern blotting. A buffer tray was filled with 20X SSC and a wetting wick 
prepared using 3 mm Whatman filter paper saturated with 20X SSC, which was then 
draped over a glass plate into the buffer tray. The destained gel was placed upside down 
on the wetting wick. Plastic wrap was used to seal all four edges of the gel. A piece of 
nitrocellulose membrane was cut to slightly smaller than the size of the gel and the upper 
right hand comer cut away to denote the position of the first well. The membrane was 
placed on top of the gel and a 2 ml serological pipet gently rolled over the membrane to 
remove any bubbles which may have formed between the membrane and gel. Six pieces 
of Whatman filter paper, roughly the size of the gel, were placed on top of the 
membrane. Brown tri-fold paper towels were stacked (approximately 1 inch) on top of 
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the filter paper and a glass plate placed over them. Two water bottles collectively 
weighing 100 g were placed on top of the glass plate to ensure adequate transfer over 20-
24 hours. 
After transfer was complete, the membrane was rinsed in 1 OX SSC for 1 0  minutes. 
The membrane was crosslinked under ultraviolet light for 2 minutes and then wrapped 
in Whatmann filter paper and allowed to dry overnight prior to hybridization (28). 
LAbeling of Probe and Membrane Hybridization 
This procedure used the Random Primers DNA Labeling System (Life Technologies, 
Carlsbad, CA) and was performed as described by Feinberg, et al. (29). 1 µl of murine 
cDNA probe for fatty acid synthase (kindly provided by Dr. Naima Moustaid-Moussa) 
was added to a microcentrifuge tube containing 23 µl of DEPC-treated water and boiled 
for 5 minutes. The mixture was then immediately transferred to ice and allowed to cool 
When sufficiently cool, 2 µI of unlabelled deoxynucleotides (0.5 mM dATP, dGTP, 
dTfP in 1 mM Tris-HCL), 20 µI Random Primers Buffer Solution (0.67 M HEPES, 0. 1 7  
M Tris-HCI, 17  m M  MgCii, 33 mM �-mercaptoethanol, 1.33 mg/ml BSA), and 5 µl of 
[<X-32P]dCTP (Perkin-Elmer, Boston, MA) were added and the solution vortexed prior to 
the addition of 1 µl of Klenow fragment. The solution was gently vortexed and allowed 
to incubate for 1 hour at 68° C. After incubation, 200 µl DEPC-treated water was added 
and the solution mixed by vortexing. 
To purify the probe, the plunger was removed from a 3 cc syringe, and a small piece 
of glass wool placed in the syringe barrel to cover the opening in the bottom of the 
syringe barrel The syringe was then placed in a 13 ml centrifuge tube and sephadex 
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added until the meniscus reached the 2 cc demarcation line, prior to centrifugation at 
1 000 rpm for 1 minute. The syringe was transferred to a clean 1 3  ml centrifuge tube and 
the probe added to the sephadex colwnn prior to centrifugation at 1000 rpm for 1 
minute. The syringe was discarded and the probe collected and transferred to a 1 .5  ml 
eppendorf tube. The probe was denatured by boiling for 5 minutes and immediately 
placed on ice to cool. The probe was considered to be sufficiently labeled when a count 
of 2 to 3 kb was detected by Geiger counter. 
The dry nitrocellulose membrane was transferred to a hybridization bottle containing 
2X SSC and placed in a hybrization oven, preheated to 68° C, for 1 0  minutes. 
UL TRAhyb ™ (Ambion, Austin, Th') hybridization buffer was preheated to 68° C until 
completely dissolved. The 2X SSC was decanted and the membrane was prehybridized 
in 6- 10 ml of ULTRAhyb"' for 30 minutes at 68° C. Following the prehybridization 
period, the UL TRAhyb ™ was decanted and the probe added to the hybridization bottle. 
The membrane was allowed to rotate for 24 hours at 68° C. 
Following hybridization, the membrane was washed in 2X SSC/0.1% SOS for 15  
minutes at room temperature. Following this wash, a Geiger counter was used to assess 
the level of radioactivity of the membrane. If the count was greater than 1 kb, the 
membrane was washed again in 2X SSC/0.1% SOS for 30 minutes. If the radioactive 
count was still in excess of 1 kb, the membrane underwent 5 minute washings in 0.5% 
SSC/0.5% SOS at 65° C until a count below 1 kb was achieved. Once sufficiently 
washed, the membrane was wrapped in plastic wrap and exposed to 5 x 7 Kodak x-ray 
film in an autoradiogram cassette for 24 hours at -20° C. After this period, the 
autoradiogram cassette was allowed to reach room temperature prior to developing the 
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film. Autoradiograms were quantitated using the Ultra Lum Electronic UV 
Transilluminator system (Ultra Lum, Inc., Paramount, CA) and Zero-D scan image 
analysis software (Scanalytics, Inc., Fairfax, VA), which performs volume densitometry 
on bands in the gel images. 
Expression of fatty acid synthase was normalized for 1 8s using the same membrane. 
After obtaining a suitable autoradiogram for FAS, the membrane was boiled for 30 
minutes in membrane stripping solution (1 M Tris-HCI, 500 mM EDTA, 1% SOS). The 
membrane was then probed for 18s and quantitated according to the procedures 
described above (29). Values are reported as FAS: 18s ratio. 
Cardiac Exsangllination and Preparation of Plasma 
Blood was collected from unfasted animals by cardiac puncture using a heparinzed 5 
cc syringe and a 20 gauge 1-inch needle. To prevent hemolysis, the needle was removed 
from the barrel of the syringe prior to transferring the blood to an EDT A-treated 
vacutainer blood collection tube. All samples were stored on ice until centrifuged at 
1000 rpm for 1 5  minutes to collect plasma. Plasma was stored at -20 °C until time of 
analysis. 
Detmmnation of Plasma Glucose Levels 
Final plasma glucose levels were determined using the glucose oxidase method as first 
described by Washko, et al. (30) and modified by Marks (31). This procedure is based on 
the following coupled enzymatic reactions: In the presence of water and oxygen, glucose 
oxidase catalyzes the conversion of glucose to gluconic acid and hydrogen peroxide. 
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With hydrogen peroxide and peroxidase available, the otherwise colorless o-diansidine 
dihydrochloride is oxidized and the product of the reaction is brown in color. The 
intensity of the brown color measured spectrophotometrically at 475 nm is proportional 
to the original glucose concentration of the sample. 
Reagents for determination of plasma glucose levels were obtained from Sigma­
Aldrich Diagnostics (St. Louis, MO). The enzyme solution was prepared by adding 1 
capsule of PGO (500 U glucose oxidase from Aspe,gilllls niger, 100 U horseradish 
peroxidase) enzymes to 100 ml distilled water in an amber bottle. The color reagent 
solution was prepared by reconstituting one vial (SO mg) of o-dianisidine dihydrochloride 
with 20 ml of distilled water. To prepare the combined enzyme-color reagent solution, 
1 .6 ml of color reagent solution was added to 100 ml of enzyme solution and mixed by 
inversion. 
For each sample, 25 µl of plasma was transferred to an appropriately labeled 
borosilicate glass culture tube containing 5 ml of combined enzyme-color reagent 
solution. A standard was similarly prepared using a known glucose standard (100 
mg/dL, Sigma-Alrich Diagnostics, St. Louis, MO). The tubes were vortexed, covered in 
foil to protect them from exposure to ambient light and allowed to incubate at room 
temperature for 45 minutes. At the end of the incubation period, the absorbance was 
read at 475 nm against a water blank. The concentration of glucose in each sample was 
calculated by dividing the absorbance of the samples by the absorbance of the glucose 
standard, and multiplying by the concentration of the glucose standard. 
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Determination of Plasma Triglyceride uvels 
Plasma triglyceride levels were determined according to the technique described by 
Buccolo, et al. (32) . Using this method, triglycerides are first hydrolyzed by lipoprotein 
lipase to glycerol and free fatty acids. Glycerol is then phosphorylated by in an ATP­
dependent reaction by glycerol kinase yielding glycerol- 1 -phosphate. The glycerol-1 -
phosphate is oxidized to dihydroxyacetone phosphate, with the concomitant reduction 
of NAD to NADH in a reaction catalyzed by glycerol-1-phosphate dehydrogenase. The 
resulting NADH is then oxidized coupled to reduction of 2-(p-iodophenyl)-3-p­
nitrophenyl-5-phenyltetrazolium chloride (INT) to fonnazan, which is pink in color, in 
the presence of diaphorase. The intensity of the color produced is directly proportional 
to the triglyceride concentration in plasma. 
The reagents used in this assay were obtained from Sigma-Aldrich Diagnostics (St. 
Louis, MO). Plasma (10 µI) was transferred to a borosilicate glass culture tube 
containing 1 ml reconstituted triglyceride INT reagent (2.0 mM ATP, 2.0 mM NAD, 3.0 
M Mg2+, 1 .0 mM 2-(p-iodophenyl)-3-p-nitrophenyl-5-phenyltetrazolium chloride, 200 
U /L glycerol kinase, 4000 U /L glycerol- 1-phosphate dehydrogenase, 455 U /L 
diaphorase, pH 7.8). A standard was similarly prepared using a known triglyceride 
standard (250 mg/dL, Sigma-Aldrich, St. Louis, MO). The samples were vortexed and 
allowed to sit at room temperature for 1 5  minutes. The absorbance of each sample was 
measured at 500 nm against a water blank. The concentration of triglycerides in each 
sample was calculated by dividing the absorbance of the samples by the absorbance of 
the triglyceride standard, and multiplying by the concentration of the triglyceride 
standard. 
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Determination of Total Cholesterol in Plasma 
Total plasma cholesterol levels were detennined using according to the method of 
Allain, et al (33) using reagents obtained from Sigma-Aldrich Diagnostics. This assay is 
based on a series of enzymatic reactions beginning with the hydrolysis of cholesterol 
esters present in plasma by cholesterol esterase to yield cholesterol and free fatty acids. 
The cholesterol produced during the previous reaction was oxidized by cholesterol 
oxidase resulting in production of cholest-4-en-3-one and hydrogen peroxide (H20i.). 
The resulting H202 is then coupled with 4-aminoantipyrine and p­
hydroxybenzenesulfonate contained in the cholesterol reagent, in the presence of 
peroxidase. This reaction produces a quinoneimine dye which has an absorbance 
maximum of 500 nm. The intensity of the color produced is directly proportional to the 
total cholesterol concentration in plasma. 
Plasma (10 µ1) was transferred to borosilicate glass culture tubes containing 1 ml of 
reconstituted cholesterol reagent (300 U /L cholesterol oxidase, > 100 U /1 cholesterol 
esterase, 1000 U /L horseradish peroxidase, 0.3 mM 4-aminoantipyrine, 30 mM p­
hydroxybenzenesulfonate, pH 6.5). A standard was similarly prepared using a known 
cholesterol standard (200 mg/dL, Sigma-Aldrich, St. Louis, MO). The samples were 
vortexed and allowed to sit at room temperature for 5 minutes prior to measuring the 
absorbance at 500 run ag.unst a water blank. The concentration of cholesterol in each 
sample was calculated by dividing the absorbance of the samples by the absorbance of 
the standard and multiplying by the concentration of the cholesterol standard. 
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Determination of P/am,a HDirCholtsterol Levels 
Plasma (500 µ.I) was added to 50 µI reconstituted HDL cholesterol reagent (Sigma­
Aldrich; 10 g/L dexttan sulfate, 0.5 mol/1 Mg2+, pH 7.0). This assay was developed by 
Warmick, et al. (34) and is based on the ability of dextran sulfate and Mg2+ to precipitate 
LDL and VLDL, leaving the HDL fraction in the supernatant. The samples were 
vortexed and allowed to sit at room temperature for 5 minutes. Subsequently, the 
samples were vortexed and centrifuged at 3000 rpm for 1 5  minutes. Following 
centrifugation, SO µI of the supernatant was added to appropriately labeled borosilicate 
glass tubes containing 1 ml of cholesterol reagent and cholesterol levels determined as 
described above. 
Determination of P/am,a Insulin Levels 
This assay is based on the double antibody technique for determination of plasma 
insulin levels in rats as described by Morgan, et al. (35) using rat insulin 
radioimmunoassay kit obtained from Llnco Research (St. Charles, MO). A standard 
curve was prepared using purified rat insulin in insulin standard buffer at the following 
concentrations: 0. 1, 0.2, 0.5, 1 .0, 2.0, 5.0, and 10.0 ng/ml. For each standard and 
sample, 50 µl of standard/sample, 50µ1 of 1251-labeled insulin, and 50 µI guinea pig anti­
rat insulin serum in assay buffer were transferred to an appropriately labeled glass culture 
tube. All tubes were vortexed, covered with foil and allowed to incubate for 20 hours at 
4°C. Following incubation, 500 µI of precipitating reagent containing goat anti-guinea 
pig IgG serum was added to each standard and sample. All tubes were vortexed and 
allowed to incubate for 30 minutes at 4° C. Subsequently, all tubes were centrifuged at 
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3000 rpm for 30 minutes and carefully decanted by inversion for 1 minute to separate 
antibody-bound from free label. Subsequently, the percentage of total binding was 
determined by counting each sample for 5 minutes in an automated gamma counter. 
The calculations necessary for determination of plasma insulin concentration was 
performed automatically using the data reduction capabilities of the gamma counter, and 
involved plotting the percentage of total binding for each sample on the y-axis and the 
known concentrations of the standards on the x-axis (36) . 
Determination of Plasma Leptin Levels 
1bis assay is based on the double antibody technique for determination of plasma 
leptin levels in human plasma described by Ma, et al. (37) using mouse leptin 
radioimmunoassay kit obtained from Linco Research. A standard curve was prepared 
using purified rat leptin in leptin standard buffer at the following concentrations: 0.2, 
0.5, 1 .0, 2.0, 5.0, 10.0 and 20.0 ng/ml. For each standard and sample, 50 µ.l of 
standard/ sample and 50 µ.l rabbit anti-rat leptin serum in assay buffer were transferred to 
an appropriately labeled glass culture tube. All tubes were vortexed, covered with foil 
and allowed to incubate for 20 hours at 4°C. Following incubation, 50 µl of t2SI-labelled 
leptin was added to each standard/ sample. The tubes were vortexed, covered with foil 
and allowed to incubate an additional 20 hours at 4° C. Following this period, 500 µl of 
precipitating reagent containing goat anti-rabbit IgG serum was added to each standard 
and sample. All tubes were vortexed and allowed to incubate for 30 minutes at 4° C. 
Subsequently, all tubes were centrifuged at 3000 rpm for 30 minutes to separate 
antibody-bound from free label. The supernatant was decanted by inverting the tubes 
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for 45 seconds and the percentage of total binding detennined for each sample by 
counting in a gamma counter for 5 minutes. The calculations necessary for 
detennination of plasma leptin concentration was performed automatically using the data 
reduction capabilities of the gamma counter, which involved plotting the percentage of 
total binding for each sample on the y-axis and the known concentrations of the 
standards on the x-axis (36). 
S tatistica/ Ana/ysis 
Data were analyzed by analysis of variance (ANOV A) to compare overall group 
means with subsequent analysis via least significant difference test to identify 
significantly different group means using the SPSS Statistics Package (38,39). Variables 
which did not follow a normal distribution were transformed according to standard 
statistical practices (log base 10, reciprocal, square root, inverse square root, square) to 
achieve normal distribution prior to AN OVA (39). When normality could not be 
achieved by accepted statistical transformations, significantly different group means were 
identified by non-parametric tests (39). 
Results 
Food Cons11mption and Ene,;gy Efficienry 
Data regarding food and energy intake during the four week study is summarized in 
Table 3. Animals consuming the standard diet consumed a slightly greater (p<0.05) 
quantity of food. However, the energy density of the carbohydrate-free and 10  en% 
sucrose diets resulted in greater energy intake by these groups (p<0.05). 
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Table 3 




10 en% Sucrose 
Gnma 
1387 .51 ± 23.58• 
1 1 57.15 ± 1 6.64b 
884.16 ± 22.36c 
1206.68 ± 49.64b 
kcal 
5355.40 ± 90.8Cf 
7280.83 ± 1 24.31 b 
5429.97 ± 161.os• 
7059.08 ± 290.37b 
Data is expressed as MC811%SEM. a. '
0
Non-similar superscripts indicate significant differences at p<0.05. 
Weight Gain and Bot!J Composition 
The data regarding body weight and adiposity are summarized in Table 4. Animals 
consuming the standard or mixed (10 en% sucrose) diets gained 90% more weight (p < 
0.05) than animals consuming the carbohydrate-free diet ad libitum (Figure 1A). 
Changes in body weight were reflected in energy efficiency (weight gain/ energy intake 
ratio) which was 90% lower (p < 0.05) in the carbohydrate-free groups compared to 
standard and 10en% sucrose diet groups (Figure 1B). 
Changes in body weight are partially reflected in fat pad mass. Epididymal fat pad 
mass was 23-44% lower (p<0.05, Figure 2A) in the carbohydrate-free groups relative to 
the standard or 10 en% sucrose groups. Subscapular fat pad mass was approximately 30 
and 79% greater (p<0.05, Figure 2B) in animals fed the standard and 10 en% sucrose 
diets, respectively, compared with the carbohydrate-free diet fed ad libitum or pair fed to 
the standard diet. 
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Table 4 
Effect of Carbohydrate Restriction on Measures of Body Composition in Heterozygous (fa/ +) Zucker Rats 
Standard 
Carb-Free 





19.80 ± 4.268 
2.00 ± 2.35b 
-0.60 ± 9.08b 
20.60 ± 5.388 
- -
Selected Subcutaneous Fat Pads (g) 
Individual Tissues Combined 
Subscapular Epididymal Mass 
0.61 ± 0.12• 0. 18 ± 0.02• 0.79 ± 0.12• 
0.47 ± 0.03b 0.17 ± 0.048 0.64 ± 0.068 
0.47 ± o.o8b 0.17 ± 0.01• 0.61 ± o.or 
0.84 ± 0.1 1• 0.29 ± 0.04b 1 .13 ± 0.14b 
Data is expressed as Mean±SEM. "'"''Non-similar superscripts indicate significant differences at p<0.05 
Selected Visceral Fat Pads (g) Combined 
Indivdual Tissues Combined Subcutaneous 
Abdominal Perirenal Maas & Visceral Fat 
6.09 ± 0.318 1 .02 ± 0.14 7.1 1  ± 0.42 7.90 ± 0.51 
5.55 ± 0.35 .... 0.94 ± 0.1 1 6.49 ± 0.40 7.13 ± 0.41 
4.79 ± 0.54b 0.89 ± 0.12 5.68 ± 0.66 6.29 ± 0.71 













Standard Carb-Free Carb-Free 10 en% 




8 2 a 
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Standard Carb-Free Carb-Free 10 en% 
-0.5 Pair Fed Sucrose 
Figure 1 .  Effect of diet on weight gain (A) and energy efficiency ratio (B) in 
heterozygous Zucker rats. Data is expressed as Mean±SEM. Non-similar superscripts 

















Standard Carb-Free Carb-Free 10 en% 










Standard Carb-Free Carb-Free 10 en% 
Pair Fed Sucrose 
Figure 2. Effect of diet on subscapular (A) and epididymal (B) fat pad mass in 
heterozygous Zucker rats. Data is expressed as Mean±SEM. Non-similar superscripts 
indicate significant differences at p<0.05. 
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Non-Fasting Plasma Metabolites 
Non-fasting plasma metabolite levels are summarized in Table 5. The diet-induced 
variations in adipose tissue deposition are reflected in circulating leptin levels, which 
were significantly greater (p<0.05) in animals consuming the 10 en% sucrose diet 
compared with the standard and carbohydrate-free pair fed groups. 
Non-fasting plasma glucose levels were significantly (p<0.05) greater in animals 
consuming the standard diet compared with the 1 0  en% sucrose and carbohydrate-free 
diet fed ad libitum or pair fed to the standard diet. Compared with animals consuming 
the 10 en% sucrose diet, plasma glucose levels were 18% lower (p<0.05) when animals 
were pair fed the carbohydrate-free diet. Regardless of energy intake, the carbohydrate­
free diet resulted in plasma HDL-cholesterol levels that were significantly greater 
(p<0.05) than in animals fed either the standard or 10 en% sucrose diet. Diet was 
without influence on plasma insulin levels. 
Patry Add Synthase Expression 
Adipose tissue fatty acid synthase (FAS) m.RNA levels were 53% lower (p<0.001) in 
animals consuming the carbohydrate-free diet compared to those consuming the semi­
purified standard diet (Figure 3A). 1bis effect was completely reversed upon addition of 
10 en% sucrose to the diet, which instead resulted in a 69% increase (p<0.01) in 
epididymal fatty acid synthase mRNA compared to the carbohydrate-free diet. Similarly, 
hepatic FAS mRNA levels were 51% and 66% higher (p<0.01) in animals consuming the 
mixed diet (10 en% sucrose) and standard diet, respectively, compared to animals 





Effect of Carbohydrate Restriction on Non-Fasting Plasma Metabolites in Heterozygous (fa/ +) Zucker Rats 
Glucose Insulin Leptin Triglycerides Cholesterol HDL 
(mg/dL) (µU/ml) (ng/mL) (mg/dL) (mg/dL) (mg/dL) 
Standard 354.54 ± 21 .88• 1 1 .86 ± 5.13 3.44 ± 1 .02• 1 19.57 ± 5.98 143.27 ± 1 1 .49 51 .98 ± 3.901 
Carb-Free 260.45 ± 8.00b,c 17.92 ± 5.89 3.99 ± 0.6<f"> 124.40 ± 6.50 1 83.27 ± 12.27 71 .68 ± 3.58b 
Carh-Free (pair fed) 250.21 ± 30.19c 12.29 ± 2.20 3.21 ± 0.598 123.37 ± 8.02 1 83.66 ± 16.26 82.78 ± 6.91b 
10% Sucrose 30535 ± 9.59b 23.82 ± 7.1 9 5.91 ± 1.27b 109.83 ± 7.49 171.35 ± 17.59 67.03 ± 2.25• 












j 0.2 ... 
0.1 
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Standard Carb-Free Carb-Free 10 en% 
Pair Fed Sucrose 
B 
1 .4 a 
QO 
.. 1 .2 
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:e 0.2 (C 
Standard Carb-Free Carb-Ftee 10 en% 
Pair Fed Sucrose 
Figure 3. Effect of diet on expression of fatty acid synthase in the epididymal fat pad 
(A) and liver (B) in heterozygous Zucker rats. Data is expressed as Mean±SEM. Non­
similar superscripts indicate significant differences at p<0.05. 
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Discussion 
The purpose of this study was to investigate the effects of a dietary carbohydrate on 
body weight, adiposity, and the expression of fatty acid synthase in a rodent model 
susceptible to diet-induced obesity. The results of this study suggest that consumption 
of a carbohydrate-free diet significantly blunts fat accumulation in heterozygous Zucker 
rats (fa/+). Tius effect is mediated, in part, by reduced expression of fatty acid synthase 
in both the liver and adipose tissue. 
The differences in weight gain and adiposity in animals fed the carbohydrate-free diet 
and 10 en% sucrose diets ad libit11m can be attributed to diet composition since the level 
of energy intake between these groups was similar. The same can be said for animals fed 
the standard diet and those fed the carbohydrate-free diet at the same level of energy 
intake. While final body weight was similar regardless of diet, adipose tissue deposition 
was reduced specifically in the subcutaneous depots (subscapular and epididymal) 
without influencing visceral adiposity. Furthermore, diet did not influence the individual 
or combined mass of selected contralateral muscles (soleus and gastrocnemius). Our 
findings are not inconsistent with those of Botion, et al. (13), who found that total 
carcass fatty acid content is maintained and loss of body fat is minimal in animals fed 
high-protein, carbohydrate-free diets despite marked reduced in vivo lipogenesis, as 
assessed by tritium into liver and carcass fatty acids. 
Based on the present studies, we can infer that the marked reduction in subcutaneous 
fat pad mass in rats consuming the carbohydrate-free diets is at least partially explained 
by reduced de novo lipogenesis in the liver and adipose tissue. Moreover, the effect of the 
carbohydrate-free diet on FAS expression in adipose tissue FAS was completely reversed 
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by the substitution of 10 en% sucrose for dietary fat. The lower level of FAS expression 
in adipose tissue of animals fed the carbohydrate-free diet relative to the 10 en% sucrose 
diet appears to be a consequence of diet composition since energy intake was similar ad 
libitum fed animals. 
In the liver, expression of FAS was higher in animals fed the standard diet compared 
to both the carbohydrate-free and 10 en% sucrose groups. Induction of FAS expression 
in the liver of animals fed the standard diet may have been enhanced by the chronic 
exposure of the liver to lipogenic substrates provided by the higher carbohydrate content 
of the standard diet. 
While we cannot determine the exact mechanism(s) mediating the observed changes 
in adiposity and lipogenic gene expression induced by the carbohydrate-free and 10  en% 
sucrose diets, our data together with other studies of rats fed high-protein, carbohydrate­
free diets permit some plausible hypotheses (13-17). 
The level of dietary sucrose in these diets did not significantly influence non-fasting 
plasma insulin levels. While others report higher plasma insulin levels in rats adapted to 
high-protein diets, Botion, et al. (13) report that insulin levels of high-protein fed rats are 
much less affected by feeding and are markedly resistant to fasting (13-15,17). In 
addition, our diets contain significantly less protein (20 en%) than the carbohydrate-free, 
high-protein (70 en%) diets typically used to study the adaptive mechanisms in energy­
linked metabolic processes (13-17). Since we did not measure plasma glucagon levels, 
we cannot exclude the possibility that a low insulin:glucagon ratio at the tissue level was 
partly responsible for suppressing lipogenesis in animals fed the carbohydrate-free diet. 
We also cannot exclude that a direct stimulatory effect of increased substrate availability 
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(carbohydrate) accelerated glucose uptake and enhanced lipogenesis in animals fed the 
standard or 1 0  en% sucrose diets. 
It is possible that the beneficial effects of the carbohydrate-free diet were due to our 
decision to supply saturated fat in the form of hydrogenated coconut oil, rather than lard 
or beef tallow, both of which contain significant amounts of cholesterol According the 
USDA nutrient database (40), hydrogenated coconut oil is 86.5% (by weight) saturated 
fat, with 45% occurring as the medium chain fatty acid, lauric acid (12:0) .  The metabolic 
response to ingestion of medium chain triglycerides (MCT, 8-12 carbons) is quite 
different from the response to long chain triglycerides (LCT, >12  carbons). MCT are 
more rapidly hydrolyzed to medium chain fatty acids (MCF A) by the action of pancreatic 
lipase than are LCT. Subsequently, MCFA are absorbed directly into portal circulation 
for rapid transport to the liver. Conversely, long chain fatty acids (LCF A) liberated by 
the hydrolysis of LCT are incorporated into chylomicrons, which circulate peripherally 
via the lymphatic system prior to reaching the liver. Once in the liver, LCF A must be 
transported across the mitochondrial membrane by camitine palmitoyl transferase (CP1) 
1 prior to undergoing �-oxidation. In contrast, MCF A do not require a transport system 
to penetrate the outer mitochondrial membrane. Consequently, MCF A gain access to 
the oxidative machinery more efficiently, and are oxidized more extensively, than are 
LCFA (41). Consistent with this, human studies have demonstrated that fat oxidation 
increases more quickly and remains elevated for a longer duration following an MCT 
versus and LCT load given at lunchtime (42) . Furthermore, in the subsequent four to six 
hours before the next meal, subjects had oxidized almost twice as much lipid after the 
MC! lunch compared with the LCT lunch (42). 
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The use of coconut oil may partially explain the differences in adipose tissue 
accumulation and body weight in our studies. Animals consuming the carbohydrate-free 
and 10 en% sucrose diets ad libitwn consumed 30-36% more energy than did animals 
consuming the standard diet ad libitwn. Nonetheless, there were no significant 
differences in final body weight between groups. The carbohydrate-free and 10 en% 
sucrose diets derived 69 and 59 en%, respectively, from coconut oil, while the standard 
diet contained 12 en% soybean oil. Portillo, et al. (43) have previously demonstrated an 
increase in interscapular brown adipose tissue (IBA 1) and the induction of UCP-1 in 
IBAT in rats fed a high-fat coconut oil (56 en% coconut oil) diet compared with control 
(1 2 en% fat) diet. Moreover, final body weight rats fed the high-fat coconut oil diet was 
only 7.8% higher than rats fed the standard diet. In comparison, other studies (44,45) 
demonstrate a range of excess body weight (20-55%) in animals fed high polyunsaturated 
fat diets compared with control diets. Nonetheless, the use of coconut oil in the present 
studies cannot be the sole factor mediating the reduction in body weight, as the addition 
of a minimal amount of sucrose to the coconut oil-based diet significantly increased 
body weight. 
The induction of UCP-1 in IBAT with coconut oil feeding suggests there is a 
compensatory increase in thermogenesis which minimizes the extent to which excess 
energy is stored in adipose tissue (43,45,46). Similarly, dietary MCT have been shown to 
suppress accumulation of body fat and reduce body weight compared with LCT in 
humans with a BMI exceeding 23 kg/m2 (47) 
In summary, we have demonstrated suppression of weight gain and subcutaneous 
adipose tissue deposition in rats fed a carbohydrate-free, high-fat diet compared with 
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semi-purified standard rodent diet or a high-fat diet in which 10 en% sucrose is 
substituted for dietary fat. These changes occurred independently of energy intake and 
in the absence of measurable changes in plasma insulin levels. The reduced 
subcutaneous adipose tissue mass in animals fed the carbohydrate-free diet are mediated, 
in part, by lower FAS expression in both the liver and adipose tissue. Moreover, the 
beneficial effects of the carbohydrate-free diet on lipogenic gene expression are 
completely reversed upon addition of a small (10 en%) amount of sucrose to the high-fat 
diet. To clarify the mechanisms responsible for these changes, additional studies are 
required. Future studies should include the assessment of total carcass fatty acid content 
to clarify the contributions of adipose tissue to changes in body weight. Additional 
studies should also endeavor to control the fatty acid composition of the diets by 
standardizing the source of dietary fat in all experimental groups. Furthermore, future 
studies should determine if the improvements in body composition observed in the 
present studies can be duplicated when dietary fat is supplied as polyunsaturated or 
monounsaturated long chain fatty acids. 
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II. Effect of Dietary Carbohydrate Source on the Development of Obesity in 
aP274-AgoutiTransgenic Mice 
Abstract 
We evaluated the effects of ad libit11m or energy restricted (70% of ad libit11m) high-fat 
diets (basal) varying in carbohydrate source on adiposity in aP2-agouti transgenic mice. 
In meal response tests, the diet containing mung bean noodles (MUNG) as the sole 
source of carbohydrate evoked a significantly lower glucose response (p<0.05) compared 
to all other foods. Moreover, the response to the sweetened instant oatmeal (IO-S) was 
approximately 23% greater (p<0.05) than the response to the flavored instant oatmeal 
(IO-F), which was similar to the rolled oats (ROLL). 
Weight gain in animals consuming the ROLL diet ad libitum for 6 weeks was 50-66% 
(p<0.05) lower compared to all other diets conswned ad libitum. While energy restriction 
during weeks 6-12, irrespective of diet, reduced body weight by 21-28% compared with 
animals continued on the basal diet ad libitum, final body weight was 17% higher in the 
basal-R compared with the ROll diet, despite equivalent energy restriction. 
Subscapu1ar fat pad mass was significantly higher (p<0.05) in the energy restricted 
basal and 10-S groups compared with the ROLL diet, at the same level of energy intake. 
Despite equivalent energy restriction, mass of both the retroperitoneal and perirenal fat 
pads were significantly lower in animals fed the ROLL and MUNG diets (p<0.05 for 
both) compared with the basal and 10-S diets. 
Plasma leptin levels were significantly lower (p<0.05) in animals fed the energy 
restricted MUNG diet compared with similarly energy restricted basal and 10-S fed 
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animals. Consumption of the basal diet, either ad libit11m or with energy restriction, led to 
larger adipocytes (p<0.05) compared with both ROLL and MUNG diets. 
In ad libit11m fed animals, the level of expression of fatty acid synthase in the liver was 
significantly lower in animals consuming the ROLL and MUNG diets compared with all 
other groups. Expression of fatty acid synthase and PP AR-et in retroperitoneal adipose 
tissue was significantly higher following unrestricted consumption of the basal diet for 6 
weeks relative to all other diets consumed ad libit11m for the same length of time. 
Expression of UCP-2 in rettoperitoneal adipose tissue was enhanced by the basal diet 
(p<0.05) consumed ad libit11m for 6 weeks and was reduced in ROLL fed (p<0.05) 
animals compared to animals consuming the IO-S and IO-F diets ad libit11m. Similarly, 
expression of PPAR-y in the retroperitoneal depot was enhanced by the basal diet 
relative to all other diets (p<0.05) and was lower in ROLL-fed (p<0.05) animals 
compared with animals fed the IO-S and IO-F diets ad libit11m for 6 weeks. 
Expression of gastrocnemius UCP-3 was 57% (p<0.05) greater in animals fed the 
energy-restricted MUNG vs. basal diets, while PPAR-a in soleus of MUNG animals was 
increased by 70% (p<0.05) vs. the basal diet at the same level of energy intake. These 
data suggest that dietary carbohydrate source modulates adipose tissue accumulation and 
body weight by shifting substrate utilization in favor of lipid oxidation in skeletal muscle 
as well as reducing lipogenesis in visceral adipose tissue. 
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Introduction 
There is considerable controversy surrounding the role of dietary carbohydrate in the 
development and/ or prevention of obesity and insulin resistance (1 -4). In fact, most 
dietary prescriptions for the prevention and treatment of overweight and obesity focus 
on reducing dietary fat conswnption (2,5-7). However, weight loss induced by fat­
reduced diets in generally modest and short-lived (8,9). 
There is no doubt that different carbohydrates vary considerably in their rate of 
absorption. Furthennore, blood glucose and insulin responses are influenced by the 
amount and type of carbohydrate in the diet (10). The Western diet typically contains 
large quantities of soft drinks, com syrup, potatoes, and processed grain products; all of 
which contain readily digestible, refined carbohydrates (1 1 ,12). The metabolic response 
to these foods is characterized by rapid increases in blood glucose and insulin levels (13-
15). However, some forms of dietary starch, often referred to as complex carbohydrates, 
elicit similar responses and consequently, the American Diabetes Association (1) has 
concluded that the chemical form of dietary carbohydrate has little clinical relevance. 
The metabolic benefits of low glycemic index foods stems from the slower rate of 
glucose absorption from the small intestine, occurring following their consumption (10). 
The slower rate of glucose absorption from the small intestine is associated with a 
reduction in the postprandial rise in gut hormones and insulin (10). Overtime, these 
hormonal changes serve to maintain lower free fatty acid and counter-regulatory 
hormone levels, in association with lower blood glucose levels, and may alter the pattern 
of substrate utilization over the long term. Higher postprandial increases in blood 
glucose and insulin levels preferentially promote carbohydrate oxidation, with a 
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reduction in the capacity for fatty acid oxidation (16,17). Reduced capacity for fat 
oxidation has been shown to promote weight gain in rodent models, as well as humans 
(18,19). 
Byrnes, et al. (20) have shown that insulin resistance can be induced by feeding rats a 
high-glycemic index starch diet. After 9 weeks of consuming a diet rich in rapidly 
digested, high-glycemic index amylopectin starch, Sprague-Dawley rats demonstrate 
slower clearance of an intravenous glucose bolus and secrete twice as much insulin to 
clear the glucose load than did rats fed a diet containing more slowly digested, amylose 
starch. Rat strain appear to exert a passive influence on the development of insulin 
resistance induced by amylopectin feeding since type of dietary starch had no effect on 
clearance of a glucose load in male Wistar rats. Nonetheless, plasma insulin response to 
the glucose challenge began to diverge in Wistar rats after 8 weeks of dietary 
intervention, such that after 12 weeks of consuming the high-amylopectin diet, the 
plasma insulin response to a glucose challenge was 100% greater than in amylose-fed 
rats. Moreover, basal plasma insulin levels in rats fed the high- amylopectin diet were 
almost double those seen in rats fed the high-amylose diet. These findings suggest that 
high-glycemic index diets contribute to the deterioration of insulin sensitivity and 
glucose tolerance (20) . Perhaps more importantly, Wiseman, et al. (21) have shown that 
insulin resistance induced by amylopectin feeding could be neither reversed nor 
prevented by a period of amylose feeding in normal rats. 
Despite the evidence supporting a role for dietary carbohydrate source per se in the 
development of insulin resistance in rodents, many professional organizations have 
concluded that the chemical form of dietary carbohydrate source has little clinical 
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relevance (1 ,22). These conclusions are largely based on studies which demonstrate 
similar postprandial blood glucose and insulin responses to dietary sucrose and starch or 
the lack of a relationship between discretionary sucrose intake and weight loss (23-27) . 
Furthennore, prevailing dietary recommendations (1,22,28) emphasize increasing 
consumption of complex carbohydrates by including among other things, high-glycemic 
index foods such as rice and potatoes (1 3,29). This may complicate the interpretation of 
studies designed to assess the metabolic effects of increasing dietary carbohydrate intake 
since many starchy foods are rapidly digested and produce higher glycemic and 
insulinemic responses than sucrose (13-1 5,26,29). West, et al. (27) found no difference 
in the amount of weight lost by subjects consuming hypocaloric, reduced-fat (33 en%) 
diets at two levels of sucrose intake. Nonetheless, epidemiological studies consistently 
demonstrate that replacing refined grains and potatoes with whole-grain, minimally 
processed foods, along with increasing consumption of fruits and vegetables, lowers 
dietary glycemic load and reduces insulin demand, which may influence risk of obesity 
and associated comorbidities (30-33) . 
The relationship between whole-grain intake and metabolic risk factors for type 2 
diabetes and cardiovascular disease was exammed using data gathered during the 
Frammgham Offspring Study (33). After adjusting for potential confounding dietary 
factors (intake of polyunsaturated fatty acids, fish, meat, fruit and vegetables), whole­
grain intake was found to be inversely associated with body mass index (p<0.05), waist­
to-hip ratio (p<0.05), LDL-cholesterol (p<0.02), and fasting insulin levels (p=0.03) (33). 
Consistent with this, data from the Nurses' Health Study (30) found a significant positive 
association between dietary glycemic load and risk of coronary heart disease, particularly 
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in women with above-average body weights. In addition, glycemic index was a stronger 
predictor of coronary heart disease risk than was the usual classification of simple versus 
complex carbohydrates (30). 
The clinical utility of glycemic index may depend on the ability of health professionals 
to properly define glycemic index and distinguishing between complex carbohydrates 
and low glycemic index foods. 1bis obstacle may have indirectly promoted the use of 
low-carbohydrate diets (34,35), as health professionals and consumers attempt to mimic 
the physiological benefits of low glucose and insulin response diets at the expense of 
dietary carbohydrate consumption. The popularity of the Atkins' Diet (34) and the Zone 
Diet (35) may be attributable to the simplicity of advocating carbohydrate restriction, as 
opposed to the consumption of carbohydrates, which would result in postprandial 
responses similar to low carbohydrate diets (31,33). 
Short-term, uncontrolled studies indicate that the Atkins' diet results in significant 
weight loss after 8 weeks, with maximum sustained weight loss of 10.3% of initial body 
weight after 24 weeks (36,37). However, until recently there were no long-term studies 
of the efficacy of low-carbohydrate, high-protein, high-fat diets for weight loss and 
reduced risk factors for coronary artery disease. The first long-tenn ( one-year), 
randomized, controlled trial of such a diet was conducted by Foster, et al. (38). While 
subjects on the low-carbohydrate diet had lost more weight than subjects on a 
conventional (low-fat) diet at 3 (p=0.001) and 6 (p=0.02) months, there was no 
significant difference in the amount of weight lost between diets at 12 months. The 
difference in weight loss in the first six months was related to an overall greater energy 
deficit in the low-carbohydrate groups, despite unrestricted protein and fat consumption 
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by these subjects and instructions to restrict energy intake in the conventional diet group. 
Both diets improved insulin sensitivity, as determined by an oral glucose tolerance test; 
progressively less insulin was secreted to maintain euglycemia (39) . Thus, these data do 
not demonstrate an effect of dietary macronutrient composition, independent of wcight 
loss, on insulin sensitivity. Nonetheless, the low-carbohydrate diet was associated with 
greater improvements in serum levels of HDL-cholesterol (p<0.05) and triglyceride 
(p<0.05) after 12 months of dietary intervention compared with subjects consuming the 
conventional diet. The magnitude of reduction in serum triglycerides and increase in 
HDL-cholesterol levels with the low-carbohydrate diet was similar to that obtained by 
pharmacological treatments, such as fibrates and niacin (40). With respect to the 
improvements in serum lipids, the benefit of the low-carbohydrate diet (38) was greater 
than that expected by moderate weight loss alone (41), suggesting the reduction in 
dietary carbohydrate was at least partially responsible. This is consistent with previous 
studies demonstrating that high-carbohydrate, low-fat diets decrease HDL levels and 
increase serum triglyceride concentrations, whereas low-carbohydrate, high-fat diets 
reduce serum triglycerides and increase HDL levels (37,42-45) . 
Using the USDA's Continuing Survey of Food Intakes by Individuals 1994-1996 
(CSFII 1994-1 996), Bowman, et al. (46) evaluated the relationships between 
carbohydrate consumption, dietary energy content, nutrient quality, and body mass 
index. Analysis of subjects consuming a wide range of carbohydrate intake, indicated 
those deriving more than 55% of total daily energy needs from dietary carbohydrate 
consumed 200 grams more total food per 1000 kcals but the lower energy density of the 
diet .reduced total caloric intake by 200-300 calories per day compared with subjects in 
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whom dietary carbohydrate accounted for a smaller percentage of total daily energy 
intake. Across a range of carbohydrate intake, it was found that as dietary fiber and 
carbohydrate intake increased, conswnption of protein, total fat and saturated, 
polyunsaturated and monounsaturated decreased. Adults conswning a high­
carbohydrate diet had the lowest total fat intake per 100 grams of food compared to 
subjects consuming lesser amounts of carbohydrate. Women in whom dietary 
carbohydrate provided at least 55% of total daily energy had lower mean BMI levels 
(p<0.05) compared to women consuming less carbohydrate; there was a nonsignificant 
trend for lower BMI in men with higher carbohydrate intake. Overall, adults who 
obtained more than 55% of total dietary energy from carbohydrates conswned energy­
restricted diets, rich in whole-grain foods and fruits and vegetables. Importantly, diets 
containing less than 30% of total energy from carbohydrates were not necessarily energy­
restrictive or nutritious compared with high-carbohydrate diets. 1bis finding is 
particularly important when considering the popularity of carbohydrate-restricted diets 
(34,35), most of which recommend carbohydrate intake at levels lower than in subjects 
classified as having very low carbohydrate intake in the study by Bowman, et al. (46) . 
In a study by Wolever, et al. (47), subjects with impaired glucose tolerance were given 
dietary counseling to encourage conswnption of a weight maintaining, high­
carbohydrate, low-glycemic index diet for four months (47) . As a result, these subjects 
experienced a significant reduction in total daily energy intake and an increase in dietary 
fiber consumption. Moreover, subjects increased their consumption of low-glycemic 
index starchy foods by 1 1  %, while there was an 8% reduction in intake of high-glycemic 
index starchy foods. In contrast, a separate group of subjects counseled on the 
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consumption of a high-carbohydrate, rugh-glycemic index diet consumed more energy, 
and increased their consumption of high-glycemic index starchy foods by 8%, while 
reducing intake of low-glycemic index starchy foods by 4%. Fasting glucose levels 
tended to rise less on the low-glycemic index versus the high-glycemic index diet. The 
low-glycemic index diet was associated with increased �-cell responsiveness, relative to 
baseline measures, as indicated by a reduction in the amount of insulin secreted 
following an intravenous glucose bolus, which occurred in the absence of changes in 
insulin sensitivity. The glucose disposition index (DI), calculated based on estimates of 
insulin sensitivity and �-cell responsiveness to intravenous glucose, is used as an index of 
the ability of the �-cell to compensate for changes in insulin sensitivity by increasing 
insulin secretion (48) . Consumption of the low-glycemic index diet for four months 
significantly improved DI (+56%, p<0.05 vs. baseline), whereas the high-glycemic index 
diet failed to improve �-cell responsiveness or glucose disposition (47). This represents 
an important physiological effect of the low-glycemic index diet since the critical factor 
associated with the deterioration of impaired glucose tolerance to diabetes is decreased 
insulin secretion in response to a glucose challenge (49). 
Advocates of carbohydrate-restricted diets (34,35) often argue that high­
carbohydrate diets increase serum triglycerides and reduce HDL levels, thereby 
enhancing risk of cardiovascular disease (30,31). However, these changes may be a 
function of an increase in dietary glycemic load occurring in response to increased 
carbohydrate consumption. While dietary glycemic load can be altered by changing 
carbohydrate intake or reducing dietary glycemic index (50), data from Wolever, et al. 
(47) suggest these manipulations have different effects in subjects with impaired glucose 
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tolerance. Specifically, reducing dietary glycemic index improved HbA1c, diastolic blood 
pressure and glucose disposition, while reducing dietary carbohydrate intake in the 
context of a high-monounsaturated diet failed to improve these parameters (47). 
Based on the controversy surrounding the practical utility of the glycemic index and 
the popularity of carbohydrate-restricted diets, we designed studies to assess the 
metabolic response to rugh-fat diets varying in dietary carbohydrate source. The 
influence of processing and added sucrose was studied by comparison of instant oatmeal 
with added sugar to rolled oats. Furthermore, we have attempted to ascertain the 
importance of endogenous dietary fiber in the metabolic benefits of low glycemic index 
foods by comparing two foods (rolled oats and mung bean noodles) previously shown to 
elicit low blood glucose responses but which differ in content of endogenous dietary 
fiber. 
Materials and Methods 
Animal Model 
The mouse agouti gene encodes a 131 amino acid secreted protein that is transiently 
expressed in neonatal skin to regulate coat color pigmentation in a paracine manner 
(51,52). Placing the agouti gene under the control of the �-actin promoter in mice or 
dominant mutations at the agouti locus, results in ubiquitous agputi expression and the 
development of "yellow obese syndrome", a phenotype characterized by yellow coat 
color, obesity, hyperinsulinem.ia, insulin resistance, increased body length and 
susceptibility to neoplasia (53,54). In white adipose tissue of agouti mutant mice, elevated 
rates of lipogenesis occur concomitantly with decreased rates of lipolysis (54) . 
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Furthermore, recombinant ago11ti protein has been shown to increase fatty acid synthase 
activity and triglyceride accumulation in adipocytes in vitro (55). 
The human homologue of the ago11ti protein is 1 32 amino acids long and functionally 
similar to the mouse protein (56). However, the human gene is normally expressed in 
adipose tissue, in obese and nonobese individuals (56) . This adipose tissue specific 
expression pattern is mimicked in aP2-ago11ti transgenic mice, in whom the ago11ti gene is 
placed under the influence of the adipocyte fatty acid binding protein (aP2) promoter 
(57). These animals express recombinant ago11ti protein specifically in adipose tissue and 
have a uniformly yellow/brown coat color (57). Unlike animals overexpressing normal 
ago11ti protein, aP2-ago11ti transgenic mice become overweight only when hyperinsulinemia 
is induced by daily subcutaneous insulin injections (57) or by chronic ingestion of a high­
sucrose diet (58). This study was approved by the University of Tennessee Institutional 
Animal Care and Use Committee. 
Comparison ofUS17  and High Fat, High S11crose Diet 
We compared the effects of two diets on weight gain and adiposity in aP274-ago11ti 
transgenic mice fed ad libitum for four weeks to determine if these diets differed in their 
ability to promote the development of obesity. Table 6 summarizes the macronutrient 
composition and energy content of these diets. The basal diet is a high-fat, high-sucrose 
diet (Research Diets, New Brunswick, NJ) previously used in this laboratory to induce 
obesity in aP2-agouti transgenic mice (59), and was compared to the US 1 7  diet 
(Monsanto, St. Louis, MO), which has a fatty acid profile similar to the typical Western 
diet, with the following energy distribution: 44.4 en% carbohydrate, 35.4 en% fat, and 
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21 .2 en% protein (60). The high-fat, high-sucrose (HFS) diet contained 62 en% 
carbohydrate (as sucrose), 24 en% fat (soybean oil and lard) and 14 en% protein (59). 
Animals were given free access to either the US17 or high-fat, high-sucrose basal diet 
ad libitum for 4 weeks. At the end of the feeding period, animals were sacrificed by 
cardiac exsanguination under anesthesia. Blood was collected into an EDTA containing 
vacutainer blood collection tube and stored on ice prior to centrifugation at 1000 rpm 
for 10 minutes to collect plasma. The liver, representative fat pads (retroperitoneal, 
subscapular, epididymaI) were dissected, weighed and immediately snap frozen. 
Meal Tolerance Tests 
The blood glucose response to test foods was determined in fasted aP274-agouti 
transgenic mice. Food was removed from the animal's cages at 07:00 and animals fasted 
for 8 hours. Blood glucose levels were determined using the One Touch Ultra hand held 
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glucometer Oohnson and Johnson, Malpitas, CA). A small amount of blood was 
obtained by tail stick using a 1 cc standard insulin syringe. After determining fasting 
blood glucose levels, animals were given access to a standard amount (t gram/kg body 
weight) of one of four test diets: mung bean (MUNG), sweetened instant oatmeal (IO­
S), flavored instant oatmeal (IO-F), or rolled oats (ROLL). Blood glucose levels were 
detennined by tail stick as previously described at 30, 45, 60, and 120 minutes after food 
ingestion for calculation of the area under the blood glucose curve (AUCg1uco .. ) (61). The 
AUCg1uco,c was determined as follows: I:((O.S*(blood glucose concentration at 30 min + 
baseline blood glucose concentration)*(30 min-0 min))+(O.S*(blood glucose 
concentration at 45 min + blood glucose concentration at 30 min)*(45 min-30 
min))+(O.S*(blood glucose concentration at 60 min + blood glucose concentration at 45 
min)*(60 min-45 min))+(O.S*(blood glucose concentration at 120 min + blood glucose 
concentration at 60 min)*(120 min-60 min)))*grams of carbohydrate consumed. 
Phase I: Ad 1.ibit11m Energy Intake 
Animals and Diets 
Sixty aP274-agouti transgenic mice of 6 to 8 weeks in age were adapted to handling for 
use in this study. Animals were housed in pairs or individually in standard shoe-box 
rodent cages in a climate-controlled (37° q environment with a 12-h light-dark cycle. 
Prior to this study, animals had been maintained on standard rodent chow. Animals 
were randomly assigned by body weight (27.34±0.46 g, Mean±SEM) to one of the five 
dietary treatment groups (n=12 per treatment). All diets (fable 7) were AIN-93 based 
(62), and were custom prepared by Research Diets, Inc. (New Brunswick, NJ). The basal 
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Mung Bean Noodles 741 
Instant Oatmeal, Sweetened 
Instant Oats 
Sucrose 
Vitamin-.Minetal Pre-Mix #42 
Instant Oatmeal, f1avored 
Instant Oats 
Sucrose 
Vitamin-Mineral Pre-J\.fix #44 
Rolled Oats 
Cellulose 50 46.3 
Soybe2n 0il 100 100 
Lard 10 to  
TBHQ 0.014 0.014 
Mineral J\.fix, (A IN-93G-MX) 7 
Mineral Mix, (special formulation) 3.5 
Calcium Carbonate 8.3 7.84 
Calcium Phosphate, Dibasic 5.7 5.7 
Potassium Phosphate, Monobasic 8 7 
Potassium Citrate 3.8 4.4 
Sodium Chloride 13.75 13.55 
Vitamin Mix 10 1 0  
Choline Bitartrate 2.5 2.5 
Macronutrient Composition, g/kg diet 
Protein, grams 143.8 143.8 
Carbohydrate, grams 647.9 648 
Fat, gnuns 1 1 0  1 1 0.4 
Fiber, grams 50 50 
Energy Distribution. % per kcal 
Protein. % per kcal 14  14 
Carbohydrate, % per kcal 62 62 



























































diet (Basal) was a high-fat, high-sucrose diet which has been previously used in our 
laboratory to induce increased adiposity, hyperinsulinemia, and weight gain in this animal 
model (59) . In the MUNG and ROLL diets, dietary carbohydrate was derived from a 
single source: mung bean noodles and rolled oats, respectively. The remaining diets 
were designed to mimic commercially available instant oatmeal with added sugar (IO-S) 
and flavored instant oatmeal with added sugar (10-F). Because these diets were 
formulated to be comparable to commercially available products, there were some 
differences in the vitamin and mineral content, as well as energy content. These 
differences were attributable to the pre-mixed vitamin and mineral supplements supplied 
by our sponsor (The Quaker Oats Company), the composition of which are shown in 
Table 8. All diets were designed to provide 14 en% protein, 62 en% carbohydrate, and 
24 en% fat and contained 4. 16  kcal/g. With the exception of potassium, the vitamin and 
mineral content of the diets was standardized to the content provided by standard 
rodent chow (62). The rolled oatmeal diet contained a significantly greater amount of 
potassium and therefore, the potassium content of all other diets was standardized to 
this level. The fiber content of the basal, mung bean, and both instant oatmeal diets was 
raised to be equivalent to standard rodent chow (1.6% fiber per kcal) (62) . The rolled 
oatmeal diet contained a significantly greater amount of fiber (2. 1 % fiber per kcal) than 
all other diets. However, since fiber content influences glycemic index, the fiber content 
of this diet was not adjusted (63) . 
All animals had ad libit11m access to food and water during the six week feeding 
period. Food intake and water were monitored and replaced daily. 
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Table 8 
Nutrient Composition of Vitamin-Mineral Pre-Mixes 
































Pre-Mix #42 for Instant Quaker Oats Pre-Mix #44, for Instant Quaker Oats 
Sweetened Variety Flavored Variety 
Amount in 100 gmms of Pre-Mix 
7890 mg 21200 mg 
1 84 mg 137 mg 
122000 IU 95000 JU 
30 mg 27 mg 
37 mg 33 mg 
540 mg 427 mg 
10900 mg 8770 mg 
813 mg 323 mg 
0.3947 JU 0.0924 JU 
61 .30 mg 57.2 mg 
8560 µg 7600 µg 
364 mg 272 mg 
97.50 mg 48.9 mg 
1 .27 mg 0.32 mg 
2 mg 2 mg 
0.45 mg 0.47 mg 
5.05 mg 2.01 mg 
W� g �48 g 
4.84 g 




1 .09 g 
1 .06 g 
15.66 g 
1 .50 g 





1 .01 g 
1 .23 g 
0.675 g 





7 .4538 g 
0.1445 g 
42.4219 kcal 
Phase II: Restricted Energy Intake 
Animals and Diets 
1bis study was divided into two 6-week stages. In the first stage (6 weeks), forty­
eight male aP274-ago11ti transgenic mice were given ad libit11m access to the basal (high-fat, 
high-sucrose) diet. Body weight was monitored every five days for 6 weeks. Following 
this first stage, animals were randomly assigned (by body weight, 34.57± 0.68 g) to one 
of seven treatment groups (n=B per treatment group). One group was continued ad 
libitum on the basal diet (basal). The other groups were maintained with energy 
restriction (-R; 70 en% ad lib) by using a pair-fed protocoi as follows. The mice in the 
basal-R group were continued on the basal diet with energy restriction. The remaining 
groups received either the MlJNG, ROLL, IO-S, or 10-F diet with energy restriction. 
At the end of this stage, animals were sacrificed and tissues collected as described below. 
Determination of Week!J Fasting Blood Gl11cose uvels 
Food was removed from the animal's cages at 07:00 and animals fasted for 8 hours. 
Fasting blood glucose levels were monitored weekly. A minimal amount of blood was 
obtained by sticking the animal's tail with a standard 1cc insulin syringe and blood 
glucose level determined using the One Touch Ultra hand held glucometer Q'ohnson 
and Johnson, Malpitas, CA). The glucometer was calibrated according to the 
manufactor's instructions prior to testing each week. 
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Colle,tion of Fasting Blood Samples and P,rparation of Plasma 
Two days prior to sacrifice, 1 cc of whole blood was obtained by tail stick using a 1 cc 
insulin syringe from fasted animals. The blood was transferred to an EDTA-treated 
vacutainer blood collection tube and stored on ice until centrifuged at 1000 rpm for 10 
minutes to obtain plasma. Plasma was transferred to 0.5 ml eppendorf tubes and stored 
at -20° C until time of analysis. 
Sacrifice of Animals 
Animals were sedated in a sealed plexiglass box saturated with CO2 prior to cardiac 
exsanguination. Blood was collected from unfasted animals by cardiac puncture using a 
heparinzed 5 cc syringe and a 20 gauge 1-inch needle which was then transferred to an 
EDTA-treated vacutainer blood collection tube. All samples were stored on ice until 
centrifuged at 1000 rpm for 15  minutes to collect plasma. Plasma was stored at -20 °C 
until time of analysis. 
Dissection and Processing ofTiss11es 
Following cardiac exsanguination, the liver, selected fat pads (epididymal, 
subscapular, retroperitoneal, perirenal), and selected contralateral muscles (soleus, 
gastrocnemius) were immediately dissected and weighed The liver, epididymal fat pad, 
subscapular fat pad, soleus muscle and gastrocnemius muscles were snap frozen in liquid 
nitrogen and stored at -80° C until time of analysis. 
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Collection and Treatment of Perirenal Fat Pads far Basal and Isoproterenol-Stim11/ated Iipo!Jsis and 
Determination of G!Jcerol &lease 
Immediately upon dissection, the perirenal fat pad was divided into two sections of 
approximately equal mass and placed into appropriately labeled six-well cell culture 
plates containing freshly prepared 1X Dulbecco's Modified Eagle Medium (DMEM; 
with high glucose, L-glutamine, 25 mM HEPES buffer, pyridoxine chloride, without 
sodium pyruvate; Life Technologies, Carlsbad, CA) supplemented with 1% fetal bovine 
serum (FBS) and 1% bovine serum albumin fraction V (BSA; Life Technologies, 
Carlsbad, CA). All samples were allowed to equilibrate at 37°C, prior to beginning the 
assay. To determine basal glycerol release, one section of the perirenal fat pad was 
transferred to an appropriately labeled well of a 24-well cell culture plate containing 1 ml 
of Kreb's Ringer Buffer (KRB; 129 mM NaCl, 5 mM NaHC03, 4.8 mM KCl, 1 .2 mM 
KH
2
P04, 1.0 mM CaC12, 1 .2 mM MgS04, 5 mM glucose, 20 mM HEPES, 1% BSA, pH 
7.3). For stimulated lipolysis, 1 µ.l of 100 µM isoproterenol was added to KRB prior to 
transferring the remaining perirenal fat pad section to the cell culture plate. The plates 
were then incubated at 37° C, 5% CO2 with 90% hwnidity for 2 hours. Following 
incubation, both the media and fat pads were transferred to appropriately labeled 
eppendorf tubes and stored at -20° C for further analysis. 
Following the procedure described by Boobis, et al. (64), lipolysis was assessed by 
glycerol release, since free fatty acids can be reesterified by adipocytes and therefore, may 
underestimate lipolysis. Conversely, glycerol reesterification by adipocytes is negligible. 
The method used for determination of glycerol in the lipolysis medium is based on the 
conversion of glycerol to dihydroxyacetone in the presence ofNAD catalyzed by 
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glycerol dehydrogenase. Prior to beginning the assay, the media aliquots collected 
following incubation of fat pads with lipolysis medium were allowed to thaw on ice. 
To establish a standard curve, 100 mM glycerol was prepared by diluting 100 µl of 
13.6 M glycerol (Sigma-Aldrich, St. Louis, MO) in 13.5 ml of freshly prepared KRB with 
1% BSA, as previously described. The working solution of 10 mM glycerol was 
prepared by dilution of 500 µ1 100 mM glycerol in 4.5 ml KRB. The standard curve was 
generated by serial dilution of 10 mM glycerol to achieve a range of O to 10 mM glycerol. 
Subsequently, 25 µl of each standard (0, 1 ,  2.5, 5, 7.5, and 10 mM glycerol) and sample 
was pipetted into appropriately labeled wells of a 96-well Packard black bottom plate 
(Hewlett Packard, Palo Alto, CA). 
After samples had been pipetted into 96-well plates, the reaction mixture was 
prepared as follows. Hydrazine buffer containing 0.2 M 100% hydrazine hydrate (a 
ketone-trapping agent), 0. 1 M 2-amino-2-methyl-1-propano� and 1 mM EDT A in 
distilled water was prepared and the pH adjusted to 9.9 with 12.4 N HCl. For each 
standard and sample assayed, 100 µl of reagent mixture containing 4 µl �-NAD (500 
mM), 200 µl hydrazine buffer and 1 µl glycerol dehydrogenase (from Enterobacter aerogenes, 
Roche Applied Sciences, Indianapolis, IN) was prepared and added to each well of the 
96-well plate containing the standards and samples. The samples were allowed to 
incubate for 90 minutes at room temperature with gentle shaking. In the presence of 
hydrazine and at pH 9.9, the reaction proceeds to completion and NADH is formed in 
stoichiometric quantities relative to glycerol in the medium. The quantity of NAD H 
formed is then determined by dual wavelength spectrophotometry with excitation at 380 
nm and emission at 520 run. 
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Quantitation for each sample was normalized for the protein content of each section 
of perirenal fat pads for each animal. Each fat pad section was homogenized in 1 ml 
KRB, which was prepared as previously described with one exception. Since these 
samples were to be assayed for protein content, BSA was not added to the KRB. 
Following homogenization, the protein content of each sample was detennined as 
described by Bradford (65) and modified for use with Coomassie® Plus Protein Assay 
Reagent (Pierce, Rockford, IL) by Spector (66). 
A fresh set of protein standards was prepared in glass culture tubes by serial dilution 
of BSA stock standards (2.0 mg/ml, Pierce, Rockford, IL) in KRB to achieve a range of 
125-2000 µg/ml. Subsequently, 50 µl of each standard and sample was transferred to 
appropriately labeled glass culture tubes and 1 .5 ml of Coomassie® Plus reagent added to 
each. The absorbance of each standard was determined by measuring the absorbance at 
595 nm against a water reference sample. The standard curve was prepared by plotting 
the absorbance of each standard against its respective concentration in µg/ml. The 
concentration of protein in each sample was then determined using the standard curve. 
Subsequently, the concentration of glycerol in each sample was normalized for the 
protein content of the sample. 
Cell Sizing 
Cell sizing was determined following the 12 week protocol. Due to the fact that 
energy restriction was employed during the final six weeks of this study, the size of the 
retroperitoneal fat pad limited our analysis to cell sizing, without analysis of gene 
expression in this depot. Upon dissection, the abdominal fat pad was placed into 
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appropriately labeled wells of a 6-well culture plate containing DMEM (Life 
Technologies, Carlsbad, CA) supplemented with 1% FBA and 1% BSA. The fat was 
then transferred to a culture dish containing 3 ml of 0.8 mg/ml collagenase (Sigrna­
Aldrich, St. Louis, MO) in Hank's Balanced Salt Solution (8 g/L Naci 400 mg/L KCL, 
60 mg/L KH2P04, 47.86 mg/I N�HP04, 1 g/L glucose) . The sample was digested in 
this medium for 30 minutes at room temperature with gentle shaking. Following 
digestion, the digested sample was passed through 400 micron nylon mesh into a 50 ml 
centrifuge tube. The sample was allowed to sit for 1-2 minutes to permit the adipocytes 
to separate from the digestion medium. Once the cells had fonned a discrete layer, the 
lower aqueous layer was removed with a transfer pipet being careful not to disturb the 
upper cell layer. The cells were then rinsed twice in DMEM supplemented with 1 % FBS 
and 1 % BSA. Following removal of DMEM, cells were rinsed twice in Isoton II Diluent 
(7.93 g/1 Naci 0.38 g/1 NaiEDTA, 0.4 g/1 KC� 1 .95 g HNaiP0
4
, 0.3 g/1 NaF; 
Beckman-Coulter, Providence, Rl). Following the final rinse, 500 µI of cell suspension 
was carefully pipeted from the upper layer and transferred to a vessel containing 1 50 ml 
of Isoton II diluent and measured by the Coulter Counter principle (67) using the 
MultiSizer 3 System (Beckman-Coulter, Providence, RI). 
Using the MultiSizer 3, adipocytes are suspended in lsoton II diluent, a weak 
electrolyte solution, and subsequently, are drawn through a small aperture separated by 
two electrodes between which an electric current flows. Voltage is applied across the 
aperture, creating a sensing zone. As particles pass through the sensing zone, an equal 
volume of conducting diluent is displaced, momentarily increasing the impedance of the 
aperture. This change in impedance produces a small but proportional current. The 
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current fluctuation is amplified and converted into a voltage pulse Jarge enough to be 
accurately quantified and measured. The Coulter principle states that the amplitude of 
the voltage pulse is directly proportional to the volume of the particle that produced the 
fluctuation. Scaling of the height of the voltage pulses in volume enables a size 
distribution to be acquired and displayed (67). 
Determination of Final Plasma G/11cose uvels 
Final plasma glucose levels were determined using the glucose oxidase method as first 
described by Washko, et al. (68) and modified by Marks (69). This procedure is based on 
the following coupled enzymatic reactions: In the presence of water and oxygen, glucose 
oxidase catalyzes the conversion of glucose to gluconic acid and hydrogen peroxide. 
With hydrogen peroxide and peroxidase available, the otherwise colorless o-diansidine 
dihydrochloride is oxidized and the product of the reaction is brown in color. The 
intensity of the brown color measured spectrophotometrically at 475 nm is proportional 
to the original glucose concentration of the sample. To quantify the glucose content of 
the samples, the absorbance of a glucose standard (100 mg/d.L, Sigma-Aldrich 
Diagnostics, St. Louis, MO) was determined. The absorbance of the sample was divided 
by the absorbance of the standard and this ratio multiplied by the concentration of the 
glucose standard. 
Reagents for determination of plasma glucose levels were obtained from Sigma­
Aldrich Diagnostics (St. Louis, MO). The enzyme solution was prepared by adding 1 
capsule of PGO enzymes to 100 ml distilled water in an amber bottle. Each capsule of 
PGO enzymes contains 500 units of glucose oxidase (Aspergillus nigery and 100 U /L 
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horseradish peroxidase. The color reagent solution was prepared by reconstituting one 
vial (50 mg) of o-dianisidine dihydrochloride with 20 ml of distilled water. To prepare 
the combined enzyme-color reagent solution, 1 .6 ml of color reagent solution was added 
to 100 ml of enzyme solution and mixed by inversion. 
For each sample, 25 µI of plasma was transferred to an appropriately labeled 
borosilicate glass culture tube containing 5 ml of combined enzyme-color reagent 
solution. A standard was similarly prepared using a known glucose standard solution 
(100 mg/dL, Sigma-Aldrich Diagnostics, St. Louis, MO). The tubes were vortexed, 
covered in foil to protect them from exposure to ambient light, and allowed to incubate 
at room temperature for 45 minutes. At the end of the incubation period, the 
absorbance was read at 475 nm against a water blank. The concentration of glucose in 
each sample was calculated by dividing the absorbance of the samples by the absorbance 
of the glucose standard, and multiplying by the concentration of the glucose standard. 
Determination of l'asting PlaJma Trigjyceride uvtls 
Plasma triglyceride levels were determined according the technique described by 
Buccolo and David (70). Using this method, triglycerides are first hydrolyzed by 
lipoprotein lipase to yield glycerol and free fatty acids. Glycerol is then phosphorylated 
in an ATP-dependent reaction by glycerol kinase yielding glycerol-1-phosphate. The 
glycerol-1-phosphate is oxidized to dihydroxyacetone phosphate, with the concomitant 
reduction ofNAD to NADH in a reaction catalyzed by glycerol-1-phosphate 
dehydrogenase. The resulting NADH is then oxidized, coupled to reduction of 2-(p­
iodophenyl)-3-p-nitrophenyl-5-phenyltetrazolium chloride (INT) to fonnazan, which is 
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pink in color, in the presence of diaphorase. The intensity of the color produced is 
directly proportional to the triglyceride concentration in plasma. 
The reagents used in this assay were obtained from Sigma-Aldrich Diagnostics (St. 
Louis, MO). Plasma (10 µl) was transferred to a borosilicate glass culture tube 
containing 1 ml reconstituted triglyceride reagent (2.0 mM ATP, 2.0 mM NAD, 3.0 M 
Mg2+, 1 .0 mM 2-(p-iodophenyl)-3-p-nitrophenyl-5-phenyltetrazolium chloride, 200 U/L 
glycerol kinase, 4000 U/L glycerol-1-phosphate dehydrogenase, 455 U/L diaphorase, pH 
7.8). A standard was similarly prepared using a known triglyceride standard (250 mg/dL, 
Sigma-Aldrich Diagnostics, St. Louis, MO). The samples were vortexed and allowed to 
sit at room temperature for 15  minutes. Following this period, the absorbance of each 
sample was measured at 500 nm against a water blank. The concentration of 
triglycerides in each sample was calculated by dividing the absorbance of the samples by 
the absorbance of the triglyceride standard, and multiplying by the concentration of the 
triglyceride standard. 
Determination of Fasting Plasma G!Jcero/ Levels 
Final plasma glycerol levels were determined using direct colorimetric kit obtained 
from Randox Laboratories (San Diego, CA). This procedure is based on the following 
reactions: glycerol kinase acts on glycerol in the presence of ATP to yield glycerol-3-
phosphate (64). Subsequently, the action of glycerol phosphate oxidase in the presence 
of oxygen yields dihydroxyacetone phosphate and hydrogen peroxide. In the presence 
of hydrogen peroxide, 3,5-dichloro-2-hydroxybenzene sulphonic acid and 4-
aminophenazone, the action of peroxidase generates n-(4-antipyryl)-3-chloro-5-
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sulphonate-p-benezoquinoneimine (ACSB), which is pink in color. The intensity of the 
pink color measured at 520 nm is proportional to the original glycerol concentration. 
The reagent mixture containing 0.4 mM 4-aminophenazone, 1 mM ATP, 0.4 U / ml 
glycerol kinase, 1.5 U/ml glycerol-3-phosphate oxidase, and 0.5 U/ml perioxidase was 
reconstituted with 15  ml of Pipes Buffer (40 mM 1 ,4-piperazinediethanesulfonic acid, 1 .5 
mM 3,5-dichloro-2-hydroxybenzene sulphonic acid, 1 7.5 mM Mg2
+, pH 7.6). In glass 
culture tubes, 30 µl of plasma was combined with 1 ml of the reagent mixture, mixed and 
allowed to sit at room temperature for 10 minutes. A standard of known glycerol 
concentration (100 µ.mol/L) was similarly prepared. Following the incubation period, 
the absorbance of the standard and samples were determined by spectrophotometry at 
520 run. To quantify the concentration of glycerol in each sample, the absorbance of a 
glycerol standard (100 µ.mol/1) was determined. The ratio of the absorbance of the 
sample to the absorbance of the standard was multiplied by the concentration of the 
glycerol standard to calculate the concentration of glycerol in each sample. 
Determination of Fasting Plasma Insulin Levels 
This assay is based on the double antibody technique for determination of plasma 
insulin levels in rats as described by Morgan, et al. (71) using the rat radioimmunoassay 
kit obtained from Linea Research (St. Charles, MO). A standard curve was prepared 
using purified rat insulin in insulin standard buffer at the following concentrations: 0. 1 ,  
0.2, 0.5, 1 .0, 2.0, 5.0, and 10.0 ng/ml. For each standard and sample, 50 µl of 
standard/sample, 50µ1 of 1251-labeled insulin, and 50 µl guinea pig anti-rat insulin serum 
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in assay buffer were transferred to appropriately labeled glass culture tubes. All tubes 
were vortexed, covered with foil and allowed to incubate for 20 hours at 4°C. 
Following incubation, 500 µl of precipitating reagent containing goat anti-guinea pig 
IgG serum was added to each standard and sample. All tubes were vortexed and allowed 
to incubate for 30 minutes at 4° C. Subsequently, all tubes were centrifuged at 3000 rpm 
for 30 minutes to separate antibody-bound from free label. The supernatant was 
decanted by inverting the tubes for 45 seconds and the percentage of total binding 
determined for each sample by counting in a gamma counter for 5 minutes. The 
calculations necessary for determination of plasma insulin concentration were performed 
automatically using the data reduction capabilities of the gamma counter, which involved 
plotting the percentage of total binding for each sample on the y-axis and the known 
concentrations of the standards on the x-axis (72). 
Detennination of Fasting Plasma Leptin uvels 
This assay is based on the double antibody technique for determination of plasma 
leptin levels in human plasma described by Ma, et al. (73) using the mouse leptin 
radioimmunoassay kit obtained from Linco Research (St. Charles, MO). A standard 
curve was prepared using purified mouse leptin in leptin standard buffer at the following 
concentrations: 0.2, 0.5, 1 .0, 2.0, 5.0, 10.0 and 20.0 ng/ml. For each standard and 
sample, 50 µl of standard/ sample and 50 µl rabbit anti-mouse leptin serum in assay 
buffer were transferred to appropriately labeled glass culture tubes. All tubes were 
vortexed, covered with foil and allowed to incubate for 20 hours at 4°C. Following 
incubation, 50 µl of 1251-labelled leptin was added to each standard/sample. The tubes 
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were vortexed, covered with foil and allowed to incubate for an additional 20 hours at 4° 
C. Following this period, 500 µI of precipitating reagent containing goat anti-rabbit IgG 
serum was added to each standard and sample. All tubes were vortexed and allowed to 
incubate for 30 minutes at 4° C. Subsequently, all tubes were centrifuged at 3000 rpm 
for 30 minutes to separate antibody-bound from free label. The supernatant was 
decanted by inverting the tubes for 45 seconds and the percentage of total binding 
detennined for each sample by counting in a gamma counter for 5 minutes. The 
calculations necessary for detennination of plasma leptin concentration were performed 
automatically using the data reduction capabilities of the gamma counter, which involved 
plotting the percentage of total binding for each sample on the y-axis and the known 
concentrations of the standards on the x-axis [12). 
RNA Isolation 
Total RNA was extracted from the medial lobe of the liver, adipose tissue, and 
muscle using the guanidine-HCL method [14) and phenol-chloroform extraction 
techniques [15). Tissue samples (0.5 to 2 gj were ground in liquid nitrogen and 
subsequently, homogenized using a polytron homogenizer in 10  ml of 4 M guanidine 
isothiocynate (GTC) with �-mercaptoethanol (14 µI per ml of GTC). The homogenate 
was then transferred to a polypropylene centrifuge tube and one starting volume of 
phenol:choloroform:isoamyl alcohol (25:24: 1 ,  pH 7.9) added prior to vortexing. The 
homogenate was placed on ice for 15 minutes prior to centrifugation at 10,000 x g for 15 
minutes at 4° C. Following centrifugation, the aqueous layer was transferred to a clean 
polypropylene centrifuge tube and 1 ml of 3 M sodium acetate added. The samples were 
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mixed by inversion. Subsequently, 5 ml of acid phenol:chlorofonn:isoamyl alcohol 
(125:24: 1 ,  pH 4.5) was added to each sample. The samples were vortexed and allowed to 
sit on ice for 15  minutes prior to centrifugation at 10,000 x g for 20 minutes at 4° C. 
Following centrifugation, the aqueous layer was transferred to a 15 ml centrifuge tube. 
Samples were allowed to precipitate overnight in 1 00% isopropanol at -20° C. 
Samples were transferred to clean polypropylene centrifuge tubes prior to 
centrifugation at 10,000 x g for 20 minutes at 4° C. Following centrifugation, the 
supernatant was decanted and the pellet allowed to air dry for 15 minutes at room 
temperature. Subsequently, the pellet was resuspended in nuclease-free water containing 
0.1 mM EDTA. The samples were allowed to precipitate for 30 minutes at -20° C prior 
to centrifugation at 10,000 x g for 30 minutes at 4° C. The supernatant was decanted 
and the pellet resuspended in 100% ethanol. The samples were allowed to incubate 
overnight at -20° C. 
Samples were transferred to a clean polypropylene centrifuge tube and centrifuged at 
10,000 x g for 20 minutes at 4° C. The supernatant was decanted and the pellet 
resuspended in forrnamide prior to quantification using dual wave length (260/280 nm) 
spectrophotometry (J6). 
Gene Expression 
Expression of murine fatty acid synthase (FAS), peroxisomal proliferator activated 
receptor (PPAR) gamma (PPAR-y), PPAR-a, uncoupling protein (UCP) 2 (UCP-2), and 
UCP-3 were quantitated by real-time reverse transcripta�e polymerase chain reaction 
(RT-PCR) (J7) using the Smart Cycler Real Time PCR System (Cepheid, Sunnyvale, CA) 
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with a TaqMan 1000 Reaction Core Reagent Kit (Applied Biosystems, Branchburg, NJ). 
The sequences for probes and forward and reverse primer sequences are provided in 
Table 9. 
To establish a standard curve for each gene, 1 µI of total RNA (concentration: 1 
ng/ µI) from each sample was pooled and subsequently, serial-diluted in the range of 
1.5625-25 ng to establish a standard curve in each tissue for each gene of interest. The 
PCR reagent mixture contained 50-200 µg RNA, 6.85 µI DEPC-treated water, 2.5 µl 10X 
PCR buffer (500 mM KCI, 100 mM Tris-HCL, pH 8.3), 5.5 µ1 25 mM MgC�, 0.75 µI 
each of 75 mM deoxynucleotide triphosphates (dATP, dGTP, dCTP, dlTP), 0.50 µI of 
10 µM forward primer, 1 .0 µI of 10µM reverse primer, 0.125 µI ofMuLV reverse 
transcriptase (50 U/µI), 0. 125 µl RNase inhibitor, 0.15 µl AmpliTaq DNA polymerase, 
and 0.25 µl of 10 µM probe. The polymerase chain reaction was perfonned according to 
the instructions for the Smart Cycler System (Cephid) and TaqMan Real Time PCR Core 
Kit (Applied Biosystems, Foster City, CA) using 50-200 ng total RNA and the following 
3-stage cycling protocol: stage 1 (reverse transcription) at 48.0° C for 1800 seconds, 
stage 2 (denaturation and inactivation of reverse transcriptase) at 95.0° C for 600 
seconds, and stage 3 (40 two-temperature cycles), denaturation at 95°C for 15 seconds, 
annealing and extension at 60°C for 60 seconds. Quantitation for each sample was 
nonnalized using the corresponding 18s expression in each tissue for each animals in the 












Sequences of Primers and Probes Used for Determination of Gene Expression by Real Time RT-PCR 
Primer Sequences {S' to 3') Probe 
Forward Reverse Sequence (5' to 3 ') 
CCCAGAGGCTfGTGCfGACf CGAATGTGCITGGCITGGT TET-CCGATCTGGAATCCGCACCGG-TAMRA 
CCTCfACGACTCfGTCAAGCAGTTCTAC CAGCCTGCCAGAATCCTGAT Cal Red-CGCTGGAGTGGTCCGCTCCCT-BHQ 
GCGTTCTGGGTACCATCCTAAC GCGACCAGCCCATTGTAGA Cal Red-CGCACTGAGGGTCCACGCAGC-BHQ 
CGATGCTGTCCTCCTfGATGA CGCGTGTGATAAAGCCATTG Cal Red-ACGCGATCAGCATCCCGTCTTTG-BHQ 
TGCGAGTGGTCTfCCATCAC GCCTATGAGCACITCACAAGAAATT Cal Red-TCTGGCCCACCAAClTCGGAATCAG-BHQ 
AGTCCCTGCCCTTTGTACACA GATCCGAGGGCCTCACTAAAC FAM-CGCCCGTCGCTACTACCGATTGG-BHQ 
S tatistkal Anafysis 
Data were analyzed by analysis of variance (ANOV A) to compare overall group 
means with subsequent analysis via least significant difference test to identify 
significantly different group means using the SPSS Statistics Package (78). Variables 
which did not follow a normal distribution were transformed according to accepted 
statistical practices (log base 10, square, square root, inverse, inverse square root) to 
achieve normal distribution prior to ANOVA (79). When normality could not be 
achieved, significantly different group means were identified by non-parametric tests 
(78,79). 
Results 
Comparison ofUS17 and Basal Diets 
Table 10 summarizes the data on body composition and plasma metabolites in 
animals consuming either the US 17 or Basal diet for 4 weeks. Total food and energy 
intake were similar between diets. There were no significant differences in body weight 
or fat pad mass between diets, although animals consuming the basal diet tended to be 
heavier and have larger fat pads. Non-fasting plasma glucose and insulin levels were 
similar between diets. Based on these findings and our previous success using the Basal 
diet to induce obesity in this animal model, the composition of all experimental diets was 







Comparison of the Effects of 4 Weeks Ad Libitum Consumption of US17 Diet and Basal Diets 
in aP274-.AgoutiTransgenic Mice 
A. Effects of Diet on Body Composition 
Body Weight (g) Selected Fat Pads (g) 
Final Gain Liver (g) Epididymal Abdominal Subscapular 
31 .28 ± 1.20· 6.34 ± 0.89 8 1.69 ± 0.053 a .073 ± 0.009 a .83 ± 0.10 • .76 ± 0.11 • 
31.18 ± 0.74 • 5.60 ± 0.71
8 
1.80 ± 0.1 1  • .090 ± 0.007 
8 
.74 ± 0.05 • .60 ± 0.06
8 
Sum of3 Fat 
Pads (g) 
1.67 ± 0.22• 
1.44 ± 0.12•  
Values are Mean±SEM; Matching superscripts indicate statistically eguivalent values. 
B. Effects of Diet on Energy Intake, Energy Efficiency, and Plasma Metabolites 
Diet Consumption Energy Non-Fastitl2' Plasma Metabolites 
Food Intake (g) Energy Intake (kcal) Efficiency Ratio• Glucose (mg/ dL) Insulin (ng/ml) 
Basal 141.90 ± 12.81 8 744.96 ± 67.24 8 .87 ± 0.12 • 238.03 ± 8.50 8 4.62 ± .42 • 
US17 141.27 ± 13.87 8 820.33 ± 80.45 • .77 ± 0.11  • 234.36 ± 15.89 a 4.32 ± .61 • 
Values are Mean ±SEM; Energy Efficiency ratio: (total energy intake/grams body weight gained)*lOO; Matching superscripts indicate statistically equivalent values. 
Meal Tolerance Tests 
Figure 4 summarizes the data regarding the blood glucose response to test foods. The 
response (AUCg1ua,oc} to MUNG was significantly lower (p<0.05) than all other foods. 
Somewhat unexpectedly, we found the response to 10-S to be approximately 23% 









10-S 10-F ROLL MUNG 
Figure 4. Area under the blood glucose response curve for test foods in aP274-.Ago11ti 
transgenic mice. Data is expressed as mean±SEM. Non-similar superscripts indicate 
gjgnificant differences at p<0.05. 
338 
Weight Gain 
The patterns of body weight change by week for ad libit11m fed and energy restricted 
animals are illustrated in Figures 5 and 6, respectively. While all diets increased body 
weight when fed ad /ibit11m for six weeks, weight gain (Figure 7 A) was 50-66% lower 
(p<0.05) in the ROIL group compared to all others. Consequently, final body weight 
was significantly lower (by 8-13%, p<0.05; Figure 7B) in the ROIL group compared 
with all other groups. 
Prior to being assigned to treatment groups for the energy restricted phase of the 
study, animals were fed the obesity-promoting basal diet ad libit11m for 6 weeks. During 
this period body weight increased from 25.43±3.92 g to 34.59±4.42 g (p<0.05 vs. 
baseline body weight), with mean weight gain of 9.15±0.48 g. Following this period, 
animals were separated into treatment groups (n=8 per treatment group) by body weight, 
such that there were no significant differences in body weight by group before beginning 
the energy restricted phase. 
As illustrated in Figure 6, body weight stabilized in animals continued on the basal 
diet ad libit11m during weeks 6-12, resulting in final body weight following 12 weeks of ad 
libitum feeding of 36.37±1 .32 g. Body weight of animals following 12 weeks of ad libit11m 
of animals following 12 weeks of ad libitum consumption of the basal diet was only 8% 
higher than for animals fed the same diet ad libit11m for 6 weeks; nonetheless, 
representative fat pad mass was 35% greater in animals fed the basal diet ad libit11m for 12  
weeks compared to animals consuming the same diet for only 6 weeks. Thus, adipose 








Baseline Week l Week 2 Week 3 Week 4 Week 5 Week 6 
Figure 5. Pattern of change in body weight over 6 weeks by dietary treatment in ad 
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Figure 6. Pattern of change in body weight by dietary treatment during weeks 6-12 in 
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Basal IO-S IO-F ROLL MUNG 
Figure 7. Effect of dietary treatment on (A) weight gam and (B) final body weight in ad 
libit11m fed aP274-Ago11ti transgenic mice. Data is expressed as mean±SEM for each 
group. Non-similar superscripts indicate significant differences at p < 0.05. 
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During the final six weeks of the study, energy restriction, irrespective of diet, 
reduced body weight by -21-28% compared with animals continued on the basal diet ad 
libitum (p<0.05; Figure SA). Despite equivalent energy restriction, final body weight in 
the Basal-R group was 17% higher (p<0.05) than in ROIL-fed animals (Figure SB). 
Liver Weight 
Following 6 weeks of ad libitum intake, the livers of animals consuming the basal and 
10-S diets were -12% heavier (p<0.05) than in animals consuming the ROIL and 
MUNG diets. Liver weight of IO-F animals differed only from the ROIL group 
(p<0.05) . 
Regardless of diet, energy restriction during weeks 6-12 reduced liver weight 
compared with unrestricted consumption o! the basal diet for 12 weeks (p<0.05). Liver 
mass of animals consuming the energy restricted ROIL and MUNG diets was 
significantly lower (p<0.05) than in Basal-R 
Adiposi!J 
Changes in body weight are reflected in adipose tissue mass. The subscapular and 
epididymal fat depots were chosen to assess the effects of diet on subcutaneous adipose 
tissue accumulation. Diets were largely without influence on epididymal fat pad mass, 
regardless of energy intake; therefore, differences in subcutaneous adipose tissue mass 
are largely accounted for by the subscapular depot. 
When energy intake was unrestricted for 6 weeks, subcutaneous fat pad mass was 38-





























Basal Basal-R 10-S IO-F ROLL MUNG 
ad lib 
Energy Restricted 
Figure 8. Effect of dietary treatment on (A) weight gain and (B) final body weight in 
energy restricted aP274-Ago11ti transgenic mice. Data is expressed as mean ± SEM for 
each group. Non-similar superscripts indicate significant differences at p<0.05. 
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ad libit11m (Figure 9A). 
Regardless of diet, energy restriction during weeks 6-12 reduced adiposity relative to 
animals consuming the basal diet ad libit11m. Subscapular fat pad mass was significantly 
higher (by 85..,98%, p<0.05) in the Basal-R and 10-S groups compared with the ROLL 
group at the identical level of energy restriction. Consequently, subcutaneous fat pad 
mass was significantly reduced in the ROLL (by 43%, p<0.05) compared with the Basal­
R and 10-S groups, which suggests that subcutaneous adipose tissue deposition is 
sensitive to both quantitative (e.g. energy) and qualitative (e.g. carbohydrate) changes in 
diet. 
Despite the fact that only negligible increases in body weight were observed in 
animals continued on the Basal diet ad Jibit11m during weeks 6-12, subcutaneous adipose 
tissue deposition appears to have continued; consequently, the combined mass of 
selected subcutaneous fat pads was -39% higher (p<0.05; Figure 9B) in animals 
consuming the basal diet for 12 weeks compared with animals consuming the same diet 
for only 6 weeks. 
Despite identical levels of energy restriction, subcutaneous adipose tissue mass was 
43% lower (p<0.05) in animals consuming the ROLL compared with basal and 10-S 
diets during the final 6 weeks of the study (Figure 9B). This suggests the ROIL diet 
reduces subcutaneous adipose tissue deposition independently of energy intake. · 
The ret:roperitoneal and perirenal fat depots were chosen to represent visceral adipose 
tissue. Retroperitoneal fat mass was 39-43% lower (p<0.05) in the ROLL group 
compared with all other diets consumed ad libit1111J. Similarly, perirenal fat pad mass was 























Basal Basal-R IO-S IO-F ROLL MUNG 
ad lib 
Energy Restricted 
Figure 9. Effect of dietary treatment on subcutaneous (subscapular & epididymal) fat 
pad mass in (A) ad libit11m fed and (B) energy restricted aP274-Ago11ti transgenic mice. 
Data is �xpressed as mean ± SEM for each group. Non-similar superscripts indicate 
significant differences at p<0.05. 
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compared with all others. Collectively, these visceral depots were 32-41 % lower 
(p<0.05) following 6 weeks of unrestricted consumption of the ROLL diet compared 
with all others (Figure 10A). Furthermore, twelve weeks of unrestricted consumption of 
the basal diet resulted in a 33% increase in visceral fat pad mass relative to animals 
consuming the same diet for only 6 weeks. 
Compared with ad libitum intake of the basal diet during weeks 6-12, energy restriction 
reduced the mass of the retroperitoneal (by 43-75%, p<0.05) and perirenal (by 43-80%, 
p<0.05) fat pads. Despite identical energy restriction, retroperitoneal fat pad mass was 
significantly lower (by 43-57%, p<0.05) in ROLL and MUNG compared with the HFS 
and 10-S groups. Similarly, the mass of the perirenal depot was significantly lower (by 
60-65%, p<0.05) in ROLL and MUNG compared with 10-S and basal at the same level 
of energy intake. Thus, visceral adipose tissue accumulation was significantly reduced in 
animals consuming the ROLL (by 59-86%, p<0.05) and MUNG (48-60%, p<0.05) 
compared with the basal-R and 10-S despite identical energy intake (Figure 10B). 
As depicted in Figure 1 1A, the combined mass of the four selected fat pads was 34-
45% lower in the ad libitum fed ROLL (p<0.05) group compared with all other diets. 
Consequently, these fat depots made a smaller contribution to overall body weight in the 
ROLL (p<0.05) animals compared with basal, 10-S, 10-F, and MUNG. 
Ad libitum consumption of the basal diet for 12 weeks further increased combined 
visceral and subcutaneous fat pad mass by -35% relative to the mass of these depots in 
animals consuming the same diet for only 6 weeks. Eqergy restriction reduced the 
individual mass of these fat pads by 44-73% (p<0.05) compared with animals continued 























Basal Basal-R 10-S 10-F ROU. MUNG 
ad lib 
Energy Restricted 
Figure 10. Effect of dietary treatment on visceral fat pad (retroperitoneal & perirenal) 
mass in (A) ad libit11m fed and (B) energy restricted aP274-Ago11ti transgenic mice. Data is 
expressed as mean ± SEM for each group. Non-similar superscripts indicate significant 




















Basal Basal-R 10-S 10-F ROLL MUNG 
ad lib 
Energy Restticted 
Figure 11.  Effect of dietary treatment on combined mass of representative fat pads 
( epididymal, subscapular, retroperitoneal, perirenal) in (A) ad libitum fed and (B) energy 
restricted aP274-Agouti transgenic mice. Data is expressed as mean ± SEM for each 
group. Non-similar superscripts indicate significant differences at p<0.05. 
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changes in individual depots, combined fat pad mass was significantly lower (p<0.05) in 
ROLL and MUNG fed animals compared with animals fed the basal-R and IO-S, 
despite identical levels of energy intake. As a result of these changes, the combined mass 
of th�se depots accounted for -12% of overall body weight in animals fed the basal diet 
ad libit11m for 12  weeks (p<0.05 vs. all energy restricted diets). However, despite identical 
energy restriction, these fat pads made a significantly greater (p<0.05) contribution to 
total body weight in basal-R and IO-S than in ROLL and MUNG fed animals. 
Fasting Plasma Leptin Levels 
Plasma leptin levels were 29-33% lower (p<0.05) in animals fed the ROLL diet ad 
libit11111 for 6 weeks compared with all other groups, which is consistent the observed 
differences in fat pad mass (Figure 12A). Furthermore, fasting plasma leptin levels in 
animals fed the basal diet ad libitlHII for 12 weeks were 90% higher (p<0.05) than leptin 
levels fed the basal ·diet for only 6 weeks. This supports the hypothesis that leptin levels 
are reflective of changes in fat mass, since body weight did not increase appreciably in 
animals continued on the basal diet during weeks 6-12. 
Plasma leptin levels were 29-61 % lower (p<0.05) in all energy restricted groups 
compared with animals continued on the basal diet ad libit11m during weeks 6-12  (Figure 
12B). As can be seen in Figure 12B, the MUNG diet appeared to exert the greatest 
influence, independent of energy restriction, leading to fasting leptin levels that were 
significantly lower (by 40-45%, p<0.05) than both basal-R and IO-S. Plasma leptin 
levels were strongly correlated with final body weight (r=0.632, p<0.01), and mass of 
individual fat pads (r=0.692-0.744, p<0.001). 
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Figure 12. Effect of dietary treatment on fasting plasma leptin levels in (A) ad libit11m fed 
and (B) energy restricted aP274-.,4go11ti transgenic mice. Data is expressed as 
mean±SEM for each group. Non-similar superscripts indicate significant differences at 
p<0.05. 
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Fasting Plasma Ins11/in Levels 
Fasting plasma insulin levels were significantly lower in animals consuming the 10-S, 
ROIL, and MUNG diets relative to the basal (p<0.05) and 10-F (p<0.05) diets 
consumed ad libitum for six weeks (Figure 13A). 
Plasma insulin levels were significantly higher in animals consuming the basal diet, 
either ad libitum for 12 weeks or with energy restriction during weeks 6-12 (Figure 13B), 
compared to the energy restricted 10-S, 10-F, ROIL, and MUNG diets. Fasting plasma 
insulin levels were positively correlated with final body weight (r=0.41 1, p<0.01) in all 
animals. 
Fasting Blood Glucose Levels 
In animals fed ad libitum, non-fasting blood glucose levels were significantly greater 
(by 7-25%, p<0.05; Figure 14A) in ROLl.rfed animals compared with all other groups. 
As illustrated in Figure 14B, fasting blood glucose levels in animals consuming the 
energy restricted ROIL and MUNG were significantly lower (p<0.05 for both) than 
animals consuming the basal diet either ad libitum or with energy restriction. 
Plasma Triglyceride Levels 
Figure 15A summarizes non-fasting plasma triglyceride levels in ad libitum fed mice. 
The energy restricted ROIL and MUNG diets lowered fasting plasma triglyceride levels 
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Figure 13. Effect of dietary treatment on fasting plasma insulin levels in (A) ad libitum 
fed and (B) energy restricted aP274-Agollli transgenic mice. Data is expressed as mean 
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Figure 14. Effect of dietary treatment on plasma glucose levels in (A) non-fasted ad 
libit11m and (B) fasted, energy restricted aP274-Agp11ti transgenic mice. Data is expressed 





























Basal Basal-R 10-S 10-F ROLL MUNG 
ad lib 
Energy Restricted 
Figure 1 5. Effect of dietary treatment on plasma triglyceride levels in (A) non-fasted ad 
libit11m fed and (B) fasted, energy restricted aP274-Ago11ti transgenic mice. Data is 
expressed as mean±SEM for each group. Non-similar superscripts indicate significant 
differences at p<0.05. 
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Adiporyte Si� 
Adipocyte size was determined in animals undergoing the 12 week feeding protocol 
(Figure 16). Adipocytes were of similar size in animals consuming the basal diet ad 
Jibiltlm or with energy restriction, with both being significantly larger (by 20-42%, p<0.05 
for both) than adipocytes from ROLL- and MUNG-fed animals. Animals continued on 
the basal diet ad libitllfll for the final 6 weeks of the study were significantly larger 
(p<0.05) than those isolated from the energy restricted 10-S, 10-F groups. 
Retroperitoneal adipocyte size was strongly correlated with the mass of this fat pad 
(r=0.833, p<0.001 ). Adipocyte size was also correlated with fasting plasma levels of 
leptin (r=0.537, p<0.01), glucose (r=0.384, p<0.01) and :insulin (r=0.306, p<0.05). 











Basal Basal-R IO-S 10-F ROLL MUNG 
ad lib 
Energy Restricted 
Figure 16. Effect of dietary treatment on retroperitoneal adipocyte size in energy 
restricted aP274-Ago11ti transgenic mice. Data is expressed as mean ± SEM for each 
group. Non-similar superscripts :indicate significant differences at p<0.05. 
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Adiporyte Iipo!ysis 
In animals fed ad libit11111 for 6 weeks, diet had no effect on basal lipolysis as assessed 
by glycerol release (Figure 17A). While isoproterenol significantly increased glycerol 
release above basal in all groups, glycerol release in response to isoproterenol was 
significantly greater (p<0.05) in ad libit11111 fed animals consuming the ROLL and MUNG 
compared to the basal and 10-S (Figure 17B). Isoproterenol-stimulated glycerol release 
(expressed as % of basal) was significantly greater in 10-F, ROLL and MUNG (p<0.05 
for all) compared with the basal and 10-S groups ad libit11111 fed animals. 
Basal glycerol release was similar in animals consuming the basal diet ad libit11111, 
regardless of duration of feeding. In addition, basal glycerol release was similar in 
animals consuming the basal diet ad libit11111 for 12 weeks and in those consuming the 
energy restricted basal diet during weeks 6-12 (Figure 18A). Basal glycerol release was 
significantly greater in animals consuming the basal diet either ad libit11111 (by 78-92%, 
p<0.05) or with energy restriction (by 45-56%, p<0.05) compared with the energy 
restricted 10-S, 10-F, ROLL, and MUNG diets. 
Isoproterenol failed to increase glycerol release (expressed as percent stimulation 
above basal) to an appreciable degree in animals consuming the basal diet ad libit11111 for 
12 weeks (Figure 18B). In contrast, isoprotetenol increased lipolysis (expressed as 
percent stimulation above basal) by 35-107% (p<0.05) in all energy restricted groups, 
with the largest increase observed in adipocytes isolated from 10-F and MUNG. 
In all animals, body weight was positively associated with both basal (r=0.645, 
p<0.001) and isoproterenol-stimulated lipolysis (r=0.509, p<0.01). Regardless of energy 
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Basal 10-S 10-F ROLL MUNG 
Figure 17. Effect of dietary treatment on (A) basal and (B) isoproterenol-stimulated 
lipolysis in ad libitum fed aP274-Agouti transgenic mice. Data is expressed as mean±SEM. 
A: There were no similar differences between groups. B: Non-similar superscripts 








































Figure 18. Effect of dietary treatment on (A) basal and (B) isoproterenol-st:imulated 
lipolysis in energy restricted aP274-.Ago11ti transgenic mice. Data is expressed as mean± 
SEM. Non-similar superscripts indicate significant differences at p<0.05. 
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and isoproterenol-stimulated lipolysis (r=0.421, p<0.01). In addition, fasting plasma 
leptin levels were positively associated with basal (r=0.508, p<0.01), but not 
isoproterenol-stimulated lipolysis. Basal lipolysis was positively correlated with adipocyte 
size (r = 0.702, p < 0.01) and was 68% higher (p<0.05) in animals fed the basal diet in 
either form compared with the remaining energy restricted groups. 
Gene Expression 
Uver 
In animals fed ad libit11111 for 6 weeks, expression of fatty acid synthase in the liver was 
43-62% lower (p<0.05) in animals consuming the ROIL and MUNG diets compared 
with the basal, 10-S, and 10-F groups (Figure 19A). Hepatic PPAR-a expression was 
approximately 42% lower (p<0.05) in ROIL-fed animals compared with those 
consuming the basal diet following six weeks of unrestricted energy intake (Figure 19B). 
Energy restriction reduced the expression of fatty acid synthase (Figure 20A) and 
PPAR-cx (Figure 20B) in the liver by -52 and 41% (p<0.05 for both), respectively, 
compared with animals continued on the basal diet ad libit11111. In energy restricted 
animals, expression of PP AR-cx was reduced (by 28%, p<0.05) in animals consuming the 
10-S, 10-F, and ROIL compared with the basal-R and MUNG, suggesting an 
independent influence of endogenous dietary fiber in suppression of PP AR-ex expression. 
In animals fed ad libit11111 for 6 weeks, there was a positive relationship between the 
expression of PPAR-cx and FAS (r=0.407, p< 0.05) in the liver. Plasma leptin levels were 
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Figure 19. Effect of dietary treatment on hepatic expression of (A) fatty acid synthase 
and (B) PPAR-<X in ad Jibit11m fed aP27 4-Agouti transgenic mice. Non-similar superscripts 
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Figure 20. Effect of dietary treatment on hepatic expression of (A) fatty acid synthase 
and (B) PP AR-ci in energy restricted aP27 4-Ago11ti transgenic mice. Data is expressed as 
mean±SEM. Non-similar superscripts indicate significant differences at p<0.05. 
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Expression of FAS and PP AR-oc in the liver were negatively correlated with grams of 
body weight lost during the period of energy restriction (r=-0.445 and -0.499, 
respectively, p<0.01 for both). During the 12 week study, hepatic FAS expression was 
positively correlated with fasting plasma glucose levels (r=0.558, p<0.001) and final body 
weight (r=0.346, p<0.05). 
Retroperitoneal Adipose Tis111e 
The expression of lipid-related genes in the rettoperitoneal fat depot was examined 
following ad libit11m energy intake for 6 weeks. Expression of fatty acid synthase in the 
rettoperitoneal fat pad was greater in basal animals (p<0.05) compared with all other 
groups. Furthermore, FAS expression in this depot was 50% lower (p<0.05) in animals 
consuming either the ROIL or MUNG diets compared with 10-S and 10-F (Figure 
21A). In all animals, the increase in body weight occurring in response to unrestricted 
energy intake for six weeks was positively associated rettoperitoneal FAS expression 
(r;::0.372, p<0.05). A positive relationship was observed between FAS expression and 
PPAR-oc (r=0.590, p < 0.05), UCP-2 (r=0.503, p<0.05), and PPAR-y (r=0.567, p<0.001) 
expression in rettoperitoneal adipose tissue. Retroperitoneal FAS expression was also 
positively correlated with FAS expression in the liver (r=0.440, p<0.05) . 
Expression of PP AR-a was enhanced by consumption of the basal diet (p<0.05 vs. all 
other groups), but there was no significant differences in PPAR-oc expression between 
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Basal IO-S 10-F ROLL MUNG 
Figure 21. Effect of dietary treatment on expression of lipid related genes in 
retroperitoneal adipose tissue of ad libit11111 fed aP274-Ago11ti transgenic mice. Data is 
expressed as mean ± SEM for each group. A: Fatty acid synthase, Non-similar 
superscripts indicate significant differences at p<0.05. B: PPAR-cx, Non-similar 
superscripts indicate significant differences at p<0.05. 
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UCP-2 expression was reduced by roughly 60% (p<0.05) in ROLL compared to 10-S 
and 10-F fed animals. Expression of UCP-2 in animals consuming the MUNG diet 
differed only from the level of expression in HFS animals. Retroperitoneal UCP-2 
expression was negatively associated with fasting glucose levels (r=-0.407, p<0.05), 
which is consistent with the role of this gene in lipid metabolism. 
Expression of PP AR-y was markedly increased (100-500%) in animals consuming the 
basal diet (p<0.05) compared with all other groups (Figure 22B). Furthermore, PPAR-y 
expression was reduced by 61 % in animals consuming the ROLL diet (p<0.05) 
compared with both the 10-S and 10-F groups. In MUNG animals, induction of 
PP AR-y expression was intermediate between ROLL and the instant oatmeal diets. 
Consistent with role of PPAR-y in the induction of adipogenesis, a positive association 
was observed between PPAR-y and FAS expression (r=0.567, p<0.01), fasting insulin 
levels (r=0.315, p<0.05) and weight gain (r=0.321, p<0.05) in this depot. 
S11bscqJ»1lar Adipose Tissue 
In ad libit11m fed animals, expression of FAS in this depot was lower (p<0.05) in 
animals consuming the 10-F diet compared with those in the basal and ROLL groups 
(Figure 23A). Energy restriction increased expression of fatty acid synthase in 
subscapular adipose tissue by nearly 200% compared with ad libitum intake of the basal 
diet (p<0.05) (Figure 23B). Expression of FAS in this depot was negatively associated 
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Basal IO-S 10-F ROLL MUNG 
Figure 22. Effect of dietary treatment on expression of lipid related genes in 
retroperitoneal adipose tissue of ad libitum fed aP274-.Agouti transgenic mice. Data is 
expressed as mean ± SEM for each group. A: UCP-2, Non-similar superscripts indicate 
significant differences at p<0.05. B: PPAR-y, Non-similar superscripts indicate 


























Basal Basal-R IO-S 10-F ROLL MUNG 
ad lib 
Energy Restricted 
Figure 23. Effect of dietary treatment on subscapular adipose tissue FAS expression in 
(A) ad libitum fed and (B) energy restricted aP274-Agouti transgenic mice. Data is 
expressed as mean ± SEM for each group. Non-similar superscripts indicate significant 
differences at p<0.05. 
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In the absence of energy restriction, expression of PPAR-« in subscapular adipose 
tissue was reduced by 70% (p<0.05) in animals consuming 10-S and 10-F compared 
with basal, ROLL and MUNG (Figure 24A). 
There was a trend for higher levels of PPAR-« in energy restricted ROLL and 
MUNG aoima1s, but these did not reach significance (Figure 24B). Nonetheless, fasting 
insulin levels were significantly corre1ated with expression of PPAR-<X (r=0.631, 
p<0.001) in this depot. While there were no differences in the level ofUCP-2 
expression between groups in ad libit11m fed or energy restricted anima1s, a positive 
re1ationship was noted between the level of UCP-2 and PP AR-« expression in 
subscapular fat (r=0.595, p<0.001). 
When consumed ad libitllHI, these diets failed to significantly influence the level of 
PPAR-y expression in subscapular fat (Figure 25A). Somewhat unexpectedly, a negative 
association was observed between subscapular fat pad mass and FAS expression (r=-
0.348, p<0.05) in ad libitllHI fed animals. Similarly, final body weight of ad libitllHI fed 
anima1s was inversely associated with the level of subscapular FAS (r=-0.377, p<0.05) 
expression. 
Expression of PPAR-y was nearly two-fold higher in energy restricted ROLL 
compared with MUNG (p<0.05) fed animals (Figure 25B), suggesting that consumption 
of the ROLL diet is associated with the emergence of smaller adipocytes in this region. 
There was a positive association between subscapular FAS and PP AR-y expression 
































Basal Basal-R 10-S 10-F ROLL MUNG 
ad lib 
Energy Restricted 
Figure 24. Effect of dietary treatment on subscapular adipose tissue PP AR-a expression 
in (A) ad libit11111 fed and (B) energy restricted aP274-.Ago11ti transgenic mice. Data is 
expressed as mean ± SEM for each group. A: Non-similar superscripts indicate 
significant differences at p<0.05. B: Matching superscripts indicate no significant 
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Basal Basal-R IO-S 10-F ROLL MUNG 
ad lib 
Energy Restricted 
Figure 25. Effect of dietary treatment on subscapular adipose tissue PP AR-y expression 
in (A) ad libit11m fed and (B) energy restricted aP274-.AgoNti transgenic mice. Data is 




Diet had no effect on expression of PP AR-ex or UCP-3 in gasttocnemius (Figures 
26A and 26B) or soleus (Figures 27A and 27B) muscle of ad libit11m fed animals. A 
significant negative association was observed between gastrocnemius PP AR-ex expression 
and fasting plasma insulin levels (r=-0.322, p<0.05) in all animals. This is consistent 
with studies demonstrating an .induction of gastrocnemius PP AR-ex expression by 
conditions which promote enhanced lipid utilization in association with reduced 
circulating insulin levels. Subcutaneous fat pad mass was inversely correlated with the 
level of PP AR-ex (r=-0.412, p<0.05) and UCP-3 (r = -0.61 6, p<0.05) in gastrocnemius 
muscle, which suggests that enhanced lipid oxidation in skeletal muscle redirects 
available lipids away from storage in adipose tissue in favor of oxidation in skeletal 
muscle . 
In energy restricted animals, expression of PPAR-cx in gastrocnemius muscle was 2-3-
fold (p<0.05) higher in basal-R, IO-S, ROIL and MUNG-fed animals compared with 
the basal ad libit11m group (Figure 28A). Energy restriction resulted in a 98% increase 
(p<0.05) in UCP-3 expression in gastrocnemius muscle (Figure 28B). Furthermore, 
expression was significantly greater in MUNG and IO-F compared with basal-R animals. 
Expression of PP AR-ex in gastrocnemius muscle was negatively correlated with final 
body weight (r=-0.489, p<0.05) and the combined mass of selected fat pads (r=-0.441, 
p<0.05). Likewise, PPAR-a expression was negatively correlated with plasma leptin 
levels (r=-0.51 6, p<0.05). Consistent with this, a positive association between 
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Figure 26. Effect of dietary treatment on expression of (A) PP AR-a and (B) UCP-3 in 
gastrocnemius muscle of ad libit11111 fed aP274-.,1gouti transgenic mice. Data is expressed 
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Basal 10-S 10-F ROLL MUNG 
Figure 27. Effect of dietary treatment on expression of (A) PPAR-cx and (B) UCP-3 in 
soleus muscle of ad libitum fed aP274-Agouti transgenic mice. Data is expressed as 
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Figure 28. Effect of dietary treatment on expression of (A) PPAR-cx and (B) UCP-3 in 
gastrocnemius muscle of energy restricted aP27 4-Ago11ti transgenic mice. Data is 































Basal Basal-R 10-S 10-F ROLL MUNG 
ad lib 
Energy Restricted 
Figure 29. Effect of dietary treatment on expression of (A) PPAR-(X and (B) UCP-3 in 
soleus muscle of energy restricted aP274-Agouti transgenic mice. Data is expressed as 
mean±SEM. Non-similar superscripts indicate significant differences at p<0.05. 
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Expression of UCP-3 in gastrocnemius muscle was inversely associated with final 
body weight (r=-0.537, p<0.05), combined mass of selected fat pads (r=-0.683, p<0.05), 
and fasting leptin levels (r=-0.555, p<0.05). Furthennore, UCP-3 expression in this 
tissue was negatively correlated with liver FAS (r=-0.509, p<0.05), while a positive 
relationship was noted with liver PPAR-a (r=0.359, p<0.05) and intrascapular FAS 
(r=0.406, p<0.05) expression. 
Discussion 
In these studies, we demonstrate that a qualitative change in diet composition, 
specifically carbohydrate source, influences weight gain, adiposity and gene expression in 
animals fed energy restricted diets. To our knowledge this is the first study to evaluate 
the effects of commonly consumed carbohydrate-containing foods on the development 
of obesity in this model of diet-induced obesity (53,57,80). Our data demonstrates that 
adipose tissue deposition is reduced in animals fed a diet containing carbohydrates which 
elicit lower blood glucose response compared with sucrose-rich diets of identical 
macronutrient composition. The pattern of gene expression in liver, adipose tissue and 
skeletal muscle suggests that within a mixed diet, carbohydrate containing foods which 
result in lower blood glucose responses, may alter the pattern of substrate utilization and 
establish an environment which enhances lipid oxidation in skeletal muscle, limiting lipid 
flux to adipose tissue. 
In fasting aP274-a!f)ll'li transgenic mice the blooq glucose response to muog bean 
noodles was significantly lower than the response to rolled oats or instant oatmeal The 
lower blood glucose response to muog bean noodles is attributable to the 
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physiochemical structure of mung bean starch (81,82). Mung bean starch is reportedly 
the best raw material for preparation of starch noodles as a result of its amylose content 
(83,84). Straight chain amylose represents 40-47% of total starch in mung beans 
(81,82,85), which is considerably more than the other legumes (86) and most cereal 
starches (87). Furthermore, mung bean starch granules are smaller and more densely 
packed than starch granules of other legumes, which makes them more resistant to 
swelling and digestion by <X-amylase (81,88,89). In normal and diabetic rats, Kabir, et al. 
(90) have determined the glycemic .index of mung bean starch is 67, relative to white 
bread. Furthermore, rats consuming mung bean starch (32% amylose) had lower blood 
glucose and insulin responses (p<0.05) compared to rats consuming waxy cornstarch 
(5% amylose) (90,91). This is consistent with the greater susceptibility ofhigh­
amylopecti.n starch to hydrolysis by <X-amylase in vitro (92). 
Oats are rich in soluble fiber and readily available in a number of highly palatable 
varieties, including rolled oats, instant oatmeal, and oat bran (93,94). Studies consistently 
report that diets rich in soluble fiber improve postprandial blood glucose, insulin, and 
lipid levels in lean and obese subjects (95-98). The component of oat bran presumed 
responsible for the benefits of diets rich in soluble fiber is the linear polysaccharide, �­
glucan (93). Viscous fibers, like �-glucan, impede glucose absorption from the lumen of 
the small intestine and consequently, prolong absorption time (93,96,9). Wood, et al. 
(96) report that 79-96% of the variation in plasma glucose and insulin responses 
following a 50 g glucose load supplemented with various doses of �-glucan can be 
explained by the increase in the viscosity of the digesta in normal women. However, 
Tappy, et al. (95) have reported that the �-glucan content of normal rolled oats (4% by 
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weight) is insufficient to significantly reduce blood glucose and insulin responses in 
subjects with NIDDM. 
The differences in the blood glucose response to the 10-S and 10-F in aP274-agouti 
transgenic mice are somewhat puzzling. Like rolled oats, instant oatmeal is considered a 
whole grain food since the bran, endosperm and germ are retained during processing 
(100). The greater blood glucose response in 10-S compared with ROLL was not 
surprising; instant oats are thinner than rolled oats. The thinner particle size in the 
instant oatmeal increases the surface area over which digestive enzymes can act (101) and 
Jenkins, et al. (102) have demonstrated that the in vitro rate of digestion for grains 
increases as particle size decreases (101). Particle size similarly affects the postprandial 
response to other cereals and legumes (101,103). However, particle size cannot be the 
sole determinant of the in vivo response, since the AUCg1ucose for 10-S was significantly 
greater than 10-F. Although �-glucan influences viscosity, and the properties of �­
glucan are related to its water soluble nature (93), this would not have been exploited in 
our study using uncooked foods (104). Prior to adding the vitamin-mineral premix the 
nutrient composition of IO-S and 10-F should have been identical. Thus, we can only 
conclude that differences in the micronutrient composition of the premixes are 
responsible for the variations in the blood glucose response between the 10-S and 10-F 
foods. 
Careful examination of the nutrient composition of the vitamin-mineral premixes 
(Table 6) reveals some differences which may have influenced the blood glucose 
response. The most glaring discrepancy between the two formulations is the energy 
content. The formulation used for 10-S provides a significantly greater amount of 
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protein and fat (g per 100 g1, resulting in total energy content of the premix for 10-S 
that is 2-fold higher than the premix used for I 0-F. Although we would have expected 
differences in the formulation of the pre-mixes to have little, if any, impact on the in vivo 
response, this remains the only factor distinguishing the 10-S from 10-F. 
These studies suggest that the dietary carbohydrate composition of a mixed diet 
influences body weight and adiposity in aP274-a�llli transgenic mice. We demonstrate 
that a qualitative change in the dietary carbohydrate composition influences body weight, 
independently of energy intake. While the macronuttient energy distribution (as % kcal) 
was identical for all diets (14% protein, 62% carbohydrate, and 24% fat), the ROLL diet 
contained significantly more fiber than all other diets. Thus, it is likely that the lower 
body weight in the ROIL animals is related to the fiber content of the dietary 
carbohydrate. 
Body weight of animals fed the basal diet for 12 weeks was only modestly greater 
than ao1mals consuming the same diet ad libitum for 6 weeks. Nonetheless, mass of 
representative fat pads was 35% greater in animals fed the basal diet for 12 weeks 
compared to those animals fed the basal diet for only six weeks. Thus, adipose tissue 
accumulation continued during weeks 6-12 without a parallel increase in body weight. 
This represents an important physiological effect of prolonged consumption of a high­
fat, sucrose-rich diet, and suggests that such a diet influences adipocyte morphology and 
metabolism without detectable changes in body weight In an examination of the 
influence of diet composition on adipocyte morphology and metabolism, Soria, et al 
(105) document some important physiological consequences of prolonged consumption 
of a sucrose-rich diet in rats. Epididymal fat mass, adipocyte volume, adipocyte 
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triglyceride content, and adipocyte number were similar in rats fed a control or sucrose­
rich diet for three weeks. Furthermore, changes in body weight in the short term 
paralleled changes in adipose tissue mass. Following 1 5  weeks of consumption of the 
control diet, epididymal fat pad mass increased in parallel with body weight, associated 
with an increase in adipocyte volume and reduction in adipocyte number. However, in 
rats fed the sucrose-rich diet for 15 weeks, there was an acceleration of adipose tissue 
deposition in the epididymal depot and a notable dissociation of the changes in body 
weight and fat mass. Increased adiposity in rats fed the sucrose-rich diet for 1 5  weeks 
was the result of adipocyte hypertrophy, as adipocyte volume was 76% higher than in 
animals fed the control diet for 15 weeks. Adipocyte hyperplasia could not account for 
the increased adipose tissue deposition, as suggested by a reduction in adipocyte number 
to 61% of control fed animals. Although we analyzed cell size only in animals 
consuming the basal diet for 1 2  weeks, it is plausible to suggest that adipocyte 
hypertrophy was an important factor contributing to the increased adiposity, but similar 
body weight, in animals fed the basal diet for 12  versus 6 weeks. 
With energy restriction, we begin to see an independent influence of dietary 
carbohydrate source on adiposity. Subscapular fat pad mass was significantly higher in 
the energy restricted basal and 10-S groups compared with ROLL, which was similar to 
10-F and MUNG. However, mass of the retroperitoneal and perirenal depots was 
reduced in both the ROLL and MUNG groups compared with the basal and 10-S 
groups, despite identical energy restriction. Thus, consumption of the MUNG and 
ROLL diets reduced visceral adipose tissue accumulation. Furthermore, this effect can 
not be assigned solely to dietary fiber since the fiber content of the MUN G diet, which 
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was less than the ROLL diet, was similar to the basal and 10-S diets. It is possible that 
the absence of sucrose in the ROLL and MUNG diets are responsible for the differences 
in adipose tissue accumulation as compared with the basal and 10-S diets, both of which 
contained sucrose. 
Chicco, et al (106) compared the effects of partial or complete substitution of dietary 
starch for sucrose on body weight and glucose and lipid metabolism in rats. Animals 
consuming a 63% w/w sucrose-rich diet (63% SRO) were markedly insulin resistant 
after only 15 weeks compared with animals consuming the control diet (0% SRO) in 
which sucrose was completely replaced by starch for the same length of time. Animals 
consuming the 63% SRO were hyperglycemic in the fasting state, yet the insulin 
secretory response to an intravenous glucose bolus was preserved. After the initial 15 
weeks, animals consuming the 63% SRO were divided into three groups. A subset of 
these animals continued on the 63% SRO for an additional 1 5  weeks experienced a 
further deterioration in glucose tolerance, which was accompanied by a nonsignificant 
reduction in the amount of insulin secreted following an intravenous glucose bolus. A 
separate subset of the animals consuming the 63% SRO for 1 5  weeks were switched to a 
modification of the 63% SRO diet, in which 30% of sucrose was replaced with starch 
(33% SRO) for the final 15  weeks of the study. Although consumption of the 33% SRO 
during weeks 15-30 improved basal hyperglycemia, these animals remained glucose 
intolerant. However, there were no significant differences in body weight between 
groups. The final subset of animals were switched to the control (0% SRD) diet for 
weeks 1 5-30. The complete substitution of starch for sucrose reduced body weight, 
normalized basal glucose levels and improved glucose tolerance to levels comparable to 
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animals consw:ning the 0% SRD diet for the entire 30 week period. Neither fasting 
plasma insulin levels nor the insulin response to intravenous glucose were significantly 
affected by diet Thus, it seems that the partial substitution of starch for sucrose 
improves body weight and glucose tolerance without affecting plasma insulin levels 
(106). 
Based on the above studies, we suggest that in our studies, the favorable effects of 
the ROIL and MUNG diets on reducing adiposity compared with the basal and IO-S 
diets are due to the sucrose content of the latter. We also found lower fasting blood 
glucose levels in animals consw:ning the energy restricted ROIL and MUNG compared 
with basal and IO-S diets, despite comparable plasma insulin levels in all groups. 
However, in contrast to Chicco, et al. (106), our findings suggest that the partial 
substitution of starch for sucrose cannot fully explain these effects as demonstrated by 
the similarities between animals fed the energy restricted basal diet, which contains 
sucrose as the sole dietary carbohydrate, and IO-S, which contains both sucrose and 
starch. 
The composition of the basal diet was chosen to mimic the typical Western diet, 
which contains significant amounts of dietary fat and refined sugars, particularly sucrose 
(1 1,12). In addition, sucrose was added to both instant oatmeal diets to make them 
similar to these foods as they would be consumed in the diet. Conversely, sucrose was 
not added to either the ROIL or MUNG diet. Consequently, we may attribute some of 
the differences to the sucrose content of the diet. It is conceivable that sucrose 
containing diets provoke greater postprandial blood glucose and insulin responses, which 
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may over time lead to changes in adiposity, adipocyte morphology, as well as altering 
expression of genes involved in carbohydrate and lipid metabolism. 
An additional factor in the retroperitoneal depot is likely adipocyte diameter, which 
was greater in the basal diet regardless of energy intake, compared with all other diets. 
Again, the effect of diet on adipocyte diameter is only partially attributable to the 
endogenous dietary fiber content of the ROLL diet, since adipocytes isolated from 
ROLL and MUNG fed animals were of similar size. Thus, a qualitative change in the 
carbohydrate content of the diet influences adipocyte diameter and this effect is only 
partially explained by dietary fiber. 
Adipocyte size is likely influenced by the sucrose content of the diets (105,107). 
Adipocyte hypertrophy has been previously demonstrated in animals fed a high-fat, 
sucrose-rich diet for 2 months (107). In our present studies, the greater mass of the 
retroperitoneal adipose tissue depot in animals fed the basal diet ad libit11m for 12 weeks 
is at least partially attributable to adipocyte hypertrophy, as adipocytes in the basal ad 
libit11111 group were 75% larger than those from energy restricted animals consuming the 
same diet and 300% larger than animals consuming the energy restricted ROLL diet. 
This is consistent with Salans, et al. (108), who demonstrated that adipocyte hypertrophy 
devdops in rats fed ad libitum. The emergence of larger adipocytes is the result of 
increased lipid accumulation, as protein content is relatively constant over a range of size 
(107,108). Furthennore, Salans, et al. (108) found that insulin responsiveness was 
reduced as fat cells enlarged, which contributes to reduced insulin sensitivity of adipose 
tissue in sucrose-fed animals. 
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In the present studies, energy restriction, irrespective of dietary carbohydrate source, 
resulted in smaller adipocytes relative to the ad libitum fed ao1ma1s. Welght loss induced 
by energy restriction has been previously demonstrated to reduce adipocyte slze in 
humans and rodents (109,1 10).  Furthermore, Osttnan, et al (109) have 'demonstrated in 
normal rats that all parameters of lipid metabolism are lmproved in parallel with the 
reduction in adipocyte slze occurring with energy restriction. 
Adipocyte diameter appears to be influenced by diet composition since adipocytes 
from the energy restricted basal group were 77% and 130% larger than those from 
MUNG and ROLL, respectively, at the same level of energy restriction. This is a finding 
slmilar to that of Lerer-Metzger, et al (1 1 1), who reported a marked decrease in 
adipocyte slze in anlmals fed a diet containing mung bean compared with wheat starch. 
In vi(ro studies have shown that large adipocytes fail to increase glucose oxidation to 
CO2 to an appreciable degree when incubated with insulin and high concentrations of 
glucose (1 12). While insulin failed to stimulate the complete oxidation of glucose under 
these conditions, incorporation of Jabeled glucose into triacy]glycerols was stimulated to 
a larger extent in large compared with small adipocytes (1 12). Despite an apparent 
reduction in the capacity to metabolize glucose once inside the adipocyte, insulin 
treatment results in a dramatic increase in glucose transport and accumulation of free 
glucose in larger cells, which may further lmpalr the metabolic characteristics of enlarged 
adipocytes (1 10,1 12,1 13). Based on these findings and our data regarding the blood 
glucose response to the test diets, as well as the positive correlation between fasting 
plasma glucose and insulin levels, it is possible that consumption of the basal and 10-S 
384 
diets exposed these animals to higher plasma glucose and insulin levels, which resulted in 
metabolic abnormalities similar to those documented in the studies described (104-1 10). 
Differences in rettoperitoneal fat mass in our studies may be at least partially 
attributable to alterations in glucose and lipid metabolism in larger adipocytes (1 1 3,1 14).  
The stimulatory effects of insulin on glucose oxidation and lipid synthesis are blunted in 
large compared with small adipocytes (1 15-117). Thus, adipocyte size, and consequently, 
insulin sensitivity can be influenced by nutritional and hormonal cues, independent of 
energy consumption. Based on the blood glucose response to the test diets, and the 
positive correlation between adipocyte size and plasma glucose and insulin levels, the 
postprandial response to the experimental diets of varying carbohydrate source may have 
contributed to alterations in adipocyte size. 
Metabolic abnormalities observed in rats consuming (14 days to 12 months) a high 
sucrose (33-70 en%) diet include elevated insulin and triglyceride levels, increased 
expression and activity of hepatic lipogenic and glycolytic enzymes, and hepatic and 
skeletal muscle insulin resistance (107-112). In the present studies, glucose homeostasis 
was assessed by evaluating fasting plasma glucose and insulin levels. While fasting 
plasma glucose levels were significantly lower in animals consuming the MUNG and 
ROLL diets compared with the basal diet (ad libitum or with energy restriction), fasting 
plasma insulin levels did not differ by diet in the energy restricted groups. However, 
changes in insulin sensitivity versus insulin .responsiveness cannot be detennined based 
on fasting insulin levels, and a single fasting insulin measurement is unable to identify the 
specific tissues contributing to changes in insulin action (1 18, 119). Nonetheless, based 
on the glucose response to our test foods, it is not unreasonable to speculate that the 
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postprandial insulin response would have followed a similar pattern, and that the 
persistence of these changes would influence whole body glucose and lipid metabolism. 
Basal glycerol release (µmol glycerol/ µg protein) tended to be higher following 6 
wee.ks ad libit11m energy intake compared with consumption of the energy restricted diets. 
Since body weight was greater in animals fed ad libit11m for 6 wee.ks compared with the 
animals fed energy restricted diets for wee.ks 6-12, one can speculate that the greater 
lipolysis is the result of the influence of body weight on basal lipolysis. In humans, basal 
lipolysis is higher in obese compared with lean subjects and this is related to larger 
adipocytes in obese subjects (120,121). In ad libilllm fed animals, the stimulation of 
lipolysis above basal levels was greater in animals consuming the IO-F, ROLL, and 
MUNG diets compared with the basal and IO-S. Interestingly, the IO-F, ROLL, and 
MUNG diets resulted in lower postprandial blood glucose response compared with IO­
S, which suggests that the postprandial hormonal milieu may influence lipolysis in the 
long term. 'Ibis hypothesis is consistent with Berger, et al (107) who report that 
accelerated lipolyti.c rates occurring in animals made hyperinsulinemic by feeding a high.­
sucrose diet is apparent only after 2 months of diet consumption. Furthermore, we can 
speculate that long-term consumption of the high-fat, high-sucrose basal diet unpau:ed 
aclipocyte metabolism based on the inability of isoproterenol to stimulate glycerol release 
above the basal rate in adipose tissue isolated from animals consuming the basal diet ad 
libitum for 12 wee.ks. Unfortunately, we did not assess the antilipolyti.c actions of insulin 
on isoproterenol-stimulated lipolysis; consequently, we can not draw any conclusions 
regarding the insulin responsiveness of aclipose tissue metabolism with respect to diet. 
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Animals consuming the basal diet ad libitum for six weeks had higher insulin levels 
compared with IO-S, ROIL, and MUNG. Energy restriction tended to reduce fasting 
insulin levels compared with animals continued on the basal diet for 12  weeks. There 
were no significant differences in plasma insulin levels in energy restricted rats 
consuming the IO-S, IO-F, ROIL, and MUNG diets, which is consistent with other 
reports (90,91 ,1 1 1). However, the influence of glycemic index on fasting insulin levels is 
debatable. Byrnes, et al (20) have shown that feeding a high-amylopectin diet to rats for 
9 weeks results in significantly higher fasting plasma glucose and insulin levels compared 
with rats fed a high-amylase diet. The high-amylopectin diet resulted in a greater insulin 
response during an intravenous glucose tolerance test, which increased with the duration 
of feeding and eventually led to fasting hyperinsulinenna (20). In contrast, Pawlak, et al. 
(122) did not find a hyperinsulinemic response in rats fed a high- glycemic index starch 
diet, despite an elevated insulin response during intravenous glucose tolerance tests. 
Thus, we can not exclude the possibility that postprandial insulin responses to the diets 
influenced body composition. 
Depending on mouse strain and age, normal plasma leptin levels are in the range of 
1 -5 ng/ ml, with hypetleptinenna generally defined as fasting plasma leptin levels 
exceeding 20 ng/ml (123,124) .  Consistent with the role of plasma leptin m regulation of 
adiposity (125), strong correlations were noted between fasting plasma leptin levels and 
fat pad mass in all animals, regardless of energy intake in the present studies. 
Furthermore, plasma leptin levels exceeded 20 ng/ml in all groups following 6 weeks of 
ad libitum feeding, which is consistent with the induction of leptin resistance by 
overfeeding a high-fat diet (126). However, leptin levels were significantly lower in 
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animals fed the ROIL diet ad libitum compared to all other groups, which suggests that 
leptin levels are influenced by qualitative changes in diet. Furthermore, leptin levels 
continued to increase when aoima]s were continued on the basal diet for an additional 
six weeks. Thus, there was a physiological adaptation to the diet which appears to have 
blocked the normal response to increases in circulating leptin levels and may have 
contributed to the increase in adipose tissue mass. 
In ad libitum fed anima]s, the normal physiological response to elevated plasma leptin 
levels (reduced energy intake, increase energy expenditure, adipose tissue depletion) is 
absent (127). However, there is some restoration of leptin responsiveness when energy 
intake is restricted. Nonetheless, while ad libitum energy intake led to gjgnificant 
hyperleptinemia, plasma leptin levels were not completely normalized following six 
weeks of energy restriction. Still the differential response of plasma leptin levels to 
energy restricted diets, suggests leptin levels are also related to qualitative changes in diet 
composition. While fasting and refeeding are known to regulate plasma leptin and ob 
gene expression in obese and lean humans and rodents (128,129), little other information 
regarding the regulation of leptin levels by dietary composition. The variations in plasma 
leptin levels following six weeks of energy restriction in the present studies may be 
related to dietary carbohydrate since all diets contained identical amounts of fat and 
protein and suggests that dietary glycemic index may have influenced plasma leptin levels 
in energy restricted animals. Despite identical energy intake and carbohydrate content of 
the diet, plasma leptin levels were lowest in MUNG animals. This is consistent with 
Hermann, et al (130) who demonstrated that the normal diurnal peak in plasma leptin 
levels occurring at 22:00 hr can be altered by dietary carbohydrate. Feeding a high� 
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glycemic index carbohydrate resulted in an earlier rise in plasma leptin levels (at 13:00 hr) 
and lugher AUCiepcia levels at 12:30 and 24:00 hr. Furthermore, these changes occurred 
despite the fact that diet did not influence fasting plasma glucose or insulin levels (131). 
Our findings of reduced plasma leptin levels in aojma1s consuming energy restricted 
diets containing carbohydrates shown to result in lower blood glucose responses, 
specifically MUNG and ROIL, are somewhat at odds with those of Kabir, et al. (131), 
who have demonstrated that a hlgh-glycemic index starch diet decreased adipose tissue 
ob gene expression after 3 weeks and reduced serum leptin levels compared with a low­
glycemic index starch fed for 12 weeks to normal rats. Despite lower plasma leptin 
levels in aojmals fed the lugh-glycemic index starch diet, aojma1s did not increase their 
food intake, leading Kabir et al (131) to hypotheme that the hlgh glycemic index starch 
diet increased leptin sensitivity m advance of wcight gain and increased adiposity. Our 
findings appear more consistent with the associations between adiposity and plasma 
leptin levels (125). However, neither the present studies nor those of Kabir, et al (131) 
are inconsistent with the involvement of factors other than adipose tissue mass in 
regulation of plasma leptin levels. While Kabir, et al (131) found no association between 
plasma leptin levels and circulating levels of glucose or insulin, a positive association was 
found between plasma leptin and free fatty acid levels. Similarly, we found no 
association between plasma leptin and insulin levels, however, leptin levels were 
positively correlated with fasting plasma glucose concentrations. Thus, it appears that 
regulation of plasma leptin levels in the present studies are dependent upon a hormonal 
and dietary factors. 
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Fatty acid synthase (FAS) is expressed in both the liver and adipose tissue and is a key 
lipogenic enzyme catalyzing the synthesis of the long chain saturated fatty acid, palmitate 
(132). FAS is subject to regulation by both nutrients and hormones in hwnans and 
rodents (132-140). In rodents and murine cell lines, FAS expression is reduced by 
fasting (133,134), polyunsaturated fatty acids (135), and diabetes (136), whereas its 
expression is enhanced by high-carbohydrate feeding (137,138), glucose (139), insulin 
(140,141), and obesity (135,142,143). 
The present studies demonstrate that induction of FAS expression in the liver can be 
altered by dietary carbohydrate source per se. In the absence of energy restriction, FAS 
expression in the liver was significantly lower in animals consuming the MUNG and 
ROIL diets compared with those consuming the Basal, 10-S, and 10-F diets. It is 
important to note that each of these diets contains sucrose while neither the ROIL nor 
MUNG diets contain any added sucrose. Thus, the greater induction of FAS expression 
in the basal and instant oatmeal diets is consistent with more vigorous induction of FAS 
in the liver of animals fed diets containing simple sugars compared with complex 
carbohydrates (138). Furthermore, these findings suggest that when glucose is readily 
available, as in ad Jibitum fed animals, the rapidity with which carbohydrate digestion and 
absorption proceeds alters the expression of FAS. However, substrate availability is only 
one factor influencing FAS expression in ad libitum fed animals, since FAS expression 
was relatively low in the ROIL group despite higher plasma glucose levels. In addition, 
insulin levels were increased in the Basal and 10-F animals compared with 10-S, 
whereas FAS expression was similar in these groups, implying involvement of a 
hormonal or nutritional factor in addition to glucose and insulin in regulation of FAS 
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expression. Our findings in ad libi/11111 fed animals are somewhat at odds with those of 
Kabir, et al. (90,91), who demonstrated that the substitution of a high-amylopectin (high 
glycemic index) starch for a low-amylopectin (low glycemic index) starch in a mixed diet 
increased FAS activity and mRNA levels in adipose tissue, but not in the liver, of normal 
rats. However, when energy intake was restricted, our results are in consistent with 
those of Kabir, et al (90,91) as dietary carbohydrate source did not independently 
influence hepatic FAS expression. 
FAS expression was significantly higher in animals consuming the basal diet ad libit11m 
for 12 weeks compared with all energy restricted groups. This is consistent with studies 
documenting increased hepatic expression in obese animals and is consistent with the 
role of insulin in regulation of FAS expression (133-136). 
Energy restriction during weeks 6-12 reduced hepatic FAS expression relative to 
animals consuming the basal diet ad libit11111 for 12 weeks, an effect consistent with the 
downregulation of FAS expression during fasting and is presumably due to lower insulin 
levels in fasting and energy restricted animals (133,136,140). In energy restricted animals, 
substrate availability appears to dominate over type of dietary carbohydrate in the 
regulation of FAS expression in the liver. Consequently, FAS mRNA levels were lower 
in all energy restricted groups compared with animals consuming the basal diet ad libit11m 
for 12 weeks. This effect is consistent with the findings of Kabir, et al. (91 ), who 
demonstrated that dietary carbohydrate type did not influence the level of FAS 
expression in the liver of energy restricted animals. 
Thus, when glucose is readily available as in ad libit11m fed animals, expression of FAS 
in the liver is influenced by the rate of carbohydrate digestion and absorption. 
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Consequently, diets containing rapidly digestible sucrose result in higher levels of FAS 
mRNA, while diets containing more slowly digested carbohydrates are associated with 
lower FAS mRNA levels in the liver. 
In the liver, PP AR-ex levels wer.e significantly greater in animals fed the basal diet ad 
libit11m for 12 weeks compared with all energy restricted groups. While high-fat feeding 
and energy restriction represent opposing physiological conditions, both are 
characterized by greater fatty acid availability (145). Hepatic PPAR-ex expression was 
increased with energy restriction relative to the level of expression observed in ad libitum 
fed animals consuming the same diet This is consistent with the role of PPAR-cx in 
mediating the response to fasting (146). Fasted PPAR-ex deficient mice suffer from 
severe impairments in hepatic oxidation, resulting in hypoglycemia, hypothermia, 
hypoketonemia, elevated plasma free fatty acids, and fatty liver (146). The phenotype of 
PP AR-ex null mice is due to the inability of elevated free fatty acids in the fasting state to 
stimulate the transcription of PP AR-cx target genes in the liver, including genes involved 
in fatty acid transport and fatty acid oxidation (146). In animals consuming the basal diet 
ad libitum for 12 weeks, expression of PPAR-cx in the liver was increased relative to 
energy restricted groups. The greater induction of hepatic PPAR-ex expression in animals 
· consuming the basal diet (14 en% fat) ad libit11m may therefore, represent a compensatory 
mechanism induced to increase hepatic �xidation in the face of elevated circulating 
fatty acids resulting from chronic consumption of the basal diet This would mimic the 
effect of PP AR-ex activation by fibrates and would be expected to increase fatty acid flux 
from peripheral tissues to the liver, reduce fatty acid synthesis, and reduce the delivery of 
triacy)glycerols to peripheral tissues (147,148). Interestingly, expression of PPAR-ex in 
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the liver was significantly greater in animals consuming the energy restricted basal and 
MUNG diets compared with 10-S, 10-F, and ROIL. 1bis is somewhat surprising due 
to the identical macronutrient composition of the diets. Based on the differences in the 
level of PP AR-ex expression among energy restricted groups, we can speculate that these 
differences are related to the endogenous dietary fiber of the oatmeal based diets, which 
over the long term may have slowed glucose absorption and consequently, prevented 
plasma free fatty acid levels from rising to levels sufficient to induce PP AR-ex expression 
to the same degree as the energy restricted basal and MUN G diets, which lacked 
endogenous dietary fiber. 
In ad libit11m fed animals, retroperitoneal fat pad mass was similar in the basal, IO-S, 
10-F, and MUNG groups. However, the pattern of gene expression in this depot 
suggests that FAS and PP AR-y responded differently to diet. If the expression of these 
genes is primarily regulated by dietary fat content, one would expect to the expression of 
these genes to respond snnila.rly across diets. 1bis is not the case. Despite similar 
rettoperitoneal fat pad mass, expression of FAS was significantly reduced by 
consumption of the ROIL and MUNG compared with all other diets. Furthermore, 
expression of PPAR-y was reduced in the ROIL group compared with basal, IO-S, and 
IO-F. Expression of UCP-2 in the retroperitoneal depot was significantly enhanced in 
animals consuming the basal, IO-S, and 10-F, relative to ROIL and MUNG diets. This 
is a response similar to the upregulation of UCP-2 gene expression in white adipose 
tissue of genetically obese (ob/ ob, db/ db) mice and rodents and humans with diet-induced 
obesity (149,150). 
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A plausible explanation for the induction of UCP-2 in retroperiteonal adipose tissue 
by 6 weeks ad libit11111 consumption of the basal diet may involve plasma lept:in levels. 
With the exclusion of aoima1s fed the ROIL diet ad libi/11111, retroperitoneal fat pad mass 
was similar in the basal, 10-S, 10-F, and MUNG groups. Nonetheless, expression of 
UCP-2 was greater in the basal, 10-S, and 10-F groups compared with MUNG. Lept:in 
has been shown to upregulate UCP-2 expression in white adipocytes, while stimulating 
fatty acid degradation (151). The variations in UCP-2 expression in the retroperitoneal 
adipose tissue depot along with variable plasma lept:in levels, may imply that UCP-2 
expression was enhanced by leptin levels in an attempt to compensate for increased flux 
of free fattr. acids and blunt adipose tissue deposition. 
In aoima1s fed ad libit11m for six weeks, expression of UCP-3 and PP AR-<X was similar 
across diets in both soleus and gastrocnemius muscle. However, energy restriction 
increased the expression of UCP-3 and PP AR-<X in gastrocnemius muscle compared with 
ad libitum consumption of the basal diet for 12 weeks. This is consistent with the 
findings of Samec, et al (152,153), who demonstrated that the metabolic differences 
between slow-twitch oxidative (soleus) and fast-twitch glycolyt:ic (gastrocnemius) muscles 
are not observed during the fed state. Furthermore, while we demonstrate that energy 
restriction is associated with a marked increase in the expression of UCP-3 in 
gastrocnemius muscle compared with ad libit11111 fed animals, this effect is absent in soleus 
muscle. This profound upregulation ofUCP-3 expression in gastrocnemius muscle of 
energy restricted aoima1s compared with the lack of response in skeletal muscle is 
consistent with the greater metabolic plasticity of gastrocnemius muscle (154,1 55). 
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Soleus muscle is heavily reliant on lipids as an energy substrate in the basal state, 
while the gastrocnemius muscle prefers glucose as an energy substrate in the well fed 
state (154,155). Consequently, gastrocnemius muscle has the capacity to increase lipid 
utilization, and expression of genes involved in lipid oxidation, as glucose becomes 
limiting. while soleus muscle approaches maximal lipid use in the well fed state (154,155). 
Furthermore, the differences in expression of UCP-3 between soleus and gastrocnemius 
muscle parallel changes in lipid flux across the mitochondria (152,156). Consequently, 
the signal for enhanced UCP-3 expression in gastrocnemius muscle of energy restricted 
animals may be related to circulating levels of free fatty acids. However, other studies 
have demonstrated that the normal surge in UCP-3 expression occurs in fasting animals 
treated with the anti-lipolytic agent, nicoti.nic acid (152,153). This suggests that free fatty 
acid flux is not the only physiological important cue regulating UCP-3 expression. Using 
a regression model which included parameters of body composition, energy expenditure, 
fasting levels of free fatty acids, glucose and insulin, and postprandial glucose responses, 
Samec, et al. (152,153) have demonstrated that glucose tolerance is the only one of these 
factors which could predict the variability in skeletal muscle expression of UCP-3 and 
further suggests a link between UCP-3 and glucose homeostasis. Consistent with this, 
we observed an inverse relationship between fasting plasma insulin and glucose levels 
and gastrocnemius expression of UCP-3 and PPAR-a. Such a relationship is consistent 
with the preferential use of glucose by gastrocnemius muscle in the well fed state, and 
the metabolic switch to lipids when glucose is limiting. 
Our findings also agree with Corbalan, et al (156) who reported that high-fat fed rats 
had lower gastrocnemius muscle UCP-3 levels and mitochondrial 02 consumption 
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compared to lean rats. Since skeletal muscle UCP-3 expression is upregulated in 
response to fasting (152), a downregulation may occur with overfeeding (156). Similarly, 
Gong, et al. (157) demonstrated a !rignificant reduction in UCP-3 levels within 24 hours 
of refeeding. Decreased UCP3 levels are also found in denerved muscles, in which 
triglyceride accumulation is increased, suggesting that fatty acid oxidation may be 
reduced Lower mitochondrial oxygen consumption is seen in high-fat fed rats and is 
indicative oflower lipid utilization in cafeteria fed rats (157,158). 
In summary, these studies demonstrate that a qualitative change in diet, specifically 
carbohydrate source, influences weight gain and body composition in aP274-agouti 
transgenic mice. We hypothesize that diets containing low-glucose response dietary 
carbohydrate result in the sustained release of glucose into circulation, which may 
prevent an exaggerated postprandial response characterized by extreme hyperglycemia 
and an enhanced insulin secretory response. Over the long term, the altered 
postprandial response permits carbohydrate oxidation to continue throughout the 
postprandial period, at the expense of fat oxidation, whether an individual is sedentary or 
active. The chronic consumption of high glycemic index carbohydrates and the 
accompanying changes in the postprandial response may alter the pattern of substrate 
utilization and energy balance, such that lipid flux to adipose tissue is favored. 
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I. Summary and Conclusions 
In summary, these studies demonstrate the importance of dietary carbohydrate in the 
development of obesity. Moreover, we demonstrate that body weight and adjposity are 
influenced by both quantitative and qualitative changes in dietary carbohydrate. 
The consumption of a high-fat, carbohydrate-free diet significantly attenuated body 
fat accumulation and reduced energy efficiency in heterozygous (fa/+) Zucker rats, 
independen� of energy intake. Moreover, the addition of a modest amount (10 en%) of 
highly refined carbohydrate (sucrose) to the high-fat diet reversed the effects of 
carbohydrate restriction, significantly enhancing adipose tissue deposition and energy 
efficiency. Consequently, aoima1s consuming a hlgh-fat diet containing a minimal 
amount of carbohydrate, weighed significantly more than animals consuming the high.­
fat, carbohydrate-free diet, despite greater energy intake by the latter. Although the exact 
mechanism for the effects of carbohydrate-restriction are unclear, the results of the 
present studies question the appropriateness of current dietary guidelines recommending 
the consumption of a low-fat, high-carbohydrate diet by all individuals, without regards 
to the prevailing metabolic state of the subject. 
In addition, we have demonstrated that carbohydrates which evoke greater 
postprandial blood glucose excursions enhance the accumulation of adipose tissue, while 
low-glucose response diets have the opposite effect. There is considerable debate 
surrounding the importance of dietary carbohydrate source in the pathogenesis of 
obesity and related conditions. The current position of the American Diabetes 
Association is that carbohydrate quantity, not quality, is the critical factor influencing 
metabolic control Based on our findings, we suggest additional research into this area. 
412 
Clearly, we have shown that dietary carbohydrate structure influences the postprandial 
response. Although the present studies were unable to determine the precise mechanism 
by which dietary carbohydrate source influences body weight and adiposity, we 
demonstrated a significant response to a qualitative change in the carbohydrate content 
of the diet Additional research is necessary to determine the physiological mediators 
responsible. In addition, the time course over which the postprandial response to 
carbohydrate containing foods significantly alters metabolic processes leading to 
accderated weight gain and adiposity are needed 
In conclusion, we demonstrate the importance of considering both the quantity and 
quality of dietary carbohydrate in the devdopment of obesity. These studies 
demonstrate the complexity of the physiological mechanisms leading to obesity and 
further suggest that there is no "one size fits all" dietary prescription. 
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SUMMARY OF EFFECT'S OF DIETARY CARBOHYDRATE SOURCE IN AD 













20891.79 ± 1139.21• 
17034.40 ± 1579.991,,e 
17400.70 ± 1105.57' 
14024.30 ± 555.98c 








Effects of Dietary Treaunent on Body Weight in Ad Libitum Fed aP274-.AgoutiTransgenic Mice 
A. Summary of Changes in Body Weight 
Baseline (g) Final (g) Grams Gained % Chanee 
Basal 26.57 ± 1.34. 33.37 ± 1.34• 6.80 ± 0.45b,c 26.28 ± 2.26b,c 
10-S 21.80 ± 0.80• 32.85 ± 1.30. 5.05 ± 0.87'¥ 18.98 ± 3.54b,c 
10-F 27.31 ± 1.2i8 34.63 ± 1.41• 7.32 ± 1.15" 27.79 ± 5.04" 
ROU. 27.60 ± 0. 9i8 30.11 ± 0.91' 2.51 ± 0.8� 9.61 ± 3.5'78 
MUNG 27.44 ±0.918 33.26 ±0.7� 5.81 ± 0.74b,c 21. 78 ± 3.21 b,c 
Values arc Mean±SEM; Matching superscripts indicate statistically eqwvalent values; a,b,"Non-similat aupencripts indicate 
significant differences at p < 0.05 
B. Weekly Changes in Body Weight 
Gross Body Weight (g) 
Baseline End Week 1 End Week 2 End Week 3 End Week 4 End Week S 
26.57 ± 1.348 28.74 ±0.53• 29. 72 ± 1.638 31.21 ± 1.57• 31.99 ± 1.54 • 32.60 ± 1.55 • 
27.80 ± 0.808 29.47 ±0.698 29.53 ± 0.53• 30.88 ± 0. 94 • 32.39 ± 0.37 8 32.88 ± 0.44 • 
27.31 ± 1.22• 29.69 ± 1.35 • 29.57 ± 1.17"' 31.30 ± 1.20 · 32.87 ± 1.25 • 34.03 ± 1.29• 
27.60 ± 0.928 28.02 ± 0. 91 b 28.11 ± 0. 9i8 28.68 ± 1.02 b 29.43 ±0.98 b 29.96 ± 1.02b 
27.44 ± 0.91• 28.67 ±0.19 • 29.40 ± 0.668 30.33 ± 0.55 • 31.88 ± 0.74 • 32.51 ± 0.86 • 
End Week 6 
33.37 ± 1.34 • 
32.85 ± 1.30 • 
34.63 ± 1.41 8 
30.11 ±0.97 b 
33.26 ±0.19 • 
Values arc Mean±SEM; Matching superscripts indicate statistically equivalent values; a,bNon-similat supencripts indicate significant difference, at p < 0.05. 
� -
Table .A3 
Effect of Dietary Treaunent on Body Weight in Energy Restricted aP274-AgoutiTransgenic Mice 
t.J 
� J  
-c:I 
, .i 
� J  
A. Summary of Changes in Body Weight During Weeks 6-12 
Week 6 (fJ 
Basal ad lib 34.81 ± 1.34 • 
Basal-R 35.23 ± 1.56 • 
10-S 34.34 ± 0.69 • 
10-F 34.19 ± 0.89. 
ROLL 35. 71 ± 3.03 • 
MUNG 33.16 ± 1,92• 
Week 12 (fJ 
36.37 ± 1.328 




25.50 ± 1,48A b,c: 







1.56 ± 1.21 D 
-7.19 ± 0.46• 
-7.19 ± 0.93 8 
-8.69 ± o. 98 • 
-10.15 ± 256 1 
-7.29 ± 1.45 • 
% Chanae 
4.85 ± 3.40 b 
-20.86 ± 2.18• 
-21.11 ± 2.90• 
-25.60 ± 3.04 • 
-28.16 ± 5.62 • 
-21.04 ± 3.00 • 
Values are Mean ± SEM; Indicates a significant decrease in body weight from baseline at p < 0.05; Matching supencripts indicate statistically 
equivalent values; �on-similar superscripts indicate significant differences at p<0.05. 
B. Body Weight During Weeks 6-12 
Gross Body Weight (fJ 
Week 6 Week 7 Week 8 Week 9 Week lO Week ll 
Basal ad lib 34.81 ± 1.34 • 36.09 ± 1.11 • 36.34 ± 1.35• 35.97 ± 1.1?8 34.72 ± 1.6?8 36.49 ± 1.13·. 
Basal-R 35.23 ± 1.56 • 34.98 ± 1,55 • 31.46 ± 1.67D 28.56 ± 1.56D 29.2.0 ± 1 .75D 28.34 ± 1.78D 
10-S 34.34 ± 0.69. 34.33 ± 1.04 • 30.91 ± 1.15b 29.49 ± 1.01 b 28.46 ± 0.95b 28.26 ± 1.08b 
10-F 34.19 ± 0.89 1 33.54 ± 0.90 1 30.21 ± 1.02b 28.68 ± 1.03b 27.58 ± 1.12', 27.03 ± 1 .11 b 
ROLL 35. 71 ± 3.03 I 33.06 ± 217• 29.44 ± 1.84b 27.58 ± 1.36b 26.53 ± 1.21 b 25.66 ± 1.56b 
MUNG 33.16 ± 1.921 33.85 ± 1.41 • 29.88 ± 1.01 b 28.26 ± 0.85b 27.19 ± 0.79b 26.72 ± 0.85b 
Values are Mean ± SEM; Matching supencripts indicate statistically equivalent values; •,v,•Non-similac supencripts indicate significant differences at p<0.05. 
Week 12 
36.37 ± 1.32• 
28.04 ± 1.81b 
27.16 ± 1,36b,c 
25.50 ± 1,48b,c 
23.92 ± 1.51" 







Effects of Dietary Treatment on Measures of Body Composition in aP274-AgoutiTransgenic Mice 
A Ad Libitum Phase 
Selected Contralateral Muscles 
Liver Soleus Gastrocnemius Combined Muscles 
% Final % Final % Final % Final 
Weight (g) Body Weight Weight (g) Body Weight Weight (g) Body Weight Weight (g) Body Weight 
1.12 ± 0.05• 5.21 ± 0.17
D 0.016 ± 0.003 0.047 ± O.ot 0.087 ± O.ot 0.26 ± 0.02 0.10 ± 0.01 0.31 ± 0.02 
1.70 ± 0.09 • 5.17 ± 0.22
b 0.020 ± 0.004 0.060 ± O.ot 0.086 ± O.ot 0.26 ± 0.02 0.1 1  ± O.ot 0.32 ± 0.02 
1.73 ± 0.08• 5.00 ± 0.18 a,
b 0.016 ± 0.003 0.045 ± 0.01 0.084 ± O.ot 0.25 ± 0.04 0.10 ± O.ot 0.30 ± 0.04 
1.52 ± 0.04
b 
5.07 ± 0.18 a,
b O.ot8 ± 0.004 0.062 ± O.ot 0.082 ± O.ot 0.28 ± 0.02 0.10 ± 0.01 0.34 ± 0.03 
1.55 ± 0.03
b 
4.67 ± 0.11 • O.ot8 ± 0.004 0.054 ± O.ot 0.074 ± O.ot 0.23 ± 0.02 0.09 ± O.ot 0.28 ± 0.02 
;; Values ate Mean±SEM; •,u,..Non-similar superscripts indicam significant differences at p<0.05. 
B. Energy Restricted Phase 
Selected Contralateral Muscles 
Liver Soleus Gastrocnemius Combined Muscles 
% Final % Final % Final % Final 
Weight (g) Body Weight Weight (g) Body Weight Weight (g) Body Weight Weight (g) Body Weight 
Basal ad lib t.93 ± 0.08• 5.36 ± 0.21 0.023 ± 0.003 0.06 ± 0.003 0.06 ± O.ot 0.17 ± O.ot • 0.09 ± O.ot 0.23 ± 0.02• 
"Cl Basal-R 1.48 ± 0.08 D 5.34 ± 0.25 0.029 ± 0.008 0.12 ± 0.05 0.07 ± O.ot 0.26 ± 0.06
D 0.10 ± 0.02 0.38 ± 0.10
D 
to �  10-S 1.31 ± 0.051,,
c 5.10 ± 0.31 0.032 ± O.ot 1 0.13 ± 0.05 0.08 ± O.ot 0.31 ± O.ot b 0.12 ± O.ot 0.44 ± 0.06
b 
t ·s 10-F 1.33 ± 0.07 1,,
c 5.26 ± 0.28 0.024 ± 0.008 0.09 ± 0.03 0.08 ± O.ot o.32 ± o.o5
b 0.11  ± 0.02 0.41 ± 0.08
b 
C: Cll 
ROLL 1.30 ± 0.10
c 5.43 ± 0.15 0.022 ± 0.001 0.09 ± 0.03 0.07 ± O.ot 0.28 ± 0.04
b 
0.09 ± 0.02 0.37 ± 0.06
b 
i;;a;:i � 
MONG 1.29 ± 0.07
c 4.99 ± 0.27 0.031 ± 0.006 0.12 ± 0.03 0.08 ± O.ot 0.32 ± 0.04
b 0.1 1  ± 0.02 0.44 ± 0.06
b 
-
Values ate Mcan±SEM; -,
u
,..Non-similar superscripts indicam significant differences at p<0.05. 
� ..... 
Table A5 
Effect of Dietary Treatment on Measures of Adiposity in Ad Libitum Fed aP274-Agouti Transgenic Mice 
A. Mass of Selected Fat Pads 
Selected Subcutaneous Fat Selected Visceral Fat 
Pads (g) Pads ru 
Sum of Sum of Sum of Visceral 
Subcutaneous Visceral & Subcutaneous 
Subscapular Epididvmal Fat Pads (g) Retroperitoneal Perirenal Fat Pads (g) Fat Pads (g) 
Basal 1.26 ± 0.19 • 0.13 ± 0.01 • 1.4-0 ± 0.20 • 1.16 ± 0.14 • o.74 ± o.09• 1.89 ± 0.22• 3.29 ± 0.41 • 
10-S 1.11 ± 0.05 • 0.13 ± 0.ot • 1.24 ± 0.05 • 1.28 ± 0.04 8 0.79 ± 0.06 8 2.06 ± 0.08 8 3.31 ± 0.11 • 
10-F 1.44 ± 0.18 • 0.12 ± 0.ot • 1.56 ± 0.19 8 1.33 ± 0.14 • 0.86 ± 0.10 • 2.20 ± 0.24• . 3.75 ± 0.42 • 
ROLL 0.65 ± 0.10 b 0.11  ± 0.01 • 0.75 ± 0.11  b 0.81 ± 0.10 b 0.49 ± 0.08 b 1.30 ± 0.18 b 2.05 ± 0.29 b 
MUNG 1.10 ± 0.10•  0.12 ± 0.ot • 1.22 ± 0.10 •  1.24 ± 0.10 · o.66 ± 0.05 • 1.91 ± 0.15 •  3. 13 ± 0.24 • 
V alucs arc Mean ± SEM; •,
u
Non-similar superscripts indicate significant differences at p<0.05. 
B. Contribution of Selected Fat Pads to Final Body Weight 
Percent Final Body Weight (%) 
Visceral Fat Pads Subcutaneous Fat Pads 
Combined Visceral Individual Tissues Individual Tissues 
& Subcutaneous Combined Combined 
Fat Pads Retroperitoneal Perirenal Visceral Epididymal Subscapular Subcutaneous 
Basal 9.58 ± 0.89 . 3.37 ± 0.31 8 2.18 ± 0.21b 5.55 ± 0.49 8 0.4-0 ± 0.03 • 3.63 ± 0.44 8 4.03 ± 0.45 11 
10-S 10.04 ± 0.25 • 3.89 ± 0.08 • 2.38 ± 0.17b 6.27 ± 0.19 • 0.39 ± 0.02• 3.38 ± 0. 14 8 3.77 ± 0.14• 
10-F 10.55 ± 0.89 • 3.77 ± 0.31 8 2.43 ± 0.23b 6.19 ± 0.53• 0.34 ± 0.03 8 4.01 ± 0.4-0 • 4.35 ± 0.39 8 
ROLL 6.60 ± 0.70 b 2.61 ± 0.25b 1.58 ± 0.22• 4.19 ± 0.44b 0.33 ± 0.02• 2.08 ± 0.26 b 2.41 ± 0.28 b 
MUNG 9.34 ± 0.60 8 3.71 ± 0.30 • 1 .99 ± 0.14 .... 5.70 ± 0.39 8 0.35 ± 0.02• 3.29 ± 0.248 3.64 ± 0.24 8 
Values arc Mean ± SEM; a,
u
Non-similar rupencripts indicate significant differences at p<0.05. 
� 
Table Al, 
Effect of Dietary Treatment on Measures of Adiposity in Energy Restricted aP274-.AputiTransgcnic Mice 
"O 
ti � 
t ·s C: m 
� �  
A. Mass of Selected Subcutaneous Fat Pads and Combined Mass of Visceral & Subcutaneous Fat Pads 
Selected Subcutaneous Fat Pads (g) 
Subscapular Epididvmal 
Basal ad lib 1.15 ± o.2s• 0.16 ± O.Q1 • 
Basal-R 0.95 ± 0.189 0.13 ± 0.02• 
10-S 0.89 ± 0.19b 0.15 ± 0.01 • 
10-F 0.62 ± 0.18 .... 0.1 1  ± 0.01 • 
ROLL 0.48 ± 0.12c 0.12 ± 0.02 • 
MUNG o.57 ± 0.08"'" 0.13 ± 0.01 • 
- -
Sum of Selected 
Subcutaneous Fat Pads (g) 
1.91 ± 0.26 · 
1.08 ± 0.181) 
1.05 ± 0.20b 
0.73 ± 0.191¥ 
0.61 ± 0.13c 
o.69 ± 0.0811,c 
Sum of Selected Visceral 
& Subcutaneous Fat Pads (g) 
4.43 ± 0.43• 
2.45 ± 0.4511 
247 ± 0.51b 
1.60 ± 0.431¥ 
1.18 ± 0.30c 
1.43 ± 0.18¥ 
Value• arc Mean ± SEM; Matching supencripts indicate •tatistically equivalent values; .,..,.Non-similar supcncripts indicate significant differences at p < 0.05. 
B. Mass of Selected Visceral Fat Pads & Retroperitoneal Adipocyte Size 
Selected Visceral Fat Pads 
Retroperitoneal Deoot Perirenal Sum of Selected 
Weight uu Adipocyte Size (um) Weight (g) Visceral Fat Pads (g) 
Basal ad lib 1.61 ± 0.11• 94.28 ± 2.00• 0.91 ± 0.12• 2.52 ± 0.21• 
Basal-R 0.92 ± 0.1811 87.98 ± 1.668 o.46 ± o. rnli 1.38 ± 0.2711 
"O 
10-S 0.91 ± 0.18b 71.C.X) ± 6.5� 0.52 ± 0.15b 1.43 ± 0.31b ti � 
t ·s 10-F o.62 ± o.1s1¥ 78.67 ± 4.01 b 0.26 ± 0.101¥ 0.88 ± 0.241¥ C: m 
0.40 ± 0.12c 66.39 ± 6.11c 0.18 ± 0.06c 0.57 ± 0.18c � �  ROLL 
MUNG 0.52 ± 0.07" 73.44 ± 4.0811,c 0.21 ± 0.04c 0.74 ± 0.11b,c 
Values arc Mean ± SEM; .,.,,.Non-similar superscripts indicate significant difference• at p < 0.05 
Basal ad lib 
Basal-R 
'C IO-S 
� �  
9 ·2 IO-F 






12.04 ± o.s2• 
8.28 ± 1.27b 
8.69 ± 1.54b 
5.84 ± 1.30b,c 
4.65 ± 1.02c 
5.51 ± 0.68b,c 
supencnp 
Table A6 (continued) 
C. Contribution of Selected Fat Pads to Final Body Weight 
Percent Final Body Wei�ht (%) 
Visceral Fat Pads Subcutaneous Fat Pads 
Individual Tissues Individual Tissues 
Combined Combined 
Retroperitoneal Perircnal Visceral Epididymal Subscapular Subcutaneous 
4.41 ± 0.21• 2.47 ± 0.30· 6.89 ± 0.48• 0.44 ± 0.02• 4.71 ± o.s1• s.16 ± 0.52• 
3.11  ± 0.54b 1.52 ± 0.29D,C 4.63 ± 0.79b 0.46 ± 0.06 8 3.19 ± 0.51b 3.66 ± 0.SOD 
3.19 ± 0.56b 1.81 ± 0.52a,c 5.00 ± 0.99b 0.55 ± 0.04• 3.13 ± 0.56b 3.69 ± 0.57b 
2.27 ± 0.46b,c 0.91 ± 0.31d 3.18 ± 0.74b,c 0.42 ± 0.04• 2.23 ± 0.54b,c 2.65 ± 0.57b,c 
1.54 ± 0.43c 0.68 ± 0.20d 2.22 ± 0.63c 0.55 ± 0.04 • 1.88 ± 0.43c 2.43 ± 0.41c 




Effect of Dietary Treatment on Circulating Glucose Levels in Ad Libitum Fed aP274-.AgoutiTransgenic Mice 
A. Fasting Plasma Glucose Levels 
Fastiniz Plasma Glucose Levels 
Baseline Final 
(mg/dL) (mg/dL) % Change 
Basal 128.15 ± 6.56 b 142.70 ± 3.988 14.55 ± 5.59 8 
10-S 150.30 ± 3.58 . 149.50 ± 6.6� -0.80 ± 8.36 • 
10-F 141.90 ± 4.28. 165.90 ± 6.79b 24.00 ± 8.52 • 
ROU. 148.05 ± 8.63 8 178.45 ± 8.76c 30.40 ± 11 .11• 
MUNG 154.83 ± 7.87 8 153.44 ± 6.50 .... -1.39 ± 11.05 b 
Values are mean± SBM; ••
0
"Non-similar superscripts indicat.e significant differences at p < 0.05. 
B. Weekly Non-Fasting Blood Glucose Levels 
Blood Glucose (mg/ dL) 
Week l Week 2 Week 3 Week 4 Week 5 
Basal 141.80 ± 5.00,.b 136.00 ± 6.83b 137.20 ± 5. 72 152.10 ± 6.13 170.15 ± 2.74b 
10-S 148.70 ± 7.18a,b,c 143.75 ± 6.51b 142.70 ± 6.31 147.20 ± 4.98 172.15 ± 5.41b 
10-F 162.05 ± 4.88c 161.95 ± 6.31• 153.30 ± 4.81 158.70 ± 8.74 171.30 ± 4.97b 
ROLL 134.40 ± 4.89- 136.20 ± 5.76b 157.75 ± 8.43 139.40 ± 3.19 159.70 ± 4.22 .  b 
MUNG 152.17 ± 6.Q4b,e 145.22 ± 6.00-,b 139.28 ± 7.79 149.44 ± 4.52 160.6 7 ± 6.21 a,b 
Values are Mean ± SEM; •,
u
"Non-similar rupencriptJ indicate significant differences at p < 0.05. 
� 
Table A8 
Effect of Dietary Treatment on Circulating Glucose Levels in Energy Restricted aP274-AgoutiTransgenic Mice 
A. Fasting Plasma Glucose Levels 
F astin ir Plasma Glucose Levels 
Baseline Final 
(mg/dL) (mg/dL) % charure 
Basal ad lib 137.29 ± 1.11 · 122.51 ± 5.15• -9.82 ± 4,72• 
Basal-R 150.71 ± 3.15 b 116.33 ± 10.148 -23.52 ± 6.48•,b 
"Cl 10-S 149.14 ± 2.63 b 113.00 ± 6.99b,c -24.32 ± 4.26..,, t �  
t ·s 10-F 152.14 ± 3.58 b 103.14 ± 9.52b,c -32.34 ± 6.00b c:l a) 
140.43 ± 2.10 • 91.00 ± 16.22° -35.27 ± 10.82b i;;i:i �  ROLL 
MUNG 136.57 ± 4.19 8 91.57 ± 6.54° -32.48 ± 5.22b 
V alucs arc Mean ± SEM; -.�,· Non-similar superscripts indicat.e significant differences at p < 0.05. 
B. Weekly Fasting Blood Glucose Levels 
Fasting Blood Glucose Levels (mg/ dL) 
Week i Week2 Week 3 Week 4 Week 5 
Basal ad lib 135.71 ± 1.61. 128.14 ± 3.618 130.00 ± 1.69a,D 125.00 ± 5.35 129.00 ± 4.178 
"Cl Basal-R 107.00 ± 1 .05
T 129.28 ± 5.18•,r 122.71 ± 3.878'T 118.43 ± 5.sot 83.43 ± 7.45b,t 
ti !  10-S 116.00 ± 7.32
t 129.29 ± 5.65 .. t 135.57 ± 2.61 b,t 118.29 ± 4.52t 69.57 ± 6.26b,t 
t ·s 10-F 107.00 ± 4.76t 126.86 ± 2.61"b,t 132 71 ± 4.69a,t,t 112.14 ± s.o8t 72.43 ± 7,94b.c.t c:l a) ROLL 112.11 ± 5.o8t 113.57 ± 4.7�t 121.30 ± 6.08 .. t 107.00 ± 9.92t 71.17 ± 3,73b.c.t 
i;;i:i �  MUNG 104.71 + 8.o8t 114.43 + 1.17b.t 12251 + 5.01 a.t 108.86 ± 7.42t 63.43 + 5,79c.t 
Values ue Mean ± SEM; Indicat.es a value significantly different from all others within column at p<0.05; 1 lndicat.es a value significantly different from baseline at p<0.05, 
a,b,c Non-similar superscripts indicat.e significant differences at p < 0.05 
� 
'ti 
t �  
t ·s 
C: • 
� �  
Table A9 
Effect of Dietary Treatment on Fasting Plasma Metabolites in aP274-AgoutiTransgenic Mice 
A. Ad Libitum Phase 
Insulin Insulin:Glucose Leptin Triglycerides Glycerol 
(µU/ml) Ratio (ng/ml) (mg/dL) (µmol/L) 
Basal 12.85 ± 1.82• 15.20 ± 3.74 15.53 ± 2.3r 124.69 ± 24.94. 631.74 ± 91.33 . 
IO-S 7.99 ± 0.711> 17.03 ± 1.78 16.27 ± 1 .46. 112.08 ± 14.91 .. ., 550.69 ± 58.85 • 
IO-F 12. 73 ± 2.83. 15.97 ± 2. 71 16.05 ± 2.41• 168.32 ± 14.SO- 676.92 ± 83.21 • 
ROLL 8.00 ± 1.1()b 17.33 ± 2.48 10.96 ± 1.411> 79.(:JJ ± 6.151, 537.29 ± 70.32 • 
MUNG 8.62 ± 0.851> 19.04 ± 3.29 15.(:JJ ± 1.64• 86.15 ± 13.531, 664.47 ± 44.88 • 
Values an, Mean ± SEM; -.u"'Non-simi!Ar supencripts indicate significant differences at p < 0.05. 
B. Energy Restricted Phase 
Insulin Insulin:Glucose Leptin Triglycerides Glycerol 
(µU/ml) Ratio (ng/ml) (mg/dL) (µmol/L) 
Basal ad lib 11.46 ± 1.638 11 .67 ± 1.30 29.49 ± 2.628 93.99 ± 7.618 423.45 ± 36.52• 
Basal-R 12.24 ± 1.71• 10.27 ± 1.62 21.08 ± 0.54D 87.82 ± 9.41 .. b 448.47 ± 47.65. 
IO-S 9.57 ± 0.66 .... 12.08 ± 1.07 19.33 ± 2.97'¥ 80.73 ± 8.8..,..., 420.23 ± 21.30• 
IO-F 8.83 ± 0.351, 11.63 ± 1.01 16.35 ± 2.211,.c 81.61 ± 7.1..,..., 473.30 ± 49.35. 
ROLL 9.85 ± 0.58 .... 9.38 ± 1 .76 14.79 ± 3.32c,,I 73.33 ± 3.561, 729.43 ± 92.941, 
MUNG 9.82 + 0.35 .... 9.40 ± 0.71 1 1 .63 ± 0.54d 72.84 ± 1 .731, 527.49 ± 93.24 .. ., -. 
Values an, Mean ± SEM; "'°�on-similar supcncriptJ indicate significant differences at p < 0.05. 
Table A10 
Effect of Dietary Treatment on Adipocyte Lipolysis in aP274-AgvutiTransgcnic Mice 
A Ad Libitum Phase 
Glycerol Release (µmo! glycerol/µg protein) 
Isoproterenol Absolute Percent 
Basal Stimulated Increase Stimulation 
Basal 8.42 ± 1.51 10.58 ± 2.37" 2.21 ± o.a1• 29.46 ± 11.41• 
10-S 6.26 ± 1.03 8.25 ± 1.468 1.99 ± 0.68• 34.76 ± 15.27" 
10-F 6.13 ± 1.12 11.45 ± 1.78 .. b 5.31 ± 1.42b 122.08 ± 47.49b 
ROLL 7.43 ± 0.82 16.38 ± 3.13b 6.22 ± 0. 901,,e 96.01 ± 22.83b 
MUNG 6.72 ± 1.18 14.77 + 1.78b 7.95 ± 1.49c 147.51 ± 38.65b 
Values ore Mean ± SEM; Matching supencripts indicate statistically equivalent values; •,u,.Non-similac supencripts indicate 
significant differences at p < 0.05 
B. Energy Restricted Phase 
Glycerol Release (µmo! glycerol/µg protein) 
Isoproterenol Absolute Percent 
Basal Stimulated Increase Stimulation 
Basal ad lib 7.32 ± 0.898 6.91 ± 0.2711,b -0.41 ± 0.95• 0.45 ± 13.428 
Basal-R 5.96 ± 1.198 7.73 ± 1.258 1.77 ±0.74b 58.80 ± 31.51 b,c 
"C 10-S 3.81 ± 0.71b 5.92 ± 1.14 ... 2.12 ± o.s2b 56.57 ± 14.001,,e ti! �  
t ·s 10-F 4.12 ± 0.92
b 8.63 ± 2.31• 4.51 ± 1 .4� 107.76 ± 26.60c 
c::: Ill 
3.98 ± 1 .26 b 4.46 ± o.3r 0.50 ± 1.00a,b 35.05 ± 21.29b i;i;:i �  ROLL 
MUNG 3.92 ± 0.77 b 6.67 ± 1.36 ... 2.75 ± 1.101,,e 81.32 ± 29.931,,e 
Values ore Mean ± SEM, ,.,..,, 'Non-similar supencripts indicate significant differences at p < 0.05 
Table All 
Effect of Dietary Treatment on Gene Expression in Ad Libitum Fed aP274-.Agouli'Transgenic Mice 
A. Liver and Skeletal Muscle Gene Expression 
Liver Gastrocnemius Muscle Soleus Muscle 
FAS:18s PP AR-u:18s UCP3:18s PP AR-ct:18s UCP3:18s PP AR-u:18s 
Basal 4.42 ± 0.638 2.91 ± 0.59- 0.56 ± 0.098 0.46 ± 0.12• 0.28 ± 0.038 0.53 ± 0.11 • 
10-S 3.28 ± 0.55• 2.31 ± 0.55 ... o.65 ± 0.08 • 0.40 ± 0.08• 0.23 ± 0.01• o.51 ± 0.15 • 
10-F 2.97 ± 0.41• 2.02 ± 0.36 .. b o.55 ± 0.08 • 0.43 ± 0.12 8 0.20 ± 0.08 • o.36 ± 0.05• 
ROLL t.76 ± o.33b 1.63 ± 0.16b 0.61 ± 0.10 • 0.26 ± 0.05 • 0.28 ± 0.01• 0.71 ± 0.12• 
MUNG 1.61 ± 0.45b 2.86 ± 0.63 ... o.67 ± 0.08• o.46 ± 0.08 • 0.25 ± 0.05 • 0.66 ± 0.208 
Values are Mean ± SEM; Matching superscripts indicate sbltistically equivalent values; -,u,.. Non-similar superscripts indicate significant differences at p < 0.05. 
B. Adipose Tissue Gene Expression 
Subscapular Adipose Tissue Retroperitoneal Adipose Tissue 
FAS:18s PP AR-ot:18s UCP2:18s PPAR-y:18s FAS:18s PPAR-u:18s UCP2:18s PP AR-y:18s 
Basal 0.85 ± 0.21• 1.08 ± 0.21• 4.58 ± 0.87 1.40 ± 0.36b 1.65 ± 0.13- 2.32 ± 0.09- 2.86 ± 0.32• 1.55 ± 0.13• 
10-S 0.34 ± 0.04b 0.52 ± 0.16b 3.72 ± 0.70 1.00 ± 0.24 ... 1.26 ± 0.12b 1.79 ± 0.20b 1. 78 ± 0.241> 0.73 ± 0.10b 
10-F 0.29 ± 0.13b 0.42 ± 0.05b 3.88 ± 0.83 o.92 ± o.288-b 1.02 ± 0.12b 1.74 ± 0.291,,e 1.69 ± 0.22b 0.61 ± 0.10b 
ROLL 0.77 ± 0.1� 1.17 ± 0.2� 4.36 ± 0.93 0.76 ± 0.10• 0.58 ± 0.08c 1.31 ± 0.15c 0.73 ± 0.15c 0.26 ± 0.05c 
MUNG 0.54 ± 0.18 ... 1.79 ± 0.608 4.39 ± 0.86 1.38 ± 0.43b 0.54 ± 0.06c 1.31 ± 0.23c 1.28 ± 0.09c 0.51 ± 0.201,,e 
Values are Mean ± SEM; •,u,•Non-simila.r superscripts indicate significant differences at p < 0.05 
Table A12 
Effect of Dietary Treatment on Gene Expression in Energy Restricted aP274-AputiTransgenic Mice 
A. Liver and Skeletal Muscle Gene Expression 
Liver Gastrocnemius Muscle Soleus Muscle 
FAS:18s PP AR-«:18s UCP3:18s PPAR-«:18s UCP3:18s PPAR-«:18s 
Basal ad lib 5.13 ± o.s1• 7.06 ± 1,07• 0.67 ± 0.05• 0.76 ± 0.138 o.32 ± 0.05• 1.13 ± 0.31• 
"Cl Basal-R 2.92 ± 0.82
b 5.00 ± 1.10b 1.01 ± 0.17" 201 ± 0.34
b 
0.20 ± 0.02b 206 ± 0.27" 
ti �  10-S 2.58 ± 0.62
b 3.95 ± 0.36" 1.18 ± 0.15b 2.84 ± o.so• 0.20 ± 0.03
b 
1.23 ± 0.268 
t ·s 10-F 1.62 ± 0.44b 3.45 ± 0.39" 1.79 ± 0.32" 1.37 ± 0.45 ... 0.32 ± 0.0� 1.32 ± 0.26· c:: It) 
ROLL 266 ± 0.38b 3.35 ± 0.60" 1.19 ± 0.051,,c 2.13 ± 0.29b,c o.26 ± oma.1> 1.40 ± 0.418 � �  
MUNG 248 ± 0.73b 5.09 ± 0.70b 1.47 ± 0.24" 2.22 ± 0.49b,c 0.27 ± 0.04 ... 276 ± 0.49b 
-
Values ate Mean ± SEM; •,u,•Non-similar superscripts indicatc significant differences at p < 0.05 
it B. Subscapular Adipose Tissue Gene Expression 
Subscapular Fat Pad 
FAS:18s PPAR-«:18s UCP2:18s PP AR-y:18s 
Basal ad lib 0.55 ±0.0� 0.61 ±0.13• 0.83 ±0.14• 0.88 ±0.308 
Basal-R 1.43 ± 0.21b 0.60 ± 0.16 8 0.63 ± 0.16 8 1.25 ± 0.26 .. b "Cl 
ti �  10-S o.so ± o.1s• o.74 ± 0.os• 0.56 ±0.10 •  0.55 ± 0.14• 
t ·s 10-F 2.84 ± 0.61" 0.52 ± 0.09 8 0.65 ± 0.07• 1 .11 ±0.21 ... c:: It) 
ROLL 2.16 ± 0.32b,c 0.85 ± 0.08
8 
0.58 ± 0.13• 1.43 ± 0.34
b 
� �  
MUNG 1.00 ±0.25 ... 0.75 ± 0.16 8 0.53 ±0.16 8 0.72 ±0.11• 
Values ace Mean ± SEM; Matching supencripts indicatc sbltistically equiwlcnt values; •,
u
,cNon-similar rupencripts indicate significant 
differences at p < 0.05 
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